

# TRANSLATION FROM GERMAN

## (12) WORLD ORGANIZATION OF INTELLECTUAL PROPERTY INTERNATIONAL APPLICATION PUBLISHED PURSUANT TO THE PATENT COOPERATION TREATY (PCT)

(19) World Organization for Intellectual Property			
International Office			
(43) International Publication Date:	PCT	(10) International Publication Number:	
18 July 2002		WO 02/055693 A2	
(51) International Patent Classification <sup>7</sup> : C12N 15/11		LIMMER,	Stephan
(21) International Application Number: PCT/EP02/00152		[GERMANY/GERMANY];	
(22) International filing date: 9 January 2002		Universitätsstrasse 30, 95447 Bayreuth	
(25) Submission language German		(GERMANY). ROST, Sylvia	
(26) Publication language German		[GERMANY/GERMANY];	
(30) Priority data:		Universitätsstrasse 30, 95447 Bayreuth	
101 00 586.5 9 January 2001 GERMANY		(GERMANY). HADWIGER, Philipp	
101 55 280.7 26 October 2001 GERMANY		[GERMANY/GERMANY; Universitätsstrasse	
101 58 411.3 29 November 2001 GERMANY	(74)	30, 95447 Bayreuth (GERMANY).	
101 60 151.4 7 December 2001 GERMANY		Attorneys: GASSNER, Rolfgang;	
(71) Applicant: <i>(for all designated states, except US):</i>		Nägelsbachstrasse 49a, 91052 Erlangen	
RIBOPHARMA AG		(GERMANY).	
[GERMANY/GERMANY]; Universitätsstrasse		(81) Designated states <i>(national)</i> : AE, AG,	
30, 95447 Bayreuth (GERMANY).		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,	
(72) Inventor and		BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK,	
(75) Inventor/Applicant <i>(for US only)</i> : KREUTZER,		DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,	
Roland [GERMANY/GERMANY];		GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,	
Universitätsstrasse 30, 95447 Bayreuth		KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,	
(GERMANY).		MD, MG, MK, MN, MW, MX, MZ, NO, NZ,	
		OM, PH, PL, PT, RO, RU, SD, SE, SG, SI,	
		SK, SL, TJ, TM, TRADENAME, TR, TT, TZ,	
		UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.	

BEST AVAILABLE COPY

(84) Regional states (*regional*): ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR). OAPI Patent (BR, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


– *without International Search Report and republished on receipt of the report*

*Refer to the "Guidance Notes on Codes and Abbreviations" at the beginning of each regular issue of the PCT Gazette for explanation of the two-letter codes and other abbreviations..*

(54) Title: **METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE**

(57) Abstract

The invention relates to a method for inhibiting the expression of a target gene in a cell, comprising the following steps: introduction of an amount of at least one dual-stranded ribonucleic acid (dsRNA I) which is sufficient to inhibit the expression of the target gene. The dsRNA I has a dual-stranded structure formed by a maximum of 49 successive nucleotide pairs. One strand (as1) or at least one section of the one strand (as1) of the dual-stranded structure is complementary to the sense strand of the target gene. The dsRNA has an overhang on the end (E1) of dsRNA I formed by 1 – 4 nucleotides.



Variant 1

Variant 2

## **METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE**

The invention concerns a method, an application and a medicament for inhibition of expression of a target gene.

Methods to inhibit expression of genes of medical or biotechnological interest by means of a double-strand ribonucleic acid (dsRNA) are known from WO 99/32619 and WO 00/44895. The known methods are highly effective. But there is also a requirement to further increase their efficiency.

The task of the present invention is to eliminate the shortcomings according to the prior art. In particular, a method, an application and a medicament are to be offered, with which even more efficient inhibition of expression of the target gene is attainable.

This task is solved by the features of Claims 1, 41 and 81. Advantageous embodiments are apparent from the features of Claims 2 to 40, 42 to 80 and 82 to 120.

With the features claimed according to the invention, a drastic increase in the effectiveness of inhibition of expression of the target gene in vitro and in vivo is surprisingly achieved. By the special design of the ends of the dsRNA, both their efficiency in mediating the inhibiting effect on expression of the target gene and their stability can be deliberately influenced. By increasing the stability, the effective concentration in the cell is increased.

Target gene according to the invention is understood to mean the DNA strand of the double-strand DNA in the cell that is complementary to a DNA strand, including all transcribed regions that serve for transcription as matrix. The target gene is therefore generally the “sense” strand. The one strand or anti-sense strand (as1) can be complementary to an RNA transcript formed during expression of the target gene or its processing product, for example, an mRNA. Insertion is understood to mean uptake in the cell. Uptake can occur by the cell itself; it also can be mediated by auxiliaries or aids. “Overhang” is understood to mean a terminal single-strand overhang that does not have paired nucleotides, according to Watson and Crick. “Double-strand

structure” is understood to mean a structure, in which the nucleotides of the individual strands are essentially paired according to Watson and Crick. A double-strand structure in the context of the present invention can also have individual mismatches.

According to a particularly advantageous embodiment, the dsRNA I has the overhang on the 3' end of one strand or the anti-sense strand as1 and/or on the 3' end of the other end or sense strand ss1. The dsRNA I can also be formed smoothly on one end. In this case, the smooth end is advantageously situated on the side of dsRNA I that has the 5' end of one strand (anti-sense strand; as1). In this form, the dsRNA I, on the one hand, has very good efficiency and, on the other hand, high stability in a living organism. The overall in vivo efficiency is excellent. The overhang is expediently formed from 1 to 4 nucleotides, preferably from 1 or 2 nucleotides.

According to another embodying feature, the efficiency of the method can be further increased if at least one additional dsRNA II, formed according to the dsRNA I according to the invention, is inserted into the cell, in which the one strand or at least a section of one strand of the double-strand structure of dsRNA I is complementary to a first region of the sense strand of the target gene, and in which an additional strand or at least a section of the additional strand of the double-strand structure of the additional dsRNA II is complementary to a second region of sense strand of the target gene. Inhibition of expression of the target gene is significantly increased in this case. The first and second region can overlap in sections, abut each other, or also be spaced from each other.

It has also proven advantageous if the dsRNA I and/or the additional dsRNA II have a length of less than 25 consecutive nucleotide pairs. A length in the range between 19 and 23 nucleotide pairs has proven to be particularly effective. The efficiency can be further increased if single-strand overhangs of 1 to 4 nucleotides are present on the double strands preferably formed from 19 to 23 nucleotide pairs.

The target gene, according to an additional embodying feature, can have the sequences SQ001 to SQ140, given in the enclosed sequence protocol. It can also be chosen from the following groups: oncogene, cytokine gene, id-protein gene, prion gene, genes for expression of



angiogenesis-inducing molecules, adhesion molecules and cell surface receptors. genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules, as well as genes for expression of the EGF receptors. The target gene can be the MDR1 gene, in particular. In this context, one of the existing sequences SQ141-173 or a combined dsRNA I/II from antisense (as) and sense sequences (ss) that go together can be used.

According to an additional advantageous embodying feature, expression is inhibited according to the principle of RNA interference.

The target gene is expediently expressed in pathogenic organisms, preferably in plasmodia. It can be a component of a virus or viroid, especially a human pathogenic virus or viroid. The virus or viroid can also be an animal or plant pathogenic virus or viroid.

According to another embodying feature, it is prescribed that the unpaired nucleotides be substituted by nucleoside thiophosphates.

At least one end of the dsRNA I/II can be modified, in order to counteract degradation in the cell or dissociation in the individual strand. Advantageously, cohesion caused by the complementary nucleotide pairs of the double-strand structure is increased by at least one chemical length. The chemical length can be formed by a covalent or ionic bond, a hydrogen bridge bond, hydrophobic interactions, preferably van-der-Waals or stacking interactions, or by metal ion coordination. It has also proven expedient and to increase stability if the chemical link is formed in the vicinity of one end. Additional advantageous embodiments with respect to chemical linking can be deduced from the features of Claims 24 to 30, without requiring a further explanation for this.

The dsRNA I/II can be incorporated particularly easily in the cell if it is enclosed in micellar structures, advantageously in liposomes. It has also proven advantageous for transport of dsRNA I/II into the cell that it is bonded to at least a viral sheath protein, originating from a virus, derived from a virus or synthetically produced, associated with the sheath protein or

enclosed by it. The sheath protein can be derived from polyoma virus. The sheath protein can contain, in particular, the virus protein 1 and/or the virus protein 2 of polyoma virus. According to another embodiment, it is prescribed that, during formation of a capsid or capsid-like structure from the sheath protein, one side face the interior of the capsid or capsid-like structure. It is also advantageous that the one strand of dsRNA I/II (as1/2) is complementary to the primary or processed RNA transcript of the target gene. The cell can be a vertebrate cell or a human cell.

It has also been found that the dsRNA I/II can advantageously be administered already in an amount of, at most, 5 mg/kg of body weight per day to a mammal, preferably a human. Even in this low dose, an excellent efficiency is achieved.

It has surprisingly been found that the dsRNA I/II can be taken up in a buffer solution for administration and then administered orally or by injection or infusion intravenously, intratumorally, by inhalation or intraperitoneally.

The use of a double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in the cell is also proposed according to the invention, in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (anti-sense strand; as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the sense strand of the target gene, and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides on at least one end.

According to an additional stipulation of the invention, a medicament for inhibiting the expression of a target gene in a cell is proposed, containing a double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of a target gene, in which the dsRNA I has a double-strand structure from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the sense strand of target gene, and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides on at least one end.

The preceding comments are referred to for the further advantageous embodiment of dsRNA I/II.

The invention is further explained on an example below, with reference to the drawings and practical examples. In the drawings:

- Fig. 1a, b        schematically depicts a first and second double-strand RNA and
- Fig. 2            schematically depicts a target gene,
- Fig. 3            depicts relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (first experiment),
- Fig. 4            shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (second experiment),
- Fig. 5            shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (third experiment),
- Fig. 6            shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (fourth experiment),
- Fig. 7            shows relative YFP fluorescence after application of different dsRNA in HeLa-S3 cells (fifth experiment),
- Fig. 8            shows fluorescence micrographs of NIH/3T3 cells after transfection with pcDNA-YFP and after cotransfection with pcDNA-YFP and different dsRNAs,
- Fig. 9            shows fluorescence micrographs of HeLa-S3 cells after transfection with pcDNA-YFP and after cotransfection with pcDNA-YFP and different dsRNAs,
- Fig. 10           shows gel electrophoretic separation of S1 after incubation in mouse serum,

- Fig. 11 shows gel electrophoretic separation of S1 after incubation in human serum,
- Fig. 12 shows gel electrophoretic separation of S7 after incubation in mouse serum,
- Fig. 13 shows gel electrophoretic separation of S7 after incubation in human serum,
- Fig. 14 shows gel electrophoretic separation of K3 after incubation in mouse serum,
- Fig. 15 shows gel electrophoretic separation of PKC1/2 after incubation in mouse serum,
- Fig. 16 shows gel electrophoretic separation of S1A/S4B after incubation in human serum,
- Fig. 17 shows gel electrophoretic separation of K2 after incubation in human serum and
- Fig. 18 shows GFP-specific immunoperoxidase staining on kidney paraffin sections of transgenic GFP mice,
- Fig. 19 shows GFP-specific immunoperoxidase staining on heart paraffin sections of transgenic GFP mice,
- Fig. 20 shows GFP-specific immunoperoxidase staining on pancreas paraffin sections transgenic GFP mice,
- Fig. 21 shows Western blot analysis of GFP expression in plasma,
- Fig. 22 shows Western blot analysis of GFP expression in the kidneys,
- Fig. 23 shows Western blot analysis of GFP expression in the heart,
- Fig. 24 shows Western blot analysis of EGFR expression in U-87 MG glioblastoma cells,

Fig. 25a shows Northern blot analysis of the MDRI mRNA levels in colon carcinoma cell line LS174T, in which the cells were harvested after 74 hours,

Fig. 25b shows quantification of the band according to Fig. 25a, in which the averages from two values are shown,

Fig. 26a shows Northern blot analysis of the MDRI mRNA levels in colon carcinoma cell line LS174T, in which the cells were harvested after 48 hours,

Fig. 26b shows quantification of the band according to Fig. 26a, in which the average values from the two values are shown,

Fig. 27 shows a comparative depiction of a transmitted light and fluorescence photomicrograph of a transfection with 175 nM dsRNA (sequence R1 in Table 4).

The double-strand ribonucleic acids dsRNA I and dsRNA II, depicted schematically in Figures 1a and 1b, each have a first end E1 and a second end E2. The first and second ribonucleic acids dsRNA I/dsRNA II have single-strand sections formed from about 1 to 4 unpaired nucleotides on their two ends E1 and E2. Two possible variants are shown (variants 1 and 2), in which variant 2 has a smooth end (E2). The smooth ends, however, can also lie on the other end (E1) in another variant.

A target gene situated on DNA is schematically shown in Fig. 2. The target gene is made recognizable by a black bar. It has a first region B1 and a second region B2.

Each strand of the first dsRNA I (as1) and the second dsRNA II (as2) is complementary to the corresponding region B1 or B2 on the target gene.

Expression of the target gene is then inhibited with particular efficiency, if the dsRNA I/dsRNA II has single strand sections on its ends E1, E2. The single-strand sections can be formed both on

strand as1 or as2 and on the counterstrand (ss1 or ss2) or on strand as1, as2 and on the counterstrand.

The regions B1 and B2, as shown in Fig. 2, can be spaced from each other. However, they can also be adjacent to each other or overlap.

#### I. Inhibition of Expression of the YFP Gene in Fibroblasts:

Double-strand RNAs (dsRNAs) were prepared from sequences of the yellow fluorescent protein (YFP), a variant of the GFP (green-fluorescent protein) of the alga *Aequoria victoria* and microinjected into fibroblasts, together with a YFP-coding plasmid. Fluorescence reduction was then evaluated relative to cells without dsRNA.

#### Experimental Protocol:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany) and ordinary chemical methods, the RNA single strands apparent from the sequence protocols SQ148, 149 and SQ159 and the single strands complementary to them were synthesized. Purification then occurred by HPLC. Hybridization of the single strands to a double-strand occurred by heating the stoichiometric mixture of single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 90°C and subsequent cooling over 6 hours to room temperature. The dsRNAs so obtained were microinjected into the test cell.

The murine fibroblast cell line NIH/3T3, ECACC no. 930615624 (European Collection of Animal Cell Cultures) served as test system for these cell culture experiments. The plasmid pcDNA-YFP was used for microinjections, which contained an 800 bp large Bam HI/Eco RI-YFP fragment in the corresponding restriction cleavage sites of the vector pcDNA3. Expression of YFP was investigated under the influence of simultaneously cotransfected sequence-homologous dsRNA. Evaluation occurred under the fluorescence microscope, at the earliest, 3 hours after injection, with reference to green fluorescence.

#### Preparation of the Cell Cultures:

Cultivation of the cells occurred in DMEM with 4.5 g/L glucose, 10% fetal calf serum (FCS), 2 mM L-glutamine, penicillin/streptomycin (100 IU/100 µg/mL, Biochrom) in an incubator under a 5% CO<sub>2</sub> atmosphere at 37°C. The cells underwent passage every 3 days, in order to keep them in the exponential growth phase. A day before performance of transfection, the cells were trypsinized (10 × trypsin/TEDTA, Biochrom) and inoculated with a cell density of  $0.73 \times 10^5$  cells into coated petri dishes (CORNING® Cell Culture Dish, 35 mM, Corning Inc., Corning, USA). The petri dishes were incubated with 0.2% gelatin (Biochrom) for at least 30 minutes at 37°C, washed once with PBS and immediately used for seeding of the cells. To permit recovery of individual cells, CELLocate coverslips from the Eppendorf company were used (square size 55 µm).

#### Microinjection:

To perform microinjection, the petri dishes were removed from the incubator for about 10 minutes. About 50 cells were microinjected per dish and batch (FemtoJet; Mikromanipulator 5171, Eppendorf). Glass capillaries (FemtoTip) from the Eppendorf company with a tip inside diameter of 0.5 µm were used for microinjection. The injection time was 0.8 seconds and the pressure 30 hPa. The microinjections were conducted on an Olympus IX50 microscope with a fluorescence device. 14 mM NaCl, 3 mM KCl, 10 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.0, was used as injection buffer, which contains 0.01 µg/mL pcDNA-YFP. To check successful microinjection, 0.08% (w/v) Dextran-70000 coupled Texas-Red (Molecular Probes, Leiden, Netherlands) was added to the injection solution. To investigate inhibition of the YFP expression with specific dsRNA, dsRNAs were added to the injection solution: batch 1: 0.1 µM dsRNA (sequence protocol SQ148/149); batch 2: 0.1 µM dsRNA (sequence protocol SQ148/159); batch 3: without RNA. After microinjection, the cells were incubated for at least three more hours in the incubator. The intracellular YFP fluorescence was then evaluated on the microscope: simultaneously red and green-fluorescent cells: microinjection was successful, no inhibition of YFP expression by dsRNA was observed; or control cells were involved, in which no dsRNA were injected; only red fluorescent cells: microinjection was successful, the dsRNA inhibits YFP expression.

### Results:

At a dsRNA concentration of 0.1  $\mu$ M, a significantly increased inhibition or expression of the YFP gene in fibroblasts could be observed during use of dsRNA with the protruding single-strand regions (sequence protocol SQ148/159) on both 3' ends by two nucleotides each, in comparison with dsRNA without protruding single-strand ends (Table 1).

The use of short dsRNA molecules, containing 19-25 base pairs with overhangs of a few, preferably 1 to 3, non-base-paired, single-strand nucleotides, therefore permits comparatively stronger inhibition of gene expression in mammal cells than the use of dsRNAs with the same number of base pairs without the corresponding single-strand overhangs at the same RNA concentration.

Batch	Name	Sequence protocol number	0.1 $\mu$ M
1	S1A/ S1B	SQ148 SQ149	+
2	S1A/ S4B	SQ148 (protruding end) SQ159	+++
3		without RNA	-

**Table 1:** The symbols show the relative percentage of non-fluorescent or weakly green fluorescent cells (+++ > 90%; ++ 60-90%; + 30-60%; - < 10%).

### II. Inhibition of Gene Expression with Target Gene in Cultivated HELA-S3 Cells and Mouse Fibroblasts by dsRNA:

The efficiency of inhibition of YFP expression after transient transfection of a YFP-coding plasmid based on RNA interference with dsRNAs can be modulated by the configuration of the 3' ends in the length of the base-paired regions.



### Practical Example:

To detect the efficiency of dsRNA during specific inhibition of gene expression, transiently transfected NIH/3T3 cells (fibroblasts from NIH Swiss mouse embryo, ECCAC (European Collection of Animal Cell Cultures) no. 93061524) and HELA-S3 (human cervical carcinoma cells, DSMZ (German Collection of Microorganisms and Cell Cultures) no. ACC 161) were used. The plasmid pcDNA-YFP was used for transfection, which contains an 800 bp Bam HI/Eco RI-YFP fragment in the corresponding cleavage sites of the vector pcDNA3. Double-strand RNAs derived from the sequence of the yellow fluorescent protein (YFP) were produced and transiently transfected with the plasmid pcDNA-YFP in the fibroblasts (the employed specific dsRNAs are complementary in their anti-sense strands to the corresponding sections of the gene sequences above YFP and GFP). After 48 hours, the fluorescence reduction was quantified. Cells that were transfected either only with pcDNA-YFP or with pcDNA-YFP and a controlled dsRNA (not derived from the YFP sequence) functioned as controls.

### Experimental Protocol:

#### dsRNA Synthesis:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany), and ordinary chemical methods, the RNA individual strands apparent from the sequence protocols and the single strands complementary to them were synthesized. Purification of the crude synthesis products then occurred by means of HPLC. The column NucleoPac PA-100, 9 × 250 mM, from the Dionex company was used; 20 mM tris, 10 mM NaClO<sub>4</sub>, pH 6.8, 10% acetonitrile as low salt buffer and 20 mM Tris, 400 mM NaClO<sub>4</sub>, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double strand occurred by heating the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

### Seeding of the Cells:

All cell culture work was conducted under sterile conditions in a corresponding work bench (HS18, Hera Safe, Kendro, Heraeus). Cultivation of NIH/3T3 cells and HELA-S3 occurred in an incubator (CO<sub>2</sub> incubator T20, Hera cell, Kendro, Heraeus) at 37°C, 5% CO<sub>2</sub> and saturated atmospheric humidity in DMEM (Dulbecco's Modified Eagle Medium, Biochrom), for the mouse fibroblasts, and Ham's F12 for the HELA cells with 10% FCS (fetal calf serum, Biochrom), 2 mM L-glutamine (Biochrom) and penicillin/streptomycin (100 IU/100 µg/mL, Biochrom). In order to keep the cells in the exponential growth phase, the cells underwent passage every 3 days. 24 hours before the forming transfection, the cells were trypsinized (10 × trypsin/EDTA, Biochrom, Germany) and seeded with a cell density of  $1.0 \times 10^4$  cells/recess into a 96-well plate (Multiwell dishes 96-well flat bottom, Labor Schubert & Weiss GmbH) in 150 µL growth medium.

### Performance of Transient Transfection:

Transfection was conducted with Lipofectamine Plus<sup>TM</sup> reagent (Life Technologies) according to the information of the manufacturer. 0.15 µg pcDNA-YFP plasmid was introduced per well. The total transfection volume was 60 µL. 3-fold samples were used in each case. Plasmid DNA was first complexed, together with dsRNA. For this purpose, the plasmid DNA and the dsRNA were diluted in a serum-free medium and 1 µL PLUS reagent was used per 0.1 µg plasmid DNA (in a volume of 10 µL) and, after mixing for 15 minutes at room temperature, they were incubated. During incubation, 0.5 µL Lipofectamine was diluted in a total of 10 µL serum-free medium per 0.1 µg plasmid DNA, thoroughly mixed, added to the plasmid/dsRNA/PLUS mixture and incubated for another 15 minutes. During incubation, a medium change was conducted. For this purpose, the cells were washed once with 200 µL serum-free medium and then with 40 µL serum-free medium and then incubated further in the incubator, up to addition of DNA/dsRNA/PLUS/Lipofectamine. After addition of 20 µL DNA/dsRNA/PLUS/Lipofectamine per well, the cells were incubated for 2.5 hours in the incubator. After incubation, the cells were then washed once with 200 µL growth medium and incubated for 24 hours until detection of the fluorescence in 200 µL growth medium in the incubator.

#### Detection of Fluorescence:

24 hours after the last medium change, the fluorescence of the cells was photographed on the fluorescence microscope (IX50-S8F2, fluorescence unit U-ULS100Hg, burner U-RFL-T200, Olympus) with a USH-I02D mercury lamp (USHIO Inc., Tokyo, Japan), equipped with a WIB fluorescence cube and a digital CCD camera (Orca IIIIm, Hamamatsu and C4742-95 camera controller). Evaluation of the fluorescence recording occurred with the analysis software 3.1 (Soft Imaging System GmbH, Germany). In order to relate the YFP fluorescence to cell density, a cell nucleus staining was carried out (Hoechst staining). For this purpose, the cells were first fixed for 5 in 100  $\mu$ L methycarnoy (75% methanol, 25% glacial acetic acid) and then again for 10 minutes in methycarnoy. After air drying, the fixed cells were incubated for 30 minutes in the dark with 100  $\mu$ L per well of Hoechst die (75 ng/mL). After washing twice with PBS (PBS Dulbecco w/o  $\text{Ca}^{2+}$ ,  $\text{M}^{2+}$ , Biochrom), the Hoechst-stained cells were photographed under the fluorescence microscope (Olympus, WU fluorescence cube for Hoechst).

Figures 3 to 9 show the results on inhibition of YFP expression by dsRNA in the cultivated cells:

The effects of YFP-specific dsRNAs and control dsRNAs on YFP expression in NIH/3T3 mouse fibroblasts after transient transfection are summarized in Figures 3, 4, 5 and 6. The experiments were run as described in the experimental protocol. The concentration of dsRNA refers to the concentration in the medium during the transfection reaction. The designations for the dsRNAs can be gathered from Table 2. The relative fluorescence per image section in area percent is shown. 3 different image sections were evaluated per well. The averages are obtained from the 3-fold batches.

The specific inhibition of YFP gene expression by dsRNAs in HELA-S3 cells is shown in Figures 7 and 9. The inhibiting effect of differently configured dsRNA constructs (Table 2) in different concentrations on expression of YFP in HELA cells is shown in Fig. 7. Fig. 8 shows representative fluorescence microscope recordings of NIH/3T3 mouse fibroblasts transiently transfected with YFP without dsRNA and with dsRNA specifically directed against YFP ( $\times 100$  magnification).

8A: YFP controls

8B: S1, 10 nM

8C: S4, 10 nM  
8D: S7, 10 nM  
8E: S7/S11, 1 nM  
8F: S7/S12, 1 nM

Fig. 9 shows representative fluorescence microscope recordings of HELA-3S cells transiently transfected with YFP without dsRNA and with dsRNAs specifically directed against YFP ( $\times 100$  magnification).

9A: K2-controls, 10 nM  
9B: S1, 10 nM  
9C: S4, 10 nM  
9D: S7, 10 nM  
9E: S7/11, 1 nM  
9F: S7/12, 1 nM  
9G: S1A/S4B, 10 nM  
9H: YFP controls

### Results:

Fig. 3 shows that YFP expression after transient cotransfection of mouse fibroblasts with the YFP plasmid and dsRNAs specifically directed against the YFP sequence is inhibited with particular efficiency when the 3' ends of the regions containing 22 and 19 base pairs of the dsRNAs have single-strand sections of two nucleotides (nt). Whereas the dsRNA S1 with smooth 3' ends at a concentration of 1 nM (referred to the concentration in the cell culture medium during performance and transfection) exhibits no inhibiting effect on YFP expression, the dsRNAs S7 (19 nucleotide pairs) and S4 (24 nucleotide pairs), each with 2 nt overhangs on both 3' ends, inhibit the YFP expression by 50 or by 70% in comparison with the corresponding control dsRNAs K3 and K2. At a concentration of 10 nM, the dsRNA denoted S1 with smooth ends inhibits YFP expression by about 65%, whereas inhibition of YFP expression by the dsRNA S4 is about 94% (Fig. 4). The inhibiting effects of the dsRNAs denoted S4 and S7 is concentration-dependent (Figures 3 and 4, see also Fig. 7).

Fig. 4 shows that, for efficient suppression of YFP gene expression, the single-strand structure is not necessary on both 3' ends (on the sense and anti-sense strand). To achieve the most effective possible inhibition of YFP expression, only the 2 nt overhang on the 3' end is necessary on the anti-sense strand. Inhibition of YFP expression at a concentration of 1 nM in the two dsRNAs S4 (with 2 nt overhangs on both 3' ends) and S1A/S4B (with the 2 nt overhang on the 3' end of the anti-sense strand) lies at about 70%. On the other hand, if the 2 nt overhang is situated on the 3' end of the sense strand (and the 3' end of the anti-sense strand carries no single-strand region), inhibition of YFP gene expression is only 50%. Similarly, inhibition at higher concentrations is much better, if at least the 3' end of the anti-sense strand carries a 2 nt overhang.

A more distinct inhibition of YFP expression is achieved, if the base-paired region has 21 nucleotide pairs instead of 22 (S1 and S4), 20 (S13 and S13/14) or 19 (S7) (Figures 5, 6 and 7). Inhibition of YFP expression by S1 (22 base pairs with smooth ends) in a concentration of 5 nM is about 40%, whereas inhibition by S7/S12 (21 base pairs with smooth ends), also with 5 nM, lies at about 92%. If the dsRNA with 21 base pairs also has a 2 nt overhang on the anti-sense strand 3' end (S7/S11), inhibition lies at ~ 97% (compared with ~ 73% inhibition with S4 and ~ 70% inhibition with S7).

### III. Investigation of Serum Stability of Double-Strand RNA (dsRNA):

The objective is to increase the effectiveness found the cell cultures of inhibition of gene expression of target genes mediated by dsRNA for use in vivo. This is achieved by improved stability of the dsRNAs in serum and by an extended residence time of the molecule in the circulation and the increased effective concentration of the functional molecules related to this, resulting from improved stability.

### Practical Example:

The serum stability of dsRNAs that inhibit GFP expression was tested in vivo in murine and human serum.

### Experimental Protocol:

Incubation with human or murine serum with the corresponding dsRNA occurred at 37°C. 85 µL serum was incubated with 15 µL 100 µM dsRNA. After specified incubation times (30 minutes, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h), the samples were frozen at -80°C. dsRNA without serum (+ 85 µL ddH<sub>2</sub>O) and dsRNA at time 0 were used as control.

For isolation of the dsRNA from the incubation charge, which occurred on ice, 400 µL with 0.1% SDS was added to the charges and these are subjected to phenol extraction: 500 µL phenol:chloroform:isoamyl alcohol (IAA, 25:24:1, Roti<sup>®</sup>-Phenol, Roth, Karlsruhe) was added per charge and vortexed for 30 seconds at the highest stage (Vortex Genie-2; Scientific Industries). After 10 minutes of incubation on ice, phase separation occurred by centrifuging at 12,000 × g, 4°C for 10 minutes (Sigma 3K30, Rotor 12131-H). The upper aqueous phase (about 200 µL) was taken off and subjected first to DNase I and the proteinase K digestion: addition of 20 µL 10-fold DNase I buffer (100 mM Tris, pH 7.5, 25 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>) and 10 U DNase I (D7291, Sigma-Aldrich), 30 minutes incubation at 37°C, addition of 6 U DNase I again and incubation for another 20 minutes at 37°C, addition of 5 µL proteinase K (20 mg/mL, 04-1075, Peqlab, Germany) and 30 minutes incubation at 37°C. Phenol extraction was then conducted. For this purpose, 500 µL phenol:chloroform:IAA (25:24:1) was added, vortexed at the highest stage for 30 seconds, 10 minutes for 12000 × g, 4°C, centrifuged, the supernatant taken off and mixed in succession with 40 µL 3M Na-Ac (sodium acetate), pH 5.2, and 1 mL 100% EtOH, mixed thoroughly in the meantime and precipitated for at least 1 hour at -80°C. The precipitate was pelletized by centrifuging at 12000 × g for 30 minutes and 4°C, washed with 70% EtOH and recentrifuged (10 minutes, 12000 × g, 4°C). The air dried pellet was taken up in 30 µL RNA gel application buffer (7 M urea, 1 × TBE (0.09 M tris-borate, 0.002 M EDTA

(ethylenediaminetetraacetate), 0.02% (w/v) bromophenol blue, 0.02% (w/v) xlenecyanol) and stored at -20°C until gel application.

For characterization of the dsRNA, an analytical, denaturing polyacrylamide gel electrophoresis (analytical PAGE) was conducted. The urea gels were prepared right before the run: 7 M urea (21 g) was dissolved during agitation in 25 mL 40% aqueous acrylamide/bisacrylamide stock solution (Rotiphoresis gel, A515.1, Roth) and 5  $\mu$ L 10  $\times$  TBE (100 g Tris, 55 g boric acid, 9.3 g EDTA per L distilled water) and made up to 50  $\mu$ L with distilled water. Right before pouring, 50  $\mu$ L TEMED (N,N,N',N'-tetramethylethylenediamine) and 500  $\mu$ L 10% APS (ammonium peroxidisulfate) were added. After polymerization, the gel was introduced to a vertical electrophoresis apparatus (Merck, Darmstadt) and a prerun was conducted for 30 minutes at a constant 40 mA current intensity. As run buffer, 1  $\times$  TBE buffer was used. Before application onto the gel, the RNA samples were heated for 5 minutes at 100°C, cooled on ice and centrifuged for 20 seconds in a table-top centrifuge (Eppendorf, minispin). 15  $\mu$ L was applied to the gel. The run occurred for about 2 hours at a constant current of 40 mA. After the run, the gel was stained for 30 minutes at RT (room temperature) with Stains all stain solution (20 mL Stains all stock solution dissolved in 200 mL formamide) mixed with 200 mL distilled water and 180 mL formamide) and the background staining eliminated after rinsing in distilled water for 45 minutes. The gels were photographed with the photo documentation system Image Master VDS from Pharmacia.

Figures 10 to 17 show the serum stability of dsRNA after incubation with human and murine serum and subsequent electrophoretic separation in 20% 7 M urea gel.

Fig. 10: Incubation of S2 (0-22-0) in mouse serum

1. at time 0 (without serum)
2. at time 0
3. for 30 minutes
4. for 1 hour
5. for 2 hours
6. for 4 hours

7. for 12 hours
8. 2  $\mu\text{L}$  100  $\mu\text{M}$  S1 without incubation
- S1A) Sense strand S1 (10  $\mu\text{L}$  20  $\mu\text{M}$  S1A)
- S1B) Anti-sense strand S1 (10  $\mu\text{L}$  20  $\mu\text{M}$  S1B)

Fig. 11: Incubation of S1 (0-22-0) in human serum

1. 2  $\mu\text{L}$  100  $\mu\text{M}$  S1 untreated (without incubation)
2. for 30 minutes
3. for 2 hours
4. for 4 hours
5. for 6 hours
6. for 8 hours
7. for 12 hours
8. for 24 hours
- S1A) Sense strand S1 (10  $\mu\text{L}$  20  $\mu\text{M}$  S1A)
- S1B) Anti-sense strand S1 (10  $\mu\text{L}$  20  $\mu\text{M}$  S1B)

Fig. 12: Incubation at S7 (2-19-20) in mouse serum

1. at time 0 (without serum)
2. for 30 minutes
3. for 4 hours
4. for 12 hours

Fig. 13: Incubation of S7 (2-19-2) in human serum

1. Sense strand S7 (10  $\mu\text{L}$  20  $\mu\text{M}$  S7A)
2. Anti-sense strand S7 (10  $\mu\text{L}$  20  $\mu\text{M}$  S7B)
3. for 30 minutes
4. for 1 hour
5. for 2 hours
6. for 4 hours
7. for 6 hours



8. for 12 hours
9. for 24 hours
10. at time 0 (without serum)

Fig. 14: Incubation of K3 (2-19-20) in mouse serum

1. Sense strand K3 (10  $\mu$ L 20  $\mu$ M K3A)
2. Anti-sense strand K3 (10 L 20  $\mu$ M K3B)
3. at time 0 (without serum)
4. at time 0 (with serum)
5. for 30 minutes
6. for 1 hour
7. for 2 hours
8. for 4 hours
9. for 12 hours

Fig. 15: Incubation of PKC1/2 (0-22-2) in mouse serum

1. for 30 minutes
2. for 1 hour
3. for 2 hours
4. for 4 hours
5. for 12 hours
6. 2  $\mu$ L 100  $\mu$ M PKC1/2 (untreated)

Fig. 16: Incubation of S1A/S4B (0-22-2) in human serum

1. at time 0 (without serum)
2. for 24 hours
3. for 12 hours
4. for 8 hours
5. for 6 hours
6. for 4 hours
7. for 2 hours

8. for 30 minutes
9. Sense strand S1A (10  $\mu$ L 20  $\mu$ M S1A)
10. Anti-sense strand S4B (10  $\mu$ L 20  $\mu$ M S4B)

Fig. 17: Incubation of K2 (2-22-2) in human serum

1. Sense strand K2 (10  $\mu$ L 20  $\mu$ M K2A)
2. Anti-sense strand K2 (10  $\mu$ L 20  $\mu$ M K2B)
3. at point 0 (without serum)
4. for 30 minutes
5. for 2 hours
6. for 4 hours
7. for 6 hours
8. for 8 hours
9. for 12 hours
10. for 24 hours

### Results:

dsRNAs without single-strand regions on the 3' ends are much more stable in both human and murine serum than dsRNAs with single-strand 2nt overhangs on the 3' ends (Figures 10 to 14 and 17). After 12 and 24 hours incubation at S1 in murine or human serum, bands in the original size are almost fully retained. On the other hand, in dsRNAs with 2nt overhangs on both 3' ends, the stability in human and murine serum diminishes significantly. After only 4 hours of incubation of S7 (Figures 12 and 13) or K3 (Fig. 14), no bands can be detected in the original size.

In order to increase the stability of dsRNA in serum, it is sufficient if the dsRNA has a smooth end. In mouse serum after 4 hours incubation (Fig. 15, track 4), the bands in the original size are scarcely broken down in comparison with S7 (after 4 hours complete degradation; Fig. 12, track 3).

As an optimal compromise with respect to biological efficacy of dsRNA, the use of dsRNA with a smooth end and a single-strand region of 2 nucleotides can be considered, in which the single-strand overhang should be situated on the 3' end of the anti-sense strand.

The sequences used here are apparent from the following Table 2 and the sequence protocols SQ148-151 and 153-167.

Name	Sequenz- proto- koll-Nr.	dsRNA-Sequenz	
S1	SQ148 SQ149	(A) 5' - CCACAUGAAGCAGCAGACUUC -3' (B) 3' - GGUGUACUUCGUCGUGCUGAAG -5'	0-22-0
S7	SQ150 SQ151	(A) 5' - CCACAUGAAGCAGCAGACUU -3' (B) 3' - CUGGUGUACUUCGUCGUGCUG -5'	2-19-2
K1	SQ153 SQ154	(A) 5' - ACAGGAUGAGGAUCGUUUCGCA -3' (B) 3' - UGUCCUACUCCUAGCAAAGCGU -5'	0-22-0
K3	SQ155 SQ156	(A) 5' - GAUGAGGAUCGUUUCGCAUGA -3' (B) 3' - UCCUACUCCUAGCAAAGCGUA -5'	2-19-2
K2	SQ157 SQ158	(A) 5' - ACAGGAUGAGGAUCGUUUCGCAUG -3' (B) 3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	2-22-2
S1A/ S4B	SQ148 SQ159	(A) 5' - CCACAUGAAGCAGCAGACUUC -3' (B) 3' - CUGGUGUACUUCGUCGUGCUGAAG -5'	0-22-2

PKC 1/2	SQ160	(A)	5' - CUUCUCCGCCUCACACCGCUGCAA -3'	2-22-0
	SQ161	(B)	3' - GAAGAGGCGGAGUGUGGCGACG -5'	
S7/S12	SQ150	(A)	5' - CCACAUGAAGCAGCACGACUU -3'	0-21-0
	SQ162	(B)	3' - GGUGUACUUCGUCGUGCUGAA -5'	
S7/S11	SQ150	(A)	5' - CCACAUGAAGCAGCACGACUU -3'	0-21-2
	SQ163	(B)	3' - CUGGUGUACUUCGUCGUGCUGAA -5'	
S13	SQ164	(A)	5' - CCACAUGAAGCAGCACGACU -3'	0-20-2
	SQ165	(B)	3' - CUGGUGUACUUCGUCGUGCUGA -5'	
S13/14	SQ164	(A)	5' - CCACAUGAAGCAGCACGACU -3'	0-20-0
	SQ166	(B)	3' - GGUGUACUUCGUCGUGCUGA -5'	
S4	SQ167	(A)	5' - CCACAUGAAGCAGCACGACUUCUU -3'	2-22-2
	SQ159	(B)	3' - CUGGUGUACUUCGUCGUGCUGAAG -5'	
K1A/ K2B	SQ153	(A)	5' - ACAGGAUGAGGAUCGUUUCGCA -3'	0-22-2
	SQ158	(B)	3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	
K1B/ K2A	SQ154	(A)	5' - ACAGGAUGAGGAUCGUUUCGCAUG -3'	2-22-0
	SQ157	(B)	3' - UGUCCUACUCCUAGCAAAGCGU -5'	
S1B/ S4A	SQ149	(A)	5' - CCACAUGAAGCAGCACGACUUCUU -3'	2-22-0
	SQ167	(B)	3' - GGUGUACUUCGUCGUGCUGAAG -5'	

Key to figure: (Headings)

Name

Sequence protocol no.

dsRNA sequence

**Table 2**

#### IV. In Vivo Study:

Double-strand RNA (dsRNA) that was derived from the GFP sequence where unspecific dsRNA was injected intravenously into the caudal vein of “GFP laboratory mice” that express the green fluorescent protein (GFP) in all cells that conduct protein biosynthesis. At the end of the experiment, the animals were killed and the GFP expression analyzed in tissue sections and in plasma.

#### Experimental Protocol:

##### Synthesis of dsRNA:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany), and ordinary chemical methods, the RNA single strands apparent from the sequence protocols and the single strand complementary to them were synthesized. Purification of the crude synthesis products then occurred with HPLC. As columns, NucleoPac PA-100, 9 × 250 mm from the Dionex company were used; 20 mM Tris, 10 mM NaClO<sub>4</sub>, pH 6.8, 10% acetonitrile was used as low salt buffer and 20 mM Tris, 400 mM NaClO<sub>4</sub>, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double strand occurred by heating of the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

##### Experimental Animal Keeping and Performance of the Experiment

The transgenic laboratory mouse strain TgN (GFPU) 5Nagy (Jackson Laboratory, Bar Harbor, Maine, USA) was used, which expresses GFP (with a beta-actin promoter and a CMV intermediate early enhancer) in all previously investigated cells (Hadjantonakis AK et al. 1993, Mech. Dev. 76: 79-90; Hadjantonakis AK et al., 1998 Nature Genetics 19: 220-222). GFP-transgenic mice can be clearly distinguished from the corresponding wild types (WT) by means of fluorescence (with a UV hand lamp). For breeding, the corresponding WT was paired with a heterozygous GFP type.

The experiment was performed according to the German Animal Protection Regulations. The animals were kept under controlled environmental conditions in groups of 3-5 animals in type III Makrolon cages from the Ehret company, Emmendingen, at a constant temperature of 22°C and a light-dark rhythm of 12 h. Softwood granulate 8/15 from the Altromin company, Lage, was used as sawdust litter. The animals received tap water and standard feed Altromin 1324 pelletized (Altromin) ad libitum.

To perform the experiment, the heterozygous GFP animals were kept in groups of 3 animals each in cages, as described above. Injections of the dsRNA solution occurred intravenously (IV) into the caudal vein in 12-hour cycles (between 5:30 and 7:00 a.m. and between 5:30 and 7:00 p.m.) over 5 days. The injection volumes were 60 µL for per 10 g of body weight and the dose was 2.5 mg dsRNA and 50 µg per kg of body weight. Division into groups was as follows:

- Group A: PBS (phosphate buffered saline) 60 µL per 10 kg of body weight,
- Group B: 2.5 mg per kg of body weight of a nonspecific control dsRNA (K1 control with smooth ends and a double-strand region of 22 nucleotide pairs),
- Group C: 2.5 mg per kg of body weight of another unspecific control dsRNA (K3 control with 2nt overhangs on both 3' ends and a double-strand region of 19 nucleotide pairs),
- Group D: 2.5 mg per kg of body weight dsRNA (specific against GFP, subsequently referred to as S1, with smooth ends and a double-strand region of 22 nucleotide pairs),
- Group E: 2.5 mg dsRNA per kg of body weight (specific against GFP, subsequently referred to as S7, with 2nt overhangs on the 3' ends of both strands and a double-strand region of 19 nucleotide pairs)
- Group F: 50 µg S1-dsRNA per kg of body weight (i.e., 1/50 of the dose of group D).

After the last injection of a total of 10 injections, the animals were killed after 14-20 h and the organs and blood taken as described.

#### Organ Removal:

Immediately after killing the animals by CO<sub>2</sub> inhalation, blood and different organs were taken (thymus, lungs, heart, spleen, stomach, intestines, pancreas, brain, kidneys and liver). The organs were rinsed briefly in cold sterile PBS and divided with a sterile scalpel. One part was fixed for immunohistochemical staining in methylcarnoys (MC, 60% methanol, 30% chloroform, 10% glacial acetic acid) for 24 hours, one part was shock frozen for frozen sections and for protein isolation immediately in liquid nitrogen and stored at -80°C, and another smaller part was frozen for RNA isolation in RNeasy-Protect (Qiagen) at -80°C. The blood was immediately held for 30 minutes on ice after sampling, mixed, centrifuged for 5 minutes at 2000 rpm (Mini spin, Eppendorf), the supernatant removed and stored at -80°C (here referred to as plasma).

#### Processing of the Biopsies:

After 24 h of fixation of the tissue in MC, the tissue pieces were dehydrated in an increasing alcohol series at RT (room temperature): every 40 minutes 70% methanol, 80% methanol, 2 × 96% methanol and 3 × 100% isopropanol. The tissue was then heated in 100% isopropanol to 60°C in an incubator, then incubated for 1 hour in an isopropanol/paraffin mixture at 60°C and 3 × for 2 hours in paraffin and then imbedded in paraffin. For immunoperoxidase staining, tissue sections with 3 µm section thickness were prepared with a rotary microtome (Leica), mounted on slides (Superfrost, Vogel) and incubated for 30 minutes at 60°C in an incubator.

#### Immunoperoxidase Staining versus GFP:

The sections were deparaffinized 3 × 5 minutes in xylene, rehydrated in an increasing alcohol series (3 × 3 min 100% ethanol, 2 × 2 min 95% ethanol) and then incubated for 20 minutes in 3% H<sub>2</sub>O<sub>2</sub>/methanol to block endogenous peroxidases. All incubation steps were conducted subsequently in a moist chamber. After 3 × 3 minutes of washing with PBS, they were incubated

with the first antibody (goat anti-GFP, sc-5384, Santa Cruz, Biotechnology) 1:500 in 1% BSA/PBS overnight at 4°C. Incubation with the biotinylated secondary antibody (donkey anti-goat; Santa Cruz Biotechnology; 1:2000 dilution) occurred for 30 minutes at RT, whereupon they were incubated for 30 minutes with Avidin D Peroxidase (1:2000 dilution, Vector Laboratories). After each antibody incubation, the sections were washed 3 × 3 min in PBS and the buffer residues removed from the sections with wadding. All antibodies were diluted in 1% bovine serum albumin (BSA)/PBS. Staining with 3,3'-diaminobenzidine (DAB) was conducted with the DAB substrate kit (Vector Laboratories) according to the manufacturer's data. As nuclear counterstain, hematoxylin III according to Gill (Merck) was used. After dehydration in a rising alcohol series at 3 × 5 minutes xylene, the sections were covered with Entellan (Merck). Microscopic evaluation of staining occurred with the IX50 microscope from Olympus, equipped with a CCD camera (Hamamatsu).

#### Protein Isolation from Tissue Pieces:

800 µL isolation buffer (50 mM HEPES, pH 7.5, 150 mM NaCl; 1 mM EDTA; 2.5 mM EGTA; 10% glycerol; 0.1% Tween; 1 mM DTT, 10 mM β-glycerol phosphate; 1 mM NaF; 0.1 mM Na<sub>3</sub>VO<sub>4</sub> with a protease inhibitor tablet "Complete" from Roche) were added to the still frozen tissue pieces and homogenized 2 × 30 seconds with an Ultraturrax (DIAX 900, dispersal die 6 G, Heidolph), and cooled in between on ice. After 30 minutes of incubation on ice, they were mixed and centrifuged for 20 minutes at 1000 × g, 4°C (3K30, Sigma). The supernatant was incubated for another 10 minutes on ice, mixed and centrifuged for 20 minutes to 15000 × g, 4°C. A protein determination according to Bradford, 1976, modified after Zor & Selinger, 1996, was conducted with the supernatant with the Roti-Nanoquant system of Roth according to the data of the manufacturer. BSA (bovine serum albumin) in concentrations from 10 to 100 µg/mL was used for the protein calibration line.

#### SDS Gel Electrophoresis:

Electrophoretic separation of the proteins occurred in a multigel long electrophoresis chamber from Biometra with a denaturing, discontinuous 15% SDS-PAGE (polyacrylamide gel electrophoresis) according to Lämmli (Nature 277: 680-685, 1970). For this purpose, a



separation gel 1.5 mM thick was initially poured: 7.5 mL acrylamide/bisacrylamide (30%, 0.9%), 3.8 mL 1.5 M Tris/HCl, pH 8.4, 150  $\mu$ L 10% SDS, 3.3 mL doubly distilled water, 250  $\mu$ L ammonium persulfate (10%), 9  $\mu$ L TEMED (N,N,N',N'-tetramethylethylenediamine) and coated up to polymerization with 0.1% SDS. The collected gel was then poured: 0.83  $\mu$ L acrylamide/bisacrylamide (30%/0.9%), 630  $\mu$ L 1 M Tris/HCl, pH 6.8, 3.4 mL doubly distilled water, 50  $\mu$ L 10% SDS, 50  $\mu$ L 10% ammonium persulfate, 5  $\mu$ L TEMED.

Before application of the gel, the proteins were mixed with a corresponding amount of 4-fold sample buffer (200 mM Tris, pH 6.8, 4% SDS, 100 mM DTT (dithiothreitol), 0.02% bromophenol blue, 20% glycerol), denatured for 5 minutes in a heating unit at 100°C, briefly centrifuged after cooling on ice and applied to the gel. The same plasma or protein amounts were used per track (3  $\mu$ L plasma and 25  $\mu$ g total protein each). Electrophoresis occurred water-cooled at RT and a constant 50 V. The protein gel marker from Bio-Rad (kaleidoscope prestained standard) was used as length standard.

#### Western Blot and Immune Detection:

Transfer of the proteins from SDS-PAGE to a PVDF (polyvinylidene difluoride) membrane (Hybond-P, Amersham) occurred in the semi-dry method according to Kyhse-Anderson (J. Biochem. Biophys. Methods 10: 203-210, 1984) at RT and a constant current intensity of 0.8 mA/cm<sup>2</sup> for 1.5 h. A Tris/glycine buffer was used as transfer buffer (39 mM glycine, 465 mM Tris, 0.1% SDS and 20% methanol). To check the electrophoretic transfer, both the gels after blotting and the blot membranes after immune detection were stained with Coomassie (0.1% Coomassie G250, 45% methanol, 10% glacial acetic acid). For saturation of nonspecific bonds, the blot membrane after transfer was incubated in 1% skim milk powder/PBS for 1 h at RT. It was then washed three times for 3 minutes with 0.1% Tween-20/PBS. All subsequent antibody incubations and washing steps occurred in 0.1% Tween-20/PBS. Incubation with the primary antibody (goat anti-GFP, sc 5384, Santa Cruz Biotechnology) occurred in a dilution of 1:1000 for 1 h at RT. It was then washed 3  $\times$  5 min and incubated for 1 hour at RT with a secondary antibody (donkey anti-goat IgG horseradish peroxidase labeled, Santa Cruz Biotechnology) in a dilution of 1:1000. Detection occurred with the ECL system from Amersham according to the data of the manufacturer.

Figures 18 to 20 show inhibition of GFP expression after intravenous injection of dsRNA specifically directed against GFP with immunoperoxidase staining relative to GFP on 3  $\mu$ m paraffin sections. During the experiment, dsRNA directed against GFP with a double-strand region of 22 nucleotide (nt) pairs without overhangs on the 3' ends (D) and the corresponding unspecific control dsRNA (B), as well as dsRNA directed specifically against GFP with a double-strand region containing 19 nucleotide pairs with 2 nt overhangs on the 3' ends (E) and the corresponding nonspecific control dsRNA (C) were applied in 12-hour cycles over 5 days. (F) received 1/50 of the dose of group D. Animals without dsRNA administration (A) and WT animals were investigated as additional controls. Fig. 18 shows inhibition of GFP expression in kidney sections, Fig. 19 in heart tissue and Fig. 20 in pancreas tissue. Figures 21 to 23 show Western blot analyses of GFP expression in plasma and tissues. Inhibition of GFP expression in plasma is shown in Fig. 21, in the kidneys in Fig. 22 and in the heart in Fig. 23. Total protein isolates from different animals are shown in Fig. 23. The same total protein amounts per track were applied. In the animals, to which unspecific control dsRNA was administered (animals of groups B and C), the GFP expression relative to animals that received no dsRNA is not reduced. Animals that received dsRNA specifically directed against GFP with 2 nt overhangs on the 3' ends of both strands and a double-strand region containing 19 nucleotide pairs exhibited a significantly inhibited GFP expression in the investigated tissues (heart, kidneys, pancreas and blood), compared with the untreated animals (Figures 18 to 23). In the animals of groups D and F, in which dsRNA directed specifically against GFP with smooth ends and double-strand region containing 22 nucleotide pairs was administered, only those animals that received dsRNA in a dose of 50  $\mu$ g/kg of body weight per day exhibited a specific inhibition of GFP expression, which, however, was much less pronounced than that of the animals in group E. The summarizing evaluation of GFP inhibition in the tissue sections and in Western blot shows that inhibition of GFP expression in blood and the kidneys is strongest (Figures 18, 21 and 22).

#### V. Inhibition of Gene Expression of EGF Receptor with dsRNA as a Therapeutic Approach in Forms of Cancer with EGFR Overexpression or EGFR-induced Proliferation:

The epidermal growth factor (EGF) receptor (EGFR) belongs to the receptor tyrosine kinases, transmembrane proteins with an intrinsic tyrosine kinase activity, which participate in the control

of a series of cellular processes, like cell growth, cell differentiation, migratory processes or cell vitality (review in: Van der Geer et al. 1994). The EGFR family consists of 4 members, EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) with a transmembrane domain, a cysteine-rich extracellular domain and an intracellular catalytic domain. The sequence of EGFR, a 170 kDa protein, has been known since 1984 (Ullrich et al., 1984).

EGFR is activated by peptide growth factors, like EGF, TGF $\alpha$  (transforming growth factor), amphiregulin, beta-cellulin, HB-EGF (heparin-binding EGF-like growth factor) and neureguline. Ligand bonding induces formation of homo- or heterodimers with subsequent autophosphorylation of cytoplasmic tyrosine (Ullrich & Schlessinger, 1990; Alroy & Yarden, 1997). The phosphorylated amino acids form the bonding sites for a number of proteins that participate in the proximal steps of signal conduction in a complex network. EGFR participates in a wide variety of tumor diseases and is therefore a suitable target for therapeutic approaches (Huang & Harari, 1999). The mechanisms that lead to an aberrant EGFR activation can be due to overexpression, amplification, constituted activation of mutant receptor forms or autocrine loops (Voldborg et al., 1997). An overexpression of EGFR was described for a number of tumors, like breast cancer (Walker & Dearing, 1999), non-small lung carcinoma (Fontanini et al., 1998), pancreatic carcinomas, colon carcinoma (Salomon et al., 1995) and glioblastomas (Rieske et al., 1998). No efficient and specific therapeutic agents have thus far been available for malignant glioblastomas, in particular.

#### Practical Example:

To demonstrate the efficacy of dsRNA during specific inhibition of EGFR gene expression, U-87 MG cells (human glioblastoma cells), ECCAC (European Collection of Animal Cell Cultures) no. 89081402 were used, which were transfected with dsRNA directed specifically against the EGF receptor (sequence protocol SQ 51). After about 72 hours' incubation, the cells were harvested, the protein isolated and the EGFR expression investigated in the Western blot method.

## Experimental Protocol:

### dsRNA Synthesis:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany) and an ordinary chemical method, the RNA single strands apparent from the sequence protocols and the single strands complementary to them were synthesized. Purification of the crude synthesis products then occurred with HPLC. The column NucleoPac PA-100, 9 × 250 mm, from the Dionex company was used; 20 mM Tris, 10 mM NaClO<sub>4</sub>, pH 6.8, 10% acetonitrile was used as low salt buffer and 20 mM Tris, 400 mM NaClO<sub>4</sub>, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double-strand occurred by heating of the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

### Seeding of the Cells:

All cell culture work was conducted under sterile conditions and an appropriate work bench (HS18, Her safe, Kendro, Heraeus). Cultivation of U-87 MG cells occurred in an incubator (CO<sub>2</sub> incubator T20, Hera cell, Kendro, Heraeus) at 37°C, 5% CO<sub>2</sub> and saturated atmospheric humidity in DMEM (Dulbecco's modified eagle medium, Biochrom) with 10% FCS (fetal calf serum, Biochrom), 2 mM L-glutamine (Biochrom), 1 mM sodium pyruvate (Biochrom), 1 × NEAA (nonessential amino acids, Biochrom) and penicillin/streptomycin (100 IU/100 µg/mL, Biochrom). In order to keep the cells in the exponential growth phase, the cells were subjected to passage every 3 days. 24 hours before application of dsRNA by transfection, the cells were trypsinized (10 × trypsin/EDTA, Biochrom, Germany) and seeded with a cell density of 5 × 10<sup>5</sup> cells/well in a 6-well plate (6-well plates, Labor Schubert & Weiss GmbH) in 1.5 mL growth medium.

### Application of dsRNA in Cultivated U-87 MG Cells:

Application of dsRNA occurred by transfection with OLIGOFECTAMINE<sup>TM</sup> reagent (Life Technologies) according to the information of the manufacturer. The total transfection volume was 1 mL. The dsRNA was first diluted in serum-free medium: for this purpose, 0.5 µL of a 20

$\mu$ m stock solution of dsRNA specifically directed against EGFR and 9.5  $\mu$ L of a 20  $\mu$ m stock solution of unspecific dsRNA (K1A/K2B) with 175  $\mu$ L serum-free medium were diluted per well (200 nM dsRNA in transfection charge and 10 nM specific EGFR-dsRNA). The OLIGOFECTAMINE™ reagent was also diluted in serum-free mediums: 3  $\mu$ L with 12  $\mu$ L medium per well and then incubated for 10 minutes at room temperature. The diluted OLIGOFECTAMINE™ reagent was then added to the dsRNAs diluted in medium, mixed and incubated for another 20 minutes at RT. During incubation, a medium change was performed. The cells were washed for this purpose once with 1 mL serum-free medium and incubated further in the incubator with 800  $\mu$ L serum-free medium, up to addition of dsRNA/OLIGOFECTAMINE™ reagent. After addition of 200  $\mu$ L dsRNA/OLIGOFECTAMINE™ reagent per well, the cells were further incubated in the incubator to protein isolation.

#### Protein Isolation:

About 72 hours after transfection, the cells were harvested and protein isolation carried out. For this purpose, the medium was removed and the cell monolayer washed once with PBS. After addition of 200  $\mu$ L protein isolation buffer (1  $\times$  protease inhibitor “Complete”, Roche, 50 mM HEPES, pH 7.5, 1509 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 10% glycerol, 0.1% Tween-20, 1 mM DTT, 10 mM  $\beta$ -glycerol phosphate, 1 mM NaF, 0.1 mM  $\text{Na}_3\text{VO}_4$ ), the cells were separated by means of a cell scraper, incubated for 10 minutes on ice, transferred to an Eppendorf reaction vessel and stored at  $-80^\circ\text{C}$  for at least 30 minutes. After thawing, the lysate was homogenized on stage 3 for 10 seconds with a disperser (DIAX 900, dispersing die 6G, Heidolph Instruments GmbH & Co KG, Schwabach), incubated on ice for 10 minutes and centrifuged for 15 minutes at  $14000 \times g$ ,  $4^\circ\text{C}$  (3K30, Sigma). A protein determination was conducted with the supernatant according to Bradford with the Roti® Nanoquant system from Roth (Roth GmbH & Co., Karlsruhe) according to the information of the manufacturer. For this purpose, 200  $\mu$ L protein solution in appropriate dilution was mixed with 800  $\mu$ L 1  $\times$  working solution and the extinction measured in semi-microcells at 450 and 590 nm versus distilled water in a Beckman spectrophotometer (DU 250). The corresponding BSA dilutions were used for the calibration line (beaded BSA, Sigma).

### SDS Gel Electrophoresis:

Electrophoretic separation of the proteins occurred in a multi-gel long electrophoresis chamber from Biometra with a denaturing, discontinuous 7.5% SDS-PAGE (polyacrylamide gel electrophoresis) according to Lämmli (Nature 277: 680-685, 1977). For this purpose, a separation gel was initially poured with 1.5 mm thickness: 3.7 mL acrylamide/bisacrylamide (30%, 0.9%), 3.8 mL 1 M Tris/HCl, pH 8.4, 150  $\mu$ L 10% SDS, 7.15 mL doubly distilled water, 150  $\mu$ L ammonium persulfate (10%), 9  $\mu$ L TEMED (N,N,N',N'-tetramethylethylenediamine) and coated with 0.1% SDS to polymerization. The collection gel was then poured: 0.83 mL acrylamide/bisacrylamide (30%/0.9%), 630  $\mu$ L 1 M Tris/HCl, pH 6.8, 3.4 mL doubly distilled water, 50  $\mu$ L 10% SDS, 50  $\mu$ L 10% ammonium persulfate, 5  $\mu$ L TEMED.

For application to the gel, the protein samples were mixed 1:3 with 4  $\times$  sample buffer (200 mM Tris, pH 6.8, 4% SDS, 100 mM DTT (dithiothreitol), 0.02% bromophenol blue, 20% glycerol), denatured for 5 minutes at 100°C, briefly centrifuged after cooling on ice and applied to the gel. 35  $\mu$ g total protein was applied per track. The run occurred water cooled at RT and a constant 50 V. The kaleidoscope protein gel marker (BioRad) was used as length standard.

### Western Blot and Immunodetection:

Transfer of the proteins from SDS-PAGE to a PVDF (polyvinylidene difluoride) membrane (Hybond-P, Amersham) occurred in the semi-dry method according to Kyhse-Anderson (J. Biochem. Biophys. Methods 10: 203-210, 1984) at RT and a constant current intensity of 0.5 mA/cm<sup>2</sup> for 1.5 h. The following were used as transfer buffer: cathode buffer (30 mM Tris, 40 mM glycine, 10% methanol, 0.01% SDS; pH 9.4), anode buffer I (300 mM Tris, pH 10.4, 10% methanol) and anode buffer II (30 mM Tris, pH 10.4, 10% methanol). Before combining the blot stack with 3 mm Whatman paper (Schleicher & Schüll), the gel was incubated in the cathode buffer and the PVDF membrane (30 seconds beforehand in 100% methanol) in anode buffer II (5 min): 2 layers 3 mm paper (anode buffer I), 1 layer 3 mm paper (anode buffer II), PVDF membrane, gel, 3 layers 3 mm paper (cathode buffer). To check electrophoretic transfer, both the gels after blotting and the blot membranes after immunodetection were stained with Coomassie (0.1% Coomassie G250, 45% methanol, 10% glacial acetic acid).

The blot membrane was incubated after transfer in 1% skim milk powder/ PBS/0.1% Tween-20 for 1 h at RT. It was then washed three times for 3 minutes with 0.1% Tween-20/PBS. All subsequent antibody incubations and washing steps occurred in 0.1% Tween-20/PBS. Incubation with the primary antibody (human EGFR extracellular domain, specific goat IgG, catalog no. AF231, R&D Systems) occurred on a rocking device for 2 h at RT and a concentration of 1.5 µg/mL. It was then washed 3 × for 6 minutes and incubated for 1 hour at RT with the secondary antibody (donkey anti-goat IgG horseradish peroxidase label, Santa Cruz Biotechnology) (diluted 1:10000). After washing (3 × 3 min in PBS/0.1% Tween-20), detection occurred immediately with ECL reaction (enhanced chemiluminescence): 200 µL solution A (250 mM luminol, Roth, dissolved in DMSO), 89 µL solution B (90 mM p-coumaric acid, Sigma, dissolved in DMSO) and 2 mL 30% H<sub>2</sub>O<sub>2</sub> solution were pipetted into 18 mL distilled water. Depending on the membrane size, 4-6 mL was pipetted directly onto the membrane, incubated for 1 minute at RT and then an x-ray film (Biomax MS, Kodak) applied immediately.

The sequences used here are shown in the following Table 3 and in the sequence protocols S!153, 157, 158, 168-173.

<b>ES-7</b>	SQ168	(A) 5' - AACACCGCAGCAUGUCAAGAU -3'	2-19-2
	SQ169	(B) 3' - UUUUGUGGCGUCGUACAGUUC -5'	
<b>ES-8</b>	SQ170	(A) 5' - AAGUUAAAUCCCCGUCGCUAU -3'	2 <sup>5</sup> -19-2 <sup>5</sup>
	SQ171	(B) 3' - CAAUUJUAAGGGCAGCGAUAGU -5'	
<b>ES2A/ ES5B</b>	SQ172	(A) 5' - AGJGUGAUCCAAGCUGUCCCAA -3'	0-22-2
	SQ173	(B) 3' - UUUCACACUAGGUUCGACAGGGUU -5'	
<b>K2</b>	SQ157	(A) 5' - ACAGGAUGAGGAUCGUUUCGCAUG -3'	2-22-2
	SQ158	(B) 3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	

<b>K1A/ K2B</b>	SQ153	(A)	5' - ACAGGAUGAGGAUCGUJUCGCA	-3'	0-22-2
	SQ158	(B)	3' - UCUGUCCUACUCCUAGCAAAGCGU	-5'	

**Table 3**

Inhibition of EGFR Expression in U-87 MG Glioblastoma Cells:

24 hours after seeding of the cells, they were transfected with 10 nM dsRNA as stated (oligofectamine). After 72 hours, the cells were harvested and the protein isolated. Separation of the proteins occurred in 7.5% SDS-PAGE. 35 µg total protein was applied per track. Fig. 4 shows the corresponding Western blot analysis, from which it follows that the EGFR expression after transfection in U-87 MG cells can be significantly inhibited relative to the corresponding controls with the dsRNA specifically directed against the EGFR gene with a 2 nt overhang on the 3' end of the anti-sense strand. This inhibition of expression of an endogenous gene by specific dsRNA therefore confirms the results stated in the practical example II concerning inhibition of expression of an artificial gene introduced to the cell after transient transfection. The inhibition of EGFR expression mediated by ES-7 and ES-8 is much lower. The dsRNAs used in Fig. 24 can be gathered from Table 3.

VI. Inhibition of Expression of the Multidrug Resistance Gene 1 (MDR1):

Experimental Protocol:

In vitro detection for blocking of MDR1 expression was conducted in the colon carcinoma cell line LS174T (ATCC – American Type Culture Collection, Tom et al., 1976). It is known of this cell line that expression of MDR1 can be induced by addition of rifampicin to the culture medium (Geick et al., 2001). Transfections were conducted with different commercial transfection kits (Lipofectamine, Oligofectamine, both Invitrogen; TransMessenger, Qiagen), in which the TransMessenger transfection kit also proved to be best suited for this cell line.



To run the RNA interference experiments, 4 short double-strand ribonucleic acids R1-R4 were used, whose sequences are shown in Table 4. The ribonucleic acids are homologous with sections of the coding sequence of MDR1 (sequence protocol SQ 30). Sequences R1-R3 consists of a 22-mer sense and a 24-mer anti-sense strand, in which the forming double-strand has a two nucleotide overhang on the 3' end of the anti-sense strand (0-22-2). The sequence R4 corresponds to R1, but consists of a 19-mer double strand with 2 nucleotide overhangs on each 3' end (2-19-2).

<u>Name</u>	<u>Sequenz- proto- koll-Nr.</u>	<u>Sequenz</u>	<u>Position in Daten- bank-# AF016535</u>
Seq R1	SQ141 SQ142	5' - CCA UCU CGA AAA GAA GUU AAG A-3' 3' -UG GGU AGA GCU UUU CUU CAA UUC U-5'	1320-1342 1335-1318
Seq R2	SQ143 SQ152	5' - UAU AGG UUC CAG GCU UGC UGU A-3' 3' -CG AUA UCC AAG GUC CGA ACG ACA U-5'	2599-2621 2621-2597
Seq R3	SQ144 SQ145	5' - CCA GAG AAG GCC GCA CCU GCA U-3' 3' -UC GGU CUC UUC CGG CGU GGA CGU A-5'	3778-3799 3799-3776
Seq R4	SQ146 SQ147	5' - CCA UCU CGA AAA GAA GUU AAG-3' 3' -UG GGU AGA GCU UUU CUU CAA U -5'	1320-1341 1339-1318
			<u>Position in Daten- bank-# AF402779</u>
K1A/ K2B	SQ153 SQ158	5' - ACA GGA UGA GGA UCG UUU CGC A-3' 3' -UC UGU CCU ACU CCU AGC AAA GCG U-5'	2829-2808 2808-2831

*Key to figure: (Headings)*

Name

Sequence Protocol no.

Sequence

**Table 4**

The sequences shown in Table 4 are shown again in the sequence protocol as sequences SQ 141-147, 152, 153, 158. The dsRNAs were transfected in a concentration of 175 nM as double charges into the cells, which were seeded the day before in 12-well plates at  $3.8 \times 10^5$  cells/well. For this purpose, 93.3  $\mu$ L EC-R buffer (TransMessenger kit, Qiagen, Hilden) was mixed with 3.2  $\mu$ L Enhancer-R per transfection charged, thoroughly mixed and incubated for 5 minutes at room temperature. After addition of 6  $\mu$ L TransMessenger transfection reagent, the transfection charges were vigorously mixed for 10 seconds and incubated for 10 minutes at room temperature. In the meantime, the medium was withdrawn from the cells by suction, washed once with PBS (phosphate buffered saline) and 200  $\mu$ L fresh medium without FCS per well was added to the cells. After 10 minutes of incubation, 100  $\mu$ L FCS-free medium was pipetted into the transfection charged, mixed and the mixture pipetted dropwise into the cells (the dsRNA concentration of 175  $\mu$ M refers to 400  $\mu$ L of medium total volume). The dsRNA/TransMessenger complexes were incubated for 4 hours at 37°C with the cells in FCS-free medium. A medium change was then conducted, in which the fresh medium contained 10  $\mu$ M Rifampicin and 10% FCS. As control, and unspecific dsRNA sequence, having no homology with the MDR1 gene sequence, was used (K) and a MOCK transfection carried out, which contained all reagents, except dsRNA.

The cells were harvested after 24, 48 and 72 hours and a total RNA extracted with the RNeasy-Mini-Kit from Qiagen. 10  $\mu$ g total RNA of each sample was separated on a 1% agarose formaldehyde gel electrophoretically, blotted onto a nylon membrane and specific probes, random marked with 5'- $\alpha^{32}$ -P-dCTP, were hybridized exposed first relative to MDR1 and, after stripping of the blot, relative to GAPDH as internal control and exposed on x-ray film.

The x-ray films were digitized (Image Master, VDS Pharmacia) and quantified with the Image-Quant software. Balancing of the MDR1-specific bands with the corresponding GAPDH bands was then carried out.

### Results:

Figures 25 and 26 show Northern blots (Figures 25a, 26a) with quantitative evaluation of the MDR1-specific bands after balancing with the corresponding GAPDH values (Figures 25b, 26b). A reduction of MDR1-mRNA by up to 55% could be observed in comparison with MOCK transfection and by up to 45% in comparison with unspecific control transfection. After 48 h, a significant reduction of MDR1-mRNA levels was achieved with the dsRNA constructs designated R1, R2, R3 (Table 4). After 48 hours, no significant reduction relative to the controls was observed with the R4 dsRNA constructs (Figures 26a, 26b). After 72 hours, a much stronger reduction of MDR1-mRNA levels was observed with R1, R2 and R2 relative to the controls, in comparison with the 48-hour values (Figures 25a and 25b).

With R4 at this point a significant reduction of MDR1-mRNA levels could also be achieved. The constructs with a 2 nt overhang on the 3' end of the anti-sense strand and a double-strand region of 22 nucleotide pairs therefore reduced the MDR1-mRNA more efficiently than the constructs of the 2 nt overhangs on the 3' ends of both strands (anti-sense and sense strand) and a double-strand region of 19 nucleotide pairs relatively independently of the sequence region homologous to the MDR1 gene (after 48 hours; Fig. 26b). The results therefore confirm the inhibition of EGFR gene expression described in practical example 4 by specific dsRNAs after transfection in U-87 MG cells.

The transfection efficiency was determined in a separate experiment by means of a Texas-Red-labeled DNA oligonucleotide (TexRed-A (GATC)<sub>5</sub>T; also 175 nM transfected) (Figures 27a, 27b; 400-fold magnification, 48 hours after transfection). The amount is about 50% based on the red fluorescent cells, in comparison with the total cell count. If one considers the transfection rate of the cells at about 50%, the observed reduction of MDR1-mRNA level lies at about 45-55% (compared with the controls), with the conclusion that in all cells that could be transfected

successfully with specific dsRNA, the MDR1-mRNA was almost fully broken down and specifically.

## Literature:

Alroy I & Yarden Y (1997): The Erb signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Letters 410: 83-86.

Bass, B.L., 2000. Double-stranded RNA as a template for gene silencing. Cell 101, 235-238.

Bosher, J.M. and Labouesse, M., 2000. RNA interference: genetic wand and genetic watchdog. Nature Cell Biology 2, E31-E36.

Bradford MM (1976): Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.

Caplen, N.C., Fleenor, J., Fire, A., and Morgan, R.A., 2000. dsRNA-mediated gene silencing in cultured *Drosophila* cells: a tissue culture model for the analysis of RNA interference. Gene 252, 95-105.

Clemens, J.C., Worby, C.A., Simonson-Leff, N., Muda, M., Maelhama, T., Hemmings, B.A., and Dixon, J.E., 2000. Use of double-stranded RNA interference in *Drosophila* cell lines to dissect signal transduction pathways. Proc.Natl.Acad.Sci.USA 97, 6499-6503.

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Liebermann G & Slamon DJ (1999): Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that

has progressed after chemotherapy for metastatic disease.  
Journal of Clinical Oncology 17: 2639-2648.

Ding, S.W., 2000. RNA silencing. Curr. Opin. Biotechnol. 11, 152-156.

Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C., 1998. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. Nature 391, 806-811.

Fire, A., 1999. RNA-triggered gene silencing. Trends Genet. 15, 358-363.

Freier, S.M., Kierzek, R., Jaeger, J.A., Sugimoto, N., Caruthers, M.H., Neilson, T., and Turner, D.H., 1986. Improved free-energy parameters for prediction of RNA duplex stability. Proc. Natl. Acad. Sci. USA 83, 9373-9377 .

Geick, A., Eichelbaum, M., Burk, O. (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276 (18), 14581-14587.

Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, Gullick W, Angeletti CA, Bevilacqua G & Ciardiello F (1998): Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIa non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic factors of survival. Clinical Cancer Research 4: 241-249.

- Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J., 2000. An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature* 404, 293-296.
- Higgins, C.F. (1995). The ABC of channel regulation. *Cell*, 82, 693-696.
- Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1993): Generating green fluorescent mice by germline transmission of green fluorescent ES cells. *Mech. Dev.* 76: 79-90.
- Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1998): Non-invasive sexing of preimplantation mammalian embryos. *Nature Genetics* 19: 220-222.
- Kyhse-Anderson J (1984): Electrophoretic transfer of multiple gels: A simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. *J. Biochem. Biophys. Methods* 10: 203-210.
- Lämmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685.
- Loc, T.W., and Clarke, D.M. (1999) *Biochem. Cell Biol.* 77, 11-23.
- Huang SM & Harari PM (1999): Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. *Investigational New Drugs* 17: 259-269.
- Limmer, S., Hofmann, H.-P., Ott, G., and Sprinzl, M., 1993. The 3'-terminal end (NCCA) of tRNA determines the structure and

stability of the aminoacyl acceptor stem. Proc. Natl. Acad. Sci. USA 90 , 6199-6202.

Montgomery, M.K. and Fire, A., 1998. Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression. Trends Genet. 14, 255-258.

Montgomery, M.K., Xu, S., and Fire, A., 1998. RNA as a target of double-stranded RNA-mediated genetic interference in *Caenorhabditis elegans*. Proc. Natl. Acad. Sci. USA 95, 15502-15507.

Rieske P, Kordek R, Bartkowiak J, Debiec-Rychter M, Bienhat W & Liberski PP (1998): A comparative study of epidermal growth factor (EGFR) and mdm2 gene amplification and protein immunoreactivity in human glioblastomas. Polish Journal of Pathology 49: 145-149.

Robert, J. (1999). Multidrug resistance in oncology: diagnostic and therapeutic approaches. Europ J Clin Invest 29, 536-545.

Stavrovskaya, A.A. (2000) Biochemistry (Moscow) 65 (1), 95-106.

Salomon DS, Brandt R, Ciardiello F & Normanno N (1995): Epidermal growth factor related peptides and their receptors in human malignancies: Critical Reviews in Oncology and Haematology 19: 183-232.

Tom, B.H., Rutzky, L.P., Jakstys, M.M., Oyasu, R., Kaye, C.I., Kahan, B.D. (1976), In vitro, 12, 180-191.



Tsuruo, T., Iida, H., Tsukagoshi, S., Sakurai, Y. (1981). Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. *Cancer Res*, 41, 1967-72.

Ui-Tei, K., Zenno, S., Miyata, Y., and Saigo, K., 2000. Sensitive assay of RNA interference in *Drosophila* and Chinese hamster cultured cells using firefly luciferase gene as target. *FEBS Lett.* 479, 79-82.

Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Liebermann TA, Schlessinger J et al. (1984): Human epidermal growth factor receptor cDNA sequences and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. *Nature* 309: 418-425.

Ullrich A & Schlessinger J (1990): Signal transduction by receptors with tyrosine kinase activity. *Cell* 61: 203-212.

Van der Geer P, Hunter T & Linberg RA (1994): Receptor protein-tyrosine kinases and their signal transduction pathways. *Annual review in Cell Biology* 10: 251-337.

Voldborg BR, Damstrup L, Spang-Thomsen M & Poulser HS (1997): Epidermal growth factor Receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. *Annals of Oncology* 8: 1197-1206.

Walker RA & Dearing SJ (1999): Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. *Breast Cancer Research Treatment* 53: 167-176.

Zamore, P.D., Tuschl, T., Sharp, P.A., and Bartel, D.P., 2000.  
RNAi: double-stranded RNA directs the ATP-dependent cleavage  
of mRNA at 21 to 23 nucleotide intervals. *Cell* 101 , 25-33.

Zor T & Selinger Z (1996): Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. *Anal. Biochem.* 236: 302-308.

## Claims

1. Method for inhibition of expression of a target gene in a cell, comprising the following steps:

introduction of at least one double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of the target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2) of dsRNA I.

2. Method according to Claim 1, in which the dsRNA has the overhang on a 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

3. Method according to Claim 1 or 2, in which the dsRNA I is formed smooth on one end (E1, E2).

4. Method according to Claim 3, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

5. Method according to one of the preceding claims, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.

6. Method according to one of the preceding claims, in which at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the preceding claims, is introduced to the cell, in which one strand (as1) or at least a section of one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which

an additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

7. Method according to one of the preceding claims, in which the dsRNA I and/or dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

8. Method according to one of the preceding claims, in which the first region (B1) and the second region (B2) overlap or abut each other in sections.

9. Method according to one of the preceding claims, in which the first region (B1) and the second region (B2) are spaced from each other.

10. Method according to one of the preceding claims, in which the target gene has one of the sequences SQ001 to SQ140.

11. Method according to one of the preceding claims, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

12. Method according to one of the preceding claims, in which the target gene is the MDR1 gene.

13. Method according to one of the preceding claims, in which one of the sequences SQ141-173 is used as dsRNA I/II and a combined dsRNA construct of the sequences SQ141-173 from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.

14. Method according to one of the preceding claims, in which expression is inhibited according to the principle of RNA interference.

15. Method according to one of the preceding claims, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
16. Method according to one of the preceding claims, in which the target gene is a component of a virus or a viroid.
17. Method according to Claim 16, in which the virus is a human pathogenic virus or viroid.
18. Method according to one of the Claims 16, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
19. Method according to one of the preceding claims, in which unpaired nucleotides are substituted by nucleoside thiophosphate.
20. Method according to one of the preceding claims, in which at least one end (E1, E2) of dsRNA I/II is modified, in order to counteract degradation in the cell or dissociation into single strands.
21. Method according to one of the preceding claims, in which the cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
22. Method according to one of the preceding claims, in which the chemical link is formed by a covalent or ionic bond, hydrogen bridge bond, hydrophobic interactions, preferably van der Waals or stacking interactions, or by metal-ion coordination.
23. Method according to one of the preceding claims, in which the chemical link is formed in the vicinity of one end (E1, E2).

24. Method according to one of the preceding claims, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
25. Method according to one of the preceding claims, in which the chemical link is formed by branched nucleotide analogs instead of nucleotides.
26. Method according to one of the preceding claims, in which the chemical link is formed by purine analogs.
27. Method according to one of the preceding claims, in which the chemical link is formed by azabenzene units.
28. Method according to one of the preceding claims, in which, to produce the chemical link, at least one of the following groups is used: methylene blue; bifunctional groups, preferably bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil, psoralene.
29. Method according to one of the preceding claims, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
30. Method according to one of the preceding claims, in which the chemical link is produced by triple helix bonds situated in the vicinity of the ends (E1, E2).
31. Method according to one of the preceding claims, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
32. Method according to one of the preceding claims, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from the virus, derived from it or synthetically produced, associated with it or enclosed by it.

33. Method according to one of the preceding claims, in which the sheath protein is derived from polyoma virus.
34. Method according to one of the preceding claims, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
35. Method according to one of the preceding claims, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
36. Method according to one of the preceding claims, in which one strand (as1/as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
37. Method according to one of the preceding claims, in which the cell is a vertebrate cell or a human cell.
38. Method according to one of the preceding claims, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.
39. Method according to one of the preceding claims, in which the dsRNA I/II is taken up in a buffer solution for application.
40. Method according to one of the preceding claims, in which the dsRNA I/II is administered orally or by means of injection or infusion, intravenously, intratumorally, by inhalation, intraperitoneally.
41. Use of a double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in a cell,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2).

42. Use according to Claim 41, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

43. Use according to Claim 41 or 42, in which the dsRNA I is formed smooth on one end (E1, E2).

44. Use according to Claim 43, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

45. Use according to one of the Claims 41 to 44, in which the overhang is formed from 1 to 4 nucleotides, preferably one or two nucleotides.

46. Use according to one of the Claims 41 to 45, in which one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 41 to 45, is introduced to the cell, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the sense strand of the target gene, and in which the other strand (as2) or at least a section of the other strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

47. Use according to one of the Claims 41 to 46, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

48. Use according to one of the Claims 41 to 47, in which the first (B1) and the second region (B2) overlap or abut each other in sections.



49. Use according to one of the Claims 41 to 48, in which the first (B1) and the second region (B2) are spaced from each other.
50. Use according to one of the Claims 41 to 49, in which the target gene has the sequences S1001 to SQ140.
51. Use according to one of the Claims 41 to 50, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.
52. Use according to one of the Claims 41 to 51, in which the target gene is the MDR1 gene.
53. Use according to one of the Claims 41 to 52, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
54. Use according to one of the Claims 41 to 53, in which expression is inhibited according to the principle of RNA interference.
55. Use according to one of the Claims 41 to 54, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
56. Use according to one of the Claims 41 to 55, in which the target gene is a component of a virus or viroid.
57. Use according to Claim 56, in which the virus is a human pathogenic virus or viroid.

58. Use according to Claim 56, in which the virus or viroid is an animal or plant pathogenic virus or viroid.

59. Use according to one of the Claims 41 to 58, in which unpaired nucleotides are substituted by nucleoside thiophosphates.

60. Use according to one of the Claims 41 to 59, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.

61. Use according to one of the Claims 41 to 60, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

62. Use according to one of the Claims 41 to 61, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.

63. Use according to one of the Claims 41 to 62, in which the chemical link is formed in the vicinity of one end (E1, E2).

64. Use according to one of the Claims 41 to 63, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.

65. Use according to one of the Claims 41 to 64, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.

66. Use according to one of the Claims 41 to 65, in which the chemical link is formed by purine analogs.

67. Use according to one of the Claims 41 to 66, in which the chemical link is formed by azabenzene units.
68. Use according to one of the Claims 41 to 67, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
69. Use according to one of the Claims 41 to 68, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
70. Use according to one of the Claims 41 to 69, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).
71. Use according to one of the Claims 41 to 70, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
72. Use according to one of the Claims 41 to 71, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
73. Use according to one of the Claims 41 to 72, in which the sheath protein is derived from polyoma virus.
74. Use according to one of the Claims 41 to 73, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
75. Use according to one of the Claims 41 to 74, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

76. Use according to one of the Claims 41 to 75, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

77. Use according to one of the Claims 41 to 76, in which the cell is a vertebrate cell or a human cell.

78. Use according to one of the Claims 41 to 77, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

79. Use according to one of the Claims 41 to 78, in which the dsRNA I/II is taken up in a buffer solution for application.

80. Use according to one of the Claims 41 to 79, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

81. Medicament to inhibit expression of a target gene in a cell, containing a double-strand ribonucleic (dsRNA I) in an amount sufficient to inhibit expression of a target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs,

and in which one strand (as1) or at least one section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed on at least one end (E1, E2) from 1 to 4 nucleotides.

82. Medicament according to Claim 81, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

83. Medicament according to Claim 81 or 82, in which the dsRNA I is formed smooth on one end (E1, E2).
84. Medicament according to one of the Claims 83, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).
85. Medicament according to one of the Claims 81 to 84, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.
86. Use according to one of the Claims 81 to 85, containing at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 81 to 85, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which the additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.
87. Use according to one of the Claims 81 to 86, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.
88. Use according to one of the Claims 81 to 87, in which the first (B1) and the second region (B2) overlap or abut each other in sections.
89. Use according to one of the Claims 81 to 88, in which the target gene has one of the sequences S1001 to SQ140.
90. Use according to one of the Claims 81 to 89, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

91. Use according to one of the Claims 81 to 90, in which the target gene is the MDR1 gene.
92. Use according to one of the Claims 81 to 91, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
93. Use according to one of the Claims 81 to 92, in which expression is inhibited according to the principle of RNA interference.
94. Use according to one of the Claims 81 to 93, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
95. Use according to one of the Claims 81 to 94, in which the target gene is a component of a virus or viroid.
96. Use according to Claim 95, in which the virus is a human pathogenic virus or viroid.
97. Use according to Claim 95, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
98. Use according to one of the Claims 81 to 97, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
99. Use according to one of the Claims 81 to 98, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
100. Use according to one of the Claims 81 to 99, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

101. Use according to one of the Claims 81 to 100, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.
102. Use according to one of the Claims 81 to 101, in which the chemical link is formed in the vicinity of one end (E1, E2).
103. Use according to one of the Claims 81 to 102, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
104. Use according to one of the Claims 81 to 103, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
105. Use according to one of the Claims 81 to 104, in which the chemical link is formed by purine analogs.
106. Use according to one of the Claims 81 to 105, in which the chemical link is formed by azabenzene units.
107. Use according to one of the Claims 81 to 106, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
108. Use according to one of the Claims 81 to 107, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
109. Use according to one of the Claims 81 to 108, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).

110. Use according to one of the Claims 81 to 109, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
111. Use according to one of the Claims 81 to 110, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
112. Use according to one of the Claims 81 to 111, in which the sheath protein is derived from polyoma virus.
113. Use according to one of the Claims 81 to 112, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
114. Use according to one of the Claims 81 to 113, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
115. Use according to one of the Claims 81 to 114, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
116. Use according to one of the Claims 81 to 114, in which the cell is a vertebrate cell or a human cell.
117. Use according to one of the Claims 81 to 116, in which the first (B1) and second region (B2) are spaced from each other.
118. Use according to one of the Claims 81 to 117, in which the dsRNA I/II is contained in an amount of, at most, 5 mg per administration unit.
119. Use according to one of the Claims 81 to 118, in which the dsRNA I/II is taken up in a buffer solution.



120. Use according to one of the Claims 81 to 119, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

121. Method for inhibition of expression of a target gene in a cell, comprising the following steps:

introduction of at least one double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of the target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA has an overhang formed from 1 to 4 nucleotides on at least one end (E1, E2) of dsRNA I.

122. Method according to Claim 1, in which the dsRNA has the overhang on a 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

123. Method according to Claim 1 or 2, in which the dsRNA I is formed smooth on one end (E1, E2).

124. Method according to Claim 3, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

125. Method according to one of the preceding claims, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.

126. Method according to one of the preceding claims, in which at least an additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the

preceding claims, is introduced to the cell, in which one strand (as1) or at least a section of one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and which an additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

127. Method according to one of the preceding claims, in which the dsRNA I and/or dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

128. Method according to one of the preceding claims, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

129. Method according to one of the preceding claims, in which the first (B1) and the second region (B2) are spaced from each other.

130. Method according to one of the preceding claims, in which the target gene has one of the sequences SQ001 to SQ140.

131. Method according to one of the preceding claims, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

132. Method according to one of the preceding claims, in which the target gene is the MDR1 gene.

133. Method according to one of the preceding claims, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of the sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.

134. Method according to one of the preceding claims, in which expression is inhibited according to the principle of RNA interference.
135. Method according to one of the preceding claims, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
136. Method according to one of the preceding claims, in which the target gene is a component of a virus or a viroid.
137. Method according to Claim 16, in which the virus is a human pathogenic virus or viroid.
138. Method according to one of the Claims 16, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
139. Method according to one of the preceding claims, in which unpaired nucleotides are substituted by nucleoside thiophosphate.
140. Method according to one of the preceding claims, in which at least one end (E1, E2) of dsRNA I/II is modified, in order to counteract degradation in the cell or dissociation into single strands.
141. Method according to one of the preceding claims, in which the cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
142. Method according to one of the preceding claims, in which the chemical link is formed by a covalent or ionic bond, hydrogen bridge bond, hydrophobic interactions, preferably van der Waals or stacking interactions, or by metal-ion coordination.
143. Method according to one of the preceding claims, in which the chemical link is formed in the vicinity of one end (E1, E2).

144. Method according to one of the preceding claims, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
145. Method according to one of the preceding claims, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
146. Method according to one of the preceding claims, in which the chemical link is formed by purine analogs.
147. Method according to one of the preceding claims, in which the chemical link is formed by azabenzene units.
148. Method according to one of the preceding claims, in which, to produce the chemical link, at least one of the following groups is used: methylene blue; bifunctional groups, preferably bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil, psoralene.
149. Method according to one of the preceding claims, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
150. Method according to one of the preceding claims, in which the chemical link is produced by triple helix bonds situated in the vicinity of the ends (E1, E2).
151. Method according to one of the preceding claims, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
152. Method according to one of the preceding claims, in which the dsRNA I/II is bonded to at least one sheath protein originating from the virus, derived from it or synthetically produced, associated with it or enclosed by it.

153. Method according to one of the preceding claims, in which the sheath protein is derived from polyoma virus.

154. Method according to one of the preceding claims, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.

155. Method according to one of the preceding claims, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

156. Method according to one of the preceding claims, in which one strand (as1/as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

157. Method according to one of the preceding claims, in which the cell is a vertebrate cell or a human cell.

158. Method according to one of the preceding claims, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

159. Method according to one of the preceding claims, in which the dsRNA I/II is taken up in a buffer solution for application.

160. Method according to one of the preceding claims, in which the dsRNA I/II is administered orally or by means of injection or infusion, intravenously, intratumorally, by inhalation, intraperitoneally.

161. Use of one of double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in a cell,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2).

162. Use according to Claim 41, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

163. Use according to Claim 41 or 42, in which the dsRNA I is formed smooth on one end (E1, E2).

164. Use according to Claim 43, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

165. Use according to one of the Claims 41 to 44, in which the overhang is formed from 1 to 4 nucleotides, preferably one or two nucleotides.

166. Use according to one of the Claims 41 to 45, in which one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 41 to 45, is introduced to the cell, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the sense strand of the target gene, and in which the other strand (as2) or at least a section of the other strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

167. Use according to one of the Claims 41 to 47, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

168. Use according to one of the Claims 41 to 47, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

169. Use according to one of the Claims 41 to 48, in which the first (B1) and the second region (B2) are spaced from each other.
170. Use according to one of the Claims 41 to 49, in which the target gene has the sequences S1001 to SQ140.
171. Use according to one of the Claims 41 to 50, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.
172. Use according to one of the Claims 41 to 51, in which the target gene is the MDR1 gene.
173. Use according to one of the Claims 41 to 52, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
174. Use according to one of the Claims 41 to 53, in which expression is inhibited according to the principle of RNA interference.
175. Use according to one of the Claims 41 to 54, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
176. Use according to one of the Claims 41 to 55, in which the target gene is a component of a virus or viroid.
177. Use according to Claim 56, in which the virus is a human pathogenic virus or viroid.

178. Use according to Claim 56, in which the virus or viroid is an animal or plant pathogenic virus or viroid.

179. Use according to one of the Claims 41 to 58, in which unpaired nucleotides are substituted by nucleoside thiophosphates.

180. Use according to one of the Claims 41 to 59, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.

181. Use according to one of the Claims 41 to 60, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

182. Use according to one of the Claims 41 to 61, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van-der-Waals or stacking interactions, or by metal ion coordination.

183. Use according to one of the Claims 41 to 62, in which the chemical link is formed in the vicinity of one end (E1, E2).

184. Use according to one of the Claims 41 to 63, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.

185. Use according to one of the Claims 41 to 64, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.

186. Use according to one of the Claims 41 to 65, in which the chemical link is formed by purine analogs.



187. Use according to one of the Claims 41 to 66, in which the chemical link is formed by azabenzene units.
188. Use according to one of the Claims 41 to 67, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
189. Use according to one of the Claims 41 to 68, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
190. Use according to one of the Claims 41 to 69, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).
191. Use according to one of the Claims 41 to 70, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
192. Use according to one of the Claims 41 to 71, in which the dsRNA I/II is bonded to at least one sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
193. Use according to one of the Claims 41 to 72, in which the sheath protein is derived from polyoma virus.
194. Use according to one of the Claims 41 to 73, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
195. Use according to one of the Claims 41 to 74, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

196. Use according to one of the Claims 41 to 75, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

197. Use according to one of the Claims 41 to 76, in which the cell is a vertebrate cell or a human cell.

198. Use according to one of the Claims 41 to 77, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

199. Use according to one of the Claims 41 to 78, in which the dsRNA I/II is taken up in a buffer solution for application.

200. Use according to one of the Claims 41 to 79, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

201. Medicament to inhibit expression of a target gene in a cell, containing a double-strand ribonucleic (dsRNA I) in an amount sufficient to inhibit expression of a target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs,

and in which one strand (as1) or at least one section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed on at least one end (E1, E2) from 1 to 4 nucleotides.

202. Medicament according to Claim 81, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

203. Medicament according to Claim 81 or 82, in which the dsRNA I is formed smooth on one end (E1, E2).
204. Medicament according to one of the Claims 83, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).
205. Medicament according to one of the Claims 81 to 84, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.
206. Use according to one of the Claims 81 to 85, containing at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 81 to 85, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which the additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.
207. Use according to one of the Claims 81 to 86, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.
208. Use according to one of the Claims 81 to 87, in which the first (B1) and the second region (B2) overlap or abut each other in sections.
209. Use according to one of the Claims 81 to 88, in which the target gene has one of the sequences S1001 to SQ140.
210. Use according to one of the Claims 81 to 89, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

211. Use according to one of the Claims 81 to 90, in which the target gene is the MDR1 gene.
212. Use according to one of the Claims 81 to 90, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
213. Use according to one of the Claims 81 to 92, in which expression is inhibited according to the principle of RNA interference.
214. Use according to one of the Claims 81 to 93, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
215. Use according to one of the Claims 81 to 94, in which the target gene is a component of a virus or viroid.
216. Use according to Claim 95, in which the virus is a human pathogenic virus or viroid.
217. Use according to Claim 95, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
218. Use according to one of the Claims 81 to 97, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
219. Use according to one of the Claims 81 to 98, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
220. Medicament according to one of the Claims 81 to 99, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

221. Medicament according to one of the Claims 81 to 100, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.
222. Medicament according to one of the Claims 81 to 101, in which the chemical link is formed in the vicinity of one end (E1, E2).
223. Medicament according to one of the Claims 81 to 102, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
224. Medicament according to one of the Claims 81 to 103, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
225. Medicament according to one of the Claims 81 to 104, in which the chemical link is formed by purine analogs.
226. Medicament according to one of the Claims 81 to 105, in which the chemical link is formed by azabenzene units.
227. Medicament according to one of the Claims 81 to 106, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
228. Medicament according to one of the Claims 81 to 107, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
229. Medicament according to one of the Claims 81 to 108, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).

230. Medicament according to one of the Claims 81 to 109, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
231. Medicament according to one of the Claims 81 to 110, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
232. Medicament according to one of the Claims 81 to 111, in which the sheath protein is derived from polyoma virus.
233. Medicament according to one of the Claims 81 to 112, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
234. Medicament according to one of the Claims 81 to 113, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
235. Medicament according to one of the Claims 81 to 114, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
236. Medicament according to one of the Claims 81 to 114, in which the cell is a vertebrate cell or a human cell.
237. Medicament according to one of the Claims 81 to 116, in which the first (B1) and second region (B2) are spaced from each other.
238. Medicament according to one of the Claims 81 to 117, in which the dsRNA I/II is contained in an amount of, at most, 5 mg per administration unit.

239. Medicament according to one of the Claims 81 to 118, in which the dsRNA I/II is taken up in a buffer solution.

240. Medicament according to one of the Claims 81 to 119, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

//Key to Figures//

Relative Fluoreszenz = Relative fluorescence

Maus = mouse

Mensch = human

MOCK Transfektion = MOCK transfection

Hellfeld = bright field

Variante = variant

Zielgen = target gene

SEQUENZPROTOKOLL = SEQUENCE PROTOCOL

<120> Method for Inhibition of Expression of a Target Gene

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R1A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R1B) of a dsRNA strand, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R2A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R3A) of a dsRNA that is homologous to the MDR1 gene

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R3B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R4A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence



<223> Description of artificial sequence anti-sense strand (R4B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S1A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S1B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S7A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S7B) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R2B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K1A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K1B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K3A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K3B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K2A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K2B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S4B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (PKC1 A) of a dsRNA that is homologous to the protein kinase C sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (PKC2 B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S12B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S11B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S13A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S13B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S14B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S13A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-7A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-7B) of a dsRNA, complementary to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-8A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-8B) of a dsRNA, complementary to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-2A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-5B) of a dsRNA, complementary to the human EGFR sequence

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES  
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum  
Internationales Büro



(43) Internationales Veröffentlichungsdatum  
18. Juli 2002 (18.07.2002)

PCT

(10) Internationale Veröffentlichungsnummer  
WO 02/055693 A2

(51) Internationale Patentklassifikation<sup>7</sup>: C12N 15/11

(21) Internationales Aktenzeichen: PCT/EP02/00152

(22) Internationales Anmeldedatum:  
9. Januar 2002 (09.01.2002)

(25) Einreichungssprache: Deutsch

(26) Veröffentlichungssprache: Deutsch

(30) Angaben zur Priorität:  
101 00 586.5 9. Januar 2001 (09.01.2001) DE  
101 55 280.7 26. Oktober 2001 (26.10.2001) DE  
101 58 411.3 29. November 2001 (29.11.2001) DE  
101 60 151.4 7. Dezember 2001 (07.12.2001) DE

LIMMER, Stephan [DE/DE]; Universitätsstrasse 30,  
95447 Bayreuth (DE). ROST, Sylvia [DE/DE]; Univer-  
sitätsstrasse 30, 95447 Bayreuth (DE). HADWIGER,  
Philipp [DE/DE]; Universitätsstrasse 30, 95447 Bayreuth  
(DE).

(74) Anwalt: GASSNER, Wolfgang; Nägelsbachstrasse 49a,  
91052 Erlangen (DE).

(81) Bestimmungsstaaten (*national*): AE, AG, AL, AM, AT,  
AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR,  
CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,  
SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,  
US, UZ, VN, YU, ZA, ZM, ZW.

(71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von  
US): RIBOPHARMA AG [DE/DE]; Universitätsstrasse  
30, 95447 Bayreuth (DE).

(72) Erfinder; und


(75) Erfinder/Anmelder (nur für US): KREUTZER, Roland  
[DE/DE]; Universitätsstrasse 30, 95447 Bayreuth (DE).

(84) Bestimmungsstaaten (*regional*): ARIPO-Patent (GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ,  
TM), europäisches Patent (AT, BE, CH, CY, DE, DK,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR),  
OAPI-Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

[Fortsetzung auf der nächsten Seite]

(54) Title: METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE

(54) Bezeichnung: VERFAHREN ZUR HEMMUNG DER EXPRESSION EINE ZIELGENS



(57) Abstract: The invention relates to a method for inhibiting the expression of a target gene in a cell, comprising the following steps: introduction of an amount of at least one dual-stranded ribonucleic acid (dsRNA I) which is sufficient to inhibit the expression of the target gene. The dsRNA I has a dual-stranded structure formed by a maximum of 49 successive nucleotide pairs. One strand (as1) or at least one section of the one strand (as1) of the dual-stranded structure is complementary to the sense strand of the target gene. The dsRNA has an overhang on the end (E1) of dsRNA I formed by 1 - 4 nucleotides.

(57) Zusammenfassung: Die Erfindung betrifft ein Verfahren zur Hemmung der Expression eines Zielgens in einer Zelle umfassend die folgenden Schritte: Einführen mindestens einer doppelsträngigen Ribonukleinsäure (dsRNA I) in einer zur Hemmung der Expression des Zielgens ausreichenden Menge, wobei die dsRNA I eine doppelsträngige aus höchstens 49 aufeinanderfolgenden Nukleotidpaaren gebildete Struktur aufweist, und wobei ein Strang (as1) oder zumindest ein Abschnitt des einen Strangs (as1) der doppelsträngigen Struktur komplementär zum Sinn-Strang des Zielgens ist, und wobei die dsRNA am einen Ende (E1) der dsRNA I einen aus 1 bis 4 Nukleotiden gebildeten Überhang aufweist.

WO 02/055693 A2



**Veröffentlicht:**

— ohne internationalen Recherchenbericht und erneut zu veröffentlichen nach Erhalt des Berichts

*Zur Erklärung der Zweibuchstaben-Codes und der anderen Abkürzungen wird auf die Erklärungen ("Guidance Notes on Codes and Abbreviations") am Anfang jeder regulären Ausgabe der PCT-Gazette verwiesen.*

## Verfahren zur Hemmung der Expression eines Zielgens

Die Erfindung betrifft ein Verfahren, eine Verwendung und ein Medikament zur Hemmung der Expression eines Zielgens.

5

Aus der WQ 99/32619 sowie der WO 00/44895 sind Verfahren zur Hemmung der Expression von medizinisch oder biotechnologisch interessanten Genen mit Hilfe einer doppelsträngigen Ribonukleinsäure (dsRNA) bekannt. Die bekannten Verfahren sind zwar  
10 hoch effektiv. Es besteht gleichwohl das Bedürfnis, deren Effizienz weiter zu steigern.

Aufgabe der vorliegenden Erfindung ist es, die Nachteile nach dem Stand der Technik zu beseitigen. Es sollen insbesondere  
15 ein Verfahren, eine Verwendung und ein Medikament angegeben werden, mit denen eine noch effizientere Hemmung der Expression eines Zielgens erreichbar ist.

Diese Aufgabe wird durch die Merkmale der Ansprüche 1, 41 und  
20 81 gelöst. Vorteilhafte Ausgestaltungen ergeben sich aus den Merkmalen der Ansprüche 2 bis 40, 42 bis 80 und 82 bis 120.

Mit den erfindungsgemäß beanspruchten Merkmalen wird überraschenderweise eine drastische Erhöhung der Effektivität der  
25 Hemmung der Expression eines Zielgens in vitro und in vivo erreicht. Durch die besondere Ausbildung der Enden der dsRNA kann sowohl deren Effizienz bei der Vermittlung der hemmenden Wirkung auf die Expression eines Zielgens als auch deren Stabilität gezielt beeinflusst werden. Durch die Vergrößerung der  
30 Stabilität wird die wirksame Konzentration in der Zelle erhöht.

Unter einem "Zielgen" im Sinne der Erfindung wird der DNA-Strang der doppelsträngigen DNA in der Zelle verstanden, welcher  
35 komplementär zu einem bei der Transkription als Matrize dienenden DNA-Strang einschließlich aller transkribierten Be-

# TRANSLATION FROM GERMAN

## (12) WORLD ORGANIZATION OF INTELLECTUAL PROPERTY INTERNATIONAL APPLICATION PUBLISHED PURSUANT TO THE PATENT COOPERATION TREATY (PCT)

(19) World Organization for Intellectual Property			
International Office			
(43) International Publication Date:	PCT	(10) International Publication Number:	
18 July 2002		WO 02/055693 A2	
(51) International Patent Classification:	C12N 15/11	LIMMER,	Stephan
(21) International Application Number:	PCT/EP02/00152	[GERMANY/GERMANY];	
(22) International filing date:	9 January 2002	Universitätsstrasse 30, 95447 Bayreuth	
(25) Submission language	German	(GERMANY). ROST, Sylvia	
(26) Publication language	German	[GERMANY/GERMANY];	
(30) Priority data:		Universitätsstrasse 30, 95447 Bayreuth	
101 00 586.5 9 January 2001 GERMANY		(GERMANY). HADWIGER, Philipp	
101 55 280.7 26 October 2001 GERMANY		[GERMANY/GERMANY; Universitätsstrasse	
101 58 411.3 29 November 2001 GERMANY	(74)	30, 95447 Bayreuth (GERMANY).	
101 60 151.4 7 December 2001 GERMANY		Attorneys: GASSNER, Rolfgang;	
(71) Applicant: (for all designated states, except US):		Nägelsbachstrasse 49a, 91052 Erlangen	
RIBOPHARMA AG		(GERMANY).	
[GERMANY/GERMANY]; Universitätsstrasse		(81) Designated states (national): AE, AG,	
30, 95447 Bayreuth (GERMANY).		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,	
(72) Inventor and		BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK,	
(75) Inventor/Applicant (for US only): KREUTZER,		DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,	
Roland [GERMANY/GERMANY];		GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,	
Universitätsstrasse 30, 95447 Bayreuth		KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,	
(GERMANY).		MD, MG, MK, MN, MW, MX, MZ, NO, NZ,	
		OM, PH, PL, PT, RO, RU, SD, SE, SG, SI,	
		SK, SL, TJ, TM, TRADENAME, TR, TT, TZ,	
		UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.	

(84) Regional states (*regional*): ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR). OAPI Patent (BR, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


– without International Search Report and republished on receipt of the report

Refer to the "Guidance Notes on Codes and Abbreviations" at the beginning of each regular issue of the PCT Gazette for explanation of the two-letter codes and other abbreviations..

(54) Title: **METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE**

(57) Abstract

The invention relates to a method for inhibiting the expression of a target gene in a cell, comprising the following steps: introduction of an amount of at least one dual-stranded ribonucleic acid (dsRNA I) which is sufficient to inhibit the expression of the target gene. The dsRNA I has a dual-stranded structure formed by a maximum of 49 successive nucleotide pairs. One strand (as1) or at least one section of the one strand (as1) of the dual-stranded structure is complementary to the sense strand of the target gene. The dsRNA has an overhang on the end (E1) of dsRNA I formed by 1 – 4 nucleotides.



Variant 1

Variant 2



## **METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE**

The invention concerns a method, an application and a medicament for inhibition of expression of a target gene.

Methods to inhibit expression of genes of medical or biotechnological interest by means of a double-strand ribonucleic acid (dsRNA) are known from WO 99/32619 and WO 00/44895. The known methods are highly effective. But there is also a requirement to further increase their efficiency.

The task of the present invention is to eliminate the shortcomings according to the prior art. In particular, a method, an application and a medicament are to be offered, with which even more efficient inhibition of expression of the target gene is attainable.

This task is solved by the features of Claims 1, 41 and 81. Advantageous embodiments are apparent from the features of Claims 2 to 40, 42 to 80 and 82 to 120.

With the features claimed according to the invention, a drastic increase in the effectiveness of inhibition of expression of the target gene in vitro and in vivo is surprisingly achieved. By the special design of the ends of the dsRNA, both their efficiency in mediating the inhibiting effect on expression of the target gene and their stability can be deliberately influenced. By increasing the stability, the effective concentration in the cell is increased.

Target gene according to the invention is understood to mean the DNA strand of the double-strand DNA in the cell that is complementary to a DNA strand, including all transcribed regions that serve for transcription as matrix. The target gene is therefore generally the “sense” strand. The one strand or anti-sense strand (as1) can be complementary to an RNA transcript formed during expression of the target gene or its processing product, for example, an mRNA. Insertion is understood to mean uptake in the cell. Uptake can occur by the cell itself; it also can be mediated by auxiliaries or aids. “Overhang” is understood to mean a terminal single-strand overhang that does not have paired nucleotides, according to Watson and Crick. “Double-strand

structure” is understood to mean a structure, in which the nucleotides of the individual strands are essentially paired according to Watson and Crick. A double-strand structure in the context of the present invention can also have individual mismatches.

According to a particularly advantageous embodiment, the dsRNA I has the overhang on the 3' end of one strand or the anti-sense strand as1 and/or on the 3' end of the other end or sense strand ss1. The dsRNA I can also be formed smoothly on one end. In this case, the smooth end is advantageously situated on the side of dsRNA I that has the 5' end of one strand (anti-sense strand; as1). In this form, the dsRNA I, on the one hand, has very good efficiency and, on the other hand, high stability in a living organism. The overall in vivo efficiency is excellent. The overhang is expediently formed from 1 to 4 nucleotides, preferably from 1 or 2 nucleotides.

According to another embodying feature, the efficiency of the method can be further increased if at least one additional dsRNA II, formed according to the dsRNA I according to the invention, is inserted into the cell, in which the one strand or at least a section of one strand of the double-strand structure of dsRNA I is complementary to a first region of the sense strand of the target gene, and in which an additional strand or at least a section of the additional strand of the double-strand structure of the additional dsRNA II is complementary to a second region of sense strand of the target gene. Inhibition of expression of the target gene is significantly increased in this case. The first and second region can overlap in sections, abut each other, or also be spaced from each other.

It has also proven advantageous if the dsRNA I and/or the additional dsRNA II have a length of less than 25 consecutive nucleotide pairs. A length in the range between 19 and 23 nucleotide pairs has proven to be particularly effective. The efficiency can be further increased if single-strand overhangs of 1 to 4 nucleotides are present on the double strands preferably formed from 19 to 23 nucleotide pairs.

The target gene, according to an additional embodying feature, can have the sequences SQ001 to SQ140, given in the enclosed sequence protocol. It can also be chosen from the following groups: oncogene, cytokine gene, id-protein gene, prion gene, genes for expression of

angiogenesis-inducing molecules, adhesion molecules and cell surface receptors. genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules, as well as genes for expression of the EGF receptors. The target gene can be the MDR1 gene, in particular. In this context, one of the existing sequences SQ141-173 or a combined dsRNA I/II from antisense (as) and sense sequences (ss) that go together can be used.

According to an additional advantageous embodying feature, expression is inhibited according to the principle of RNA interference.

The target gene is expediently expressed in pathogenic organisms, preferably in plasmodia. It can be a component of a virus or viroid, especially a human pathogenic virus or viroid. The virus or viroid can also be an animal or plant pathogenic virus or viroid.

According to another embodying feature, it is prescribed that the unpaired nucleotides be substituted by nucleoside thiophosphates.

At least one end of the dsRNA I/II can be modified, in order to counteract degradation in the cell or dissociation in the individual strand. Advantageously, cohesion caused by the complementary nucleotide pairs of the double-strand structure is increased by at least one chemical length. The chemical length can be formed by a covalent or ionic bond, a hydrogen bridge bond, hydrophobic interactions, preferably van-der-Waals or stacking interactions, or by metal ion coordination. It has also proven expedient and to increase stability if the chemical link is formed in the vicinity of one end. Additional advantageous embodiments with respect to chemical linking can be deduced from the features of Claims 24 to 30, without requiring a further explanation for this.

The dsRNA I/II can be incorporated particularly easily in the cell if it is enclosed in micellar structures, advantageously in liposomes. It has also proven advantageous for transport of dsRNA I/II into the cell that it is bonded to at least a viral sheath protein, originating from a virus, derived from a virus or synthetically produced, associated with the sheath protein or

enclosed by it. The sheath protein can be derived from polyoma virus. The sheath protein can contain, in particular, the virus protein 1 and/or the virus protein 2 of polyoma virus. According to another embodiment, it is prescribed that, during formation of a capsid or capsid-like structure from the sheath protein, one side face the interior of the capsid or capsid-like structure. It is also advantageous that the one strand of dsRNA I/II (as1/2) is complementary to the primary or processed RNA transcript of the target gene. The cell can be a vertebrate cell or a human cell.

It has also been found that the dsRNA I/II can advantageously be administered already in an amount of, at most, 5 mg/kg of body weight per day to a mammal, preferably a human. Even in this low dose, an excellent efficiency is achieved.

It has surprisingly been found that the dsRNA I/II can be taken up in a buffer solution for administration and then administered orally or by injection or infusion intravenously, intratumorally, by inhalation or intraperitoneally.

The use of a double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in the cell is also proposed according to the invention, in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (anti-sense strand; as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the sense strand of the target gene, and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides on at least one end.

According to an additional stipulation of the invention, a medicament for inhibiting the expression of a target gene in a cell is proposed, containing a double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of a target gene, in which the dsRNA I has a double-strand structure from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the sense strand of target gene, and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides on at least one end.

The preceding comments are referred to for the further advantageous embodiment of dsRNA I/II.

The invention is further explained on an example below, with reference to the drawings and practical examples. In the drawings:

- Fig. 1a, b      schematically depicts a first and second double-strand RNA and
- Fig. 2            schematically depicts a target gene,
- Fig. 3            depicts relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (first experiment),
- Fig. 4            shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (second experiment),
- Fig. 5            shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (third experiment),
- Fig. 6            shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (fourth experiment),
- Fig. 7            shows relative YFP fluorescence after application of different dsRNA in HeLa-S3 cells (fifth experiment),
- Fig. 8            shows fluorescence micrographs of NIH/3T3 cells after transfection with pcDNA-YFP and after cotransfection with pcDNA-YFP and different dsRNAs,
- Fig. 9            shows fluorescence micrographs of HeLa-S3 cells after transfection with pcDNA-YFP and after cotransfection with pcDNA-YFP and different dsRNAs,
- Fig. 10           shows gel electrophoretic separation of S1 after incubation in mouse serum,

- Fig. 11 shows gel electrophoretic separation of S1 after incubation in human serum,
- Fig. 12 shows gel electrophoretic separation of S7 after incubation in mouse serum,
- Fig. 13 shows gel electrophoretic separation of S7 after incubation in human serum,
- Fig. 14 shows gel electrophoretic separation of K3 after incubation in mouse serum,
- Fig. 15 shows gel electrophoretic separation of PKC1/2 after incubation in mouse serum,
- Fig. 16 shows gel electrophoretic separation of S1A/S4B after incubation in human serum,
- Fig. 17 shows gel electrophoretic separation of K2 after incubation in human serum and
- Fig. 18 shows GFP-specific immunoperoxidase staining on kidney paraffin sections of transgenic GFP mice,
- Fig. 19 shows GFP-specific immunoperoxidase staining on heart paraffin sections of transgenic GFP mice,
- Fig. 20 shows GFP-specific immunoperoxidase staining on pancreas paraffin sections transgenic GFP mice,
- Fig. 21 shows Western blot analysis of GFP expression in plasma,
- Fig. 22 shows Western blot analysis of GFP expression in the kidneys,
- Fig. 23 shows Western blot analysis of GFP expression in the heart,
- Fig. 24 shows Western blot analysis of EGFR expression in U-87 MG glioblastoma cells,

- Fig. 25a shows Northern blot analysis of the MDRI mRNA levels in colon carcinoma cell line LS174T, in which the cells were harvested after 74 hours,
- Fig. 25b shows quantification of the band according to Fig. 25a, in which the averages from two values are shown,
- Fig. 26a shows Northern blot analysis of the MDRI mRNA levels in colon carcinoma cell line LS174T, in which the cells were harvested after 48 hours,
- Fig. 26b shows quantification of the band according to Fig. 26a, in which the average values from the two values are shown,
- Fig. 27 shows a comparative depiction of a transmitted light and fluorescence photomicrograph of a transfection with 175 nM dsRNA (sequence R1 in Table 4).

The double-strand ribonucleic acids dsRNA I and dsRNA II, depicted schematically in Figures 1a and 1b, each have a first end E1 and a second end E2. The first and second ribonucleic acids dsRNA I/dsRNA II have single-strand sections formed from about 1 to 4 unpaired nucleotides on their two ends E1 and E2. Two possible variants are shown (variants 1 and 2), in which variant 2 has a smooth end (E2). The smooth ends, however, can also lie on the other end (E1) in another variant.

A target gene situated on DNA is schematically shown in Fig. 2. The target gene is made recognizable by a black bar. It has a first region B1 and a second region B2.

Each strand of the first dsRNA I (as1) and the second dsRNA II (as2) is complementary to the corresponding region B1 or B2 on the target gene.

Expression of the target gene is then inhibited with particular efficiency, if the dsRNA I/dsRNA II has single strand sections on its ends E1, E2. The single-strand sections can be formed both on

strand as1 or as2 and on the counterstrand (ss1 or ss2) or on strand as1, as2 and on the counterstrand.

The regions B1 and B2, as shown in Fig. 2, can be spaced from each other. However, they can also be adjacent to each other or overlap.

#### I. Inhibition of Expression of the YFP Gene in Fibroblasts:

Double-strand RNAs (dsRNAs) were prepared from sequences of the yellow fluorescent protein (YFP), a variant of the GFP (green-fluorescent protein) of the alga *Aequoria victoria* and microinjected into fibroblasts, together with a YFP-coding plasmid. Fluorescence reduction was then evaluated relative to cells without dsRNA.

#### Experimental Protocol:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany) and ordinary chemical methods, the RNA single strands apparent from the sequence protocols SQ148, 149 and SQ159 and the single strands complementary to them were synthesized. Purification then occurred by HPLC. Hybridization of the single strands to a double-strand occurred by heating the stoichiometric mixture of single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 90°C and subsequent cooling over 6 hours to room temperature. The dsRNAs so obtained were microinjected into the test cell.

The murine fibroblast cell line NIH/3T3, ECACC no. 930615624 (European Collection of Animal Cell Cultures) served as test system for these cell culture experiments. The plasmid pcDNA-YFP was used for microinjections, which contained an 800 bp large Bam HI/Eco RI-YFP fragment in the corresponding restriction cleavage sites of the vector pcDNA3. Expression of YFP was investigated under the influence of simultaneously cotransfected sequence-homologous dsRNA. Evaluation occurred under the fluorescence microscope, at the earliest, 3 hours after injection, with reference to green fluorescence.



#### Preparation of the Cell Cultures:

Cultivation of the cells occurred in DMEM with 4.5 g/L glucose, 10% fetal calf serum (FCS), 2 mM L-glutamine, penicillin/streptomycin (100 IU/100 µg/mL, Biochrom) in an incubator under a 5% CO<sub>2</sub> atmosphere at 37°C. The cells underwent passage every 3 days, in order to keep them in the exponential growth phase. A day before performance of transfection, the cells were trypsinized (10 × trypsin/TEDTA, Biochrom) and inoculated with a cell density of  $0.73 \times 10^5$  cells into coated petri dishes (CORNING® Cell Culture Dish, 35 mM, Corning Inc., Corning, USA). The petri dishes were incubated with 0.2% gelatin (Biochrom) for at least 30 minutes at 37°C, washed once with PBS and immediately used for seeding of the cells. To permit recovery of individual cells, CELLocate coverslips from the Eppendorf company were used (square size 55 µm).

#### Microinjection:

To perform microinjection, the petri dishes were removed from the incubator for about 10 minutes. About 50 cells were microinjected per dish and batch (FemtoJet; Mikromanipulator 5171, Eppendorf). Glass capillaries (FemtoTip) from the Eppendorf company with a tip inside diameter of 0.5 µm were used for microinjection. The injection time was 0.8 seconds and the pressure 30 hPa. The microinjections were conducted on an Olympus IX50 microscope with a fluorescence device. 14 mM NaCl, 3 mM KCl, 10 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.0, was used as injection buffer, which contains 0.01 µg/mL pcDNA-YFP. To check successful microinjection, 0.08% (w/v) Dextran-70000 coupled Texas-Red (Molecular Probes, Leiden, Netherlands) was added to the injection solution. To investigate inhibition of the YFP expression with specific dsRNA, dsRNAs were added to the injection solution: batch 1: 0.1 µM dsRNA (sequence protocol SQ148/149); batch 2: 0.1 µM dsRNA (sequence protocol SQ148/159); batch 3: without RNA. After microinjection, the cells were incubated for at least three more hours in the incubator. The intracellular YFP fluorescence was then evaluated on the microscope: simultaneously red and green-fluorescent cells: microinjection was successful, no inhibition of YFP expression by dsRNA was observed; or control cells were involved, in which no dsRNA were injected; only red fluorescent cells: microinjection was successful, the dsRNA inhibits YFP expression.

### Results:

At a dsRNA concentration of 0.1  $\mu$ M, a significantly increased inhibition or expression of the YFP gene in fibroblasts could be observed during use of dsRNA with the protruding single-strand regions (sequence protocol SQ148/159) on both 3' ends by two nucleotides each, in comparison with dsRNA without protruding single-strand ends (Table 1).

The use of short dsRNA molecules, containing 19-25 base pairs with overhangs of a few, preferably 1 to 3, non-base-paired, single-strand nucleotides, therefore permits comparatively stronger inhibition of gene expression in mammal cells than the use of dsRNAs with the same number of base pairs without the corresponding single-strand overhangs at the same RNA concentration.

Batch	Name	Sequence protocol number	0.1 $\mu$ M
1	S1A/ S1B	SQ148 SQ149	+
2	S1A/ S4B	SQ148 (protruding end) SQ159	+++
3		without RNA	—

**Table 1:** The symbols show the relative percentage of non-fluorescent or weakly green fluorescent cells (+++ > 90%; ++ 60-90%; + 30-60%; - < 10%).

### II. Inhibition of Gene Expression with Target Gene in Cultivated HELA-S3 Cells and Mouse Fibroblasts by dsRNA:

The efficiency of inhibition of YFP expression after transient transfection of a YFP-coding plasmid based on RNA interference with dsRNAs can be modulated by the configuration of the 3' ends in the length of the base-paired regions.

### Practical Example:

To detect the efficiency of dsRNA during specific inhibition of gene expression, transiently transfected NIH/3T3 cells (fibroblasts from NIH Swiss mouse embryo, ECCAC (European Collection of Animal Cell Cultures) no. 93061524) and HELA-S3 (human cervical carcinoma cells, DSMZ (German Collection of Microorganisms and Cell Cultures) no. ACC 161) were used. The plasmid pcDNA-YFP was used for transfection, which contains an 800 bp Bam HI/Eco RI-YFP fragment in the corresponding cleavage sites of the vector pcDNA3. Double-strand RNAs derived from the sequence of the yellow fluorescent protein (YFP) were produced and transiently transfected with the plasmid pcDNA-YFP in the fibroblasts (the employed specific dsRNAs are complementary in their anti-sense strands to the corresponding sections of the gene sequences above YFP and GFP). After 48 hours, the fluorescence reduction was quantified. Cells that were transfected either only with pcDNA-YFP or with pcDNA-YFP and a controlled dsRNA (not derived from the YFP sequence) functioned as controls.

### Experimental Protocol:

#### dsRNA Synthesis:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany), and ordinary chemical methods, the RNA individual strands apparent from the sequence protocols and the single strands complementary to them were synthesized. Purification of the crude synthesis products then occurred by means of HPLC. The column NucleoPac PA-100,  $9 \times 250$  mM, from the Dionex company was used; 20 mM tris, 10 mM NaClO<sub>4</sub>, pH 6.8, 10% acetonitrile as low salt buffer and 20 mM Tris, 400 mM NaClO<sub>4</sub>, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double strand occurred by heating the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

#### Seeding of the Cells:

All cell culture work was conducted under sterile conditions in a corresponding work bench (HS18, Hera Safe, Kendro, Heraeus). Cultivation of NIH/3T3 cells and HELA-S3 occurred in an incubator (CO<sub>2</sub> incubator T20, Hera cell, Kendro, Heraeus) at 37°C, 5% CO<sub>2</sub> and saturated atmospheric humidity in DMEM (Dulbecco's Modified Eagle Medium, Biochrom), for the mouse fibroblasts, and Ham's F12 for the HELA cells with 10% FCS (fetal calf serum, Biochrom), 2 mM L-glutamine (Biochrom) and penicillin/streptomycin (100 IU/100 µg/mL, Biochrom). In order to keep the cells in the exponential growth phase, the cells underwent passage every 3 days. 24 hours before the forming transfection, the cells were trypsinized (10 × trypsin/EDTA, Biochrom, Germany) and seeded with a cell density of  $1.0 \times 10^4$  cells/recess into a 96-well plate (Multiwell dishes 96-well flat bottom, Labor Schubert & Weiss GmbH) in 150 µL growth medium.

#### Performance of Transient Transfection:

Transfection was conducted with Lipofectamine Plus<sup>TM</sup> reagent (Life Technologies) according to the information of the manufacturer. 0.15 µg pcDNA-YFP plasmid was introduced per well. The total transfection volume was 60 µL. 3-fold samples were used in each case. Plasmid DNA was first complexed, together with dsRNA. For this purpose, the plasmid DNA and the dsRNA were diluted in a serum-free medium and 1 µL PLUS reagent was used per 0.1 µg plasmid DNA (in a volume of 10 µL) and, after mixing for 15 minutes at room temperature, they were incubated. During incubation, 0.5 µL Lipofectamine was diluted in a total of 10 µL serum-free medium per 0.1 µg plasmid DNA, thoroughly mixed, added to the plasmid/dsRNA/PLUS mixture and incubated for another 15 minutes. During incubation, a medium change was conducted. For this purpose, the cells were washed once with 200 µL serum-free medium and then with 40 µL serum-free medium and then incubated further in the incubator, up to addition of DNA/dsRNA/PLUS/Lipofectamine. After addition of 20 µL DNA/dsRNA/PLUS/Lipofectamine per well, the cells were incubated for 2.5 hours in the incubator. After incubation, the cells were then washed once with 200 µL growth medium and incubated for 24 hours until detection of the fluorescence in 200 µL growth medium in the incubator.

#### Detection of Fluorescence:

24 hours after the last medium change, the fluorescence of the cells was photographed on the fluorescence microscope (IX50-S8F2, fluorescence unit U-ULS100Hg, burner U-RFL-T200, Olympus) with a USH-I02D mercury lamp (USHIO Inc., Tokyo, Japan), equipped with a WIB fluorescence cube and a digital CCD camera (Orca IIIIm, Hamamatsu and C4742-95 camera controller). Evaluation of the fluorescence recording occurred with the analysis software 3.1 (Soft Imaging System GmbH, Germany). In order to relate the YFP fluorescence to cell density, a cell nucleus staining was carried out (Hoechst staining). For this purpose, the cells were first fixed for 5 in 100  $\mu$ L methylcarnoy (75% methanol, 25% glacial acetic acid) and then again for 10 minutes in methylcarnoy. After air drying, the fixed cells were incubated for 30 minutes in the dark with 100  $\mu$ L per well of Hoechst die (75 ng/mL). After washing twice with PBS (PBS Dulbecco w/o  $\text{Ca}^{2+}$ ,  $\text{M}^{2+}$ , Biochrom), the Hoechst-stained cells were photographed under the fluorescence microscope (Olympus, WU fluorescence cube for Hoechst).

Figures 3 to 9 show the results on inhibition of YFP expression by dsRNA in the cultivated cells:

The effects of YFP-specific dsRNAs and control dsRNAs on YFP expression in NIH/3T3 mouse fibroblasts after transient transfection are summarized in Figures 3, 4, 5 and 6. The experiments were run as described in the experimental protocol. The concentration of dsRNA refers to the concentration in the medium during the transfection reaction. The designations for the dsRNAs can be gathered from Table 2. The relative fluorescence per image section in area percent is shown. 3 different image sections were evaluated per well. The averages are obtained from the 3-fold batches.

The specific inhibition of YFP gene expression by dsRNAs in HELA-S3 cells is shown in Figures 7 and 9. The inhibiting effect of differently configured dsRNA constructs (Table 2) in different concentrations on expression of YFP in HELA cells is shown in Fig. 7. Fig. 8 shows representative fluorescence microscope recordings of NIH/3T3 mouse fibroblasts transiently transfected with YFP without dsRNA and with dsRNA specifically directed against YFP ( $\times 100$  magnification).

8A: YFP controls

8B: S1, 10 nM

- 8C: S4, 10 nM
- 8D: S7, 10 nM
- 8E: S7/S11, 1 nM
- 8F: S7/S12, 1 nM

Fig. 9 shows representative fluorescence microscope recordings of HELA-3S cells transiently transfected with YFP without dsRNA and with dsRNAs specifically directed against YFP ( $\times 100$  magnification).

- 9A: K2-controls, 10 nM
- 9B: S1, 10 nM
- 9C: S4, 10 nM
- 9D: S7, 10 nM
- 9E: S7/11, 1 nM
- 9F: S7/12, 1 nM
- 9G: S1A/S4B, 10 nM
- 9H: YFP controls

### Results:

Fig. 3 shows that YFP expression after transient cotransfection of mouse fibroblasts with the YFP plasmid and dsRNAs specifically directed against the YFP sequence is inhibited with particular efficiency when the 3' ends of the regions containing 22 and 19 base pairs of the dsRNAs have single-strand sections of two nucleotides (nt). Whereas the dsRNA S1 with smooth 3' ends at a concentration of 1 nM (referred to the concentration in the cell culture medium during performance and transfection) exhibits no inhibiting effect on YFP expression, the dsRNAs S7 (19 nucleotide pairs) and S4 (24 nucleotide pairs), each with 2 nt overhangs on both 3' ends, inhibit the YFP expression by 50 or by 70% in comparison with the corresponding control dsRNAs K3 and K2. At a concentration of 10 nM, the dsRNA denoted S1 with smooth ends inhibits YFP expression by about 65%, whereas inhibition of YFP expression by the dsRNA S4 is about 94% (Fig. 4). The inhibiting effects of the dsRNAs denoted S4 and S7 is concentration-dependent (Figures 3 and 4, see also Fig. 7).

Fig. 4 shows that, for efficient suppression of YFP gene expression, the single-strand structure is not necessary on both 3' ends (on the sense and anti-sense strand). To achieve the most effective possible inhibition of YFP expression, only the 2 nt overhang on the 3' end is necessary on the anti-sense strand. Inhibition of YFP expression at a concentration of 1 nM in the two dsRNAs S4 (with 2 nt overhangs on both 3' ends) and S1A/S4B (with the 2 nt overhang on the 3' end of the anti-sense strand) lies at about 70%. On the other hand, if the 2 nt overhang is situated on the 3' end of the sense strand (and the 3' end of the anti-sense strand carries no single-strand region), inhibition of YFP gene expression is only 50%. Similarly, inhibition at higher concentrations is much better, if at least the 3' end of the anti-sense strand carries a 2 nt overhang.

A more distinct inhibition of YFP expression is achieved, if the base-paired region has 21 nucleotide pairs instead of 22 (S1 and S4), 20 (S13 and S13/14) or 19 (S7) (Figures 5, 6 and 7). Inhibition of YFP expression by S1 (22 base pairs with smooth ends) in a concentration of 5 nM is about 40%, whereas inhibition by S7/S12 (21 base pairs with smooth ends), also with 5 nM, lies at about 92%. If the dsRNA with 21 base pairs also has a 2 nt overhang on the anti-sense strand 3' end (S7/S11), inhibition lies at ~ 97% (compared with ~ 73% inhibition with S4 and ~ 70% inhibition with S7).

### III. Investigation of Serum Stability of Double-Strand RNA (dsRNA):

The objective is to increase the effectiveness found the cell cultures of inhibition of gene expression of target genes mediated by dsRNA for use in vivo. This is achieved by improved stability of the dsRNAs in serum and by an extended residence time of the molecule in the circulation and the increased effective concentration of the functional molecules related to this, resulting from improved stability.

### Practical Example:

The serum stability of dsRNAs that inhibit GFP expression was tested in vivo in murine and human serum.

### Experimental Protocol:

Incubation with human or murine serum with the corresponding dsRNA occurred at 37°C. 85 µL serum was incubated with 15 µL 100 µM dsRNA. After specified incubation times (30 minutes, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h), the samples were frozen at -80°C. dsRNA without serum (+ 85 µL ddH<sub>2</sub>O) and dsRNA at time 0 were used as control.

For isolation of the dsRNA from the incubation charge, which occurred on ice, 400 µL with 0.1% SDS was added to the charges and these are subjected to phenol extraction: 500 µL phenol:chloroform:isoamyl alcohol (IAA, 25:24:1, Roti<sup>®</sup>-Phenol, Roth, Karlsruhe) was added per charge and vortexed for 30 seconds at the highest stage (Vortex Genie-2; Scientific Industries). After 10 minutes of incubation on ice, phase separation occurred by centrifuging at 12,000 × g, 4°C for 10 minutes (Sigma 3K30, Rotor 12131-H). The upper aqueous phase (about 200 µL) was taken off and subjected first to DNase I and the proteinase K digestion: addition of 20 µL 10-fold DNase I buffer (100 mM Tris, pH 7.5, 25 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>) and 10 U DNase I (D7291, Sigma-Aldrich), 30 minutes incubation at 37°C, addition of 6 U DNase I again and incubation for another 20 minutes at 37°C, addition of 5 µL proteinase K (20 mg/mL, 04-1075, Peqlab, Germany) and 30 minutes incubation at 37°C. Phenol extraction was then conducted. For this purpose, 500 µL phenol:chloroform:IAA (25:24:1) was added, vortexed at the highest stage for 30 seconds, 10 minutes for 12000 × g, 4°C, centrifuged, the supernatant taken off and mixed in succession with 40 µL 3M Na-Ac (sodium acetate), pH 5.2, and 1 mL 100% EtOH, mixed thoroughly in the meantime and precipitated for at least 1 hour at -80°C. The precipitate was pelletized by centrifuging at 12000 × g for 30 minutes and 4°C, washed with 70% EtOH and recentrifuged (10 minutes, 12000 × g, 4°C). The air dried pellet was taken up in 30 µL RNA gel application buffer (7 M urea, 1 × TBE (0.09 M tris-borate, 0.002 M EDTA



(ethylenediaminetetraacetate), 0.02% (w/v) bromophenol blue, 0.02% (w/v) xylene cyanol) and stored at -20°C until gel application.

For characterization of the dsRNA, an analytical, denaturing polyacrylamide gel electrophoresis (analytical PAGE) was conducted. The urea gels were prepared right before the run: 7 M urea (21 g) was dissolved during agitation in 25 mL 40% aqueous acrylamide/bisacrylamide stock solution (Rotiphoresis gel, A515.1, Roth) and 5  $\mu$ L 10  $\times$  TBE (100 g Tris, 55 g boric acid, 9.3 g EDTA per L distilled water) and made up to 50  $\mu$ L with distilled water. Right before pouring, 50  $\mu$ L TEMED (N,N,N',N'-tetramethylethylenediamine) and 500  $\mu$ L 10% APS (ammonium peroxodisulfate) were added. After polymerization, the gel was introduced to a vertical electrophoresis apparatus (Merck, Darmstadt) and a prerun was conducted for 30 minutes at a constant 40 mA current intensity. As run buffer, 1  $\times$  TBE buffer was used. Before application onto the gel, the RNA samples were heated for 5 minutes at 100°C, cooled on ice and centrifuged for 20 seconds in a table-top centrifuge (Eppendorf, minispin). 15  $\mu$ L was applied to the gel. The run occurred for about 2 hours at a constant current of 40 mA. After the run, the gel was stained for 30 minutes at RT (room temperature) with Stains all stain solution (20 mL Stains all stock solution dissolved in 200 mL formamide) mixed with 200 mL distilled water and 180 mL formamide) and the background staining eliminated after rinsing in distilled water for 45 minutes. The gels were photographed with the photo documentation system Image Master VDS from Pharmacia.

Figures 10 to 17 show the serum stability of dsRNA after incubation with human and murine serum and subsequent electrophoretic separation in 20% 7 M urea gel.

Fig. 10: Incubation of S2 (0-22-0) in mouse serum

1. at time 0 (without serum)
2. at time 0
3. for 30 minutes
4. for 1 hour
5. for 2 hours
6. for 4 hours

7. for 12 hours
8. 2  $\mu\text{L}$  100  $\mu\text{M}$  S1 without incubation
- S1A) Sense strand S1 (10  $\mu\text{L}$  20  $\mu\text{M}$  S1A)
- S1B) Anti-sense strand S1 (10  $\mu\text{L}$  20  $\mu\text{M}$  S1B)

Fig. 11: Incubation of S1 (0-22-0) in human serum

1. 2  $\mu\text{L}$  100  $\mu\text{M}$  S1 untreated (without incubation)
2. for 30 minutes
3. for 2 hours
4. for 4 hours
5. for 6 hours
6. for 8 hours
7. for 12 hours
8. for 24 hours
- S1A) Sense strand S1 (10  $\mu\text{L}$  20  $\mu\text{M}$  S1A)
- S1B) Anti-sense strand S1 (10  $\mu\text{L}$  20  $\mu\text{M}$  S1B)

Fig. 12: Incubation at S7 (2-19-20) in mouse serum

1. at time 0 (without serum)
2. for 30 minutes
3. for 4hours
4. for 12 hours

Fig. 13: Incubation of S7 (2-19-2) in human serum

1. Sense strand S7 (10  $\mu\text{L}$  20  $\mu\text{M}$  S7A)
2. Anti-sense strand S7 (10  $\mu\text{L}$  20  $\mu\text{M}$  S7B)
3. for 30 minutes
4. for 1 hour
5. for 2 hours
6. for 4 hours
7. for 6 hours

8. for 12 hours
9. for 24 hours
10. at time 0 (without serum)

**Fig. 14: Incubation of K3 (2-19-20) in mouse serum**

1. Sense strand K3 (10  $\mu$ L 20  $\mu$ M K3A)
2. Anti-sense strand K3 (10 L 20  $\mu$ M K3B)
3. at time 0 (without serum)
4. at time 0 (with serum)
5. for 30 minutes
6. for 1 hour
7. for 2 hours
8. for 4 hours
9. for 12 hours

**Fig. 15: Incubation of PKC1/2 (0-22-2) in mouse serum**

1. for 30 minutes
2. for 1 hour
3. for 2 hours
4. for 4 hours
5. for 12 hours
6. 2  $\mu$ L 100  $\mu$ M PKC1/2 (untreated)

**Fig. 16: Incubation of S1A/S4B (0-22-2) in human serum**

1. at time 0 (without serum)
2. for 24 hours
3. for 12 hours
4. for 8 hours
5. for 6 hours
6. for 4 hours
7. for 2 hours

8. for 30 minutes
9. Sense strand S1A (10  $\mu$ L 20  $\mu$ M S1A)
10. Anti-sense strand S4B (10  $\mu$ L 20  $\mu$ M S4B)

Fig. 17: Incubation of K2 (2-22-2) in human serum

1. Sense strand K2 (10  $\mu$ L 20  $\mu$ M K2A)
2. Anti-sense strand K2 (10  $\mu$ L 20  $\mu$ M K2B)
3. at point 0 (without serum)
4. for 30 minutes
5. for 2 hours
6. for 4 hours
7. for 6 hours
8. for 8 hours
9. for 12 hours
10. for 24 hours

#### Results:

dsRNAs without single-strand regions on the 3' ends are much more stable in both human and murine serum than dsRNAs with single-strand 2nt overhangs on the 3' ends (Figures 10 to 14 and 17). After 12 and 24 hours incubation at S1 in murine or human serum, bands in the original size are almost fully retained. On the other hand, in dsRNAs with 2nt overhangs on both 3' ends, the stability in human and murine serum diminishes significantly. After only 4 hours of incubation of S7 (Figures 12 and 13) or K3 (Fig. 14), no bands can be detected in the original size.

In order to increase the stability of dsRNA in serum, it is sufficient if the dsRNA has a smooth end. In mouse serum after 4 hours incubation (Fig. 15, track 4), the bands in the original size are scarcely broken down in comparison with S7 (after 4 hours complete degradation; Fig. 12, track 3).

As an optimal compromise with respect to biological efficacy of dsRNA, the use of dsRNA with a smooth end and a single-strand region of 2 nucleotides can be considered, in which the single-strand overhang should be situated on the 3' end of the anti-sense strand.

The sequences used here are apparent from the following Table 2 and the sequence protocols SQ148-151 and 153-167.

Name	Sequenz- proto- koll-Nr.	dsRNA-Sequenz	
S1	SQ148 SQ149	(A) 5' - CCACAUGAAGCAGCAGACUUC -3' (B) 3' - GGUGUACUUCGUCGUGCUGAAG -5'	0-22-0
S7	SQ150 SQ151	(A) 5' - CCACAUGAAGCAGCAGACUU -3' (B) 3' - CUGGUGUACUUCGUCGUGCUG -5'	2-19-2
K1	SQ153 SQ154	(A) 5' - ACAGGAUGAGGAUCGUUUCGCA -3' (B) 3' - UGUCCUACUCCUAGCAAAGCGU -5'	0-22-0
K3	SQ155 SQ156	(A) 5' - GAUGAGGAUCGUUUCGCAUGA -3' (B) 3' - UCCUACUCCUAGCAAAGCGUA -5'	2-19-2
K2	SQ157 SQ158	(A) 5' - ACAGGAUGAGGAUCGUUUCGCAUG -3' (B) 3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	2-22-2
S1A/ S4B	SQ148 SQ159	(A) 5' - CCACAUGAAGCAGCAGACUUC -3' (B) 3' - CUGGUGUACUUCGUCGUGCUGAAG -5'	0-22-2

PKC 1/2	SQ160	(A)	5' - CUUCUCCGCCUCACACCGCUGCAA -3'	2-22-0
	SQ161	(B)	3' - GAAGAGGCGGAGUGUGGCGACG -5'	
S7/S12	SQ150	(A)	5' - CCACAUGAAGCAGCACGACUU -3'	0-21-0
	SQ162	(B)	3' - GGUGUACUUCGUCGUGCUGAA -5'	
S7/S11	SQ150	(A)	5' - CCACAUGAAGCAGCACGACUU -3'	0-21-2
	SQ163	(B)	3' - CUGGUGUACUUCGUCGUGCUGAA -5'	
S13	SQ164	(A)	5' - CCACAUGAAGCAGCACGACU -3'	0-20-2
	SQ165	(B)	3' - CUGGUGUACUUCGUCGUGCUGA -5'	
S13/14	SQ164	(A)	5' - CCACAUGAAGCAGCACGACU -3'	0-20-0
	SQ166	(B)	3' - GGUGUACUUCGUCGUGCUGA -5'	
S4	SQ167	(A)	5' - CCACAUGAAGCAGCACGACUUCUU -3'	2-22-2
	SQ159	(B)	3' - CUGGUGUACUUCGUCGUGCUGAAG -5'	
K1A/ K2B	SQ153	(A)	5' - ACAGGAUGAGGAUCGUUUCGCA -3'	0-22-2
	SQ158	(B)	3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	
K1B/ K2A	SQ154	(A)	5' - ACAGGAUGAGGAUCGUUUCGCAUG -3'	2-22-0
	SQ157	(B)	3' - UGUCCUACUCCUAGCAAAGCGU -5'	
S1B/ S4A	SQ149	(A)	5' - CCACAUGAAGCAGCACGACUUCUU -3'	2-22-0
	SQ167	(B)	3' - GGUGUACUUCGUCGUGCUGAAG -5'	

*Key to figure: (Headings)*

Name

Sequence protocol no.

dsRNA sequence

**Table 2**

#### IV. In Vivo Study:

Double-strand RNA (dsRNA) that was derived from the GFP sequence where unspecific dsRNA was injected intravenously into the caudal vein of “GFP laboratory mice” that express the green fluorescent protein (GFP) in all cells that conduct protein biosynthesis. At the end of the experiment, the animals were killed and the GFP expression analyzed in tissue sections and in plasma.

#### Experimental Protocol:

##### Synthesis of dsRNA:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany), and ordinary chemical methods, the RNA single strands apparent from the sequence protocols and the single strand complementary to them were synthesized. Purification of the crude synthesis products then occurred with HPLC. As columns, NucleoPac PA-100, 9 × 250 mm from the Dionex company were used; 20 mM Tris, 10 mM NaClO<sub>4</sub>, pH 6.8, 10% acetonitrile was used as low salt buffer and 20 mM Tris, 400 mM NaClO<sub>4</sub>, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double strand occurred by heating of the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

##### Experimental Animal Keeping and Performance of the Experiment

The transgenic laboratory mouse strain TgN (GFPU) 5Nagy (Jackson Laboratory, Bar Harbor, Maine, USA) was used, which expresses GFP (with a beta-actin promoter and a CMV intermediate early enhancer) in all previously investigated cells (Hadjantonakis AK et al. 1993, Mech. Dev. 76: 79-90; Hadjantonakis AK et al., 1998 Nature Genetics 19: 220-222). GFP-transgenic mice can be clearly distinguished from the corresponding wild types (WT) by means of fluorescence (with a UV hand lamp). For breeding, the corresponding WT was paired with a heterozygous GFP type.

The experiment was performed according to the German Animal Protection Regulations. The animals were kept under controlled environmental conditions in groups of 3-5 animals in type III Makrolon cages from the Ehret company, Emmendingen, at a constant temperature of 22°C and a light-dark rhythm of 12 h. Softwood granulate 8/15 from the Altromin company, Lage, was used as sawdust litter. The animals received tap water and standard feed Altromin 1324 pelletized (Altromin) ad libitum.

To perform the experiment, the heterozygous GFP animals were kept in groups of 3 animals each in cages, as described above. Injections of the dsRNA solution occurred intravenously (IV) into the caudal vein in 12-hour cycles (between 5:30 and 7:00 a.m. and between 5:30 and 7:00 p.m.) over 5 days. The injection volumes were 60 µL for per 10 g of body weight and the dose was 2.5 mg dsRNA and 50 µg per kg of body weight. Division into groups was as follows:

- Group A: PBS (phosphate buffered saline) 60 µL per 10 kg of body weight,
- Group B: 2.5 mg per kg of body weight of a nonspecific control dsRNA (K1 control with smooth ends and a double-strand region of 22 nucleotide pairs),
- Group C: 2.5 mg per kg of body weight of another unspecific control dsRNA (K3 control with 2nt overhangs on both 3' ends and a double-strand region of 19 nucleotide pairs),
- Group D: 2.5 mg per kg of body weight dsRNA (specific against GFP, subsequently referred to as S1, with smooth ends and a double-strand region of 22 nucleotide pairs),
- Group E: 2.5 mg dsRNA per kg of body weight (specific against GFP, subsequently referred to as S7, with 2nt overhangs on the 3' ends of both strands and a double-strand region of 19 nucleotide pairs)
- Group F: 50 µg S1-dsRNA per kg of body weight (i.e., 1/50 of the dose of group D).



After the last injection of a total of 10 injections, the animals were killed after 14-20 h and the organs and blood taken as described.

#### Organ Removal:

Immediately after killing the animals by CO<sub>2</sub> inhalation, blood and different organs were taken (thymus, lungs, heart, spleen, stomach, intestines, pancreas, brain, kidneys and liver). The organs were rinsed briefly in cold sterile PBS and divided with a sterile scalpel. One part was fixed for immunohistochemical staining in methycarnoy's (MC, 60% methanol, 30% chloroform, 10% glacial acetic acid) for 24 hours, one part was shock frozen for frozen sections and for protein isolation immediately in liquid nitrogen and stored at -80°C, and another smaller part was frozen for RNA isolation in RNAsasy-Protect (Qiagen) at -80°C. The blood was immediately held for 30 minutes on ice after sampling, mixed, centrifuged for 5 minutes at 2000 rpm (Mini spin, Eppendorf), the supernatant removed and stored at -80°C (here referred to as plasma).

#### Processing of the Biopsies:

After 24 h of fixation of the tissue in MC, the tissue pieces were dehydrated in an increasing alcohol series at RT (room temperature): every 40 minutes 70% methanol, 80% methanol, 2 × 96% methanol and 3 × 100% isopropanol. The tissue was then heated in 100% isopropanol to 60°C in an incubator, then incubated for 1 hour in an isopropanol/paraffin mixture at 60°C and 3 × for 2 hours in paraffin and then imbedded in paraffin. For immunoperoxidase staining, tissue sections with 3 µm section thickness were prepared with a rotary microtome (Leica), mounted on slides (Superfrost, Vogel) and incubated for 30 minutes at 60°C in an incubator.

#### Immunoperoxidase Staining versus GFP:

The sections were deparaffinized 3 × 5 minutes in xylene, rehydrated in an increasing alcohol series (3 × 3 min 100% ethanol, 2 × 2 min 95% ethanol) and then incubated for 20 minutes in 3% H<sub>2</sub>O<sub>2</sub>/methanol to block endogenous peroxidases. All incubation steps were conducted subsequently in a moist chamber. After 3 × 3 minutes of washing with PBS, they were incubated

with the first antibody (goat anti-GFP, sc-5384, Santa Cruz, Biotechnology) 1:500 in 1% BSA/PBS overnight at 4°C. Incubation with the biotinylated secondary antibody (donkey anti-goat; Santa Cruz Biotechnology; 1:2000 dilution) occurred for 30 minutes at RT, whereupon they were incubated for 30 minutes with Avidin D Peroxidase (1:2000 dilution, Vector Laboratories). After each antibody incubation, the sections were washed 3 × 3 min in PBS and the buffer residues removed from the sections with wadding. All antibodies were diluted in 1% bovine serum albumin (BSA)/PBS. Staining with 3,3'-diaminobenzidine (DAB) was conducted with the DAB substrate kit (Vector Laboratories) according to the manufacturer's data. As nuclear counterstain, hematoxylin III according to Gill (Merck) was used. After dehydration in a rising alcohol series at 3 × 5 minutes xylene, the sections were covered with Entellan (Merck). Microscopic evaluation of staining occurred with the IX50 microscope from Olympus, equipped with a CCD camera (Hamamatsu).

#### Protein Isolation from Tissue Pieces:

800 µL isolation buffer (50 mM HEPES, pH 7.5, 150 mM NaCl; 1 mM EDTA; 2.5 mM EGTA; 10% glycerol; 0.1% Tween; 1 mM DTT, 10 mM β-glycerol phosphate; 1 mM NaF; 0.1 mM Na<sub>3</sub>VO<sub>4</sub> with a protease inhibitor tablet "Complete" from Roche) were added to the still frozen tissue pieces and homogenized 2 × 30 seconds with an Ultraturrax (DIAX 900, dispersal die 6 G, Heidolph), and cooled in between on ice. After 30 minutes of incubation on ice, they were mixed and centrifuged for 20 minutes at 1000 × g, 4°C (3K30, Sigma). The supernatant was incubated for another 10 minutes on ice, mixed and centrifuged for 20 minutes to 15000 × g, 4°C. A protein determination according to Bradford, 1976, modified after Zor & Selinger, 1996, was conducted with the supernatant with the Roti-Nanoquant system of Roth according to the data of the manufacturer. BSA (bovine serum albumin) in concentrations from 10 to 100 µg/mL was used for the protein calibration line.

#### SDS Gel Electrophoresis:

Electrophoretic separation of the proteins occurred in a multigel long electrophoresis chamber from Biometra with a denaturing, discontinuous 15% SDS-PAGE (polyacrylamide gel electrophoresis) according to Lämmli (Nature 277: 680-685, 1970). For this purpose, a

separation gel 1.5 mM thick was initially poured: 7.5 mL acrylamide/bisacrylamide (30%, 0.9%), 3.8 mL 1.5 M Tris/HCl, pH 8.4, 150  $\mu$ L 10% SDS, 3.3 mL doubly distilled water, 250  $\mu$ L ammonium persulfate (10%), 9  $\mu$ L TEMED (N,N,N',N'-tetramethylethylenediamine) and coated up to polymerization with 0.1% SDS. The collected gel was then poured: 0.83  $\mu$ L acrylamide/bisacrylamide (30%/0.9%), 630  $\mu$ L 1 M Tris/HCl, pH 6.8, 3.4 mL doubly distilled water, 50  $\mu$ L 10% SDS, 50  $\mu$ L 10% ammonium persulfate, 5  $\mu$ L TEMED.

Before application of the gel, the proteins were mixed with a corresponding amount of 4-fold sample buffer (200 mM Tris, pH 6.8, 4% SDS, 100 mM DTT (dithiothreitol), 0.02% bromophenol blue, 20% glycerol), denatured for 5 minutes in a heating unit at 100°C, briefly centrifuged after cooling on ice and applied to the gel. The same plasma or protein amounts were used per track (3  $\mu$ L plasma and 25  $\mu$ g total protein each). Electrophoresis occurred water-cooled at RT and a constant 50 V. The protein gel marker from Bio-Rad (kaleidoscope prestained standard) was used as length standard.

#### Western Blot and Immune Detection:

Transfer of the proteins from SDS-PAGE to a PVDF (polyvinylidene difluoride) membrane (Hybond-P, Amersham) occurred in the semi-dry method according to Kyte-Anderson (J. Biochem. Biophys. Methods 10: 203-210, 1984) at RT and a constant current intensity of 0.8 mA/cm<sup>2</sup> for 1.5 h. A Tris/glycine buffer was used as transfer buffer (39 mM glycine, 465 mM Tris, 0.1% SDS and 20% methanol). To check the electrophoretic transfer, both the gels after blotting and the blot membranes after immune detection were stained with Coomassie (0.1% Coomassie G250, 45% methanol, 10% glacial acetic acid). For saturation of nonspecific bonds, the blot membrane after transfer was incubated in 1% skim milk powder/PBS for 1 h at RT. It was then washed three times for 3 minutes with 0.1% Tween-20/PBS. All subsequent antibody incubations and washing steps occurred in 0.1% Tween-20/PBS. Incubation with the primary antibody (goat anti-GFP, sc 5384, Santa Cruz Biotechnology) occurred in a dilution of 1:1000 for 1 h at RT. It was then washed 3  $\times$  5 min and incubated for 1 hour at RT with a secondary antibody (donkey anti-goat IgG horseradish peroxidase labeled, Santa Cruz Biotechnology) in a dilution of 1:1000. Detection occurred with the ECL system from Amersham according to the data of the manufacturer.

Figures 18 to 20 show inhibition of GFP expression after intravenous injection of dsRNA specifically directed against GFP with immunoperoxidase staining relative to GFP on 3  $\mu$ m paraffin sections. During the experiment, dsRNA directed against GFP with a double-strand region of 22 nucleotide (nt) pairs without overhangs on the 3' ends (D) and the corresponding unspecific control dsRNA (B), as well as dsRNA directed specifically against GFP with a double-strand region containing 19 nucleotide pairs with 2 nt overhangs on the 3' ends (E) and the corresponding nonspecific control dsRNA (C) were applied in 12-hour cycles over 5 days. (F) received 1/50 of the dose of group D. Animals without dsRNA administration (A) and WT animals were investigated as additional controls. Fig. 18 shows inhibition of GFP expression in kidney sections, Fig. 19 in heart tissue and Fig. 20 in pancreas tissue. Figures 21 to 23 show Western blot analyses of GFP expression in plasma and tissues. Inhibition of GFP expression in plasma is shown in Fig. 21, in the kidneys in Fig. 22 and in the heart in Fig. 23. Total protein isolates from different animals are shown in Fig. 23. The same total protein amounts per track were applied. In the animals, to which unspecific control dsRNA was administered (animals of groups B and C), the GFP expression relative to animals that received no dsRNA is not reduced. Animals that received dsRNA specifically directed against GFP with 2 nt overhangs on the 3' ends of both strands and a double-strand region containing 19 nucleotide pairs exhibited a significantly inhibited GFP expression in the investigated tissues (heart, kidneys, pancreas and blood), compared with the untreated animals (Figures 18 to 23). In the animals of groups D and F, in which dsRNA directed specifically against GFP with smooth ends and double-strand region containing 22 nucleotide pairs was administered, only those animals that received dsRNA in a dose of 50  $\mu$ g/kg of body weight per day exhibited a specific inhibition of GFP expression, which, however, was much less pronounced than that of the animals in group E. The summarizing evaluation of GFP inhibition in the tissue sections and in Western blot shows that inhibition of GFP expression in blood and the kidneys is strongest (Figures 18, 21 and 22).

#### V. Inhibition of Gene Expression of EGF Receptor with dsRNA as a Therapeutic Approach in Forms of Cancer with EGFR Overexpression or EGFR-induced Proliferation:

The epidermal growth factor (EGF) receptor (EGFR) belongs to the receptor tyrosine kinases, transmembrane proteins with an intrinsic tyrosine kinase activity, which participate in the control

of a series of cellular processes, like cell growth, cell differentiation, migratory processes or cell vitality (review in: Van der Geer et al. 1994). The EGFR family consists of 4 members, EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) with a transmembrane domain, a cysteine-rich extracellular domain and an intracellular catalytic domain. The sequence of EGFR, a 170 kDa protein, has been known since 1984 (Ullrich et al., 1984).

EGFR is activated by peptide growth factors, like EGF, TGF $\alpha$  (transforming growth factor), amphiregulin, beta-cellulin, HB-EGF (heparin-binding EGF-like growth factor) and neuregulin. Ligand bonding induces formation of homo- or heterodimers with subsequent autophosphorylation of cytoplasmic tyrosine (Ullrich & Schlessinger, 1990; Alroy & Yarden, 1997). The phosphorylated amino acids form the bonding sites for a number of proteins that participate in the proximal steps of signal conduction in a complex network. EGFR participates in a wide variety of tumor diseases and is therefore a suitable target for therapeutic approaches (Huang & Harari, 1999). The mechanisms that lead to an aberrant EGFR activation can be due to overexpression, amplification, constituted activation of mutant receptor forms or autocrine loops (Voldborg et al., 1997). An overexpression of EGFR was described for a number of tumors, like breast cancer (Walker & Dearing, 1999), non-small lung carcinoma (Fontanini et al., 1998), pancreatic carcinomas, colon carcinoma (Salomon et al., 1995) and glioblastomas (Rieske et al., 1998). No efficient and specific therapeutic agents have thus far been available for malignant glioblastomas, in particular.

#### Practical Example:

To demonstrate the efficacy of dsRNA during specific inhibition of EGFR gene expression, U-87 MG cells (human glioblastoma cells), ECCAC (European Collection of Animal Cell Cultures) no. 89081402 were used, which were transfected with dsRNA directed specifically against the EGF receptor (sequence protocol SQ 51). After about 72 hours' incubation, the cells were harvested, the protein isolated and the EGFR expression investigated in the Western blot method.

## Experimental Protocol:

### dsRNA Synthesis:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany) and an ordinary chemical method, the RNA single strands apparent from the sequence protocols and the single strands complementary to them were synthesized. Purification of the crude synthesis products then occurred with HPLC. The column NucleoPac PA-100, 9 × 250 mm, from the Dionex company was used; 20 mM Tris, 10 mM NaClO<sub>4</sub>, pH 6.8, 10% acetonitrile was used as low salt buffer and 20 mM Tris, 400 mM NaClO<sub>4</sub>, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double-strand occurred by heating of the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

### Seeding of the Cells:

All cell culture work was conducted under sterile conditions and an appropriate work bench (HS18, Her safe, Kendro, Heraeus). Cultivation of U-87 MG cells occurred in an incubator (CO<sub>2</sub> incubator T20, Hera cell, Kendro, Heraeus) at 37°C, 5% CO<sub>2</sub> and saturated atmospheric humidity in DMEM (Dulbecco's modified eagle medium, Biochrom) with 10% FCS (fetal calf serum, Biochrom), 2 mM L-glutamine (Biochrom), 1 mM sodium pyruvate (Biochrom), 1 × NEAA (nonessential amino acids, Biochrom) and penicillin/streptomycin (100 IU/100 µg/mL, Biochrom). In order to keep the cells in the exponential growth phase, the cells were subjected to passage every 3 days. 24 hours before application of dsRNA by transfection, the cells were trypsinized (10 × trypsin/EDTA, Biochrom, Germany) and seeded with a cell density of 5 × 10<sup>5</sup> cells/well in a 6-well plate (6-well plates, Labor Schubert & Weiss GmbH) in 1.5 mL growth medium.

### Application of dsRNA in Cultivated U-87 MG Cells:

Application of dsRNA occurred by transfection with OLIGOFECTAMINE™ reagent (Life Technologies) according to the information of the manufacturer. The total transfection volume was 1 mL. The dsRNA was first diluted in serum-free medium: for this purpose, 0.5 µL of a 20

$\mu\text{m}$  stock solution of dsRNA specifically directed against EGFR and 9.5  $\mu\text{L}$  of a 20  $\mu\text{m}$  stock solution of unspecific dsRNA (K1A/K2B) with 175  $\mu\text{L}$  serum-free medium were diluted per well (200 nM dsRNA in transfection charge and 10 nM specific EGFR-dsRNA). The OLIGOFECTAMINE<sup>TM</sup> reagent was also diluted in serum-free mediums: 3  $\mu\text{L}$  with 12  $\mu\text{L}$  medium per well and then incubated for 10 minutes at room temperature. The diluted OLIGOFECTAMINE<sup>TM</sup> reagent was then added to the dsRNAs diluted in medium, mixed and incubated for another 20 minutes at RT. During incubation, a medium change was performed. The cells were washed for this purpose once with 1 mL serum-free medium and incubated further in the incubator with 800  $\mu\text{L}$  serum-free medium, up to addition of dsRNA/OLIGOFECTAMINE<sup>TM</sup> reagent. After addition of 200  $\mu\text{L}$  dsRNA/OLIGOFECTAMINE<sup>TM</sup> reagent per well, the cells were further incubated in the incubator to protein isolation.

#### Protein Isolation:

About 72 hours after transfection, the cells were harvested and protein isolation carried out. For this purpose, the medium was removed and the cell monolayer washed once with PBS. After addition of 200  $\mu\text{L}$  protein isolation buffer (1  $\times$  protease inhibitor “Complete”, Roche, 50 mM HEPES, pH 7.5, 1509 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 10% glycerol, 0.1% Tween-20, 1 mM DTT, 10 mM  $\beta$ -glycerol phosphate, 1 mM NaF, 0.1 mM  $\text{Na}_3\text{VO}_4$ ), the cells were separated by means of a cell scraper, incubated for 10 minutes on ice, transferred to an Eppendorf reaction vessel and stored at  $-80^\circ\text{C}$  for at least 30 minutes. After thawing, the lysate was homogenized on stage 3 for 10 seconds with a disperser (DIAX 900, dispersing die 6G, Heidolph Instruments GmbH & Co KG, Schwabach), incubated on ice for 10 minutes and centrifuged for 15 minutes at  $14000 \times g$ ,  $4^\circ\text{C}$  (3K30, Sigma). A protein determination was conducted with the supernatant according to Bradford with the Roti<sup>®</sup> Nanoquant system from Roth (Roth GmbH & Co., Karlsruhe) according to the information of the manufacturer. For this purpose, 200  $\mu\text{L}$  protein solution in appropriate dilution was mixed with 800  $\mu\text{L}$  1  $\times$  working solution and the extinction measured in semi-microcells at 450 and 590 nm versus distilled water in a Beckman spectrophotometer (DU 250). The corresponding BSA dilutions were used for the calibration line (beaded BSA, Sigma).

### SDS Gel Electrophoresis:

Electrophoretic separation of the proteins occurred in a multi-gel long electrophoresis chamber from Biometra with a denaturing, discontinuous 7.5% SDS-PAGE (polyacrylamide gel electrophoresis) according to Lämmli (Nature 277: 680-685, 197). For this purpose, a separation gel was initially poured with 1.5 mm thickness: 3.7 mL acrylamide/bisacrylamide (30%, 0.9%), 3.8 mL 1 M Tris/HCl, pH 8.4, 150  $\mu$ L 10% SDS, 7.15 mL doubly distilled water, 150  $\mu$ L ammonium persulfate (10%), 9  $\mu$ L TEMED (N,N,N',N'-tetramethylethylenediamine) and coated with 0.1% SDS to polymerization. The collection gel was then poured: 0.83 mL acrylamide/bisacrylamide (30%/0.9%), 630  $\mu$ L 1 M Tris/HCl, pH 6.8, 3.4 mL doubly distilled water, 50  $\mu$ L 10% SDS, 50  $\mu$ L 10% ammonium persulfate, 5  $\mu$ L TEMED.

For application to the gel, the protein samples were mixed 1:3 with 4  $\times$  sample buffer (200 mM Tris, pH 6.8, 4% SDS, 100 mM DTT (dithiothreitol), 0.02% bromophenol blue, 20% glycerol), denatured for 5 minutes at 100°C, briefly centrifuged after cooling on ice and applied to the gel. 35  $\mu$ g total protein was applied per track. The run occurred water cooled at RT and a constant 50 V. The kaleidoscope protein gel marker (BioRad) was used as length standard.

### Western Blot and Immunodetection:

Transfer of the proteins from SDS-PAGE to a PVDF (polyvinylidene difluoride) membrane (Hybond-P, Amersham) occurred in the semi-dry method according to Kyte-Anderson (J. Biochem. Biophys. Methods 10: 203-210, 1984) at RT and a constant current intensity of 0.5 mA/cm<sup>2</sup> for 1.5 h. The following were used as transfer buffer: cathode buffer (30 mM Tris, 40 mM glycine, 10% methanol, 0.01% SDS; pH 9.4), anode buffer I (300 mM Tris, pH 10.4, 10% methanol) and anode buffer II (30 mM Tris, pH 10.4, 10% methanol). Before combining the blot stack with 3 mm Whatman paper (Schleicher & Schüll), the gel was incubated in the cathode buffer and the PVDF membrane (30 seconds beforehand in 100% methanol) in anode buffer II (5 min): 2 layers 3 mm paper (anode buffer I), 1 layer 3 mm paper (anode buffer II), PVDF membrane, gel, 3 layers 3 mm paper (cathode buffer). To check electrophoretic transfer, both the gels after blotting and the blot membranes after immunodetection were stained with Coomassie (0.1% Coomassie G250, 45% methanol, 10% glacial acetic acid).



The blot membrane was incubated after transfer in 1% skim milk powder/ PBS/0.1% Tween-20 for 1 h at RT. It was then washed three times for 3 minutes with 0.1% Tween-20/PBS. All subsequent antibody incubations and washing steps occurred in 0.1% Tween-20/PBS. Incubation with the primary antibody (human EGFR extracellular domain, specific goat IgG, catalog no. AF231, R&D Systems) occurred on a rocking device for 2 h at RT and a concentration of 1.5 µg/mL. It was then washed 3 × for 6 minutes and incubated for 1 hour at RT with the secondary antibody (donkey anti-goat IgG horseradish peroxidase label, Santa Cruz Biotechnology) (diluted 1:10000). After washing (3 × 3 min in PBS/0.1% Tween-20), detection occurred immediately with ECL reaction (enhanced chemiluminescence): 200 µL solution A (250 mM luminol, Roth, dissolved in DMSO), 89 µL solution B (90 mM p-coumaric acid, Sigma, dissolved in DMSO) and 2 mL 30% H<sub>2</sub>O<sub>2</sub> solution were pipetted into 18 mL distilled water. Depending on the membrane size, 4-6 mL was pipetted directly onto the membrane, incubated for 1 minute at RT and then an x-ray film (Biomax MS, Kodak) applied immediately.

The sequences used here are shown in the following Table 3 and in the sequence protocols S!153, 157, 158, 168-173.

<b>ES-7</b>	SQ168	(A) 5' - AACACCGCAGCAUGUCAAGAU -3'	2-19-2
	SQ169	(B) 3' - UUUUGUGGCGUCGUACAGUUC -5'	
<b>ES-8</b>	SQ170	(A) 5' - AAGUUAAAUCCCCGUCGCUAU -3'	2 <sup>5</sup> -19-2 <sup>5</sup>
	SQ171	(B) 3' - CAAUUUUAAGGGCAGCGAUAGU -5'	
<b>ES2A/ ES5B</b>	SQ172	(A) 5' - AGJGUGAUCCAAGCUGUCCCAA -3'	0-22-2
	SQ173	(B) 3' - UUUCACACUAGGUUCGACAGGGUU -5'	
<b>K2</b>	SQ157	(A) 5' - ACAGGAUGAGGAUCGUUUCGCAUG -3'	2-22-2
	SQ158	(B) 3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	

<b>K1A/ K2B</b>	SQ153	(A)	5' - ACAGGAUGAGGAUCGUJUCGCA	-3'	<b>0-22-2</b>
	SQ158	(B)	3' - UCUGUCCUACUCCUAGCAAAGCGU	-5'	

**Table 3**

Inhibition of EGFR Expression in U-87 MG Glioblastoma Cells:

24 hours after seeding of the cells, they were transfected with 10 nM dsRNA as stated (oligofectamine). After 72 hours, the cells were harvested and the protein isolated. Separation of the proteins occurred in 7.5% SDS-PAGE. 35 µg total protein was applied per track. Fig. 4 shows the corresponding Western blot analysis, from which it follows that the EGFR expression after transfection in U-87 MG cells can be significantly inhibited relative to the corresponding controls with the dsRNA specifically directed against the EGFR gene with a 2 nt overhang on the 3' end of the anti-sense strand. This inhibition of expression of an endogenous gene by specific dsRNA therefore confirms the results stated in the practical example II concerning inhibition of expression of an artificial gene introduced to the cell after transient transfection. The inhibition of EGFR expression mediated by ES-7 and ES-8 is much lower. The dsRNAs used in Fig. 24 can be gathered from Table 3.

VI. Inhibition of Expression of the Multidrug Resistance Gene 1 (MDR1):

Experimental Protocol:

In vitro detection for blocking of MDR1 expression was conducted in the colon carcinoma cell line LS174T (ATCC – American Type Culture Collection, Tom et al., 1976). It is known of this cell line that expression of MDR1 can be induced by addition of rifampicin to the culture medium (Geick et al., 2001). Transfections were conducted with different commercial transfection kits (Lipofectamine, Oligofectamine, both Invitrogen; TransMessenger, Qiagen), in which the TransMessenger transfection kit also proved to be best suited for this cell line.

To run the RNA interference experiments, 4 short double-strand ribonucleic acids R1-R4 were used, whose sequences are shown in Table 4. The ribonucleic acids are homologous with sections of the coding sequence of MDR1 (sequence protocol SQ 30). Sequences R1-R3 consists of a 22-mer sense and a 24-mer anti-sense strand, in which the forming double-strand has a two nucleotide overhang on the 3' end of the anti-sense strand (0-22-2). The sequence R4 corresponds to R1, but consists of a 19-mer double strand with 2 nucleotide overhangs on each 3' end (2-19-2).

<u>Name</u>	<u>Sequenz- proto- koll-Nr.</u>	<u>Sequenz</u>	<u>Position in Daten- bank-# AF016535</u>
Seq R1	SQ141 SQ142	5' - CCA UCU CGA AAA GAA GUU AAG A-3' 3' -UG GGU AGA GCU UUU CUU CAA UUC U-5'	1320-1342 1335-1318
Seq R2	SQ143 SQ152	5' - UAU AGG UUC CAG GCU UGC UGU A-3' 3' -CG AUA UCC AAG GUC CGA ACG ACA U-5'	2599-2621 2621-2597
Seq R3	SQ144 SQ145	5' - CCA GAG AAG GCC GCA CCU GCA U-3' 3' -UC GGU CUC UUC CGG CGU GGA CGU A-5'	3778-3799 3799-3776
Seq R4	SQ146 SQ147	5' - CCA UCU CGA AAA GAA GUU AAG-3' 3' -UG GGU AGA GCU UUU CUU CAA U -5'	1320-1341 1339-1318
			<u>Position in Daten- bank-# AF402779</u>
K1A/ K2B	SQ153 SQ158	5' - ACA GGA UGA GGA UCG UUU CGC A-3' 3' -UC UGU CCU ACU CCU AGC AAA GCG U-5'	2829-2808 2808-2831

*Key to figure: (Headings)*

Name

Sequence Protocol no.

Sequence

**Table 4**

The sequences shown in Table 4 are shown again in the sequence protocol as sequences SQ 141-147, 152, 153, 158. The dsRNAs were transfected in a concentration of 175 nM as double charges into the cells, which were seeded the day before in 12-well plates at  $3.8 \times 10^5$  cells/well. For this purpose, 93.3  $\mu$ L EC-R buffer (TransMessenger kit, Qiagen, Hilden) was mixed with 3.2  $\mu$ L Enhancer-R per transfection charged, thoroughly mixed and incubated for 5 minutes at room temperature. After addition of 6  $\mu$ L TransMessenger transfection reagent, the transfection charges were vigorously mixed for 10 seconds and incubated for 10 minutes at room temperature. In the meantime, the medium was withdrawn from the cells by suction, washed once with PBS (phosphate buffered saline) and 200  $\mu$ L fresh medium without FCS per well was added to the cells. After 10 minutes of incubation, 100  $\mu$ L FCS-free medium was pipetted into the transfection charged, mixed and the mixture pipetted dropwise into the cells (the dsRNA concentration of 175  $\mu$ M refers to 400  $\mu$ L of medium total volume). The dsRNA/TransMessenger complexes were incubated for 4 hours at 37°C with the cells in FCS-free medium. A medium change was then conducted, in which the fresh medium contained 10  $\mu$ M Rifampicin and 10% FCS. As control, and unspecific dsRNA sequence, having no homology with the MDR1 gene sequence, was used (K) and a MOCK transfection carried out, which contained all reagents, except dsRNA.

The cells were harvested after 24, 48 and 72 hours and a total RNA extracted with the RNeasy-Mini-Kit from Qiagen. 10  $\mu$ g total RNA of each sample was separated on a 1% agarose formaldehyde gel electrophoretically, blotted onto a nylon membrane and specific probes, random marked with 5'- $\alpha^{32}$ -P-dCTP, were hybridized exposed first relative to MDR1 and, after stripping of the blot, relative to GAPDH as internal control and exposed on x-ray film.

The x-ray films were digitized (Image Master, VDS Pharmacia) and quantified with the Image-Quant software. Balancing of the MDR1-specific bands with the corresponding GAPDH bands was then carried out.

#### Results:

Figures 25 and 26 show Northern blots (Figures 25a, 26a) with quantitative evaluation of the MDR1-specific bands after balancing with the corresponding GAPDH values (Figures 25b, 26b). A reduction of MDR1-mRNA by up to 55% could be observed in comparison with MOCK transfection and by up to 45% in comparison with unspecific control transfection. After 48 h, a significant reduction of MDR1-mRNA levels was achieved with the dsRNA constructs designated R1, R2, R3 (Table 4). After 48 hours, no significant reduction relative to the controls was observed with the R4 dsRNA constructs (Figures 26a, 26b). After 72 hours, a much stronger reduction of MDR1-mRNA levels was observed with R1, R2 and R2 relative to the controls, in comparison with the 48-hour values (Figures 25a and 25b).

With R4 at this point a significant reduction of MDR1-mRNA levels could also be achieved. The constructs with a 2 nt overhang on the 3' end of the anti-sense strand and a double-strand region of 22 nucleotide pairs therefore reduced the MDR1-mRNA more efficiently than the constructs of the 2 nt overhangs on the 3' ends of both strands (anti-sense and sense strand) and a double-strand region of 19 nucleotide pairs relatively independently of the sequence region homologous to the MDR1 gene (after 48 hours; Fig. 26b). The results therefore confirm the inhibition of EGFR gene expression described in practical example 4 by specific dsRNAs after transfection in U-87 MG cells.

The transfection efficiency was determined in a separate experiment by means of a Texas-Red-labeled DNA oligonucleotide (TexRed-A (GATC)<sub>5</sub>T; also 175 nM transfected) (Figures 27a, 27b; 400-fold magnification, 48 hours after transfection). The amount is about 50% based on the red fluorescent cells, in comparison with the total cell count. If one considers the transfection rate of the cells at about 50%, the observed reduction of MDR1-mRNA level lies at about 45-55% (compared with the controls), with the conclusion that in all cells that could be transfected

successfully with specific dsRNA, the MDR1-mRNA was almost fully broken down and specifically.

## Literature:

Airoy I & Yarden Y (1997): The Erb signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Letters 410: 83-86.

Bass,B.L., 2000. Double-stranded RNA as a template for gene silencing. Cell 101, 235-238.

Bosher,J.M. and Labouesse,M., 2000. RNA interference: genetic wand and genetic watchdog. Nature Cell Biology 2, E31-E36.

Bradford MM (1976): Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.

Caplen,N.C., Fleenor,J., Fire,A., and Morgan,R.A., 2000. dsRNA-mediated gene silencing in cultured *Drosophila* cells: a tissue culture model for the analysis of RNA interference. Gene 252, 95-105.

Clemens,J.C., Worby,C.A., Simonson-Leff,N., Muda,M., Maelhama,T., Hemmings,B.A., and Dixon,J.E., 2000. Use of double-stranded RNA interference in *Drosophila* cell lines to dissect signal transduction pathways. Proc.Natl.Acad.Sci.USA 97, 6499-6503.

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Liebermann G & Slamon DJ (1999): Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that

has progressed after chemotherapy for metastatic disease.  
Journal of Clinical Oncology 17: 2639-2648.

Ding, S.W., 2000. RNA silencing. Curr. Opin. Biotechnol. 11, 152-156.

Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C., 1998. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. Nature 391, 806-811.

Fire, A., 1999. RNA-triggered gene silencing. Trends Genet. 15, 358-363.

Freier, S.M., Kierzek, R., Jaeger, J.A., Sugimoto, N., Caruthers, M.H., Neilson, T., and Turner, D.H., 1986. Improved free-energy parameters for prediction of RNA duplex stability. Proc. Natl. Acad. Sci. USA 83, 9373-9377 .

Geick, A., Eichelbaum, M., Burk, O. (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276 (18), 14581-14587.

Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, Gullick W, Angeletti CA, Bevilacqua G & Ciardiello F (1998): Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIa non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic factors of survival. Clinical Cancer Research 4: 241-249.



Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J., 2000. An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature* 404, 293-296.

Higgins, C.F. (1995). The ABC of channel regulation. *Cell*, 82, 693-696.

Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1993): Generating green fluorescent mice by germline transmission of green fluorescent ES cells. *Mech. Dev.* 76: 79-90.

Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1998): Non-invasive sexing of preimplantation mammalian embryos. *Nature Genetics* 19: 220-222.

Kyhse-Anderson J (1984): Electrophoretic transfer of multiple gels: A simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. *J. Biochem. Biophys. Methods* 10: 203-210.

Lämmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685.

Loo, T.W., and Clarke, D.M. (1999) *Biochem. Cell Biol.* 77, 11-23.

Huang SM & Harari PM (1999): Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. *Investigational New Drugs* 17: 259-269.

Limmer, S., Hofmann, H.-P., Ott, G., and Sprinzl, M., 1993. The 3'-terminal end (NCCA) of tRNA determines the structure and

stability of the aminoacyl acceptor stem. Proc. Natl. Acad. Sci. USA 90 , 6199-6202.

Montgomery, M.K. and Fire, A., 1998. Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression. Trends Genet. 14, 255-258.

Montgomery, M.K., Xu, S., and Fire, A., 1998. RNA as a target of double-stranded RNA-mediated genetic interference in *Caenorhabditis elegans*. Proc. Natl. Acad. Sci. USA 95, 15502-15507.

Rieske P, Kordek R, Bartkowiak J, Debiec-Rychter M, Bienhat W & Liberski PP (1998): A comparative study of epidermal growth factor (EGFR) and mdm2 gene amplification and protein immunoreactivity in human glioblastomas. Polish Journal of Pathology 49: 145-149.

Robert, J. (1999). Multidrug resistance in oncology: diagnostic and therapeutic approaches. Europ J Clin Invest 29, 536-545.

Stavrovskaya, A.A. (2000) Biochemistry (Moscow) 65 (1), 95-106.

Salomon DS, Brandt R, Ciardiello F & Normanno N (1995): Epidermal growth factor related peptides and their receptors in human malignancies: Critical Reviews in Oncology and Haematology 19: 183-232.

Tom, B.H., Rutzky, L.P., Jakstys, M.M., Oyasu, R., Kaye, C.I., Kahan, B.D. (1976), In vitro, 12, 180-191.

Tsuruo, T., Iida, H., Tsukagoshi, S., Sakurai, Y. (1981).  
Overcoming of vincristine resistance in P388 leukemia in vivo  
and in vitro through enhanced cytotoxicity of vincristine and  
vinblastine by verapamil. *Cancer Res*, 41, 1967-72.

Ui-Tei, K., Zenno, S., Miyata, Y., and Saigo, K., 2000. Sensitive  
assay of RNA interference in *Drosophila* and Chinese hamster  
cultured cells using firefly luciferase gene as target. *FEBS  
Lett.* 479, 79-82.

Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW,  
Lee J, Yarden Y, Liebermann TA, Schlessinger J et al. (1984):  
Human epidermal growth factor receptor cDNA sequences and ab-  
errant expression of the amplified gene in A431 epidermoid  
carcinoma cells. *Nature* 309: 418-425.

Ullrich A & Schlessinger J (1990): Signal transduction by re-  
ceptors with tyrosine kinase activity. *Cell* 61: 203-212.

Van der Geer P, Hunter T & Linberg RA (1994): Receptor pro-  
tein-tyrosine kinases and their signal transduction pathways.  
*Annual review in Cell Biology* 10: 251-337.

Voldborg BR, Damstrup L, Spang-Thomsen M & Poulser HS  
(1997): Epidermal growth factor Receptor (EGFR) and EGFR mu-  
tations, function and possible role in clinical trials. *Annu-  
als of Oncology* 8: 1197-1206.

Walker RA & Dearing SJ (1999): Expression of epidermal growth  
factor receptor mRNA and protein in primary breast carcino-  
mas. *Breast Cancer Research Treatment* 53: 167-176.

Zamore, P.D., Tuschl, T., Sharp, P.A., and Bartel, D.P., 2000.  
RNAi: double-stranded RNA directs the ATP-dependent cleavage  
of mRNA at 21 to 23 nucleotide intervals. Cell 101 , 25-33.

Zor T & Selinger Z (1996): Linearization of the Bradford pro-  
tein assay increases its sensitivity: theoretical and experi-  
mental studies. Anal. Biochem. 236: 302-308.

## Claims

1. Method for inhibition of expression of a target gene in a cell, comprising the following steps:

introduction of at least one double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of the target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2) of dsRNA I.

2. Method according to Claim 1, in which the dsRNA has the overhang on a 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

3. Method according to Claim 1 or 2, in which the dsRNA I is formed smooth on one end (E1, E2).

4. Method according to Claim 3, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

5. Method according to one of the preceding claims, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.

6. Method according to one of the preceding claims, in which at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the preceding claims, is introduced to the cell, in which one strand (as1) or at least a section of one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which

an additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

7. Method according to one of the preceding claims, in which the dsRNA I and/or dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

8. Method according to one of the preceding claims, in which the first region (B1) and the second region (B2) overlap or abut each other in sections.

9. Method according to one of the preceding claims, in which the first region (B1) and the second region (B2) are spaced from each other.

10. Method according to one of the preceding claims, in which the target gene has one of the sequences SQ001 to SQ140.

11. Method according to one of the preceding claims, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

12. Method according to one of the preceding claims, in which the target gene is the MDR1 gene.

13. Method according to one of the preceding claims, in which one of the sequences SQ141-173 is used as dsRNA I/II and a combined dsRNA construct of the sequences SQ141-173 from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.

14. Method according to one of the preceding claims, in which expression is inhibited according to the principle of RNA interference.

15. Method according to one of the preceding claims, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
16. Method according to one of the preceding claims, in which the target gene is a component of a virus or a viroid.
17. Method according to Claim 16, in which the virus is a human pathogenic virus or viroid.
18. Method according to one of the Claims 16, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
19. Method according to one of the preceding claims, in which unpaired nucleotides are substituted by nucleoside thiophosphate.
20. Method according to one of the preceding claims, in which at least one end (E1, E2) of dsRNA I/II is modified, in order to counteract degradation in the cell or dissociation into single strands.
21. Method according to one of the preceding claims, in which the cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
22. Method according to one of the preceding claims, in which the chemical link is formed by a covalent or ionic bond, hydrogen bridge bond, hydrophobic interactions, preferably van der Waals or stacking interactions, or by metal-ion coordination.
23. Method according to one of the preceding claims, in which the chemical link is formed in the vicinity of one end (E1, E2).

24. Method according to one of the preceding claims, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
25. Method according to one of the preceding claims, in which the chemical link is formed by branched nucleotide analogs instead of nucleotides.
26. Method according to one of the preceding claims, in which the chemical link is formed by purine analogs.
27. Method according to one of the preceding claims, in which the chemical link is formed by azabenzene units.
28. Method according to one of the preceding claims, in which, to produce the chemical link, at least one of the following groups is used: methylene blue; bifunctional groups, preferably bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil, psoralene.
29. Method according to one of the preceding claims, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
30. Method according to one of the preceding claims, in which the chemical link is produced by triple helix bonds situated in the vicinity of the ends (E1, E2).
31. Method according to one of the preceding claims, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
32. Method according to one of the preceding claims, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from the virus, derived from it or synthetically produced, associated with it or enclosed by it.



33. Method according to one of the preceding claims, in which the sheath protein is derived from polyoma virus.
34. Method according to one of the preceding claims, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
35. Method according to one of the preceding claims, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
36. Method according to one of the preceding claims, in which one strand (as1/as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
37. Method according to one of the preceding claims, in which the cell is a vertebrate cell or a human cell.
38. Method according to one of the preceding claims, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.
39. Method according to one of the preceding claims, in which the dsRNA I/II is taken up in a buffer solution for application.
40. Method according to one of the preceding claims, in which the dsRNA I/II is administered orally or by means of injection or infusion, intravenously, intratumorally, by inhalation, intraperitoneally.
41. Use of a double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in a cell,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2).

42. Use according to Claim 41, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

43. Use according to Claim 41 or 42, in which the dsRNA I is formed smooth on one end (E1, E2).

44. Use according to Claim 43, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

45. Use according to one of the Claims 41 to 44, in which the overhang is formed from 1 to 4 nucleotides, preferably one or two nucleotides.

46. Use according to one of the Claims 41 to 45, in which one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 41 to 45, is introduced to the cell, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the sense strand of the target gene, and in which the other strand (as2) or at least a section of the other strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

47. Use according to one of the Claims 41 to 46, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

48. Use according to one of the Claims 41 to 47, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

49. Use according to one of the Claims 41 to 48, in which the first (B1) and the second region (B2) are spaced from each other.
50. Use according to one of the Claims 41 to 49, in which the target gene has the sequences S1001 to SQ140.
51. Use according to one of the Claims 41 to 50, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.
52. Use according to one of the Claims 41 to 51, in which the target gene is the MDR1 gene.
53. Use according to one of the Claims 41 to 52, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
54. Use according to one of the Claims 41 to 53, in which expression is inhibited according to the principle of RNA interference.
55. Use according to one of the Claims 41 to 54, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
56. Use according to one of the Claims 41 to 55, in which the target gene is a component of a virus or viroid.
57. Use according to Claim 56, in which the virus is a human pathogenic virus or viroid.

58. Use according to Claim 56, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
59. Use according to one of the Claims 41 to 58, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
60. Use according to one of the Claims 41 to 59, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
61. Use according to one of the Claims 41 to 60, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
62. Use according to one of the Claims 41 to 61, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.
63. Use according to one of the Claims 41 to 62, in which the chemical link is formed in the vicinity of one end (E1, E2).
64. Use according to one of the Claims 41 to 63, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
65. Use according to one of the Claims 41 to 64, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
66. Use according to one of the Claims 41 to 65, in which the chemical link is formed by purine analogs.

67. Use according to one of the Claims 41 to 66, in which the chemical link is formed by azabenzene units.
68. Use according to one of the Claims 41 to 67, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
69. Use according to one of the Claims 41 to 68, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
70. Use according to one of the Claims 41 to 69, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).
71. Use according to one of the Claims 41 to 70, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
72. Use according to one of the Claims 41 to 71, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
73. Use according to one of the Claims 41 to 72, in which the sheath protein is derived from polyoma virus.
74. Use according to one of the Claims 41 to 73, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
75. Use according to one of the Claims 41 to 74, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

76. Use according to one of the Claims 41 to 75, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

77. Use according to one of the Claims 41 to 76, in which the cell is a vertebrate cell or a human cell.

78. Use according to one of the Claims 41 to 77, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

79. Use according to one of the Claims 41 to 78, in which the dsRNA I/II is taken up in a buffer solution for application.

80. Use according to one of the Claims 41 to 79, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

81. Medicament to inhibit expression of a target gene in a cell, containing a double-strand ribonucleic (dsRNA I) in an amount sufficient to inhibit expression of a target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs,

and in which one strand (as1) or at least one section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed on at least one end (E1, E2) from 1 to 4 nucleotides.

82. Medicament according to Claim 81, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

83. Medicament according to Claim 81 or 82, in which the dsRNA I is formed smooth on one end (E1, E2).
84. Medicament according to one of the Claims 83, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).
85. Medicament according to one of the Claims 81 to 84, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.
86. Use according to one of the Claims 81 to 85, containing at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 81 to 85, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which the additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.
87. Use according to one of the Claims 81 to 86, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.
88. Use according to one of the Claims 81 to 87, in which the first (B1) and the second region (B2) overlap or abut each other in sections.
89. Use according to one of the Claims 81 to 88, in which the target gene has one of the sequences S1001 to SQ140.
90. Use according to one of the Claims 81 to 89, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

91. Use according to one of the Claims 81 to 90, in which the target gene is the MDR1 gene.
92. Use according to one of the Claims 81 to 91, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
93. Use according to one of the Claims 81 to 92, in which expression is inhibited according to the principle of RNA interference.
94. Use according to one of the Claims 81 to 93, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
95. Use according to one of the Claims 81 to 94, in which the target gene is a component of a virus or viroid.
96. Use according to Claim 95, in which the virus is a human pathogenic virus or viroid.
97. Use according to Claim 95, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
98. Use according to one of the Claims 81 to 97, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
99. Use according to one of the Claims 81 to 98, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
100. Use according to one of the Claims 81 to 99, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.



101. Use according to one of the Claims 81 to 100, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.
102. Use according to one of the Claims 81 to 101, in which the chemical link is formed in the vicinity of one end (E1, E2).
103. Use according to one of the Claims 81 to 102, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
104. Use according to one of the Claims 81 to 103, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
105. Use according to one of the Claims 81 to 104, in which the chemical link is formed by purine analogs.
106. Use according to one of the Claims 81 to 105, in which the chemical link is formed by azabenzene units.
107. Use according to one of the Claims 81 to 106, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
108. Use according to one of the Claims 81 to 107, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
109. Use according to one of the Claims 81 to 108, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).

110. Use according to one of the Claims 81 to 109, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
111. Use according to one of the Claims 81 to 110, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
112. Use according to one of the Claims 81 to 111, in which the sheath protein is derived from polyoma virus.
113. Use according to one of the Claims 81 to 112, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
114. Use according to one of the Claims 81 to 113, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
115. Use according to one of the Claims 81 to 114, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
116. Use according to one of the Claims 81 to 114, in which the cell is a vertebrate cell or a human cell.
117. Use according to one of the Claims 81 to 116, in which the first (B1) and second region (B2) are spaced from each other.
118. Use according to one of the Claims 81 to 117, in which the dsRNA I/II is contained in an amount of, at most, 5 mg per administration unit.
119. Use according to one of the Claims 81 to 118, in which the dsRNA I/II is taken up in a buffer solution.

120. Use according to one of the Claims 81 to 119, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

121. Method for inhibition of expression of a target gene in a cell, comprising the following steps:

introduction of at least one double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of the target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA has an overhang formed from 1 to 4 nucleotides on at least one end (E1, E2) of dsRNA I.

122. Method according to Claim 1, in which the dsRNA has the overhang on a 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

123. Method according to Claim 1 or 2, in which the dsRNA I is formed smooth on one end (E1, E2).

124. Method according to Claim 3, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

125. Method according to one of the preceding claims, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.

126. Method according to one of the preceding claims, in which at least an additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the

preceding claims, is introduced to the cell, in which one strand (as1) or at least a section of one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and which an additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

127. Method according to one of the preceding claims, in which the dsRNA I and/or dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

128. Method according to one of the preceding claims, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

129. Method according to one of the preceding claims, in which the first (B1) and the second region (B2) are spaced from each other.

130. Method according to one of the preceding claims, in which the target gene has one of the sequences SQ001 to SQ140.

131. Method according to one of the preceding claims, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

132. Method according to one of the preceding claims, in which the target gene is the MDR1 gene.

133. Method according to one of the preceding claims, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of the sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.

134. Method according to one of the preceding claims, in which expression is inhibited according to the principle of RNA interference.
135. Method according to one of the preceding claims, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
136. Method according to one of the preceding claims, in which the target gene is a component of a virus or a viroid.
137. Method according to Claim 16, in which the virus is a human pathogenic virus or viroid.
138. Method according to one of the Claims 16, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
139. Method according to one of the preceding claims, in which unpaired nucleotides are substituted by nucleoside thiophosphate.
140. Method according to one of the preceding claims, in which at least one end (E1, E2) of dsRNA I/II is modified, in order to counteract degradation in the cell or dissociation into single strands.
141. Method according to one of the preceding claims, in which the cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
142. Method according to one of the preceding claims, in which the chemical link is formed by a covalent or ionic bond, hydrogen bridge bond, hydrophobic interactions, preferably van der Waals or stacking interactions, or by metal-ion coordination.
143. Method according to one of the preceding claims, in which the chemical link is formed in the vicinity of one end (E1, E2).

144. Method according to one of the preceding claims, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.

145. Method according to one of the preceding claims, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.

146. Method according to one of the preceding claims, in which the chemical link is formed by purine analogs.

147. Method according to one of the preceding claims, in which the chemical link is formed by azabenzene units.

148. Method according to one of the preceding claims, in which, to produce the chemical link, at least one of the following groups is used: methylene blue; bifunctional groups, preferably bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil, psoralene.

149. Method according to one of the preceding claims, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.

150. Method according to one of the preceding claims, in which the chemical link is produced by triple helix bonds situated in the vicinity of the ends (E1, E2).

151. Method according to one of the preceding claims, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.

152. Method according to one of the preceding claims, in which the dsRNA I/II is bonded to at least one sheath protein originating from the virus, derived from it or synthetically produced, associated with it or enclosed by it.

153. Method according to one of the preceding claims, in which the sheath protein is derived from polyoma virus.

154. Method according to one of the preceding claims, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.

155. Method according to one of the preceding claims, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

156. Method according to one of the preceding claims, in which one strand (as1/as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

157. Method according to one of the preceding claims, in which the cell is a vertebrate cell or a human cell.

158. Method according to one of the preceding claims, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

159. Method according to one of the preceding claims, in which the dsRNA I/II is taken up in a buffer solution for application.

160. Method according to one of the preceding claims, in which the dsRNA I/II is administered orally or by means of injection or infusion, intravenously, intratumorally, by inhalation, intraperitoneally.

161. Use of one of double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in a cell,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2).

162. Use according to Claim 41, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

163. Use according to Claim 41 or 42, in which the dsRNA I is formed smooth on one end (E1, E2).

164. Use according to Claim 43, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

165. Use according to one of the Claims 41 to 44, in which the overhang is formed from 1 to 4 nucleotides, preferably one or two nucleotides.

166. Use according to one of the Claims 41 to 45, in which one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 41 to 45, is introduced to the cell, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the sense strand of the target gene, and in which the other strand (as2) or at least a section of the other strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

167. Use according to one of the Claims 41 to 47, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

168. Use according to one of the Claims 41 to 47, in which the first (B1) and the second region (B2) overlap or abut each other in sections.



169. Use according to one of the Claims 41 to 48, in which the first (B1) and the second region (B2) are spaced from each other.
170. Use according to one of the Claims 41 to 49, in which the target gene has the sequences S1001 to SQ140.
171. Use according to one of the Claims 41 to 50, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.
172. Use according to one of the Claims 41 to 51, in which the target gene is the MDR1 gene.
173. Use according to one of the Claims 41 to 52, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
174. Use according to one of the Claims 41 to 53, in which expression is inhibited according to the principle of RNA interference.
175. Use according to one of the Claims 41 to 54, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
176. Use according to one of the Claims 41 to 55, in which the target gene is a component of a virus or viroid.
177. Use according to Claim 56, in which the virus is a human pathogenic virus or viroid.

178. Use according to Claim 56, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
179. Use according to one of the Claims 41 to 58, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
180. Use according to one of the Claims 41 to 59, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
181. Use according to one of the Claims 41 to 60, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
182. Use according to one of the Claims 41 to 61, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van-der-Waals or stacking interactions, or by metal ion coordination.
183. Use according to one of the Claims 41 to 62, in which the chemical link is formed in the vicinity of one end (E1, E2).
184. Use according to one of the Claims 41 to 63, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
185. Use according to one of the Claims 41 to 64, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
186. Use according to one of the Claims 41 to 65, in which the chemical link is formed by purine analogs.

187. Use according to one of the Claims 41 to 66, in which the chemical link is formed by azabenzene units.
188. Use according to one of the Claims 41 to 67, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
189. Use according to one of the Claims 41 to 68, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
190. Use according to one of the Claims 41 to 69, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).
191. Use according to one of the Claims 41 to 70, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
192. Use according to one of the Claims 41 to 71, in which the dsRNA I/II is bonded to at least one sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
193. Use according to one of the Claims 41 to 72, in which the sheath protein is derived from polyoma virus.
194. Use according to one of the Claims 41 to 73, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
195. Use according to one of the Claims 41 to 74, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

196. Use according to one of the Claims 41 to 75, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

197. Use according to one of the Claims 41 to 76, in which the cell is a vertebrate cell or a human cell.

198. Use according to one of the Claims 41 to 77, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

199. Use according to one of the Claims 41 to 78, in which the dsRNA I/II is taken up in a buffer solution for application.

200. Use according to one of the Claims 41 to 79, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

201. Medicament to inhibit expression of a target gene in a cell, containing a double-strand ribonucleic (dsRNA I) in an amount sufficient to inhibit expression of a target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs,

and in which one strand (as1) or at least one section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed on at least one end (E1, E2) from 1 to 4 nucleotides.

202. Medicament according to Claim 81, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

203. Medicament according to Claim 81 or 82, in which the dsRNA I is formed smooth on one end (E1, E2).
204. Medicament according to one of the Claims 83, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).
205. Medicament according to one of the Claims 81 to 84, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.
206. Use according to one of the Claims 81 to 85, containing at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 81 to 85, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which the additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.
207. Use according to one of the Claims 81 to 86, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.
208. Use according to one of the Claims 81 to 87, in which the first (B1) and the second region (B2) overlap or abut each other in sections.
209. Use according to one of the Claims 81 to 88, in which the target gene has one of the sequences S1001 to SQ140.
210. Use according to one of the Claims 81 to 89, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

211. Use according to one of the Claims 81 to 90, in which the target gene is the MDR1 gene.
212. Use according to one of the Claims 81 to 90, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
213. Use according to one of the Claims 81 to 92, in which expression is inhibited according to the principle of RNA interference.
214. Use according to one of the Claims 81 to 93, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
215. Use according to one of the Claims 81 to 94, in which the target gene is a component of a virus or viroid.
216. Use according to Claim 95, in which the virus is a human pathogenic virus or viroid.
217. Use according to Claim 95, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
218. Use according to one of the Claims 81 to 97, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
219. Use according to one of the Claims 81 to 98, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
220. Medicament according to one of the Claims 81 to 99, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

221. Medicament according to one of the Claims 81 to 100, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.
222. Medicament according to one of the Claims 81 to 101, in which the chemical link is formed in the vicinity of one end (E1, E2).
223. Medicament according to one of the Claims 81 to 102, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
224. Medicament according to one of the Claims 81 to 103, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
225. Medicament according to one of the Claims 81 to 104, in which the chemical link is formed by purine analogs.
226. Medicament according to one of the Claims 81 to 105, in which the chemical link is formed by azabenzene units.
227. Medicament according to one of the Claims 81 to 106, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
228. Medicament according to one of the Claims 81 to 107, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
229. Medicament according to one of the Claims 81 to 108, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).

230. Medicament according to one of the Claims 81 to 109, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
231. Medicament according to one of the Claims 81 to 110, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
232. Medicament according to one of the Claims 81 to 111, in which the sheath protein is derived from polyoma virus.
233. Medicament according to one of the Claims 81 to 112, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
234. Medicament according to one of the Claims 81 to 113, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
235. Medicament according to one of the Claims 81 to 114, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
236. Medicament according to one of the Claims 81 to 114, in which the cell is a vertebrate cell or a human cell.
237. Medicament according to one of the Claims 81 to 116, in which the first (B1) and second region (B2) are spaced from each other.
238. Medicament according to one of the Claims 81 to 117, in which the dsRNA I/II is contained in an amount of, at most, 5 mg per administration unit.



239. Medicament according to one of the Claims 81 to 118, in which the dsRNA I/II is taken up in a buffer solution.

240. Medicament according to one of the Claims 81 to 119, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

//Key to Figures//

Relative Fluoreszenz = Relative fluorescence

Maus = mouse

Mensch = human

MOCK Transfektion = MOCK transfection

Hellfeld = bright field

Variante = variant

Zielgen = target gene

SEQUENZPROTOKOLL = SEQUENCE PROTOCOL

<120> Method for Inhibition of Expression of a Target Gene

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R1A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R1B) of a dsRNA strand, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R2A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R3A) of a dsRNA that is homologous to the MDR1 gene

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R3B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R4A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R4B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S1A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S1B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S7A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S7B) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R2B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K1A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K1B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K3A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K3B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K2A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K2B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S4B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (PKC1 A) of a dsRNA that is homologous to the protein kinase C sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (PKC2 B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S12B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S11B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S13A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S13B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S14B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S13A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-7A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-7B) of a dsRNA, complementary to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-8A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-8B) of a dsRNA, complementary to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-2A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-5B) of a dsRNA, complementary to the human EGFR sequence

reiche ist. Bei dem "Zielgen" handelt es sich also im allgemeinen um den Sinnstrang. Der eine Strang bzw. Antisinnstrang (as1) kann komplementär zu einem bei der Expression des Zielgens gebildeten RNA-Transkript oder deren Prozessierungsprodukt, z.B. eine mRNA, sein. Unter "Einführen" wird die Aufnahme in die Zelle verstanden. Die Aufnahme kann durch die Zelle selbst erfolgen; sie kann auch durch Hilfsstoffe oder Hilfsmittel vermittelt werden. Unter einem "Überhang" wird ein endständiger einzelsträngiger Überstand verstanden, welcher nicht nach Watson & Crick gepaarte Nukleotide aufweist. Unter einer "doppelsträngigen Struktur" wird eine Struktur verstanden, bei der die Nukleotide der Einzelstränge im Wesentlichen nach Watson & Crick gepaart sind. Im Rahmen der vorliegenden Erfindung kann eine doppelsträngige Struktur auch einzelne Fehlpaarungen ("Mismatches") aufweisen.

Nach einer besonders vorteilhaften Ausgestaltung weist die dsRNA I den Überhang am 3'-Ende des einen Strangs bzw. Antisinnstrangs as1 und/oder am 3'-Ende des anderen Strangs bzw. Sinnstrangs ss1 auf. Die dsRNA I kann auch an einem Ende glatt ausgebildet sein. In diesem Fall befindet sich das glatte Ende vorteilhafterweise auf der Seite der dsRNA I, die das 5'-Ende des einen Strangs (Antisinnstrang; as1). In dieser Ausbildung zeigt die dsRNA I einerseits eine sehr gute Effektivität und andererseits eine hohe Stabilität im lebenden Organismus. Die Effektivität insgesamt in vivo ist hervorragend. Der Überhang ist zweckmäßigerweise aus 1 bis 4 Nukleotiden, vorzugsweise aus 1 oder 2 Nukleotiden, gebildet.

Nach einem weiteren Ausgestaltungsmerkmal kann die Effektivität des Verfahrens weiter erhöht werden, wenn zumindest eine entsprechend der erfindungsgemäßen dsRNA I ausgebildete weitere dsRNA II in die Zelle eingeführt wird, wobei der eine Strang oder zumindest ein Abschnitt des einen Strangs der doppelsträngigen Struktur der dsRNA I komplementär zu einem ersten Bereich des Sinnstrangs des Zielgens ist, und wobei

ein weiterer Strang oder zumindest ein Abschnitt des weiteren Strangs der doppelsträngigen Struktur der weiteren dsRNA II komplementär zu einem zweiten Bereich des Sinnstrangs des Zielgens ist. Die Hemmung der Expression des Zielgens ist in diesem Fall deutlich gesteigert. Der erste und der zweite Bereich können abschnittsweise überlappen, aneinander grenzen oder auch voneinander beabstandet sein.

Es hat sich weiter als vorteilhaft erwiesen, wenn die dsRNA I und/oder die weitere dsRNA II eine Länge von weniger als 25 aufeinander folgenden Nukleotidpaaren aufweisen. Als besonders effektiv hat sich eine Länge im Bereich zwischen 19 und 23 Nukleotidpaaren erwiesen. Die Effizienz kann weiter gesteigert werden, wenn an den vorzugsweise aus 19 bis 23 Nukleotidpaaren gebildeten Doppelsträngen einzelsträngige Überhänge von 1 bis 4 Nukleotiden vorhanden sind.

Das Zielgen kann nach einem weiteren Ausgestaltungsmerkmal eine der in dem anhängenden Sequenzprotokoll wiedergegebenen Sequenzen SQ001 bis SQ140 aufweisen. Es kann auch aus der folgenden Gruppe ausgewählt sein: Onkogen, Cytokin-Gen, Id-Protein-Gen, Prionen, Gene zur Expression von Angiogenese induzierenden Molekülen, von Adhäsions-Molekülen und Zelloberflächenrezeptoren, Gene von Proteinen, die an metastasierenden und/oder invasiven Prozessen beteiligt sind, Gene von Proteinasen sowie Apoptose- und Zellzyklus-regulierende Molekülen sowie Gene zur Expression des EGF-Rezeptors. Beim Zielgen kann es sich insbesondere um das MDR1-Gen handeln. Es kann in diesem Zusammenhang eine der Sequenzen SQ141 - 173 bestehende bzw. ein aus jeweils zusammengehörenden Antisinn (as)- und Sinnsequenzen (ss) kombinierte dsRNA I/II verwendet werden.

Nach einem weiteren vorteilhaften Ausgestaltungsmerkmal wird die Expression nach dem Prinzip der RNA-Interferenz gehemmt.

Das Zielgen wird zweckmäßigerweise in pathogenen Organismen, vorzugsweise in Plasmodien, exprimiert. Es kann Bestandteil eines Virus oder Viroids, insbesondere eines humanpathogenen Virus oder Viroids, sein. Das Virus oder Viroid kann auch ein  
5 tier- oder pflanzenpathogenes Virus oder Viroid sein.

Nach einem weiteren Ausgestaltungsmerkmal ist vorgesehen, dass die ungepaarten Nukleotide durch Nukleosidthiophosphate substituiert sind.

10

Zumindest ein Ende der dsRNA I/II kann modifiziert werden, um einem Abbau in der Zelle oder einer Dissoziation in die Einzelstränge entgegenzuwirken. Vorteilhafterweise wird dazu der durch die komplementären Nukleotidpaare bewirkte Zusammenhalt  
15 der doppelsträngigen Struktur durch mindestens eine chemische Verknüpfung erhöht. Die chemische Verknüpfung kann durch eine kovalente oder ionische Bindung, eine Wasserstoffbrückenbindung, hydrophobe Wechselwirkungen, vorzugsweise van-der-Waals- oder Stapelungswechselwirkungen, oder durch Metall-  
20 Ionenkoordination gebildet werden. Es hat sich weiter als zweckmäßig und die Stabilität erhöhend erwiesen, wenn die chemische Verknüpfung in der Nähe des einen Endes gebildet ist. Weitere vorteilhafte Ausgestaltungen hinsichtlich der chemischen Verknüpfung können den Merkmalen der Ansprüche 24  
25 bis 30 entnommen werden, ohne dass es dafür einer näheren Erläuterung bedarf.

Die dsRNA I/II kann dann besonders einfach in die Zelle eingeschleust werden, wenn sie in micellare Strukturen, vorteil-  
30 hafterweise in Liposomen, eingeschlossen wird. Zum Transport der dsRNA I/II in die Zelle hat es sich auch als vorteilhaft erwiesen, dass diese an mindestens ein von einem Virus stammendes, davon abgeleitetes oder ein synthetisch hergestelltes virales Hüllprotein gebunden, damit assoziiert oder davon um-  
35 geben werden. Das Hüllprotein kann vom Polyomavirus abgeleitet sein. Das Hüllprotein kann insbesondere das Virus-Protein



1 und/oder das Virus-Protein 2 des Polyomavirus enthalten. Nach einer weiteren Ausgestaltung ist vorgesehen, dass bei Bildung eines Kapsids oder kapsidartigen Gebildes aus dem Hüllprotein die eine Seite zum Inneren des Kapsids oder kapsidartigen Gebildes gewandt ist. Ferner ist es von Vorteil, dass der eine Strang der dsRNA I/II (as1/2) zum primären oder prozessierten RNA-Transkript des Zielgens komplementär ist. Die Zelle kann eine Vertebratenzelle oder eine menschliche Zelle sein.

Weiterhin hat es sich gezeigt, dass die dsRNA I/II vorteilhafterweise bereits in einer Menge von höchstens 5 mg/kg Körpergewicht pro Tag einem Säugetier, vorzugsweise einem Menschen, verabreicht werden kann. Bereits in dieser geringen Dosis wird eine ausgezeichnete Effektivität erzielt.

Überraschenderweise hat sich gezeigt, dass die dsRNA I/II zur Applikation in eine Pufferlösung aufgenommen und dann oral oder mittels Injektion oder Infusion intravenös, intratumoral, inhalativ, intraperitoneal verabreicht werden kann.

Erfindungsgemäß ist weiterhin die Verwendung einer doppelsträngigen Ribonukleinsäure (dsRNA I) zur Hemmung der Expression eines Zielgens in einer Zelle vorgesehen, wobei die dsRNA I eine doppelsträngige aus höchstens 49 aufeinander folgenden Nukleotidpaaren gebildete Struktur aufweist, und wobei ein Strang (Antisinnstrang; as1) oder zumindest ein Abschnitt des einen Strangs (as1) der doppelsträngigen Struktur komplementär zum Sinnstrang des Zielgens ist, und wobei die dsRNA I zumindest an einem Ende einen aus 1 bis 4 Nukleotiden gebildeten Überhang aufweist.

Nach weiterer Maßgabe der Erfindung ist ein Medikament zur Hemmung der Expression eines Zielgens in einer Zelle vorgesehen, enthaltend eine doppelsträngige Ribonukleinsäure (dsRNA I) in einer zur Hemmung der Expression des Zielgens ausrei-



tung unter dem Fluoreszenzmikroskop erfolgte frühestens 3 Stunden nach Injektion anhand der grünen Fluoreszenz.

#### Vorbereitung der Zellkulturen:

5 Die Kultivierung der Zellen erfolgte in DMEM mit 4,5 g/l Glucose, 10 % fötalem Kälberserum (FCS), 2 mM L-Glutamin, Penicillin/Streptomycin (100 IE/100 µg/ml, Biochrom) im Brutschrank unter 5 % CO<sub>2</sub>-Atmosphäre bei 37°C. Die Zellen wurden alle 3 Tage passagiert, um sie in der exponentiellen Wachstumsphase zu halten. Einen Tag vor der Durchführung der Transfektion wurden die Zellen trypsiniert (10x Trypsin/TEDTA, Biochrom) und mit einer Zelldichte von  $0,3 \times 10^5$  Zellen in beschichteten Petrischalen (CORNING® Cell Culture Dish, 35 mm, Corning Inc., Corning, USA) ausgesät. Die Petrischalen wurden mit 0,2 % Gelatine (Biochrom) für mindestens 15 30 Minuten bei 37°C inkubiert, einmal mit PBS gewaschen und sofort für die Aussaat der Zellen verwendet. Um ein Wiederfinden individueller Zellen zu ermöglichen, wurden CELLocate Coverslips der Fa. Eppendorf (Square size 55 µm) verwendet.

20

#### Mikroinjektion:

Zur Durchführung der Mikroinjektion wurden die Petrischalen ca. 10 Minuten aus dem Brutschrank genommen. Pro Schale und Ansatz wurden ca. 50 Zellen mikroinjiziert (FemtoJet; Mikromanipulator 5171, Eppendorf). Für die Mikroinjektion wurden 25 Glaskapillaren (FemtoTip) der Firma Eppendorf mit einem Spitzeninnendurchmesser von 0,5 µm verwendet. Die Injektionsdauer betrug 0,8 Sekunden und der Druck 30 hPa. Durchgeführt wurden die Mikroinjektionen an einem Olympus IX50 Mikroskop mit 30 Fluoreszenzeinrichtung. Als Injektionspuffer wurde 14 mM NaCl, 3 mM KCl, 10 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7,0 verwendet, der 0,01 µg/µl pcDNA-YFP enthielt. Zur Überprüfung einer erfolgreichen Mikroinjektion wurde der Injektionslösung jeweils 0,08% (w/v) an Dextran-70000 gekoppeltes Texas-Rot (Molecular Probes, 35 Leiden, Niederlande) zugesetzt. Um die Inhibition der YFP-Expression mit spezifischer dsRNA zu untersuchen, wurden der

Injektionslösung dsRNAs zugegeben: Ansatz 1: 0,1  $\mu$ M dsRNA (Sequenzprotokoll SQ148/149); Ansatz 2: 0,1  $\mu$ M dsRNA (Sequenzprotokoll SQ148/159); Ansatz 3: ohne RNA. Nach der Mikroinjektion wurden die Zellen für mindestens drei weitere  
5 Stunden im Brutschrank inkubiert. Danach wurden die intrazelluläre YFP-Fluoreszenz am Mikroskop ausgewertet:  
gleichzeitig rot und grün-fluoreszierende Zellen: Mikroinjektion war erfolgreich, es wird keine Inhibition der YFP-Expression durch dsRNA beobachtet; bzw. es handelt sich um  
10 Kontrollzellen, in die keine dsRNA injiziert wurde;  
nur rot-fluoreszierende Zellen: Mikroinjektion war erfolgreich, die dsRNA inhibiert YFP-Expression.

#### Ergebnisse:

15 Bei einer dsRNA-Konzentration von 0,1  $\mu$ M konnte beim Einsatz der dsRNA mit den an beiden 3'-Enden um je zwei Nukleotide überstehenden Einzelstrangbereichen (Sequenzprotokoll SQ148/159) eine merklich erhöhte Hemmung der Expression des YFP-Gens in Fibroblasten beobachtet werden im Vergleich zur  
20 dsRNA ohne überstehende Einzelstrangenden (Tabelle 1).

Die Verwendung von kurzen, 19-25 Basenpaare enthaltenden, dsRNA-Molekülen mit Überhängen aus wenigen, vorzugsweise 1 bis 3 nicht-basengepaarten, einzelsträngigen Nukleotiden ermöglicht somit eine vergleichsweise stärkere Hemmung der  
25 Genexpression in Säugerzellen als die Verwendung von dsRNAs mit derselben Anzahl von Basenpaaren ohne die entsprechenden Einzelstrangüberhänge bei jeweils gleichen RNA-Konzentrationen.

Ansatz	Name	Sequenzprotokoll-Nr.	0.1 $\mu$ M
1	S1A/ S1B	SQ148 SQ149	+
2	S1A/ S4B	SQ148 (überstehende Enden) SQ159	+++
3		ohne RNA	-

Tabelle 1: Die Symbole geben den relativen Anteil an nicht oder schwach grün-fluoreszierenden Zellen an (+++ > 90%; ++ 60-90%; + 30-60%; - < 10%).

5

II. Hemmung der Genexpression eines Zielgens in kultivierten HELA-S3-Zellen und Mausfibroblasten durch dsRNA:

- 10 Die Effektivität der Inhibition der YFP-Expression nach transienter Transfektion eines YFP-codierenden Plasmids auf der Basis der RNA-Interferenz mit dsRNAs läßt sich durch Gestaltung der 3'-Enden und der Länge des basengepaarten Bereichs modulieren.

15

Ausführungsbeispiel:

- Zum Wirksamkeitsnachweis der dsRNA bei der spezifischen Inhibition der Genexpression wurden transient transfizierte
- 20 NIH/3T3-Zellen (Fibroblasten aus NIH Swiss Mausembryo, ECCAC (European collection of animal cell culture) Nr. 93061524) und HELA-S3 (humane cervikale Karzinomzellen, DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) Nr. ACC 161) verwendet. Für die Transfektion wurde das Plasmid pcDNA-YFP
- 25 verwendet, das ein 800 bp großes Bam HI /Eco RI-YFP-Fragment in den entsprechenden Schnittstellen des Vektors pcDNA3 enthält. Aus der Sequenz des gelb-fluoreszierenden Proteins (YFP) abgeleitete doppelsträngige RNAs (dsRNAs) wurden herge-

stellt und zusammen mit dem Plasmid pcDNA-YFP transient in die Fibroblasten transfiziert (Die verwendeten spezifischen dsRNAs sind in ihren Antisinn-Strängen komplementär zu entsprechenden Abschnitten der Gensequenzen von sowohl YFP als auch GFP). Nach 48 Stunden wurde die Fluoreszenzabnahme quantifiziert. Als Kontrollen fungierten Zellen, die entweder nur mit pcDNA-YFP oder mit pcDNA-YFP und einer Kontroll-dsRNA (nicht aus der YFP-Sequenz abgeleitet) transfiziert wurden.

10 Versuchsprotokoll:

dsRNA-Synthese:

Mittels eines RNA-Synthesizers (Typ Expedite 8909, Applied Biosystems, Weiterstadt, Deutschland) und herkömmlicher chemischer Verfahren wurden die aus den Sequenzprotokollen ersichtlichen RNA-Einzelstränge und die zu ihnen komplementären Einzelstränge synthetisiert. Anschließend erfolgte die Reinigung der rohen Syntheseprodukte mit Hilfe der HPLC. Verwendet wurde die Säule NucleoPac PA-100, 9x250 mm, der Fa. Dionex; als Niedersalz-Puffer 20 mM Tris, 10 mM NaClO<sub>4</sub>, pH 6,8, 10% Acetonitril und als Hochsalz-Puffer 20 mM Tris, 400 mM NaClO<sub>4</sub>, pH 6,8, 10% Acetonitril. Der Fluß betrug 3 ml/Minute. Die Hybridisierung der Einzelstränge zum Doppelstrang erfolgte durch Erhitzen des stöchiometrischen Gemischs der Einzelstränge in 10 mM Natriumphosphatpuffer, pH 6,8, 100 mM NaCl, auf 80-90°C und nachfolgendes langsames Abkühlen über 6 Stunden auf Raumtemperatur.

Aussaat der Zellen:

30 Alle Zellkulturarbeiten wurden unter sterilen Bedingungen in einer entsprechenden Werkbank (HS18, Hera Safe, Kendro, Heraeus) durchgeführt. Die Kultivierung der NIH/3T3-Zellen und der HELA-S3 erfolgte im Brutschrank (CO<sub>2</sub>-Inkubator T20, Hera cell, Kendro, Heraeus) bei 37°C, 5% CO<sub>2</sub> und gesättigter

Luftfeuchtigkeit in DMEM (Dulbecco's modified eagle medium, Biochrom), für die Mausfibroblasten, und Ham's F12 für die HELA-Zellen mit 10% FCS (fetal calf serum, Biochrom), 2 mM L-Glutamin (Biochrom) und Penicillin/Streptomycin (100 IE/100 µg/ml, Biochrom). Um die Zellen in der exponentiellen Wachstumsphase zu halten, wurden die Zellen alle 3 Tage passagiert. 24 Stunden vor der Durchführung der Transfektion wurden die Zellen trypsiniert (10x Trypsin/EDTA, Biochrom, Deutschland) und mit einer Zelldichte von  $1,0 \times 10^4$  Zellen/Vertiefung in einer 96-Loch-Platte (Multiwell Schalen 96-Well Flachboden, Labor Schubert & Weiss GmbH) in 150 µl Wachstumsmedium ausgesät.

15

#### Durchführung der transienten Transfektion:

Die Transfektion wurde mit Lipofectamine Plus™ Reagent (Life Technologies) gemäß den Angaben des Herstellers durchgeführt. Pro Well wurden 0,15 µg pcDNA-YFP-Plasmid eingesetzt. Das Gesamt-Transfektionsvolumen betrug 60 µl. Es wurden jeweils 3-fach-Proben angesetzt. Die Plasmid-DNA wurde zuerst zusammen mit der dsRNA komplexiert. Dazu wurde die Plasmid-DNA und die dsRNA in serumfreiem Medium verdünnt und pro 0,1 µg Plasmid-DNA 1 µl PLUS Reagent eingesetzt (in einem Volumen von 10 µl) und nach dem Mischen für 15 Minuten bei Raumtemperatur inkubiert. Während der Inkubation wurde pro 0,1 µg Plasmid-DNA 0,5 µl Lipofectamine in insgesamt 10 µl serumfreiem Medium verdünnt, gut gemischt, zu dem Plasmid/dsRNA/PLUS-Gemisch zugegeben und nochmals 15 Minuten inkubiert. Während der Inkubation wurde ein Mediumwechsel durchgeführt. Die Zellen wurden dazu 1 x mit 200 µl serumfreiem Medium gewaschen und danach mit 40 µl serumfreiem Medium bis zur Zugabe von DNA/dsRNA/PLUS/Lipofectamine weiter im Brutschrank inkubiert. Nach der Zugabe von 20 µl DNA/dsRNA/PLUS/Lipofectamine pro

Well wurden die Zellen für 2,5 Stunden im Brutschrank inkubiert. Anschließend wurden die Zellen nach der Inkubation 1 x mit 200 µl Wachstumsmedium gewaschen und für 24 Stunden bis zur Detektion der Fluoreszenz in 200 µl Wachstumsmedium im Brutschrank inkubiert.

#### Detektion der Fluoreszenz:

24 Stunden nach dem letzten Mediumwechsel wurde die Fluoreszenz der Zellen am Fluoreszenz-Mikroskop (IX50-S8F2, Fluoreszenz-Einheit U-ULS100Hg, Brenner U-RFL-T200, Olympus) mit einer USH-I02D-Quecksilber-Lampe (USHIO Inc., Tokyo, Japan), ausgestattet mit einem WIB-Fluoreszenz-Würfel und einer digitalen CCD-Kamera (Orca IIm, Hamamatsu) und C4742-95 Kamera-Controller) photographiert. Die Auswertung der Fluoreszenzaufnahmen erfolgte mit der analysis-Software 3.1 (Soft Imaging Sytem GmbH, Deutschland). Um die YFP-Fluoreszenz in Relation zur Zelldichte zu setzen, wurde eine Zellkernfärbung (Hoechst-Staining) durchgeführt. Dazu wurden die Zellen in 100 µl Methycarnoy (75% Methanol, 25% Eisessig) zuerst für 5 und danach nochmals für 10 Minuten in Methycarnoy fixiert. Nach dem Lufttrocknen wurden die fixierten Zellen für 30 Minuten im Dunkeln mit 100 µl pro Well Hoechst-Farbstoff (75 ng/ml) inkubiert. Nach 2maligem Waschen mit PBS (PBS Dulbecco w/o Ca<sup>2+</sup>, Mg<sup>2+</sup>, Biochrom) wurden die Hoechst-gefärbten Zellen unter dem Fluoreszenz-Mikroskop (Olympus, WU-Fluoreszenz-Würfel für Hoechst) photographiert.

In den Fig. 3 bis 9 sind die Ergebnisse zur Inhibition der YFP-Expression durch dsRNA in kultivierten Zellen zusammengefasst:

30

In Fig. 3, 4, 5 und 6 sind die Effekte von YFP-spezifischen dsRNAs und von Kontroll-dsRNAs auf die YFP-Expression in NIH/3T3-Mausfibroblasten nach transienter Transfektion zusammengefasst. Die Experimente wurden wie im Versuchsprotokoll



Die Fig. 10 bis 17 zeigen die Serumstabilität der dsRNA nach Inkubation mit humanem bzw. murinem Serum und nachfolgender elektrophoretischer Auftrennung im 20%igem 7M Harnstoffgel.

5 **Fig. 10: Inkubation von S1 (0-22-0) in Maus-Serum**

1. zum Zeitpunkt 0 (ohne Serum)
2. zum Zeitpunkt 0
3. für 30 Minuten
4. für 1 Stunde
- 10 5. für 2 Stunden
6. für 4 Stunden
7. für 12 Stunden
8. 2  $\mu$ l 100  $\mu$ M S1 ohne Inkubation
- S1A) Sinnstrang S1 (10  $\mu$ l 20  $\mu$ M S1A)
- 15 S1B) Antisinnstrang S1 (10  $\mu$ l 20  $\mu$ M S1B)

**Fig. 11: Inkubation von S1 (0-22-0) in humanem Serum**

1. 2  $\mu$ l 100  $\mu$ M S1 unbehandelt (ohne Inkubation)
2. für 30 Minuten
3. für 2 Stunden
- 20 4. für 4 Stunden
5. für 6 Stunden
6. für 8 Stunden
7. für 12 Stunden
8. für 24 Stunden
- 25 S1A) Sinnstrang S1 (10  $\mu$ l 20  $\mu$ M S1A)
- S1B) Antisinnstrang S1 (10  $\mu$ l 20  $\mu$ M S1B)

**Fig. 12: Inkubation von S7 (2-19-2) in Maus-Serum**

1. zum Zeitpunkt 0 (ohne Serum)
2. für 30 Minuten
- 30 3. für 4 Stunden
4. für 12 Stunden

**Fig. 13: Inkubation von S7 (2-19-2) in humanem Serum**

1. Sinnstrang S7 (10  $\mu$ l 20  $\mu$ M S7A)

2. Antisinnstrang S7 (10  $\mu$ l 20  $\mu$ M S7B)
3. für 30 Minuten
4. für 1 Stunde
5. für 2 Stunden
- 5 6. für 4 Stunden
7. für 6 Stunden
8. für 12 Stunden
9. für 24 Stunden
10. zum Zeitpunkt 0 (ohne Serum)

10 **Fig. 14: Inkubation von K3 (2-19-2) in Maus-Serum**

1. Sinnstrang K3 (10  $\mu$ l 20  $\mu$ M K3A)
2. Antisinnstrang K3 (10  $\mu$ l 20  $\mu$ M K3B)
3. zum Zeitpunkt 0 (ohne Serum)
4. zum Zeitpunkt 0 (mit Serum)
- 15 5. für 30 Minuten
6. für 1 Stunde
7. für 2 Stunden
8. für 4 Stunden
9. für 12 Stunden

20 **Fig. 15: Inkubation von PKC1/2 (0-22-2) in Maus-Serum**

1. für 30 Minuten
2. für 1 Stunde
3. für 2 Stunden
4. für 4 Stunden
- 25 5. für 12 Stunden
6. 2  $\mu$ l 100  $\mu$ M PKC1/2 (unbehandelt)

**Fig. 16: Inkubation von S1A/S4B (0-22-2) in humanem Serum**

1. zum Zeitpunkt 0 (ohne Serum)
2. für 24 Stunden
- 30 3. für 12 Stunden
4. für 8 Stunden
5. für 6 Stunden
6. für 4 Stunden

7. für 2 Stunden
8. für 30 Minuten
9. Sinnstrang S1A (10  $\mu$ l 20  $\mu$ M S1A)
10. Antisinnstrang S4B (10  $\mu$ l 20  $\mu$ M S4B)

5 **Fig. 17: Inkubation von K2 (2-22-2) in humanem Serum**

1. Sinnstrang K2 (10  $\mu$ l 20  $\mu$ M K2A)
2. Antisinnstrang K2 (10  $\mu$ l 20  $\mu$ M K2B)
3. zum Zeitpunkt 0 (ohne Serum)
4. für 30 Minuten
- 10 5. für 2 Stunden
6. für 4 Stunden
7. für 6 Stunden
8. für 8 Stunden
9. für 12 Stunden
- 15 10. für 24 Stunden

Ergebnisse:

dsRNAs ohne einzelsträngige Bereiche an den 3'-Enden sind im  
20 Serum sowohl von Mensch und Maus wesentlich stabiler als  
dsRNAs mit einzelsträngigen 2nt-Überhängen an den 3'-Enden  
(Fig. 10 bis 14 und 17). Nach 12 bzw. 24 Stunden Inkubation  
von S1 in murinem bzw. humanem Serum ist noch immer eine Ban-  
de in der ursprünglichen Größe fast vollständig erhalten. Da-  
25 gegen nimmt bei dsRNAs mit 2nt-Überhängen an beiden 3'-Enden  
die Stabilität in humanem als auch im murinen Serum deutlich  
ab. Bereits nach 4 Stunden Inkubation von S7 (Fig. 12 und 13)  
oder K3 (Fig. 14) ist keine Bande in der Originalgröße mehr  
detektierbar.

30

Um die Stabilität von dsRNA im Serum zu erhöhen, ist es aus-  
reichend, wenn die dsRNA ein glattes Ende besitzt. Im Maus-  
Serum ist nach 4 Stunden Inkubation (Fig. 15, Bahn 4) die

Bande in der Originalgröße kaum abgebaut im Vergleich zu S7 (nach 4 Stunden vollständiger Abbau; Fig. 12, Bahn 3).

- Als optimaler Kompromiß hinsichtlich der biologischen Wirksamkeit von dsRNA kann die Verwendung von dsRNA mit einem glattem Ende und einem einzelsträngigem Bereich von 2 Nukleotiden angesehen werden, wobei sich der einzelsträngige Überhang am 3'-Ende des Antisinn-Stranges befinden sollte.
- 10 Die hier verwendeten Sequenzen sind aus der nachstehenden Tabelle 2 und den Sequenzprotokollen SQ148-151 und 153-167 ersichtlich.

Name	Sequenz- proto- koll-Nr.	dsRNA-Sequenz	
S1	SQ148 SQ149	(A) 5'- CCACAUGAAGCAGCACGACUUC -3' (B) 3'- GGUGUACUUCGUCGUGCUGAAG -5'	0-22-0
S7	SQ150 SQ151	(A) 5'- CCACAUGAAGCAGCACGACUU -3' (B) 3'- CUGGUGUACUUCGUCGUGCUG -5'	2-19-2
K1	SQ153 SQ154	(A) 5'- ACAGGAUGAGGAUCGUUUCGCA -3' (B) 3'- UGUCCUACUCCUAGCAAAGCGU -5'	0-22-0
K3	SQ155 SQ156	(A) 5'-GAUGAGGAUCGUUUCGCAUGA-3' (B) 3'-UCCUACUCCUAGCAAAGCGUA-5'	2-19-2
K2	SQ157 SQ158	(A) 5'- ACAGGAUGAGGAUCGUUUCGCAUG -3' (B) 3'- UCUGUCCUACUCCUAGCAAAGCGU -5'	2-22-2
S1A/ S4B	SQ148 SQ159	(A) 5'- CCACAUGAAGCAGCACGACUUC -3' (B) 3'- CUGGUGUACUUCGUCGUGCUGAAG -5'	0-22-2

PKC 1/2	SQ160	(A)	5'- CUUCUCCGCCUCACACCGCUGCAA -3'	2-22-0
	SQ161	(B)	3'- GAAGAGGCGGAGUGUGGCGACG -5'	
S7/S12	SQ150	(A)	5'- CCACAUGAAGCAGCACGACUU -3'	0-21-0
	SQ162	(B)	3'- GGUGUACUUCGUCGUGCUGAA -5'	
S7/S11	SQ150	(A)	5'- CCACAUGAAGCAGCACGACUU -3'	0-21-2
	SQ163	(B)	3'- CUGGUGUACUUCGUCGUGCUGAA -5'	
S13	SQ164	(A)	5'- CCACAUGAAGCAGCACGACU -3'	0-20-2
	SQ165	(B)	3'- CUGGUGUACUUCGUCGUGCUGA -5'	
S13/14	SQ164	(A)	5'- CCACAUGAAGCAGCACGACU -3'	0-20-0
	SQ166	(B)	3'- GGUGUACUUCGUCGUGCUGA -5'	
S4	SQ167	(A)	5'- CCACAUGAAGCAGCACGACUUCUU -3'	2-22-2
	SQ159	(B)	3'- CUGGUGUACUUCGUCGUGCUGAAG -5'	
K1A/ K2B	SQ153	(A)	5'- ACAGGAUGAGGAUCGUUUCGCA -3'	0-22-2
	SQ158	(B)	3'- UCUGUCCUACUCCUAGCAAAGCGU -5'	
K1B/ K2A	SQ154	(A)	5'- ACAGGAUGAGGAUCGUUUCGCAUG -3'	2-22-0
	SQ157	(B)	3'- UGUCCUACUCCUAGCAAAGCGU -5'	
S1B/ S4A	SQ149	(A)	5'- CCACAUGAAGCAGCACGACUUCUU -3'	2-22-0
	SQ167	(B)	3'- GGUGUACUUCGUCGUGCUGAAG -5'	

Tabelle 2

IV. In vivo-Studie:

5

Es wurde „GFP-Labormäusen“, die das Grün-fluoreszierende Protein (GFP) in allen Proteinbiosynthese betreibenden Zellen exprimieren, doppelsträngige RNA (dsRNA), die aus der GFP-Sequenz abgeleitet wurde, bzw. unspezifische dsRNA intravenös

10 in die Schwanzvene injiziert. Am Versuchsende wurden die Tie-

SDS überschichtet. Danach wurde das Sammelgel gegossen: 0,83  $\mu$ l Acrylamid/Bisacrylamid (30%/0,9%), 630  $\mu$ l 1 M Tris/HCl, pH 6,8, 3,4 ml Aqua bidest., 50  $\mu$ l 10% SDS, 50  $\mu$ l 10% Ammoniumpersulfat, 5  $\mu$ l TEMED.

5

Vor dem Auftrag auf das Gel wurden die Proteine mit einer entsprechenden Menge an 4fach Probenpuffer (200 mM Tris, pH 6,8, 4% SDS, 100 mM DTT (Dithiotreitol), 0,02% Bromphenolblau, 20% Glycerin) versetzt, für 5 min im Heizblock bei 100°C denaturiert, nach dem Abkühlen auf Eis kurz abzentrifugiert und auf das Gel aufgetragen. Pro Bahn wurde die gleichen Plasma- bzw. Proteinmengen eingesetzt (je 3  $\mu$ l Plasma bzw. 25  $\mu$ g Gesamtprotein). Die Elektrophorese erfolgte wassergekühlt bei RT und konstant 50 V. Als Längenstandard wurde der Proteingelmarker von Bio-Rad (Kaleidoscope Prestained Standard) verwendet.

#### Western Blot und Immundetektion:

Der Transfer der Proteine vom SDS-PAGE auf eine PVDF (Polyvinylidendifluorid)-Membran (Hybond-P, Amersham) erfolgte im semidry Verfahren nach Kyhse-Anderson (J. Biochem. Biophys. Methods 10: 203-210, 1984) bei RT und einer konstanten Stromstärke von 0,8 mA/cm<sup>2</sup> für 1,5 h. Als Transferpuffer wurde ein Tris/Glycin-Puffer eingesetzt (39 mM Glycin, 46 mM Tris, 0,1 % SDS und 20% Methanol). Zum Überprüfen des elektrophoretischen Transfers wurden sowohl die Gele nach dem Blotten als auch die Blotmembranen nach der Immundetektion mit Coomassie gefärbt (0,1% Coomassie G250, 45% Methanol, 10% Eisessig). Zum Absättigen unspezifischer Bindungen wurde die Blotmembran nach dem Transfer in 1% Magermilchpulver/PBS für 1h bei RT inkubiert. Danach wurde je dreimal für 3 min mit 0,1% Tween-20/PBS gewaschen. Alle nachfolgenden Antikörperinkubationen und Waschschrte erfolgten in 0,1% Tween-20/ PBS. Die Inkubation mit dem Primärantikörper (goat anti-GFP, sc-5384, San-

ta Cruz Biotechnology) in einer Verdünnung von 1:1000 erfolgte für 1h bei RT. Danach wurde 3 x 5 min gewaschen und für 1h bei RT mit dem Sekundärantikörper (donkey anti-goat IgG Horseradish Peroxidase gelabelt, Santa Cruz Biotechnology) in einer Verdünnung von 1 : 10.000 inkubiert. Die Detektion erfolgte mit dem ECL-System von Amersham nach den Angaben des Herstellers.

In den Fig. 18 bis 20 ist die Inhibition der GFP-Expression nach intravenöser Injektion von spezifisch gegen GFP gerichteter dsRNA mit Immunperoxidase-Färbungen gegen GFP an 3 µm Paraffinschnitten dargestellt. Im Versuchsverlauf wurde gegen GFP gerichtete dsRNA mit einem doppelsträngigen Bereich von 22 Nukleotid-(nt)paaren ohne Überhänge an den 3'-Enden (D) und die entsprechende unspezifische Kontroll-dsRNA (B) sowie spezifisch gegen GFP gerichtete dsRNA mit einem 19 Nukleotidpaare umfassenden Doppelstrangbereich mit 2nt-Überhängen an den 3'-Enden (E) und die entsprechende unspezifische Kontroll-dsRNA (C) im 12 Stunden-Turnus über 5 Tage hinweg appliziert. (F) erhielt 1/50 der Dosis von Gruppe D. Als weitere Kontrolle wurden Tiere ohne dsRNA-Gabe (A) bzw. WT-Tiere untersucht. Die Fig. 18 zeigt die Inhibition der GFP-Expression in Nierenschnitten, Fig. 19 in Herz- und Fig. 20 in Pankreasgewebe. In den Fig. 21 bis 23 sind Western Blot-Analysen der GFP-Expression in Plasma und Geweben dargestellt. In der Fig. 21 ist die Inhibition der GFP-Expression im Plasma, in Fig. 22 in der Niere und in Fig. 23 in Herz gezeigt. In Fig. 23 sind Gesamtproteinisolate aus verschiedenen Tieren aufgetragen. Es wurden jeweils gleiche Gesamtproteinmengen pro Bahn aufgetragen. In den Tieren, denen unspezifische Kontroll-dsRNA verabreicht wurde (Tiere der Gruppen B und C), ist die GFP-Expression gegenüber Tieren, die keinerlei dsRNA erhielten, nicht reduziert. Tiere, die spezifisch gegen GFP gerichtete dsRNA mit 2nt-Überhängen an den 3'-Enden

beider Stränge und einen 19 Nukleotidpaare umfassenden Doppelstrangbereich erhielten, zeigten eine signifikant inhibierte GFP-Expression in den untersuchten Geweben (Herz, Niere, Pankreas und Blut), verglichen mit unbehandelten Tieren (Fig. 18 bis 23). Bei den Tieren der Gruppen D und F, denen spezifisch gegen GFP gerichtete dsRNA mit glatten Enden und einem 22 Nukleotidpaare umfassenden Doppelstrangbereich appliziert wurde, zeigten nur jene Tiere, die die dsRNA in einer Dosis von 50 µg/kg Körpergewicht pro Tag erhielten, eine spezifische Inhibition der GFP-Expression, die allerdings weniger deutlich ausgeprägt war als die der Tiere in Gruppe E.

Die zusammenfassende Auswertung von GFP-Inhibition in den Gewebeschnitten und im Western Blot ergibt, dass die Inhibition der GFP-Expression im Blut und in der Niere am stärksten ist (Fig. 18, 21 und 22).

V. Hemmung der Genexpression des EGF-Rezeptors mit dsRNA als therapeutischer Ansatz bei Krebsformen mit EGFR-Überexpression oder EGFR-induzierter Proliferation:

Der Epidermal Growth Factor (=EGF)-Rezeptor (=EGFR) gehört zu den Rezeptor-Tyrosinkinasen, transmembranen Proteinen mit einer intrinsischen Tyrosinkinase-Aktivität, die an der Kontrolle einer Reihe von zellulären Prozessen wie Zellwachstum, Zelldifferenzierungen, migratorischen Prozessen oder der Zellvitalität beteiligt sind (Übersicht in: Van der Geer et al. 1994). Die Familie der EGFR besteht aus 4 Mitgliedern, EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3) und HER4 (ErbB4) mit einer transmembranen Domäne, einer cysteinreichen extrazellulären Domäne und einer intrazellulären katalytischen Domäne. Die Sequenz des EGFR, einem 170 kDa Protein, ist seit 1984 bekannt (Ullrich et al., 1984).



Aktiviert wird der EGFR durch Peptid-Wachstumsfaktoren wie EGF, TGF $\alpha$  (transforming growth factor), Amphiregulin, Beta-cellulin, HB-EGF (heparin-binding EGF-like growth factor) und Neureguline. Ligandenbindung induziert die Bildung von Homo- oder Heterodimeren mit nachfolgender Autophosphorylierung zytoplasmatischer Tyrosine (Ullrich & Schlessinger, 1990; Alroy & Yarden, 1997). Die phosphorylierten Aminosäuren bilden die Bindungsstellen für eine Vielzahl von Proteinen, die an den proximalen Schritten der Signalweiterleitung in einem komplexen Netzwerk beteiligt sind. Der EGFR ist an den verschiedensten Tumorerkrankungen beteiligt und damit ein geeignetes Target für therapeutische Ansätze (Huang & Harari, 1999). Die Mechanismen, die zu einer aberranten EGFR-Aktivierung führen, können auf Überexpression, Amplifikation, konstitutiver Aktivierung mutanter Rezeptor-Formen oder autokrinen Loops beruhen (Voldborg et al., 1997). Eine Überexpression des EGFR wurde für eine Reihe von Tumoren beschrieben, wie z.B. Brustkrebs (Walker & Dearing, 1999); Nicht-Klein-Lungenkarzinom (Fontanini et al., 1998), Pankreaskarzinom, Kolonkarzinom (Salomon et al., 1995) und Glioblastomen (Rieske et al., 1998). Insbesondere für maligne Glioblastome sind bisher keine effizienten und spezifischen Therapeutika verfügbar.

#### 25 Ausführungsbeispiel:

Zum Nachweis der Wirksamkeit der dsRNA bei der spezifischen Inhibition der EGFR-Genexpression wurden U-87 MG-Zellen (humane Glioblastomzellen), ECCAC (European collection of animal cell culture) Nr. 89081402, verwendet, die mit spezifisch gegen den EGF-Rezeptor (Sequenzprotokoll SQ 51) gerichteten dsRNA transfiziert wurden. Nach ca. 72 Stunden Inkubation wurden die Zellen geerntet, Protein isoliert und im Western Blot Verfahren die EGFR-Expression untersucht.

Versuchsprotokoll:dsRNA-Synthese:

- 5 Mittels eines RNA-Synthesizers (Typ Expedite 8909, Applied Biosystems, Weiterstadt, Deutschland) und herkömmlicher chemischer Verfahren wurden die aus den Sequenzprotokollen ersichtlichen RNA-Einzelstränge und die zu ihnen komplementären Einzelstränge synthetisiert. Anschließend erfolgte die Reinigung der rohen Syntheseprodukte mit Hilfe der HPLC. Verwendet wurde die Säule NucleoPac PA-100, 9x250 mm, der Fa. Dionex; als Niedersalz-Puffer 20 mM Tris, 10 mM NaClO<sub>4</sub>, pH 6,8, 10% Acetonitril und als Hochsalz-Puffer 20 mM Tris, 400 mM NaClO<sub>4</sub>, pH 6,8, 10% Acetonitril. Der Fluß betrug 3 ml/Minute.
- 10
- 15 Die Hybridisierung der Einzelstränge zum Doppelstrang erfolgte durch Erhitzen des stöchiometrischen Gemischs der Einzelstränge in 10 mM Natriumphosphatpuffer, pH 6,8, 100 mM NaCl, auf 80-90°C und nachfolgendes langsames Abkühlen über 6 Stunden auf Raumtemperatur.

20

Aussaat der Zellen:

- Alle Zellkulturarbeiten wurden unter sterilen Bedingungen in einer entsprechenden Werkbank (HS18, Hera Safe, Kendro, Heraeus) durchgeführt. Die Kultivierung der U-87 MG-Zellen erfolgte im Brutschrank (CO<sub>2</sub>-Inkubator T20, Hera cell, Kendro, Heraeus) bei 37°C, 5% CO<sub>2</sub> und gesättigter Luftfeuchtigkeit in DMEM (Dulbecco's modified eagle medium, Biochrom) mit 10% FCS (fetal calf serum, Biochrom), 2 mM L-Glutamin (Biochrom), 1 mM Natrium-Pyruvat (Biochrom), 1xNEAA (Non-essential Aminoacids, Biochrom) und Penicillin/Streptomycin (100 IE/100 µg/ml, Biochrom). Um die Zellen in der exponentiellen Wachstumsphase zu halten, wurden die Zellen alle 3 Tage passagiert. 24 Stunden vor der Applikation der dsRNA mittels Transfektion wurden die Zellen trypsiniert (10x Trypsin/EDTA,
- 25
- 30

Kontrolle wurde eine unspezifische dsRNA-Sequenz, die keinerlei Homologie mit der MDR1-Gensequenz aufweist, eingesetzt (K) und eine MOCK-Transfektion durchgeführt, die alle Reagenzien außer dsRNA enthielt.

5

Die Zellen wurden nach 24, 48 und 72 Stunden geerntet und die Gesamt-RNA mit dem RNeasy-Mini-Kit von Qiagen extrahiert. 10 µg Gesamt-RNA jeder Probe wurden auf einem 1%igen Agarose-Formaldehyd-Gel elektrophoretisch aufgetrennt, auf eine Nylon-Membran gebロットet und mit 5'-α<sup>32</sup>P-dCTP random-markierten, spezifischen Sonden zuerst gegen MDR1 und nach dem Strippen des Blots gegen GAPDH als interne Kontrolle hybridisiert und auf Röntgenfilmen exponiert.

15 Die Röntgenfilme wurden digitalisiert (Image Master, VDS Pharmacia) und mit der Image-Quant-Software quantifiziert. Dabei wurde ein Abgleich der MDR1-spezifischen Banden mit den entsprechenden GAPDH-Banden durchgeführt.

20 Ergebnisse:

Die Fig. 25 und 26 zeigen Northern-Blots (Fig. 25a, 26a) mit quantitativer Auswertung der MDR1-spezifischen Banden nach Abgleich mit den entsprechenden GAPDH-Werten (Fig. 25b, 26b). Es konnte eine Reduktion der MDR1-mRNA um bis zu 55 % im Vergleich zur MOCK-Transfektion und um bis zu 45 % im Vergleich zur unspezifischen Kontroll-Transfektion beobachtet werden. Nach 48 h ist eine signifikante Reduktion des MDR1-mRNA-Niveaus mit den als R1, R2, R3 (Tabelle 4) bezeichneten dsRNA-Konstrukten erreicht worden. Mit den R4-dsRNA-Konstrukten wurde nach 48 h keine signifikante Reduktion gegenüber den Kontrollen beobachtet (Fig. 26a und 26b). Nach 74 h war eine deutlich stärkere Reduktion des MDR1-mRNA-Levels mit R1, R2 und R3 gegenüber den Kontrollen im Vergleich zu den 48 h-Werten zu beobachten (Fig. 25a und 25b).

Mit R4 konnte zu diesem Zeitpunkt ebenfalls eine signifikante Verringerung des MDR1-mRNA-Niveaus erzielt werden. Somit reduzieren die Konstrukte mit einem 2nt-Überhang am 3'-Ende des Antisinnstrangs und einem doppelsträngigen Bereich aus 22 Nukleotidpaaren, relativ unabhängig von dem jeweiligen zum MDR1-Gen homologen Sequenzbereich (nach 48 h; Fig. 26b) das MDR1-mRNA-Level effizienter als die Konstrukte mit mit 2nt-Überhängen an den 3'-Enden beider Stränge (Antisinn- und Sinnstrang) und einem Doppelstrangbereich von 19 Nukleotidpaaren. Die Ergebnisse bekräftigen damit die in Ausführungsbeispiel IV beschriebene Inhibition der EGFR-Genexpression durch spezifische dsRNAs nach Transfektion in U-87 MG-Zellen.

Die Transfektionseffizienz wurde in einem getrennten Experiment mit Hilfe eines Texas-Red-markierten DNA-Oligonukleotids (TexRed-A(GATC)<sub>5</sub>T; ebenfalls 175 nM transfiziert) ermittelt (Fig. 27a, 27b; 400fache Vergrößerung, 48h nach Transfektion). Sie betrug etwa 50% auf der Grundlage der rot fluoreszierenden Zellen im Vergleich zur Gesamtzellzahl. Berücksichtigt man die Transfektionsrate der Zellen von etwa 50%, so liegt die beobachtete Verringerung des MDR1-mRNA-Niveaus um ca. 45-55% liegt (verglichen mit den Kontrollen), den Schluss nahe, dass in allen Zellen, die mit spezifischer dsRNA erfolgreich transfiziert werden konnten, die MDR1-mRNA nahezu vollständig und spezifisch abgebaut wurde.

Literatur:

Alroy I & Yarden Y (1997): The Erb signalling network in embryogenesis and oncogenesis: signal diversification through  
5 combinatorial ligand-receptor interactions. FEBS Letters 410: 83-86.

Bass, B.L., 2000. Double-stranded RNA as a template for gene  
10 silencing. Cell 101, 235-238.

Bosher, J.M. and Labouesse, M., 2000. RNA interference: genetic  
wand and genetic watchdog. Nature Cell Biology 2, E31-E36.

Bradford MM (1976): Rapid and sensitive method for the quan-  
15 titation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.

Caplen, N.J., Fleenor, J., Fire, A., and Morgan, R.A., 2000.  
dsRNA-mediated gene silencing in cultured *Drosophila* cells: a  
20 tissue culture model for the analysis of RNA interference. Gene 252, 95-105.

Clemens, J.C., Worby, C.A., Simonson-Leff, N., Muda, M., Maehama, T., Hemmings, B.A., and Dixon, J.E., 2000. Use of double-  
25 stranded RNA interference in *Drosophila* cell lines to dissect signal transduction pathways. Proc. Natl. Acad. Sci. USA 97, 6499-6503.

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Liebermann G &  
30 Slamon DJ (1999): Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that

has progressed after chemotherapy for metastatic disease.  
Journal of Clinical Oncology 17: 2639-2648.

Ding, S.W., 2000. RNA silencing. Curr. Opin. Biotechnol. 11,  
5 152-156.

Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E.,  
and Mello, C.C., 1998. Potent and specific genetic interfer-  
ence by double-stranded RNA in *Caenorhabditis elegans*. Nature  
10 391, 806-811.

Fire, A., 1999. RNA-triggered gene silencing. Trends Genet.  
15, 358-363.

15 Freier, S.M., Kierzek, R., Jaeger, J.A., Sugimoto, N., Caruth-  
ers, M.H., Neilson, T., and Turner, D.H., 1986. Improved free-  
energy parameters for prediction of RNA duplex stability.  
Proc. Natl. Acad. Sci. USA 83, 9373-9377 .

20 Geick, A., Eichelbaum, M., Burk, O. (2001). Nuclear receptor  
response elements mediate induction of intestinal MDR1 by ri-  
fampin. J. Biol. Chem. 276 (18), 14581-14587.

Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M,  
25 Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR,  
Gullick W, Angeletti CA, Bevilacqua G & Ciardiello F (1998):  
Evaluation of epidermal growth factor-related growth factors  
and receptors and of neoangiogenesis in completely resected  
stage I-IIIa non-small-cell lung cancer: amphiregulin and mi-  
30 crovessel count are independent prognostic factors of sur-  
vival. Clinical Cancer Research 4: 241-249.

- Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J., 2000. An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature* 404, 293-296.
- 5 Higgins, C.F. (1995). The ABC of channel regulation. *Cell*, 82, 693-696.
- Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1993): Generating green fluorescent mice by germline transmission of green fluorescent ES cells. *Mech. Dev.* 76: 79-90.
- 10 Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1998): Non-invasive sexing of preimplantation mammalian embryos. *Nature Genetics* 19: 220-222.
- 15 Kyhse-Anderson J (1984): Electroblotting of multiple gels: A simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. *J. Biochem. Biophys. Methods* 10: 203-210.
- 20 Lämmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685.
- 25 Loo, T.W., and Clarke, D.M. (1999) *Biochem. Cell Biol.* 77, 11-23.
- Huang SM & Harari PM (1999): Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. *Investigational New Drugs* 17: 259-269.
- 30 Limmer, S., Hofmann, H.-P., Ott, G., and Sprinzl, M., 1993. The 3'-terminal end (NCCA) of tRNA determines the structure and

47. Verwendung nach einem der Ansprüche 41 bis 47, wobei die dsRNA I und/oder die dsRNA II eine Länge von weniger als 25, vorzugsweise 19 bis 23, aufeinander folgenden Nukleotidpaaren aufweist/en.

48. Verwendung nach einem der Ansprüche 41 bis 47, wobei der erste (B1) und der zweite Bereich (B2) abschnittsweise überlappen oder aneinander grenzen.

49. Verwendung nach einem der Ansprüche 41 bis 48, wobei der erste (B1) und der zweite Bereich (B2) voneinander beabstandet sind.

50. Verwendung nach einem der Ansprüche 41 bis 49, wobei das Zielgen eine der Sequenzen SQ001 bis SQ140 aufweist.

51. Verwendung nach einem der Ansprüche 41 bis 50, wobei das Zielgen aus der folgenden Gruppe ausgewählt ist: Onkogen, Cytokin-Gen, Id-Protein-Gen, Priongen, Gene von Angiogenese induzierenden Molekülen, von Adhäsions-Molekülen und von Zelloberflächenrezeptoren, Gene von Proteinen, die an metastasierenden und/oder invasiven Prozessen beteiligt sind, Gene von Proteinasen sowie von Apoptose- und Zellzyklusregulierenden Molekülen.

52. Verwendung nach einem der Ansprüche 41 bis 51, wobei das Zielgen das MRD1-Gens ist.

53. Verwendung nach einem der Ansprüche 41 bis 52, wobei als dsRNA I/II eine der Sequenzen SQ141 -173 bzw. ein aus zwei jeweils zusammengehörenden Antisinn- (as1/2) und Sinnsequenzen (ss1/2) kombiniertes dsRNA-Konstrukt der Sequenzen SQ141 - 173 verwendet wird.



54. Verwendung nach einem der Ansprüche 41 bis 53, wobei die Expression nach dem Prinzip der RNA-Interferenz gehemmt wird.
- 5 55. Verwendung nach einem der Ansprüche 41 bis 54, wobei das Zielgen in pathogenen Organismen, vorzugsweise in Plasmodien, exprimiert wird.
56. Verwendung nach einem der Ansprüche 41 bis 55, wobei das  
10 Zielgen Bestandteil eines Virus oder Viroids ist.
57. Verwendung nach Anspruch 56, wobei das Virus ein humanpathogenes Virus oder Viroid ist.
- 15 58. Verwendung nach Anspruch 56, wobei das Virus oder Viroid ein tier- oder pflanzenpathogenes Virus oder Viroid ist.
59. Verwendung nach einem der Ansprüche 41 bis 58, wobei ungepaarte Nukleotide durch Nukleosidthiophosphate substituiert  
20 sind.
60. Verwendung nach einem der Ansprüche 41 bis 59, wobei zumindest ein Ende (E1, E2) der dsRNA modifiziert wird, um einem Abbau in der Zelle oder einer Dissoziation in die Einzel-  
25 stränge entgegenzuwirken.
61. Verwendung nach einem der Ansprüche 41 bis 60, wobei der durch die komplementären Nukleotidpaare bewirkte Zusammenhalt der doppelsträngigen Struktur durch mindestens eine chemische  
30 Verknüpfung erhöht wird.
62. Verwendung nach einem der Ansprüche 41 bis 61, wobei die chemische Verknüpfung durch eine kovalente oder ionische Bindung, eine Wasserstoffbrückenbindung, hydrophobe Wechselwir-

kungen, vorzugsweise van-der-Waals- oder Stapelungswechselwirkungen, oder durch Metall-Ionenkoordination gebildet wird.

63. Verwendung nach einem der Ansprüche 41 bis 62, wobei die  
5 chemische Verknüpfung in der Nähe des einen Endes (E1, E2) gebildet ist.

64. Verwendung nach einem der Ansprüche 41 bis 63, wobei die  
10 chemische Verknüpfung mittels einer oder mehrerer Verbindungsgruppen gebildet wird, wobei die Verbindungsgruppen vorzugsweise Poly-(oxyphosphinicoxy-1,3-propandiol)- und/oder Oligoethylenglycol-Ketten sind.

65. Verwendung nach einem der Ansprüche 41 bis 64, wobei die  
15 chemische Verknüpfung durch anstelle von Nukleotiden benutzte verzweigte Nukleotidanaloga gebildet wird.

66. Verwendung nach einem der Ansprüche 41 bis 65, wobei die  
20 chemische Verknüpfung durch Purinanaloga gebildet wird.

67. Verwendung nach einem der Ansprüche 41 bis 66, wobei die  
chemische Verknüpfung durch Azabenzoleinheiten gebildet wird.

68. Verwendung nach einem der Ansprüche 41 bis 67, wobei zur  
25 Herstellung der chemischen Verknüpfung mindestens eine der folgenden Gruppen benutzt wird: Methylenblau; bifunktionelle Gruppen, vorzugsweise Bis-(2-chlorethyl)-amin; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamin; 4-Thiouracil; Psoralen.

69. Verwendung nach einem der Ansprüche 41 bis 68, wobei die  
30 chemische Verknüpfung durch in der Nähe der Enden (E1, E2) des doppelsträngigen Bereichs angebrachte Thiophosphoryl-Gruppen gebildet wird.

70. Verwendung nach einem der Ansprüche 41 bis 69, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) befindliche Tripelhelix-Bindungen hergestellt wird.

5 71. Verwendung nach einem der Ansprüche 41 bis 70, wobei die dsRNA I/II in micellare Strukturen, vorteilhafterweise in Liposomen, eingeschlossen wird.

72. Verwendung nach einem der Ansprüche 41 bis 71, wobei die  
10 dsRNA I/II an mindestens ein von einem Virus stammendes, davon abgeleitetes oder ein synthetisch hergestelltes virales Hüllprotein gebunden, damit assoziiert oder davon umgeben wird/werden.

15 73. Verwendung nach einem der Ansprüche 41 bis 72, wobei das Hüllprotein vom Polyomavirus abgeleitet ist.

74. Verwendung nach einem der Ansprüche 41 bis 73, wobei das Hüllprotein das Virus-Protein 1 (VP1) und/oder das Virus-  
20 Protein 2 (VP2) des Polyomavirus enthält.

75. Verwendung nach einem der Ansprüche 41 bis 74, wobei bei Bildung eines Kapsids oder kapsidartigen Gebildes aus dem Hüllprotein die eine Seite zum Inneren des Kapsids oder kap-  
25 sidartigen Gebildes gewandt ist.

76. Verwendung nach einem der Ansprüche 41 bis 75, wobei der eine Strang (as1, as2) der dsRNA I/II zum primären oder prozessierten RNA-Transkript des Zielgens komplementär ist.

30

77. Verwendung nach einem der Ansprüche 41 bis 76, wobei die Zelle eine Vertebratenzelle oder eine menschliche Zelle ist.

78. Verwendung nach einem der Ansprüche 41 bis 77, wobei die dsRNA I/II in einer Menge von höchstens 5 mg je Kilogramm Körpergewicht pro Tag einem Säugetier, vorzugsweise einem Menschen, verabreicht wird.

5

79. Verwendung nach einem der Ansprüche 41 bis 78, wobei die dsRNA I/II zur Applikation in eine Pufferlösung aufgenommen ist.

10 80. Verwendung nach einem der Ansprüche 41 bis 79, wobei die dsRNA I/II oral oder mittels Injektion oder Infusion intravenös, intratumoral, inhalativ, intraperitoneal verabreicht wird.

15 81. Medikament zur Hemmung der Expression eines Zielgens in einer Zelle enthaltend eine doppelsträngige Ribonukleinsäure (dsRNA I) in einer zur Hemmung der Expression des Zielgens ausreichenden Menge,

20 wobei die dsRNA I eine doppelsträngige aus höchstens 49 aufeinander folgenden Nukleotidpaaren gebildete Struktur aufweist,

und wobei ein Strang (as1) oder zumindest ein Abschnitt des  
25 einen Strangs (as1) der doppelsträngigen Struktur komplementär zum Zielgen ist,

und wobei die dsRNA I zumindest am einen Ende (E1, E2) einen aus 1 bis 4 Nukleotiden gebildeten Überhang aufweist.

30

82. Medikament nach Anspruch 81, wobei die dsRNA I den Überhang am 3'-Ende des einen Strangs (as1) und/oder am 3'-Ende des anderen Strangs (ss1) aufweist.

126. Verfahren nach einem der vorhergehenden Ansprüche, wobei  
zumindest eine entsprechend der dsRNA I nach einem der vor-  
hergehenden Ansprüche ausgebildete weitere doppelsträngige  
Ribonukleinsäure (dsRNA II) in die Zelle eingeführt wird,  
5 wobei der eine Strang (as1) oder zumindest ein Abschnitt des  
einen Strangs (as1) der dsRNA I komplementär zu einem ersten  
Bereich (B1) des Zielgens ist, und wobei ein weiterer Strang  
(as2) oder zumindest ein Abschnitt des weiteren Strangs (as2)  
der dsRNA II komplementär zu einem zweiten Bereich (B2) des  
10 Zielgens ist.

127. Verfahren nach einem der vorhergehenden Ansprüche, wobei  
die dsRNA I und/oder die dsRNA II eine Länge von weniger als  
25, vorzugsweis 19 bis 23, aufeinander folgenden Nukleo-  
15 tidpaaren aufweist/en.

128. Verfahren nach einem der vorhergehenden Ansprüche, wobei  
der erste (B1) und der zweite Bereich (B2) abschnittsweise  
überlappen oder aneinander grenzen.

20

129. Verfahren nach einem der vorhergehenden Ansprüche, wobei  
der erste (B1) und der zweite Bereich (B2) voneinander beab-  
standet sind.

25 130. Verfahren nach einem der vorhergehenden Ansprüche, wobei  
das Zielgen eine der Sequenzen SQ001 bis SQ140 aufweist.

131. Verfahren nach einem der vorhergehenden Ansprüche, wobei  
das Zielgen aus der folgenden Gruppe ausgewählt ist: Onkogen,  
30 Cytokin-Gen, Id-Protein-Gen, Priongen, Gene von Angiogenese  
induzierenden Molekülen, von Adhäsions-Molekülen und von  
Zelloberflächenrezeptoren, Gene von Proteinen, die an meta-  
stasierenden und/oder invasiven Prozessen beteiligt sind, Ge-

ne von Proteinasen sowie Apoptose- und Zellzyklus-regulierenden Molekülen.

132. Verfahren nach einem der vorhergehenden Ansprüche, wobei  
5 das Zielgen das MDR1-Gens ist.

133. Verfahren nach einem der vorhergehenden Ansprüche, wobei  
als dsRNA I/II eine der Sequenzen SQ141 -173 bzw. ein aus  
zwei jeweils zusammengehörenden Antisinn- (as1/2) und Sinnse-  
10 quenzen (ss1/2) kombiniertes dsRNA-Konstrukt der Sequenzen  
SQ141 - 173 verwendet wird.

134. Verfahren nach einem der vorhergehenden Ansprüche, wobei  
die Expression nach dem Prinzip der RNA-Interferenz gehemmt  
15 wird.

135. Verfahren nach einem der vorhergehenden Ansprüche, wobei  
das Zielgen in pathogenen Organismen, vorzugsweise in Plasmo-  
dien, exprimiert wird.

20

136. Verfahren nach einem der vorhergehenden Ansprüche, wobei  
das Zielgen Bestandteil eines Virus oder Viroids ist.

137. Verfahren nach Anspruch 16, wobei das Virus ein humanpa-  
25 thogenes Virus oder Viroid ist.

138. Verfahren nach Anspruch 16, wobei das Virus oder Viroid  
ein tier- oder pflanzenpathogenes Virus oder Viroid ist.

30 139. Verfahren nach einem der vorhergehenden Ansprüche, wobei  
ungepaarte Nukleotide durch Nukleosidthiophosphate substitu-  
iert sind.

140. Verfahren nach einem der vorhergehenden Ansprüche, wobei zumindest ein Ende (E1, E2) der dsRNA I/II modifiziert wird, um einem Abbau in der Zelle oder einer Dissoziation in die Einzelstränge entgegenzuwirken.

5

141. Verfahren nach einem der vorhergehenden Ansprüche, wobei der durch die komplementären Nukleotidpaare bewirkte Zusammenhalt der doppelsträngigen Struktur durch mindestens eine chemische Verknüpfung erhöht wird.

10

142. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch eine kovalente oder ionische Bindung, eine Wasserstoffbrückenbindung, hydrophobe Wechselwirkungen, vorzugsweise van-der-Waals- oder Stapelungswechselwirkungen, oder durch Metall-Ionenkoordination gebildet wird.

15

143. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung in der Nähe des einen Endes (E1, E2) gebildet ist.

20

144. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung mittels einer oder mehrerer Verbindungsgruppen gebildet wird, wobei die Verbindungsgruppen vorzugsweise Poly-(oxyphosphinicoxy-1,3-propandiol)- und/oder Oligoethylenglycol-Ketten sind.

25

145. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch anstelle von Nukleotiden benutzte verzweigte Nukleotidanaloga gebildet wird.

30

146. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch Purinanaloga gebildet wird.

147. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch Azabenzoleinheiten gebildet wird.

5 148. Verfahren nach einem der vorhergehenden Ansprüche, wobei zur Herstellung der chemischen Verknüpfung mindestens eine der folgenden Gruppen benutzt wird: Methylenblau; bifunktionelle Gruppen, vorzugsweise Bis-(2-chlorethyl)-amin; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamin; 4-Thiouracil; Psoralen.  
10

149. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) des doppelsträngigen Bereichs angebrachte Thiophosphoryl-  
15 Gruppen gebildet wird.

150. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) befindliche Tripelhelix-Bindungen hergestellt wird.  
20

151. Verfahren nach einem der vorhergehenden Ansprüche, wobei die dsRNA I/II in micellare Strukturen, vorteilhafterweise in Liposomen, eingeschlossen wird.

25 152. Verfahren nach einem der vorhergehenden Ansprüche, wobei die dsRNA I/II an mindestens ein von einem Virus stammendes, davon abgeleitetes oder ein synthetisch hergestelltes virales Hüllprotein gebunden, damit assoziiert oder davon umgeben wird/werden.

30 153. Verfahren nach einem der vorhergehenden Ansprüche, wobei das Hüllprotein vom Polyomavirus abgeleitet ist.



154. Verfahren nach einem der vorhergehenden Ansprüche, wobei das Hüllprotein das Virus-Protein 1 (VP1) und/oder das Virus-Protein 2 (VP2) des Polyomavirus enthält.

5 155. Verfahren nach einem der vorhergehenden Ansprüche, wobei bei Bildung eines Kapsids oder kapsidartigen Gebildes aus dem Hüllprotein die eine Seite zum Inneren des Kapsids oder kapsidartigen Gebildes gewandt ist.

10 156. Verfahren nach einem der vorhergehenden Ansprüche, wobei der eine Strang (as1, as2) der dsRNA I/II zum primären oder prozessierten RNA-Transkript des Zielgens komplementär ist.

15 157. Verfahren nach einem der vorhergehenden Ansprüche, wobei die Zelle eine Vertebratenzelle oder eine menschliche Zelle ist.

158. Verfahren nach einem der vorhergehenden Ansprüche, wobei die dsRNA I/II in einer Menge von höchstens 5 mg je Kilogramm  
20 Körpergewicht pro Tag einem Säugetier, vorzugsweise einem Menschen, verabreicht wird.

159. Verfahren nach einem der vorhergehenden Ansprüche, wobei die dsRNA I/II zur Applikation in eine Pufferlösung aufgenommen  
25 ist.

160. Verfahren nach einem der vorhergehenden Ansprüche, wobei die dsRNA I/II oral oder mittels Injektion oder Infusion intravenös, intratumoral, inhalativ, intraperitoneal verab-  
30 reicht wird.

198. Verwendung nach einem der Ansprüche 41 bis 77, wobei die dsRNA I/II in einer Menge von höchstens 5 mg je Kilogramm Körpergewicht pro Tag einem Säugetier, vorzugsweise einem Menschen, verabreicht wird.

5

199. Verwendung nach einem der Ansprüche 41 bis 78, wobei die dsRNA I/II zur Applikation in eine Pufferlösung aufgenommen ist.

10 200. Verwendung nach einem der Ansprüche 41 bis 79, wobei die dsRNA I/II oral oder mittels Injektion oder Infusion intravenös, intratumoral, inhalativ, intraperitoneal verabreicht wird.

15 201. Medikament zur Hemmung der Expression eines Zielgens in einer Zelle enthaltend eine doppelsträngige Ribonukleinsäure (dsRNA I) in einer zur Hemmung der Expression des Zielgens ausreichenden Menge,

20 wobei die dsRNA I eine doppelsträngige aus höchstens 49 aufeinander folgenden Nukleotidpaaren gebildete Struktur aufweist,

und wobei ein Strang (as1) oder zumindest ein Abschnitt des  
25 einen Strangs (as1) der doppelsträngigen Struktur komplementär zum Zielgen ist,

und wobei die dsRNA I zumindest am einen Ende (E1, E2) einen aus 1 bis 4 Nukleotiden gebildeten Überhang aufweist.

30

202. Medikament nach Anspruch 81, wobei die dsRNA I den Überhang am 3'-Ende des einen Strangs (as1) und/oder am 3'-Ende des anderen Strangs (ss1) aufweist.

Cytokin-Gen, Id-Protein-Gen, Prionen, Gene von Angiogenese induzierenden Molekülen, von Adhäsions-Molekülen und von Zelloberflächenrezeptoren, Gene von Proteinen, die an metastasierenden und/oder invasiven Prozessen beteiligt sind, Gene von Proteinasen sowie von Apoptose- und Zellzyklusregulierende Molekülen.

211. Medikament nach einem der Ansprüche 81 bis 90, wobei das Zielgen das MRD1-Gen ist.

10

212. Medikament nach einem der Ansprüche 81 bis 91, wobei als dsRNA eine der Sequenzen SQ141 -173 bzw. ein aus zwei jeweils zusammengehörenden Antisinn- (as1/2) und Sinnsequenzen (ss1/2) kombiniertes dsRNA-Konstrukt der Sequenzen SQ141 - 173 verwendet wird.

15

213. Medikament nach einem der Ansprüche 81 bis 92, wobei die Expression nach dem Prinzip der RNA-Interferenz gehemmt wird.

214. Medikament nach einem der Ansprüche 81 bis 93, wobei das Zielgen in pathogenen Organismen, vorzugsweise in Plasmodien, exprimierbar ist.

20

215. Medikament nach einem der Ansprüche 81 bis 94, wobei das Zielgen Bestandteil eines Virus oder Viroids ist.

25

216. Medikament nach Anspruch 95, wobei das Virus ein humanpathogenes Virus oder Viroid ist.

217. Medikament nach Anspruch 95, wobei das Virus oder Viroid ein tier- oder pflanzenpathogenes Virus oder Viroid ist.

30

218. Medikament nach einem der Ansprüche 81 bis 97, wobei ungepaarte Nukleotide durch Nukleosidthiophosphate substituiert sind.
- 5 219. Medikament nach einem der Ansprüche 81 bis 98, wobei zumindest ein Ende (E1, E2) der dsRNA modifiziert ist, um einem Abbau in der Zelle oder einer Dissoziation in die Einzelstränge entgegenzuwirken.
- 10 220. Medikament nach einem der Ansprüche 81 bis 99, wobei der durch die komplementären Nukleotidpaare bewirkte Zusammenhalt der doppelsträngigen Struktur durch mindestens eine chemische Verknüpfung erhöht ist.
- 15 221. Medikament nach einem der Ansprüche 81 bis 100, wobei die chemische Verknüpfung durch eine kovalente oder ionische Bindung, eine Wasserstoffbrückenbindung, hydrophobe Wechselwirkungen, vorzugsweise van-der-Waals- oder Stapelungswechselwirkungen, oder durch Metall-Ionenkoordination gebildet
- 20 ist.
222. Medikament nach einem der Ansprüche 81 bis 101, wobei die chemische Verknüpfung in der Nähe des einen Endes (E1, E2) gebildet ist.
- 25 223. Medikament nach einem der Ansprüche 81 bis 102, wobei die chemische Verknüpfung mittels einer oder mehrerer Verbindungsgruppen gebildet wird, wobei die Verbindungsgruppen vorzugsweise Poly-(oxyphosphinicoxy-1,3-propandiol)- und/oder
- 30 Oligoethylenglycol-Ketten sind.
224. Medikament nach einem der Ansprüche 81 bis 103, wobei die chemische Verknüpfung durch anstelle von Nukleotiden benutzte verzweigte Nukleotidanaloga gebildet ist.

225. Medikament nach einem der Ansprüche 81 bis 104, wobei die chemische Verknüpfung durch Purinanaloga gebildet ist.
- 5 226. Medikament nach einem der Ansprüche 81 bis 105, wobei die chemische Verknüpfung durch Azabenzoleinheiten gebildet ist.
227. Medikament nach einem der Ansprüche 81 bis 106, wobei  
10 zur Herstellung der chemischen Verknüpfung mindestens eine der folgenden Gruppen benutzt wird: Methylenblau; bifunktionelle Gruppen, vorzugsweise Bis-(2-chlorethyl)-amin; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamin; 4-Thiouracil; Psoralen.
- 15 228. Medikament nach einem der Ansprüche 81 bis 107, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) des doppelsträngigen Bereichs angebrachte Thiophosphoryl-Gruppen gebildet ist.
- 20 229. Medikament nach einem der Ansprüche 81 bis 108, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) befindliche Tripelhelix-Bindungen hergestellt ist.
- 25 230. Medikament nach einem der Ansprüche 81 bis 109, wobei die dsRNA I/II in micellare Strukturen, vorteilhafterweise in Liposomen, eingeschlossen ist.
- 30 231. Medikament nach einem der Ansprüche 81 bis 110, wobei die dsRNA I an mindestens ein von einem Virus stammendes, davon abgeleitetes oder ein synthetisch hergestelltes virales Hüllprotein gebunden, damit assoziiert oder davon umgeben ist/sind.

232. Medikament nach einem der Ansprüche 81 bis 111, wobei das Hüllprotein vom Polyomavirus abgeleitet ist.

233. Medikament nach einem der Ansprüche 81 bis 112, wobei  
5 das Hüllprotein das Virus-Protein 1 (VP1) und/oder das Virus-Protein 2 (VP2) des Polyomavirus enthält.

234. Medikament nach einem der Ansprüche 81 bis 113, wobei  
bei Bildung eines Kapsids oder kapsidartigen Gebildes aus dem  
10 Hüllprotein die eine Seite zum Inneren des Kapsids oder kapsidartigen Gebildes gewandt ist.

235. Medikament nach einem der Ansprüche 81 bis 114, wobei  
der eine Strang (as1, as2) der dsRNA I zum primären oder pro-  
15 zessierten RNA-Transkript des Zielgens komplementär ist.

236. Medikament nach einem der Ansprüche 81 bis 115, wobei  
die Zelle eine Vertebratenzelle oder eine menschliche Zelle  
ist.

20

237. Medikament nach einem der Ansprüche 81 bis 116, wobei  
der erste (B1) und der zweite Bereich (B2) voneinander beab-  
standet sind.

25 238. Medikament nach einem der Ansprüche 81 bis 117, wobei  
die dsRNA in einer Menge von höchstens 5 mg pro Verabrei-  
chungseinheit enthalten ist.

239. Medikament nach einem der Ansprüche 81 bis 118, wobei  
30 die dsRNA in eine Pufferlösung aufgenommen ist.

240. Medikament nach einem der Ansprüche 81 bis 119, wobei  
die dsRNA oral oder mittels Injektion oder Infusion intrave-

nös, intratumoral, inhalativ, intraperitoneal verabreichbar  
ist.

**WO 02/055693**

**PCT/EP02/00152**



7/20




Fig. 10






Fig. 11


8/20



**Fig. 12**



**Fig. 13**



**Fig. 14**

9/20




Fig. 15





Fig. 16

10/20



**Fig. 17**

11/20




Fig. 18

**WO 02/055693**

**PCT/EP02/00152**

20/20




Fig. 27

## SEQUENZPROTOKOLL

&lt;110&gt; Ribopharma AG

5 <120> Verfahren zur Hemmung der Expression  
eines Zielgens

&lt;130&gt;

10 &lt;140&gt;

&lt;141&gt;

&lt;160&gt; 142

15 &lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 2955

&lt;212&gt; DNA

20 &lt;213&gt; Homo sapiens

&lt;300&gt;

&lt;302&gt; Eph A1

&lt;310&gt; NM00532

25

&lt;300&gt;

&lt;302&gt; ephrin A1

&lt;310&gt; NM00532

30 &lt;400&gt; 1

atggagcggc	gctggcccct	ggggctaggg	ctggtgctgc	tgctctgcgc	cccgtgccc	60
ccgggggagc	gcgccaagga	agttactctg	atggacacaa	gcaaggcaca	gggagagctg	120
ggctggctgc	tggatcccc	aaaagatggg	tggagtgaac	agcaacagat	actgaatggg	180
acaccctct	acatgtacca	ggactgcca	atgcaaggac	gcagagacac	tgaccactgg	240
35	cttcgctcca	attggatcta	ccgcggggag	gaggcttccc	gcgtccacgt	ggagctgcag 300
	ttcaccgtgc	gggactgcaa	gagtttccct	gggggagccg	ggcctctggg	ctgcaaggag 360
	accttcaacc	ttctgtacat	ggagagtgc	caggatgtgg	gcattcagct	ccgacggccc 420
	ttgttcaga	aggtaaccac	ggtggctgca	gaccagagct	tcaccattcg	agaccttgcg 480
	tctggctccg	tgaagctgaa	tgtggagcgc	tgctctctgg	gccgcctgac	ccgccgtggc 540
40	ctctacctcg	ctttccacaa	cccgggtgcc	tgtgtggccc	tggtgtctgt	ccgggtcttc 600
	taccagcgt	gtcctgagac	cctgaatggc	ttggcccaat	tcccagacac	tctgcctggc 660
	cccgtgggt	tggtggaagt	ggcgggcacc	tgcttgcccc	acgcgcgggc	cagccccagg 720
	ccctcaggtg	caccccgcat	gcactgcagc	cctgatggcg	agtggctggg	gcctgtagga 780
	cggtgccact	gtgagcctgg	ctatgaggaa	ggtggcagtg	gcgaagcatg	tgttgcctgc 840
45	cctagcggct	cctaccggat	ggacatggac	acacccatt	gtctcacgtg	ccccagcag 900
	agcactgctg	agtctgaggg	ggccaccatc	tgtacctgtg	agagcggcca	ttacagagct 960
	cccggggagg	gccccagggt	ggcatgcaca	ggtccccct	cggccccccg	aaacctgagc 1020
	ttctctgcct	cagggactca	gctctccctg	cgttgggaac	ccccagcaga	tacgggggga 1080
	cgccaggatg	tcagatacag	tgtgaggtgt	tcccagtgct	agggcacagc	acaggacggg 1140
50	gggcccctgcc	agccctgtgg	ggtgggcgtg	cacttctcgc	cggggggccc	ggcgctcacc 1200
	acacctgcag	tgcattgtcaa	tggccttgaa	ccttatgcc	actacacctt	taatgtggaa 1260
	gccccaaaatg	gagtgtcagg	gctgggcagc	tctggccatg	ccagcacctc	agtcagcatc 1320
	agcatggggc	atgcagagtc	actgtcaggc	ctgtctctga	gactggtgaa	gaaagaaccg 1380
	aggcaactag	agctgacctg	ggcggggtcc	cggccccgaa	gccctggggc	gaacctgacc 1440
55	tatgagctgc	acgtgctgaa	ccaggatgaa	gaacggatcc	agatgggtct	agaaccagg 1500
	gtcttgctga	cagagctgca	gcctgacacc	acatacatcg	tcagagtccg	aatgctgacc 1560
	ccactgggtc	ctggcccttt	ctccctgat	catgagtttc	ggaccagccc	accagtgtcc 1620
	aggggcctga	ctggaggaga	gattgtagcc	gtcatctttg	ggctgctgct	tggtgcagcc 1680
	ttgctgcttg	ggattctcgt	tttccgggtc	aggagagccc	agcggcagag	gcagcagagg 1740
60	cacgtgaccg	cgccaccgat	gtggatcgag	aggacaagct	gtgctgaagc	cttatgtggt 1800
	acctccaggc	atacaggagc	cctgcacagg	gagccttgga	ctttaccggg	aggctggtct 1860
	aattttcctt	cccgggagct	tgatccagcg	tggctgatgg	tggacactgt	cataggagaa 1920



5 ggagagtttg gggaagtgtg tcgagggacc ctcaggctcc ccagccagga ctgcaagact 1980  
 gtggccatta agaccttaaa agacacatcc ccagggtggcc agtgggtggaa cttccttcga 2040  
 gaggcaacta tcatgggcca gtttagccac ccgcatattc tgcattctgga aggcgtcgtc 2100  
 acaaagcgaa agccgatcat gatcatcaca gaatttatgg agaatgcagc cctggatgcc 2160  
 10 ttcctgaggg agcgggagga ccagctggtc cctgggcagc tagtggccat gctgcagggc 2220  
 atagcatctg gcatgaacta cctcagtaat cacaattatg tccaccggga cctggctgcc 2280  
 agaaacatct tggatgaatca aaacctgtgc tgcaagggtg ctgactttgg cctgactcgc 2340  
 ctccctggatg actttgatgg cacatacgaa acccaggag gaaagatccc tatccgttgg 2400  
 acagcccctg aagccattgc ccatcggaac ttcaccacag ccagcgatgt gtggagcttt 2460  
 15 gggattgtga tgtgggaggt gctgagcttt ggggacaagc cttatgggga gatgagcaat 2520  
 caggaggtta tgaagagcat tgaggatggg taccggttgc cccctcctgt ggactgccct 2580  
 gcccctctgt atgagctcat gaagaactgc tgggcataat accgtgcccg ccggccacac 2640  
 ttccagaagc ttcaggcaca tctggagcaa ctgcttgcca acccccactc cctgcggacc 2700  
 attgccaaact ttgaccccag ggtgactctt cgcctgcccga gcctgagtggt ctcatatggg 2760  
 20 atcccgtatc gaaccgtctc tgagtggctc gagtccatac gcatgaaacg ctacatcctg 2820  
 cacttccact cggctgggct ggacaccatg gagtgtgtgc tggagctgac cgctgaggac 2880  
 ctgacgcaga tgggaatcac actgcccggg caccagaagc gcattctttg cagtattcag 2940  
 ggattcaagg actga 2955  
 25 <210> 2  
 <211> 3042  
 <212> DNA  
 <213> Homo sapiens  
 30 <300>  
 <302> ephrin A2  
 <310> XM002088  
 35 <400> 2  
 gaagttgctg gcaggccggc gggcgggagc ggacaccgag gccggcgctgc aggcgtgcgg 60  
 gtgtgctggga gccgggctcg gggggatcg accgagagcg agaagcgcg catggagctc 120  
 caggcagccc gcgcctgctt cgcctgctg tggggctgtg cgctggccgc ggcccgcg 180  
 40 ggcgagggca aggaagtggg actgctggac tttgctgcag ctggagggga gctcggctgg 240  
 ctcacacacc cgtatggcaa aggggtgggac ctgatgcaga acatcatgaa tgacatgccg 300  
 atctacatgt actccgtgtg caacgtgatg tctggcgacc aggacaactg gctccgcacc 360  
 aactgggtgt accgaggaga ggctgagcgt atcttcattg agctcaagtt tactgtacgt 420  
 gactgcaaca gcttccctgg tggcgccagc tctgcaagg agactttcaa cctctactat 480  
 gccgagtcgg acctggacta cggcaccaac ttccagaagc gcctgttcac caagattgac 540  
 45 accattgccc ccgatgagat caccgtcagc agcgacttcg aggcacgcca cgtgaagctg 600  
 aacgtggagg agcgctccgt ggggcggctc acccgcaaag gcttctacct ggcttccag 660  
 gatattcggtg cctgtgtggc gctgctctcc gtccgtgtct actacaagaa gtgccccgag 720  
 ctgctgcagg gcctggccca cttccctgag accatcgccg gctctgatgc acctccctg 780  
 gccactgtgg ccggcacctg tgtggaccat gccgtggtgc caccgggggg tgaagagccc 840  
 50 cgtatgcact gtgcagtggg tggcgagtgg ctgggtgcca ttgggcagtg cctgtgccag 900  
 gcaggctacg agaaggtgga ggatgcctgc caggcctgct cgcttgattt ttttaagttt 960  
 gaggcatctg agagccctg cttggagtgc cctgagcaca cgctgccatc ccctgagggg 1020  
 gccacctcct gcgagtgtga ggaaggcttc ttccgggcac ctcaggacct agcgtcgatg 1080  
 ccttgacacac gacccccctc cgcaccacac tacctcacag ccgtgggcat gggtgccaag 1140  
 55 gtggagctgc gctggacgcc cctcaggac agcggggggc gcgaggacat tgtctacagc 1200  
 gtcacctgcg aacagtgtg gcccagtgct ggggaatgag ggcagtggtg ggccagtgtg 1260  
 cgctactcgg agcctcctca cggactgacc cgaccagtg tgacagttag cgacctggag 1320  
 cccacatga actacacctt caccgtggag gcccgcaatg gcgtctcagg cctggtaacc 1380  
 agccgcagct tccgtactgc cagtgtcagc atcaaccaga cagagcccc caaggtgagg 1440  
 60 ctggagggcc gcagcaccac ctgccttagc gtctcctgga gcaccccc gccgcagcag 1500  
 agccagtggt ggaagtacga ggtcacttac cgcaagaagg gagactccaa cagctacaat 1560  
 gtgcgcgcga ccgaggggtt ctccgtgacc ctggacgacc tggccccaga caccacctac 1620  
 ctggtccagg tgcaggcact gacgcaggag ggccaggggg ccggcagcaa ggtgcacgaa 1680  
 ttccagacgc tgtccccgga gggatctggc aacttggcgg tgattggcgg cgtggctgtc 1740  
 65 ggtgtggtcc tgcctctggg gctggcagga gttggcttct ttatccaccg caggaggaag 1800  
 aaccagctg cccgcagtc cccggaggac gtttacttct ccaagtcaga acaactgaag 1860  
 cccctgaaga catacgtgga cccccacaca tatgaggacc ccaaccaggc tgtgttgaag 1920



5      ataccattg   ataaagttgt   tggagcaggt   gaatttggag   aggtgtgcag   tggtcgctta   1920  
       aaacttcctt   caaaaaaaga   gattttcagtg   gccattaaaa   ccctgaaagt   tggctacaca   1980  
       gaaaagcaga   ggagagactt   cctgggagaa   gcaagcatta   tgggacagtt   tgaccacccc   2040  
       aatatcattc   gactggaagg   agttgttacc   aaaagtaagc   cagttatgat   tgtcacagaa   2100  
       tacatggaga   atgggttcctt   ggatagtttc   ctacgtaaac   acgatgccc   gtttactgtc   2160  
       attcagctag   tggggatgct   tcgagggata   gcatctggca   tgaagtacct   gtcagacatg   2220  
       ggctatgttc   accgagacct   cgctgctcgg   aacatcttga   tcaacagtaa   cttggtgtgt   2280  
       aagggtttctg   atttcggact   ttcgcgtgtc   ctggaggatg   acccagaagc   tgcttatata   2340  
 10      acaagaggag   ggaagatccc   aatcagggtg   acatcaccag   aagctatagc   ctaccgcaag   2400  
       ttcacgtcag   ccagcgatgt   atggagttaa   gggattgttc   tctgggaggt   gatgtcttat   2460  
       ggagagagac   catactggga   gatgtccaat   caggatgtaa   ttaaagctgt   agatgagggc   2520  
       tatcgactgc   cccccccat   ggactgccc   gctgccttgt   atcagctgat   gctggactgc   2580  
       tggcagaaaag   acaggaacaa   cagacccaag   tttgagcaga   ttgttagtat   tctggacaag   2640  
       cttatccgga   atcccggcag   cctgaagatc   atcaccagtg   cagccgcaag   gccatcaaac   2700  
 15      cttcttcttg   accaaagcaa   tgtggatata   tctaccttc   gcacaacagg   tgactggctt   2760  
       aatgggtgtc   ggacagcaca   ctgcaaggaa   atcttcacgg   gcgtggagta   cagtctctgt   2820  
       gacacaatag   ccaagatttc   cacagatgac   atgaaaaagg   ttggtgtcac   cgtggttggg   2880  
       ccacagaaga   agatcatcag   tagcattaaa   gctctagaaa   cgcaatcaaa   gaatggccca   2940  
       gttcccgtgt   aaa   2953  
  
 20      <210> 4  
       <211> 2784  
       <212> DNA  
 25      <213> Homo sapiens  
  
       <300>  
       <302> ephrin A4  
       <310> XM002578  
 30      <400> 4  
       atggatgaaa   aaaatacacc   aatccgaacc   taccaagtgt   gcaatgtgat   ggaaccagc   60  
       cagaataact   ggctacgaac   tgattggatc   acccgagaag   gggctcagag   ggtgtatatt   120  
       gagattaaat   tcaccttgag   ggactgcaat   agtcttccgg   gcgtcatggg   gacttgcaag   180  
 35      gagacgttta   acctgtacta   ctatgaatca   gacaacgaca   aagagcgttt   catcagagag   240  
       aaccagtttg   tcaaaattga   caccattgct   gctgatgaga   gcttcaccca   agtggacatt   300  
       ggtgacagaa   tcatgaagct   gaacaccgag   atccgggatg   tagggccatt   aagcaaaaag   360  
       gggtttttacc   tggcttttca   ggatgtgggg   gcctgcatcg   ccctgggtatc   agtccgtgtg   420  
       ttctataaaa   agtgtccact   cacagtccgc   aatctggccc   agtttcctga   caccatcaca   480  
 40      ggggctgata   cgtcttccct   ggtggaagtt   cgaggctcct   gtgtcaacaa   ctcagaagag   540  
       aaagatgtgc   caaaaatgta   ctgtggggca   gatggtgaat   ggctgggtacc   cattggcaac   600  
       tgccatgca   acgctgggca   tgaggagcgg   agcggagaat   gccaaagctt   caaaattgga   660  
       tattacaagg   ctctctccac   ggatgccacc   tgtgccaatg   gccaccccca   cagctactct   720  
       gtctgggaag   gagccacctc   gtgcacctgt   gaccgaggct   ttttcagagc   tgacaacgat   780  
 45      gctgcctcta   tgccctgcac   cgtccacca   tctgtcctcc   tgaacttgat   ttcaaatgtc   840  
       aacgagacat   ctgtgaactt   ggaatggagt   agccctcaga   atacaggtgg   ccgccaggac   900  
       atttcctata   atgtggtatg   caagaaatgt   ggagctggtg   accccagcaa   gtgccgacct   960  
       tgtggaagtg   ggggtccacta   caccacacag   cagaatggct   tgaagaccac   caaagtctcc   1020  
       atcaactgacc   tcctagctca   taccatttac   acctttgaaa   tctgggctgt   gaatggagtg   1080  
 50      tccaaatata   accctaacc   agaccaatca   gtttctgtca   ctgtgaccac   caaccaagca   1140  
       gcaccatcat   ccattgcttt   ggtccaggct   aaagaagtca   caagatacag   tgtggcactg   1200  
       gcttggcttg   aaccagatcg   gcccaatggg   gtaatcctgg   aatatgaagt   caagtattat   1260  
       gagaaggatc   agaatgagcg   aagctatcgt   atagtccgga   cagctgccag   gaacacagat   1320  
       atcaaaggcc   tgaacctct   cacttcctat   gttttccacg   tgcgagccag   gacagcagct   1380  
 55      ggctatggag   acttcagtga   gcccttggag   gttacaacca   acacagtgcc   tccccggatc   1440  
       attggagatg   gggctaactc   cacagtcctt   ctggtctctg   tctcggggcag   tgtggtgtgt   1500  
       tcttcctctg   tcttcctctg   tcttcctctg   tcttcctctg   tcttcctctg   tcttcctctg   1560

<211> 3147  
 <212> DNA  
 <213> Homo sapiens

5 <300>  
 <302> alpha v intergrin  
 <310> NM0022210

<400> 12  
 10 atggccttttc cgccgcggcg acggctgcgc ctccggctccc ggggcctccc gcttcttctc 60  
 tcgggactcc tgctacctct gtgcgcgcgc ttcaacctag acgtggacag tcctgccgag 120  
 tactctggcc ccgagggaag ttacttcggc ttccgcgtgg atttcttcgt gccagcgcg 180  
 tcttcccggg tgttcttctc cgtgggagct cccaaagcaa acaccacca gcctgggatt 240  
 gtggaaggag ggcaggctct caaatgtgac tggctctcta ccgcgggtg ccagccaatt 300  
 15 gaatttgatg caacaggcaa tagagattat gccaggatg atccattgga atttaagtcc 360  
 catcagtggg ttggagcatc tgtgaggtcg aaacaggata aaattttggc ctgtgcccc 420  
 ttgtaccatt ggagaactga gatgaaacag gagegagagc ctgttggaac atgctttctt 480  
 caagatggaa caaagactgt tgagtatgct ccatgtagat cacaagatat tgatgctgat 540  
 ggacagggat tttgtcaagg aggatccagc attgatttta ctaaagctga cagagtactt 600  
 20 cttgttggtc ctggtagctt ttattggcaa ggtcagctta ttccgatca agtggcagaa 660  
 atcgatatcta aatacgacct caatgtttac agcatcaagt ataataacca attagcaact 720  
 cggactgcac aagctatttt tgatgacagc tatttgggtt attctgtggc tgtcggagat 780  
 ttcaatgggtg atggcataga tgactttggt tcaggagttc caagagcagc aaggactttg 840  
 ggaatggttt atatttatga tgggaagaac atgtcctcct tatacaattt tactggcgag 900  
 25 cagatggctg catatttcgg attttctgta gctgccactg acattaatgg agatgattat 960  
 gcagatgtgt ttattggagc acctctcttc atggatcgtg gctctgatgg caaactccaa 1020  
 gaggtggggc aggtctcagt gtctctacag agagcttcag gagacttcca gacgacaaag 1080  
 ctgaatggat ttgaggtctt tgcacggttt ggcagtgcca tagctccttt gggagatctg 1140  
 gaccaggatg gtttcaatga tattgcaatt gctgctccat atgggggtga agataaaaaa 1200  
 30 ggaattgttt atatcttcaa tggaaagatc acaggcttga acgcagctcc atctcaaate 1260  
 cttgaagggtc agtgggctgc tcgaagcatg ccaccaagct ttggctattc aatgaaagga 1320  
 gccacagata tagacaaaaa tggatatcca gacttaattg taggagcttt tgggtgtgat 1380  
 cgagctatct tatacagggtc cagaccagtt atcactgtaa atgctgggtc tgaagtgtac 1440  
 cctagcattt taaatcaaga caataaaacc tgctcactgc ctggaacagc tctcaaagtt 1500  
 35 tctgttttta atgttaggtt ctgcttaag gcagatggca aaggagtact tccaggaa 1560  
 cttaatttcc aggtggaact tcttttggat aaactcaagc aaaaggagc aattcgagc 1620  
 gcactgtttc tctacagcag gtccccaagt cactccaaga acatgactat ttcaagggg 1680  
 ggactgatgc agtgtgagga attgatagcg tatctgcggg atgaatctga atttagagac 1740  
 aaactcactc caattactat ttttatggaa tatcggttgg attatagaac agctgctgat 1800  
 40 acaacaggct tgcaaccat tcttaaccag ttcacgctg ctaacattag tcgacaggc 1860  
 cacattctac ttgactgtgg tgaagacaat tctctgtaac ccaagctgga agtttctgta 1920  
 gatagtgatc aaaagaagat ctatattggg gatgacaacc ctctgacatt gattgttaag 1980  
 gctcagaatc aaggagaagg tgccctacgaa gctgagctca togtttccat tccactgcag 2040  
 gctgatttca ccggggttgt ccgaaacaat gaagccttag caagactttc ctgtgcattt 2100  
 45 aagacagaaa accaaactcg ccagggtgta tgtgacctg gaaacccaat gaaggctgga 2160  
 actcaactct tagctgggtc tcgtttcagt gtgcaccagc agtcagagat ggatacttct 2220  
 gtgaaatttg acttacaat ccaaagctca aatctatttg acaaagtaag cccagttgta 2280  
 tctcacaag ttgatcttgc tgttttagct gcagttgaga taagaggagt ctcgagtcct 2340  
 gatcatatct ttcttccgat tccaaactgg gagcacaagg agaaccctga gactgaagaa 2400  
 50 gatgttgggc cagttgttca gcacatctat gagctgagaa acaatggtcc aagttcattc 2460  
 agcaaggcaa tgctccatct tcagtggcct tacaaatata ataataacac tctgttgtat 2520  
 atccttcatt atgatattga tggaccaatg aactgcactt cagatatgga gatcaaccct 2580  
 ttgagaattt agatctcatc tttgcaaaac actgaaaaga atgacacggg tgccgggcaa 2640  
 ggtgagcggg accatctcat cactaagcgg gatcttgccc tcagtgaagg agatattcac 2700  
 55 actttgggtt gtggagtgc tcagtgttg taagattgtc gccagttgg gagattagac 2760  
 agaggaaaaga gtgcaatctt gtactgaaag tcattactgt ggactgagac ttttatgaat 2820  
 aaagaaaatc agaattcttc ctattctctg aagtcgtctg cttcatttaa tgtcatagag 2880  
 tttccttata agaattcttc aattgaggat atcaccact ccacattggg taccactaat 2940  
 gtcacctggg gcattcagcc agcgcctatg cctgtgctg tgtgggtgat catttttagca 3000  
 60 gttctagcag tattgttgct actggctgtt ttggtatttg taatgtacag gatgggctt 3060  
 ttttaacggg tccggccacc tcaagaagaa agcagcttca acctcatgaa 3120  
 aatggtgaag gaaactcaga aacttaa 3147

```

5   <210> 13
    <211> 402
    <212> DNA
    <213> Homo sapiens

    <300>
    <302> CaSm (cancer associated SM-like oncogene)
10  <310> AF000177

    <400> 13
    atgaactata tgcctggcac cgccagcctc atcgaggaca ttgacaaaaa gcacttggtt 60
    ctgcttcgag atggaaggac acttataggc tttttaagaa gcattgatca atttgcaaac 120
15  ttagtgctac atcagactgt ggagcgtatt catgtgggca aaaaatacgg tgatattcct 180
    cgagggattt ttgtggtcag aggagaaaat gtggtcctac taggagaaat agacttggaa 240
    aaggagagtg acacaccctt ccagcaagta tccattgaag aaattctaga agaacaaagg 300
    gtggaacagc agaccaagct ggaagcagag aagttgaaag tgcaggccct gaaggaccga 360
20  ggtctttcca ttcctcgagc agatactctt gatgagtact aa 402

    <210> 14
    <211> 1923
    <212> DNA
25  <213> Homo sapiens

    <300>
    <302> c-myb
    <310> NM005375
30

    <400> 14
    atggcccga gaccccgga cagcatatat agcagtgacg aggatgatga ggactttgag 60
    atgtgtgacc atgactatga tgggctgctt cccaagtctg gaaagcgtca cttggggaaa 120
35  acaagggtga cccgggaaga ggatgaaaaa ctgaagaagc tgggtggaaca gaatggaaca 180
    gatgactgga aagttattgc caattatctc ccgaatcgaa cagatgtgca gtgccagcac 240
    cgatggcaga aagtactaaa ccctgagctc atcaagggtc cttggacca aagaagaagat 300
    cagagagtga tagagcttgt acagaaatac ggtccgaaac gttggtctgt tattgccaag 360
    cacttaaagg ggagaattgg aaaacaatgt agggagaggt ggcataacca cttgaatcca 420
40  gaagttaaga aaacctcctg gacagaagag gaagacagaa ttatttacca ggcacacaag 480
    agactgggga acagatgggc agaatctgca aagctactgc ctggacgaac tgataatgct 540
    atcaagaacc actggaattc tacaatgctg cggaagggtc aacaggaagg ttatctgcag 600
    gagtcttcaa aagccagcca gccagcagtg gccacaagct tccagaagaa cagtcatttg 660
    atgggttttg ctcaggctcc gcctacagct caactccctg ccactggcca gccactgtt 720
45  aacaacgact attcctatta ccacatttct gaagcacaaa atgtctccag tcatgttcca 780
    taccctgtag cgttacatgt aaatatagtc aatgtccctc agccagctgc cgcagccatt 840
    cagagacact ataatgatga agaccctgag aaggaaaagc gaataaagga attagaattg 900
    ctctaatgt caaccgagaa tgagctaaaa ggacagcagg tgctaccaac acagaaccac 960
    acatgcagct accccgggtg gcacagcacc accattgccg accacaccag acctcatgga 1020
50  cagcagtgac ctgtttcctg tttgggagaa caccactcca ctccatctct gccagcggat 1080
    cctggctccc tacctgaaga aagcgcctcg ccagcaaggt gcatgatcgt ccaccagggc 1140
    accattctgg ataatgttaa gaacctctta gaatttgag aaacactcca atttatagat 1200
    tctttcttaa acacttccag taaccatgaa aactcagact tggaaatgcc ttctttaact 1260
    tccacccccc tcattggtca caaattgact gttacaacac catttcatag agaccagact 1320
55  gtgaaaactc aaaaggaaaa tactgttttt agaaccctag ctatcaaaaag gtcaatctta 1380
    gaaagctctc caagaactcc tacaccattc aaacatgcat ttgcagctca agaaattaaa 1440
    tacggtcccc tgaagatgct acctcagaca cctctcatc tagtagaaga tctgcaggat 1500
    gtgatcaaac aggaatctga tgaatctgga tttgttgctg agtttcaaga aaatggacca 1560
    cccttactga agaaaatcaa acaagaggtg gaatctccaa ctgataaatc aggaaacttc 1620
    ttctgctcac accactggga aggggacagt ctgaataccc aactgttcac gcagacctcg 1680
60  cctgtgcgag atgcaccgaa tattcttaca agtccggtt taatggcacc agcatcagaa 1740
    gatgaagaca gtgttctcaa agcatttaca gtacctaaaa acaggtcctt ggcgagcccc 1800
    ttgcagcctt gtagcagtag ctgggaacct gcactcctgtg gaaagatgga ggagcagatg 1860

```

```

acatctttcca gtcaagctcg taaatacgtg aatgcattct cagcccggac gctgggtcatg 1920
tga                                                    1923

5  <210> 15
   <211> 544
   <212> DNA
   <213> Homo sapiens

10 <300>
   <302> c-myc
   <310> J00120

15 <400> 15
   gacccccgag ctgtgctgct cgcggccgcc accgcccggc cccggccgctc cctgggtccc 60
   ctccctgcctc gagaagggca gggctttctca gaggcttggc gggaaaaaga acggagggag 120
   ggatcgcgctc gagtataaaa gccgggttttc ggggctttat ctaactcgct gtagtaattc 180
   cagcgagaggc cagagggagc gagcgggcgg cccggctaggg tggagagacc gggcgagcag 240
   agctgcgctg cgggcgtcct ggggaaggag atccggagcg aatagggggc ttcgcctctg 300
20 gcccagccct cccgctgata ccccagccag cggctccgaa cccttgccgc atccacgaaa 360
   ctttgcccat accagcgggc gggcactttg cactggaaact tacaacacc gagcaaggac 420
   gcgactctcc cgacgcgggg aggctattct gccatttgg ggacacttcc ccgccgctgc 480
   caggaccgcg ttctctgaaa ggctctcctt gcagctgctt agacgctgga tttttttcgg 540
   gtag                                                    544

25 <210> 16
   <211> 618
   <212> DNA
30 <213> Homo sapiens

   <300>
   <302> ephrin-A1
   <310> NM004428

35 <400> 16
   atggagttcc tctgggcccc tctcttgggt ctgtgctgca gtctggccgc tgetgatcgc 60
   cacaccgtct tctggaacag ttcaaattcc aagttccgga atgaggacta caccatacat 120
   gtgcagctga atgactacgt ggacatcatc tgtccgcact atgaagatca ctctgtggca 180
40 gacgctgcca tggagcagta catactgtac ctggtggagc atgaggagta ccagctgtgc 240
   cagccccagt ccaaggacca agtccgctgg cagtgcgaac ggcccagtgc caagcatggc 300
   ccggagaagc tgtctgagaa gttccagcgc ttcacacctt tcacctggg caaggagtgc 360
   aaagaaggac acagctacta ctacatctcc aaacctatcc accagcatga agaccgctgc 420
   ttgaggttga aggtgactgt cagtggcaaa atcactcaca gtcctcaggc ccatgtcaat 480
45 ccacaggaga agagacttgc agcagatgac ccagaggtag gggttctaca tagcatcgg 540
   cacagtgtctg cccacgcct cttcccactt gcctggactg tgctgctcct tccacttctg 600
   ctgctgcaaa ccccgtag                                                    618

50 <210> 17
   <211> 642
   <212> DNA
   <213> Homo sapiens

55 <400> 17
   atggcgcccg cgcagcgccc getgctcccc ctgctgctcc tgctgttacc gctgccgccc 60
   ccgcccttcg cgcgcgccga ggacgcgcc cgcgccaaact cggaccgcta cgcgctctac 120
   tggaaaccgca gcaaccccag gttccacgca ggcgcggggg acgacggcgg gggctacacg 180
   gtggagggtga gcatcaatga ctacctggac atctactgcc cgcactatgg ggcgcgcgtg 240
60 ccgccggccc agcgcagatga gcactacgtg ctgtacatgg tcaacggcga gggccacgcc 300
   tcctgcgacc accgccagcg cggcttcaag cgctgggagt gcaaccggcc cgcggcgccc 360
   gggggggccc tcaagttctc ggagaagttc cagctcttca cgccttctc cctgggcttc 420

```

gagttccggc cgggccacga gtattactac atctctgcc a cgcctcccaa tgctgtggac 480  
 cgccctgcc tgcgactgaa ggtgtacgtg cggccgacca acgagaccct gtacgaggct 540  
 cctgagccca tcttcaccag caataactcg tgtagcagcc cgggcggtg ccgcctcttc 600  
 5 ctcagcacca tccccgtgct ctggaccctc ctgggttcct ag 642

<210> 18  
 <211> 717  
 <212> DNA  
 10 <213> Homo sapiens

<300>  
 <302> ephrin-A3  
 <310> XM001787  
 15

<400> 18  
 atggcgggcgt ctccgctgct gctgctgctg ctgctcgtgc ccgtgcgct gctgcgctg 60  
 ctggcccaag ggcccgagg ggcgctggga aaccggcatg cgggtgactg gaacagctcc 120  
 aaccagcacc tgcggcgaga gggctacacc gtgcagggtga acgtgaacga ctatctggat 180  
 20 attactgcc cgcactacaa cagctcgggg gtgggccccg gggcgggacc gggggccgga 240  
 ggcggggagc agcagtagct gctgtacatg gtgagccgca acggctaccg cacctgcaac 300  
 gccagccagg gcttcaagcg ctgggagtg aaccggccgc acgcccgcga cagccccatc 360  
 aagttctcgg agaagttcca gcgtacagc gccttctctc tgggctacga gttccacgcc 420  
 ggccacgagt actactacat ctccacgccc actcacaacc tgcactggaa gtgtctgagg 480  
 25 atgaaggtgt tcgtctgctg cgcctccaca tcgcactccg gggagaagcc ggtccccact 540  
 ctccccagt tcaccatggg ccccaatatg aagatcaacg tgctggaaga ctttgaggga 600  
 gagaaccctc aggtgcccaa gcttgagaag agcatcagcg ggaccagccc caaacgggaa 660  
 cacctgcccc tggccgtggg catcgccttc ttctcatga cgttcttggc ctccatg 717

30  
 <210> 19  
 <211> 606  
 <212> DNA  
 <213> Homo sapiens

35  
 <300>  
 <302> ephrin-A3  
 <310> XM001784

40  
 <400> 19  
 atgcggctgc tgccctgct gcggactgtc ctctgggccc cgttcctcgg ctccccctctg 60  
 cgcgggggct ccagcctccg ccacgtagtc tactggaact ccagtaacct cagggttctt 120  
 cgaggagacg ccgtggtgga gctgggcctc aacgattacc tagacattgt ctgccccac 180  
 45 tacgaaggcc cagggccccc tgagggcccc gagacgtttg ctttgtacat ggtggactgg 240  
 ccaggctatg agtcctgcca ggcagagggc ccccgggcct acaagcgctg ggtgtgctcc 300  
 ctgccctttg gccatgttca attctcagag aagattcagc gcttcacacc cttctccctc 360  
 ggctttgagt tcttacctgg agagacttac tactacatct cggtgcccac tccagagagt 420  
 tctggccagt gcttgaggct ccagggtgtc gtctgctgca aggagaggaa gtctgagtca 480  
 gccatcctg ttgggagccc tggagagagt ggcacatcag ggtggcgagg gggggacact 540  
 50 cccagccccc tctgtctctt gctattactg ctgcttctga ttcttcgtct tctgcgaatt 600  
 ctgtga 606

55  
 <210> 20  
 <211> 687  
 <212> DNA  
 <213> Homo sapiens

60  
 <300>  
 <302> ephrin-A5  
 <310> NM001962

```

<400> 20
atgttgcacg tggagatggt gacgctgggtg tttctgggtgc tctggatgtg tgtgttcagc 60
caggaccccg gctccaaggc cgtcgccgac cgctacgctg tctactggaa cagcagcaac 120
cccagattcc agaggggtga ctaccatatt gatgtctgta tcaatgacta cctggatgtt 180
5 tctgccctc actatgagga ctccgtccca gaagataaga ctgagcgcta tgcctctac 240
atggtgaact ttgatggcta cagtgcctgc gaccacactt ccaaaggggt caagagatgg 300
gaatgtaacc ggccctcactc tccaaatgga ccgctgaagt tctctgaaaa attccagctc 360
ttcactccct tttctctagg atttgaattc aggccaggcc gagaatattt ctacatctcc 420
tctgcaatcc cagataatgg aagaagggtcc tgtctaaagc tcaaagtctt tgtgagacca 480
10 acaaatagtc gtatgaaaac tataggtgtt catgatcgtg ttttcgatgt taacgacaaa 540
gtagaaaatt cattagaacc agcagatgac accgtacatg agtcagccga gccatcccg 600
ggcgagaacg cggcacaaaac accaaggata ccagcccgcc ttttggcaat cctactgttc 660
ctcctggcga tgcttttgac attatag 687

15
<210> 21
<211> 2955
<212> DNA
<213> Homo sapiens

20
<400> 21
atggcccttg attatctact actgctcctc ctggcatccg cagtggctgc gatggaagaa 60
acgttaaatg acaccagaac ggctactgca gagctgggct ggacggccaa tcctgcgtcc 120
gggtgggaag aagtcagtggt ctacgatgaa aacctgaaca ccatccgcac ctaccaggtg 180
25 tgcaatgtct tcgagcccaa ccagaacaat tggctgctca ccaccttcat caaccggcgg 240
ggggcccatc gcatctacac agagatgcgc ttcactgtga gagactgcag cagcctccct 300
aatgtcccag gatcctgcaa ggagaccttc aacttgtatt actatgagac tgactctgtc 360
attgccacca agaagtcagc cttctgggtc gagggccctt acctcaaagt agacaccatt 420
gctgcagatg agagcttctc ccaggtggac tttgggggaa ggctgatgaa ggtaaacaca 480
30 gaagtcagga gctttgggcc tcttactcgg aatgggtttt acctcgcttt tcaggattat 540
ggagcctgta tgtctcttct ttctgtccgt gtcttcttca aaaagtgtcc cagcattgtg 600
caaaattttg cagtgtttcc agagactatg acaggggcag agagcacatc tctggtgatt 660

```



<213> Homo sapiens

<400> 27

```
5 atggggccccc cccattcttg ggcggggggc gtgcgagtcg gggccctgct gctgctgggg 60
gttttggggc tgggtgtctg gctcagcctg gagecctgtct actggaactc ggccaataag 120
agggttccagg cagagggtgg ttatgtgctg taccctcaga tcggggaccg gctagacctg 180
ctctgcccc gggcccgcc tcttgccct cactcctctc ctaattatga gttctacaag 240
ctgtacctgg taggggggtg tcagggcccg cgctgtgagg caccctctgc cccaaacctc 300
cttctcactt gtgatcgccc agacctggat ctccgcttca ccatcaagt ccaggagtat 360
10 agccctaata tctggggcca cgagttccgc tcgcaccacg attactacat cattgccaca 420
tcggatggga cccgggagg cctggagagc ctgcaggag gtgtgtgcct aaccagaggc 480
atgaaggtgc ttctccagt gggacaaaagt ccccgaggag gggctgtccc ccgaaaacct 540
gtgtctgaaa tgcccatgga aagagaccga ggggcagccc acagcctgga gcctgggaag 600
gagaacctgc caggtgacct caccagcaat gcaacctccc ggggtgctga aggccccctg 660
15 cccctccca gcatgcctgc agtggtcggg gcagcagggg ggctggcgct gctcttgctg 720
ggcgtggcag gggctggggg tgccatgtgt tggcgagac ggcgggcaa gccttcggag 780
agtcgccacc ctggtcctgg ctcttcggg aggggagggt ctctgggctt ggggggtgga 840
gggtgggatgg gacctcgga ggctgagcct ggggagctag ggatagctct gcggggtggc 900
ggggctgcag atccccctt ctgccccac tatgagaagg tgagtggtag ctatgggcat 960
20 cctgtgtata tcgtgcagga tggggccccc cagagccctc caaacatcta ctacaaggta 1020
tga 1023
```

<210> 28

25 <211> 3399

<212> DNA

<213> Homo sapiens

<300>

30 <302> telomerase reverse transcriptase

<310> AF015950

<400> 28

```
35 atgccgcgcg ctccccgctg ccgagccgtg cgctccctgc tgcgcagcca ctaccgcgag 60
gtgctgccgc tggccacgtt cgtgcggcgc ctggggcccc agggctggcg gctgggtgcag 120
cgcggggacc cggcgcttt ccgcgcgtg gtggccagtg gcttgggtgt cgtgccctgg 180
gacgcacggc cgcccccgcc cgccccctcc ttccgccagg tgctctgcct gaaggagctg 240
gtggcccgag tgctgcagag gctgtgcgag cgcggcgcga agaactgtct ggcttcggc 300
ttcgcgctgc tggacggggc ccgcgggggc ccccccagag ccttcaccac cagcgtgcgc 360
40 agctacctgc ccaacacggt gaccgacgca ctgcggggga gcgggcgctg ggggctgctg 420
ctgcgcgcgc tggcgacga cgtgctggtt cactgctgg cagctgcgc gctctttgtg 480
ctgggtggctc ccagctgcgc ctaccaggtg tgcgggcgcg cgctgtacca gctcggcgct 540
gccactcagg cccggccccc gccacacgct agtggaaccc gaaggcgtct gggatgcgaa 600
cgggcctgga accatagcgt caggagaggc ggggtcccc tgggcctgcc agccccgggt 660
45 gcgaggaggc gcgggggcag tgccagccga agtctgccgt tgcccaagag gccaggcgt 720
ggcgctgccc ctgagccgga gcgacgccc gttgggcagg ggtcctggg ccaccgggc 780
aggacgcgtg gaccgagtga ccgtggtttc tgtgtggtgt cactgccag acccgccgaa 840
gaagccacct ctttgagggt tgcgtctctt ggcacgcgcc actcccacc atcgtgggc 900
cgccagcacc acgcgggccc cccatccaca tcgcggccac cactccctg ggacacgcct 960
50 tgtccccggg tgtacgccga gaccaagcac ttctctact cctcaggcga caaggagcag 1020
ctgcggccct cttctact cagctctctg aggccagcc tgactggcgc tcggaggctc 1080
gtggagacca tctttctggg ttccaggccc tggatgccag ggactccccg cagggtgccc 1140
cgctgcccc agcgtactg gcaaagtgcg cccctgtttc tggagctgct tgggaaccac 1200
gcgcagtgcc cctacggggt gctcctcaag acgcactgcc cgctgcgagc tgcggtcacc 1260
55 ccagcagccg gtgtctgtgc cggggagaag cccagggtct ctgtggcggc ccccgaggag 1320
gaggacacag acccccgtc cctggtgcag ctgctccgc agcacagcag cccctggcag 1380
gtgtacggct tcgtgcggc ctgctgcgc cggctgggtc cccaggcct ctggggctcc 1440
aggcacaacg aacgccgctt cctcaggaa accaagaagt tcctctccct ggggaagcat 1500
gccaagctct cgctgcagga gctgacgtgg aagatgagc tgcgggactg cgcttggctg 1560
60 cgcaggagcc cagggttggt ctgtgttccg gccgcagagc accgtctgcg tgaggagatc 1620
ctggccaagt tctgcaactg gctgatgagt gtgtacgtcg tcgagctgct caggctcttc 1680
ttttatgtca cggagaccac gtttcaaaag aacaggctct ttttctaccg gaagagtgtc 1740
```

5 tggagcaagt tgcaaagcat tggaaatcaga cagcacttga agaggggtgca gctgcgggag 1800  
 ctgtcgggaag cagaggtcag gcagcatcgg gaagccaggc ccgccctgct gacgtccaga 1860  
 ctccgcttca tccccaagcc tgacgggctg cggccgattg tgaacatgga ctacgtcgtg 1920  
 ggagccagaa cgttccgcag agaaaagagg gccgagcgctc tcacctcgag ggtgaaggca 1980  
 ctgttcagcg tgctcaacta cgagcgggcg cggcgccccg gcctcctggg cgctctgtg 2040  
 ctggggcctgg acgatatcca cagggcctgg cgcaacctcg tgctgcgtgt gcgggcccag 2100  
 gaccgcgcgc ctgagctgta ctttgtcaag gtggatgtga cgggcgcgta cgacaccatc 2160  
 ccccaggaca ggctcacgga ggtcatcgcc agcatcatca aaccccagaa cacgtactgc 2220  
 gtgcgtcgggt atgccgtgggt ccagaaggcc gcccatgggc acgtccgcaa ggccttcaag 2280  
 10 agccacgtct ctaccttgac agacctccag ccgtacatgc gacagtctgt ggctcacctg 2340  
 caggagacca gcccgctgag ggatgcgctc gtcacgagc agagctcctc cctgaatgag 2400  
 gccagcagtg gcctcttcga cgtcttctta cgcttcattg gccaccacgc cgtgcgcac 2460  
 aggggcaagt cctacgtcca gtgccagggg atcccgagg gctccatcct ctccacgtg 2520  
 ctctgcagcc tgtgctacgg cgacatggag aacaagctgt ttgcggggat tcggcgggac 2580  
 15 gggctgctcc tgcggttgggt ggatgatttc ttgttgggtga cacctcacct caccacgcg 2640  
 aaaaccttcc tcaggaccct ggtccgaggt gtccctgagt atggctgcgt ggtgaacttg 2700  
 cggaagacag tgggtgaactt ccctgtagaa gacgaggccc tgggtggcac ggcttttgt 2760  
 cagatgcccg cccacggcct attcccctgg tgcggcctgc tgctggatac ccggaccctg 2820  
 gaggtgcaga gcgactactc cagctatgcc cggacctcca tcagagccag tctcaccttc 2880  
 20 aaccgcggct tcaaggctgg gaggaacatg cgtcgcaaac tctttgggggt ctgcggctg 2940  
 aagtgtcaca gcctgtttct ggatttgtag gtgaacagcc tccagacggt gtgcaccaac 3000  
 atctacaaga tcctcctgct gcaggcgtag aggtttcacg catgtgtgct gcagctccca 3060  
 tttcatcagc aagtttgga gaaacccaca ttttctctgc gcgtcatctc tgacacggcc 3120  
 tccctctgct actccatcct gaaagccaag aacgcaggga tgtcgctggg ggccaagggc 3180  
 25 gccgcggccc ctctgccttc cgaggccgtg cagtggctgt gccaccaagc attcctgctc 3240  
 aagctgactc gacaccgtgt cacctacgtg ccactcctgg ggtcactcag gacagcccag 3300  
 acgcagctga gtcggaagct cccggggagc acgctgactg ccctggaggc cgacgccaac 3360  
 ccggcactgc cctcagactt caagaccatc ctggactga 3399

30  
 <210> 29  
 <211> 567  
 <212> DNA  
 <213> Homo sapiens

35  
 <300>  
 <302> K-ras  
 <310> M54968

40  
 <400> 29  
 atgactgaat ataaacttgt ggtagttgga gcttgtggcg taggcaagag tgccttgacg 60  
 atacagctaa ttcagaatca ttttgtggac gaatatgatc caacaataga ggattcctac 120  
 aggaagcaag tagtaattga tggagaaacc tgtctcttgg atattctcga cacagcagg 180  
 caagaggagt acagtgcaat gaggggaccag tacatgagga ctggggaggg ctttctttgt 240  
 45 gtatttggca taaataatac taaatcattt gaagatattc accattatag agaacaatt 300  
 aaaagagtta aggactctga agatgtacct atggctcctag taggaaataa atgtgatttg 360  
 ccttctagaa cagtagacac aaaacaggct caggacttag caagaagtta tgggaattcct 420  
 tttattgaaa catcagcaaa gacaagacag ggtgttgatg atgccttcta tacattagtt 480  
 cgagaaattc gaaaacataa agaaaagatg agcaaagatg gtaaaaaaga gaaaaagaag 540  
 50 tcaaagacaa agtgtgtaat tatgttaa 567

<210> 30  
 <211> 3840  
 55 <212> DNA  
 <213> Homo sapiens

<300>  
 <302> mdr-1  
 60 <310> AF016535

<400> 30

	atggatcttg	aaggggaccg	caatggagga	gcaaagaaga	agaacttttt	taaactgaac	60
	aataaaagt	aaaaagataa	gaaggaaaag	aaaccaactg	tcagtgtatt	ttcaatgttt	120
	cgctattcaa	attggcttga	caagttgtat	atgggtggg	gaactttggc	tgccatcatc	180
5	catggggctg	gacttcctct	catgatgctg	gtgtttggag	aaatgacaga	tatctttgca	240
	aatgcaggaa	atttagaaga	tctgatgtca	aacatcacta	atagaagtga	tatcaatgat	300
	acagggttct	tcatgaatct	ggaggaagac	atgaccaggt	atgcctatta	ttacagtgga	360
	attgggtgctg	gggtgctggg	tgctgcttac	attcaggttt	cattttgggtg	cctggcagct	420
	ggaagacaaa	tacacaaaat	tagaaaacag	ttttttcatg	ctataatgcg	acaggagata	480
	ggctgggttg	atgtgcacga	tggtggggag	cttaacaccc	gacttacaga	tgatgtctcc	540
10	aagattaatg	aaggaattgg	tgacaaaatt	ggaatgttct	ttcagtcaat	ggcaacattt	600
	ttcactgggt	ttatagtagg	atttacacgt	gggtggaagc	taacccttgt	gattttggcc	660
	atcagtcctg	ttcttggaact	gtcagctgct	gtctgggcaa	agatactatc	ttcatttact	720
	gataaagaac	tcttagcgta	tgcaaaagct	ggagcagtag	ctgaagaggt	cttggcagca	780
	attagaactg	tgattgcatt	tggaggacaa	aagaaagaac	ttgaaaggtg	caacaaaaat	840
15	ttagaagaag	ctaaaagaat	tgggataaag	aaagctatta	cagccaatat	ttctataggt	900
	gctcctttcc	tgctgatcta	tgcatcttat	gctctggcct	tctggtatgg	gaccaccttg	960
	gtcctctcag	gggaatatct	tattggacaa	gtactcactg	tattttctgt	attaattggg	1020
	gcttttagtg	ttggacaggc	atctccaagc	attgaagcat	ttgcaaatgc	aagaggagca	1080
	gcttatgaaa	tcttcaagat	aattgataat	aagccaagta	ttgacagcta	ttcgaagagt	1140
20	gggcacaaac	cagataatat	taagggaaat	ttggaattca	gaaatgttca	cttcagttac	1200
	ccatctcgaa	aagaagttaa	gatcttgaag	ggcttgaacc	tgaaggtgca	gagtgggacg	1260
	acggtggccc	tggttggaag	cagtggctgt	gggaagagca	caacagtcga	gctgatgcag	1320
	aggctctatg	acccacaga	gggatgggtc	agtgttgatg	gacaggatat	taggaccata	1380
	aatgtaaggt	ttctacggga	aatcattggg	gtgggtgagtc	aggaacctgt	attgtttgcc	1440
25	accacgatag	ctgaaaacat	tcgctatggc	cgtgaaaatg	tcaccatgga	tgagattgag	1500
	aaagctgtca	aggaagccaa	tgccatgac	tttatcatga	aactgcctca	taaatgtgac	1560
	accctggttg	gagagagagg	ggcccagttg	gtgggtgggc	agaagcagag	gatcgccatt	1620
	gcacgtgccc	tggttcgcaa	ccccaaagtc	ctcctgctgg	atgaggccac	gtcagccttg	1680
	gacacagaaa	gcgaagcagt	gggttcaggtg	gctctggata	aggccagaaa	aggctcgacc	1740
30	accattgtga	tagctcatcg	tttgtctaca	gttcgtaatg	ctgacgtcat	cgctgggttc	1800
	gatgtggag	tcattgtgga	gaaaggaat	catgatgaac	tcatgaaaga	gaaagccatt	1860
	tacttcaaac	ttgtcacaa	gcagacagca	ggaaatgaag	ttgaattaga	aaatgcagct	1920
	gatgaatcca	aaagtgaat	tgatgccttg	gaaatgtctt	caaatgattc	aagatccagt	1980
	ctaataagaa	aaagatcaac	tcgtaggagt	gtccgtggat	cacaagccca	agacagaaaag	2040
35	cttagtacca	aagaggctct	ggatgaaagt	atacctccag	tttccttttg	gaggattatg	2100
	aagctaaatt	taactgaatg	gccttatttt	gttgttgggtg	tattttgtgc	cattataaat	2160
	ggaggcctgc	aaccagcatt	tgcaataata	ttttcaaaga	ttataggggt	ttttacaaga	2220
	attgatgatc	ctgaaacaaa	acgacagaat	agtaacttgt	tttactattt	gtttctagcc	2280
	cttggaattt	tttcttttat	tacatttttc	cttcagggtt	tcacatttgg	caaagctgga	2340
40	gagatcctca	ccaagcggct	ccgatacatg	gttttccgat	ccatgctcag	acagatgtg	2400
	agttggtttg	atgaccctaa	aaacaccatg	ggagcattga	ctaccaggct	cgccaatgat	2460
	gctgctcaag	ttaaaggggc	tataggttcc	aggcttgctg	taattaccca	gaatatagca	2520
	aatcttggga	caggaataat	tatatccttc	atctatgggt	ggcaactaac	actgttactc	2580
	ttagcaattg	tacccatcat	tgcaatagca	ggagttgttg	aaatgaaaat	gttgtctgga	2640
45	caagcactga	aagataagaa	agaactagaa	ggtgctggga	agatcgctac	tgaagcaata	2700
	gaaaacttcc	gaaccgttgt	ttctttgact	caggagcaga	agtttgaaca	tatgtatgct	2760
	cagagtttgc	aggtaccata	cagaaactct	ttgaggaaag	cacacatctt	tgggaattaca	2820
	ttttccttca	cccaggcaat	gatgtatttt	tcctatgctg	gatgtttccg	gtttggagcc	2880
	tacttggtgg	cacataaact	catgagcttt	gaggatgttc	tgtagtattt	ttcagctgtt	2940
50	gtctttgggtg	ccatggccgt	ggggcaagtc	agttcatttg	ctcctgacta	tgccaaagcc	3000
	aaaatatcag	cagccacatc	catcatgatc	attgaaaaaa	cccctttgat	tgacagctac	3060
	agcacggaag	gcctaattgcc	gaacacattg	gaaggaaatg	tcacatttgg	tgaagttgta	3120
	ttcaactatc	ccaccgcacc	ggacatccca	gtgcttcagg	gactgagcct	ggaggtgaag	3180
	aagggccaga	cgctggctct	ggtgggcagc	agtggctgtg	ggaagagcac	agtgggtccag	3240
55	ctcctggagc	ggttctacga	ccccttggca	gggaaagtgc	tgcttgatgg	caaagaaata	3300
	aagcgactga	atgttcagtg	gtcccgagca	cacctgggca	tcgtgtccca	ggagcccac	3360
	ctgtttgact	tgagcattgc	tgagaacatt	gcctatggag	acaacagccg	gggtgtgtca	3420
	caggaagaga	ttgtgagggc	agcaaaggag	gccaacatac	atgccttcat	cgagtacttg	3480
	cctaataaat	atagcactaa	agtaggagac	aaaggaactc	agctctctgg	tggccagaaa	3540
60	caacgcattg	ccatagctcg	tgcccttgtt	agacagcctc	atattttgct	tttggatgaa	3600
	gccacgtcag	ctctggatag	agaaagtga	aaggttgttc	aagaagccct	ggacaagcc	3660
	agagaaggcc	gcacctgcat	tgtgattgct	caccgcctgt	ccaccatcca	gaatgcagac	3720

ttaatagtgg tgttttcagaa tggcagagtc aaggagcatg gcacgcatca gcagctgctg 3780  
gcacagaaag gcatctatctt ttcaatggtc agtgtccagg ctggaacaaa ggcgcagtgga 3840

5 <210> 31  
<211> 1318  
<212> DNA  
<213> Homo sapiens

10 <300>  
<302> UPAR (urokinase-type plasminogen activator receptor)  
<310> XM009232

<400> 31  
15 atggggtcacc cgccgctgct gccgctgctg ctgctgctcc acacctgegt cccagcctct 60  
tggggcctgc ggtgcatgca gtgtaagacc aacggggatt gccgtgtgga agagtgcgcc 120  
ctgggacagg acctctgcag gaccacgacg gtgcgcttgt gggagaagagg agaagagctg 180  
gagctggtgg agaaaagctg taccactca gagaagacca acaggaccct gagctatcgg 240  
actggcttga agatcaccag ccttaccgag gttgtgtgtg ggtagactt gtgcaaccag 300  
20 ggcaactctg gccgggctgt cacctattcc cgaagccgtt acctcgaatg cattedcctgt 360  
ggctcatcag acatgagctg tgagaggggc cggcaccaga gcctgcagtg ccgcagccct 420  
gaagaacagt gcctggatgt ggtgacccac tggatccagg aagggtgaaga agggcgctca 480  
aaggatgacc gccacctccg tggctgtggc taccttcccg gctgcccggg ctccaatggg 540  
ttccacaaca acgacacctt ccacttccctg aaatgctgca acaccacca atgcaacgag 600  
25 ggcccaatcc tggagcttga aaatctgccg cagaatggcc gccagtgtta cagctgcaag 660  
gggaacagca cccatggatg ctctcttgaa gagactttcc tcattgactg ccgaggcccc 720  
atgaatcaat gtctggtagc caccggcact cacgaaccga aaaaccaaag ctatatggtg 780  
agaggctgtg caaccgcctc aatgtgccaa catgccacc tgggtgacgc cttcagcatg 840  
aaccacatg atgtctcctg ctgtactaaa agtggctgta accaccaga cctggatgtc 900  
30 cagtaccgca gtggggctgc tcctcagcct ggccctgccc atctcagcct caccatcacc 960  
ctgctaataa ctgccagact gtggggaggc actctcctct ggacctaaac ctgaaatccc 1020  
cctctctgcc ctggctggat ccgggggacc cctttgccct tccctcgggt cccagcccta 1080  
cagacttgct gtgtgacctc aggccagtgt gccgacctct ctgggcctca gttttcccag 1140  
ctatgaaaac agctatctca caaagttgtg tgaagcagaa gagaaaagct ggagggaaggc 1200  
35 cgtgggccaa tgggagagct cttgttatta ttaatatgtg tgccgctgtt gtgtgtgtgt 1260  
tattaattaa tattcatatt atttatttta tacttacata aagattttgt accagtggt 1318

<210> 32  
40 <211> 636  
<212> DNA  
<213> Homo sapiens

<300>  
45 <302> Bak  
<310> U16811

<400> 32  
50 atggcttcgg ggcaaggccc aggtcctccc aggcaggagt gcggagagcc tgccctgccc 60  
tctgcttctg aggagcaggt agcccaggac acagaggagg ttttccgcag ctacgttttt 120  
taccgccatc agcaggaaca ggaggctgaa ggggtggctg cccctgccga cccagagatg 180  
gtcaccttac ctgctgaacc tagcagcacc atggggcagg tgggacggca gctcgccatc 240  
atcggggacg acatcaaccg acgctatgac tcagagtctc agaccatgtt gcagcacctg 300  
cagcccacgg cagagaatgc ctatgagtac ttcaccaaga ttgccaccag cctgttttag 360  
55 agtggcatca attggggccg tgtgggtggc cttctgggct tcggctaccg tctggcccta 420  
cacgtctacc agcatggcct gactggcttc ctaggccagg tgaccgctt cgtggctgac 480  
ttcatgctgc atcactgcat tgcccgggtg attgcacaga ggggtggctg ggtggcagcc 540  
ctgaacttgg gcaatggctc catcctgaac gtgctgggtg ttctgggtgt ggttctgttg 600  
60 ggccagtttg tggtagaag attcttcaaa tcatga 636

<210> 33

<211> 579  
<212> DNA  
<213> Homo sapiens

5 <300>  
<302> Bax alpha  
<310> L22473

<400> 33  
10 atggacgggt ccggggagca gcccagaggc ggggggcca ccagctctga gcagatcatg 60  
aagacagggg cccttttgct tcagggtttc atccaggatc gagcagggcg aatggggggg 120  
gaggcaccgc agctggccct ggaccgggtg cctcaggatg cgtccaccaa gaagctgagc 180  
gagtgtctca agcgcatcgg ggacgaactg gacagtaaca tggagctgca gaggatgatt 240  
gccgcccgtg acacagactc ccccgagag gtctttttcc gagtggcagc tgacatgttt 300  
15 tctgacggca acttcaactg gggccgggtt gtcgcccttt tctactttgc cagcaaactg 360  
gtgctcaagg ccctgtgcac caagggtgcc gaactgatca gaaccatcat gggctggaca 420  
ttggacttcc tccgggagcg gctgttgggc tggatccaag accaggggtg ttgggacggc 480  
ctcctctcct actttgggac gcccacgtgg cagaccgtga ccatctttgt ggcgggagtg 540  
20 ctcaccgcct cgctaccat ctggaagaag atgggctga 579

<210> 34  
<211> 657  
<212> DNA  
25 <213> Homo sapiens

<300>  
<302> Bax beta  
<310> L22474

30 <400> 34  
atggacgggt ccggggagca gcccagaggc ggggggcca ccagctctga gcagatcatg 60

gaggatgctg aggtccagct ctccttccag ctacagatca atgtccctgt ccgagtgtg 1260  
 gagctaagtg agagccaccc tgacagtggg gaacagacag tccgctgtcg tggccggggc 1320  
 atgccccagc cgaacatcat ctggtctgcc tgcagagacc tcaaaagggtg tccacgtgag 1380  
 5 ctgccgcccga cgctgctggg gaacagttcc gaagaggaga gccagctgga gactaacgtg 1440  
 acgtactggg agggaggagca ggagtttgag gtggtgagca cactgctgtc gcagcagctg 1500  
 gatcgggccac tgtcgggtgcg ctgcacgctg cgcaacgctg tgggccagga cacgcaggag 1560  
 gtcatcgtgg tgccacactc cttgcccttt aagggtggtg tgatctcagc catcctggcc 1620  
 ctggtggtgc tcaccatcat ctcccttatc atcctcatca tgctttggca gaagaagcca 1680  
 10 cgttacgaga tccgatggaa ggtgattgag tctgtgagct ctgacggcca tgagtacatc 1740  
 tacgtggacc ccatgcagct gccctatgac tccacgtggg agctgccgag ggaccagctt 1800  
 gtgctgggac gcacccctcg ctctggggcc tttgggcagg tgggtggaggc cacggttcat 1860  
 ggctgagcc attttcaagc cccaatgaaa gtggccgtca aaaatgctta a 1911

15 <210> 46  
 <211> 1176  
 <212> DNA  
 <213> Homo sapiens

20 <300>  
 <302> TGFbeta1  
 <310> NM000660

25 <400> 46  
 atgccgccct ccgggctgcg gctgctgccg ctgctgctac cgctgctgtg gctactggtg 60  
 ctgacgcctg gcccgccggc cgcgggacta tccacctgca agactatcga catggagctg 120  
 gtgaagcggga agcgcacatga ggccatccgc ggccagatcc tgtccaagct gcggctcgcc 180  
 agccccccga gccaggggga ggtgccgccc ggcccgctgc ccgaggccgt gctcgccctg 240  
 30 tacaacagca cccgcgaccg ggtggccggg gagagtgcag aaccggagcc cgagcctgag 300  
 gccgactact acgccaagga ggtcaccgcg gtgctaattg tggaaaccca caacgaaatc 360  
 tatgacaagt tcaagcagag tacacacagc atatatatgt tcttcaacac atcagagctc 420  
 cgagaagcgg tacctgaacc cgtgttgctc tcccgggcag agctgctgtc gctgaggagg 480  
 ctcaagttaa aagtggagca gcacgtggag ctgtaccaga aatacagcaa caattcctgg 540  
 cgatacctca gcaaccggct gctggcaccg agcgactcgc cagagtgggt atcttttgat 600  
 35 gtcaccggag ttgtgcggca gtggttgagc cgtggagggg aaattgaggg ctttcgcctt 660  
 agcgccact gctcctgtga cagcagggat aacacactgc aagtggacat caacgggttc 720  
 actaccggcc gccgaggtga cctggccacc attcatggca tgaaccggcc tttcctgctt 780  
 ctcatggcca ccccgctgga gaggggccag catctgcaaa gctcccggca ccgccgagcc 840  
 ctggacacca actattgctt cagctccacg gagaagaact gctgctgtgc gcagctgtac 900  
 40 attgacttcc gcaaggacct cggctggaag tggatccacg agcccaaggg ctaccatgcc 960  
 aactctctgc tcgggccctg cccctacatt tggagcctgg acacgcagta cagcaaggtc 1020  
 ctggccctgt acaaccagca taaccgggac gcctcgccgg cgccgtgctg cgtgccgcag 1080  
 gcgctggagc cgctgcccac cgtgtactac gtgggcccga agcccaagggt ggagcagctg 1140  
 45 tccaacatga tcgtgcgctc ctgcaagtgag agctga 1176

<210> 47  
 <211> 1245  
 <212> DNA  
 50 <213> Homo sapiens

<300>  
 <302> TGFbeta2  
 <310> NM003238

55 <400> 47  
 atgcactact gtgtgctgag cgcttttctg atcctgcacg tggtcacggg cgcgctcagc 60  
 ctgtctacct gcagcacact cgatatggac cagtcatgc gcaagaggat cgaggcgatc 120  
 cgccgggcaga tcctgagcaa gctgaagctc accagtcccc cagaagacta tcctgagccc 180  
 60 gaggaagtcc ccccgagggt gatttccatc tacaacagca ccagggactt gctccaggag 240  
 aaggcgagcc ggagggcggc cgctgagga gacgacgaaga gtactacgcc 300  
 aaggagggtt acaaaataga catgccgccc ttcttcccct ccgaaaatgc catcccgcgc 360

actttctaca gaccctactt cagaattggt cgatttgacg tctcagcaat ggagaagaat 420  
 gcttccaatt tgggtgaaagc agagttcaga gtctttcggt tgcagaaccc aaaagccaga 480  
 gtgcctgaac aacggattga gctatatcag attctcaagt ccaaagattt aacatctcca 540  
 acccagcgct acatcgacag caaagtgtgtg aaaacaagag cagaaggcga atgggtctctc 600  
 5 ttcgatgtaa ctgatgctgt tcatgaatgg cttcaccata aagacaggaa cctgggattt 660  
 aaaataagct tacactgtcc ctgctgcact tttgtacat ctaataatta catcatcca 720  
 aataaaaagtg aagaactaga agcaagattt gcaggtattg atggcacctc cacatatacc 780  
 agtgggtgatc agaaaactat aaagtccact agggaaaaaa acagtgggaa gacccacat 840  
 ctcctgctaa tgttattgcc ctctacaga cttgagtcac aacagaccaa cggcggaag 900  
 10 aagcgtgctt tggatgcggc ctattgcttt agaaatgtgc aggataattg ctgcctacgt 960  
 ccactttaca ttgatttcaa gaggatcta ggggtgaaat ggatacacga acccaaagg 1020  
 tacaatgcca acttctgtgc tggagcatgc ccgtatttat ggagttcaga cactcagcac 1080  
 agcaggggtcc tgagcttata taataccata aatccagaag catctgcttc tccttgctgc 1140  
 gtgtcccaag atttagaacc tctaaccatt ctctactaca ttggcaaaac acccaagatt 1200  
 15 gaacagcttt ctaatatgat tgtaaagtct tgcaaatgca gctaa 1245

<210> 48  
 <211> 1239  
 20 <212> DNA  
 <213> Homo sapiens

<300>  
 <302> TGFbeta3  
 25 <310> XM007417

<400> 48  
 atgaagatgc acttgcaaag ggctctggtg gtcttgccc tgctgaactt tgccacggtc 60  
 agcctctctc tgtccacttg caccaccttg gacttcggcc acatcaagaa gaagaggggtg 120  
 30 gaagccatta ggggacagat cttgagcaag ctcaggctca ccagccccc tgagccaacg 180  
 gtgatgacct acgtccccta tcaggctctg gccctttaca acagcaccg ggagctgctg 240  
 gaggagatgc atggggagag ggaggaaggc tgcacccagg aaaacaccga gtcggaatac 300  
 tatgccaaag aaatccataa attcgacatg atccaggggc tggcggagca caacgaactg 360  
 gctgtctgcc ctaaaggaat tacctccaag gttttccgct tcaatgtgtc ctcagtggag 420  
 35 aaaaatagaa ccaacctatt ccgagcagaa ttccgggtct tgccgggtgcc caacccacg 480  
 tctaagcggg atgagcagag gatcgagctc ttccagatcc ttcggccaga tgagcacatt 540  
 gccaaacagc gctatatcgg tggcaagaat ctgccacac ggggcactgc cgagtggctg 600  
 tcctttgatg tctactgacac tgtgcgtgag tggctgttga gaagagagtc caacttaggt 660  
 ctagaaatca gcattcactg tccatgtcac acctttcagc ccaatggaga tatcctggaa 720  
 40 aacattcacg aggtgatgga aatcaaattc aaaggcgtgg acaatgagga tgaccatggc 780  
 cgtggagatc tggggcgct caagaagcag aaggatcacc acaaccctca tctaactctc 840  
 atgatgattc cccacaccg gctcgacaac cggggccagg ggggtcagag gaagaagcgg 900  
 gctttggaca ccaattactg cttccgcaac ttggaggaga actgctgtgt gcgccccctc 960  
 tacattgact tccgacagga tctgggctgg aagtgggtcc atgaacctaa gggctactat 1020  
 45 gccaaacttct gctcaggccc ttgccatcac ctccgcagtg cagacacaac ccacagcacg 1080  
 gtgctgggac tgtacaacac tctgaaccct gaagcatctg cctcgccctg ctgcgtgccc 1140  
 caggacctgg agccctgac catcctgtac tatgttggga ggacccccaa agtggagcag 1200  
 ctctccaaca tgggtggtgaa gtcttgtaaa tgtagctga 1239

50 <210> 49  
 <211> 1704  
 <212> DNA  
 <213> Homo sapiens

55 <300>  
 <302> TGFbetaR2  
 <310> XM003094

60 <400> 49  
 atgggtcggg ggctgctcag gggcctgtgg ccgctgcaca tcgtcctgtg gacgcgtatc 60  
 gccagcacga tcccaccgca cgttcagaag tcggttaata acgacatgat agtcactgac 120

```

aacaacggtg cagtcaagtt tccacaactg tgtaaatfff gtgatgtgag attttccacc 180
tgtgacaacc agaaatcctg catgagcaac tgcagcatca cctccatctg tgagaagcca 240
caggaagtct gtgtggctgt atggagaaaag aatgacgaga acataaact agagacagtt 300
tgccatgacc ccaagctccc ctaccatgac tttattctgg aagatgctgc ttctccaaag 360
5  tgcattatga aggaaaaaaa aaagcctggt gagactttct tcatgtgttc ctgtagctct 420
gatgagtcca atgacaacat catcttctca gaagaatata acaccagcaa tctgacttg 480
ttgctagtca tttttcaagt gacaggcatc agcctcctgc caccactggg agttgccata 540
tctgtcatca tcatcttcta ctgctaccgc gtttaaccggc agcagaagct gagttcaacc 600
tgggaaaccg gcaagacgcg gaagctcatg gagttcagcg agcactgtgc catcatcctg 660
10 gaagatgacc gctctgacat cagctccacg tgtgccaaca acatcaacca caacacagag 720
ctgctgcccc ttgagctgga caccctgggt gggaaaaggtc gctttgctga ggtctataag 780
gccaagctga agcagaacac ttcagagcag tttgagacag tggcagtcaa gatctttccc 840
tatgaggagt atgcctcttg gaagacagag aaggacatct tctcagacat caatctgaag 900
catgagaaca tactccagtt cctgacggct gaggagcggg agacggagtt ggggaaacaa 960
15 tactggctga tcaccgcctt ccacgccaaag ggcaacctac aggagtacct gacgcggcat 1020
gtcatcagct gggaggacct gcgcaagctg ggcagctccc tcgcccgggg gattgtcac 1080
ctccacagtg atcacactcc atgtgggagg cccaagatgc ccatcgtgca caggacctc 1140
aagagctcca atatcctcgt gaagaacgac ctaacctgct gcctgtgtga ctttgggctt 1200
tccctgcgtc tggaccttac tctgtctgtg gatgacctgg ctaacagtgg gcagggtgga 1260
20 actgcaagat acatggctcc agaagtccta gaatccagga tgaatttgga gaatgttgag 1320
tcttcaagc agaccgatgt ctactccatg gctctgggtg tctgggaaat gacatctcgc 1380
tgtaatgcag tgggagaagt aaaagattat gagcctccat ttggttccaa ggtgcgggag 1440
caccctgtg tcgaaagcat gaaggacaac gtgttgagag atcgagggcg accagaaatt 1500
cccagcttct ggctcaacca ccagggcatc cagatggtgt gtgagacgtt gactgagtgc 1560
25 tgggaccacg acccagaggc cgtctcaca gccagtggtg tggcagaacg cttcagttag 1620
ctggagcatc tggacaggct ctggggagg agctgctcgg aggagaagat tctggaagac 1680
ggctccctaa acactaccaa atag 1704

30 <210> 50
    <211> 609
    <212> DNA
    <213> Homo sapiens

35 <300>
    <302> TGFbeta3
    <310> XM001924

    <400> 50
40 atgtctcatt acaccattat tgagaatatt tgtcctaaag atgaatctgt gaaattctac 60
   agtcccaaga gagtgcactt tctatcccc caagctgaca tggataagaa gcgattcagc 120
   tttgtcttca agcctgtctt caacacctca ctgctctttc tacagtgtga gctgacgtg 180
   tgtacgaaga tggagaagca cccccagaag ttgcctaagt gtgtgcctcc tgacgaagcc 240
   tgcacctcgc tggacgcctc gataatctgg gccatgatgc agaataagaa gacgttcaact 300
45 aagcccttg ctgtgatcca ccatgaagca gaatctaaag aaaaaggctc aagcatgaag 360
   gaaccaaata caatttctcc accaattttc catggtctgg acaccctaac cgtgatgggc 420
   attgcgtttg cagcctttgt gatcggagca ctctgacgg gggccttgtg gtacatctat 480
   tctcacacag gggagacagc aggaaggcag caagtcccca cctccccgcc agcctcgga 540
   aacagcagtg ctgccacag catcggcagc acgcagagca cgccttgctc cagcagcagc 600
50 acggcctag 609

    <210> 51
    <211> 3633
55 <212> DNA
    <213> Homo sapiens

    <300>
    <302> EGFR
60 <310> X00588

    <400> 51

```



	atgcgaccct	ccgggacggc	cggggcagcg	ctcctggcgc	tgctggctgc	gctctgcccg	60
	gcgagtcggg	ctctggagga	aaagaaagt	tgccaaggca	cgagtaacaa	gctcacgcag	120
	ttgggcactt	ttgaagatca	ttttctcagc	ctccagagga	tggtcaataa	ctgtgaggtg	180
5	gtccttgagg	atgttgaaat	tacctatgtg	cagaggaatt	atgatctttc	cttcttaaag	240
	accatccagg	aggtggctgg	ttatgtcctc	attgccctca	acacagtggg	gcgaattcct	300
	ttggaaaacc	tgcatatcat	cagaggaat	atgtactacg	aaaattccta	tgcccttagca	360
	gtcttatcta	actatgatgc	aaataaaaacc	ggactgaagg	agctgcccac	gagaaattta	420
	caggaaatcc	tgcatggcgc	cgtgcgggtc	agcaacaacc	ctgccctgtg	caacgtggag	480
	agcatccagt	ggcgggacat	agtcagcagt	gactttctca	gcaacatgtc	gatggacttc	540
10	cagaaccacc	tgggcagctg	ccaaaagtgt	gatccaagct	gtcccaatgg	gagctgctgg	600
	ggtgcaggag	aggagaactg	ccagaaactg	accaaataca	tctgtgccc	gcagtgtctc	660
	gggcgctgcc	gtggcaagtc	ccccagtgac	tgctgccaca	accagtgtgc	tgaggctgctc	720
	acaggccccc	gggagagcga	ctgcctggtc	tgccgcaaat	tccgagacga	agccacgtgc	780
	aaggacacct	gccccccact	catgtctctac	aacccccacca	cgtaccagat	ggatgtgaac	840
15	cccaggggca	aatacagctt	tggtgccacc	tgctgaaga	agtgtccccg	taattatgtg	900
	gtgacagatc	acggctcgtg	cgtccgagcc	tggtggggccg	acagctatga	gatggaggaa	960
	gacggcgtcc	gcaagtgtaa	gaagtgcgaa	gggccttgcc	gcaaagtgtg	taacggaata	1020
	ggtattgggtg	aatttaaaga	ctcactctcc	ataaatgcta	cgaatattaa	acacttcaaa	1080
	aactgcacct	ccatcagtgg	cgatctccac	atcctgccgg	tggtatttag	gggtgactcc	1140
20	ttcacacata	ctcctcctct	ggatccacag	gaactggata	ttctgaaaac	cgtaaaggaa	1200
	atcacagggt	ttttgtgat	tcaggcttgg	cctgaaaaca	ggacggacct	ccatgccttt	1260
	gagaacctag	aaatcatacg	cggcaggacc	aagcaacatg	gtcagttttc	tcttgagctc	1320
	gtcagcctga	acataacatc	cttgggatta	cgtccctca	aggagataag	tgatggagat	1380
	gtgataattt	caggaaacaa	aaatttgtgc	tatgcaaata	caataaactg	gaaaaaactg	1440
25	tttgggacct	ccggtcagaa	aacaaaaatt	ataagcaaca	gaggtgaaaa	cagctgcaag	1500
	gccacaggcc	aggtctgcca	tgcttgtgct	tccccgagg	gctgctgggg	cccgagccc	1560
	agggactgcg	tctcttgccg	gaatgtcagc	cgaggcaggg	aatgctgga	caagtgcagg	1620
	cttctggagg	gtgagccaag	ggagtttgtg	gagaactctg	agtgcataca	gtgccacca	1680
	gagtgcctgc	ctcaggccat	gaacatcacc	tgacaggac	ggggaccaga	caactgtatc	1740
30	cagtgtgccc	actacattga	cggccccccac	tgctcaaga	cctgcccggc	aggagtcatg	1800
	ggagaaaaca	acaccctggt	ctggaagtac	gcagacgccg	gccatgtgtg	ccacctgtgc	1860
	catccaaaact	gcacctacgg	atgcactggg	ccaggtcttg	aaggctgtcc	aacgaattgg	1920
	cctaagatcc	cgtccatcgc	cactgggatg	gtggggggccc	tctcttgc	gctggtggtg	1980
	gccctgggga	tcggcctctt	catgcgaagg	cgccacatcg	ttcggaagcg	cacgctgcgg	2040
35	aggctgctgc	aggagaggga	gcttgtggag	cctcttacac	ccagtggaga	agctcccaac	2100
	caagctctct	tgaggatctt	gaaggaaact	gaattcaaaa	agatcaaagt	gctgggctcc	2160
	ggtgcgttcg	gcacgggtga	taagggactc	tggtcccg	aagggtgaga	agttaaaatt	2220
	cccgtcgcta	tcaaggaatt	aagagaagca	acatctccga	aagccaacaa	ggaaatcctc	2280
	gatgaagcct	acgtgatggc	cagcgtggac	aacccccacg	tggtccgcct	gctgggcatc	2340
40	tgccctacct	ccaccgtgca	actcatcagc	cagctcatgc	ccttcggctg	cctcctggac	2400
	tatgtccggg	aacacaaaga	caatattggc	tcccagtacc	tgctcaactg	gtgtgtgcag	2460
	atcgcaaaag	catagaacta	cttggaggac	cgtcgcttgg	tgaccgcga	cctggcagcc	2520
	aggaacgtac	tggtgaaaac	accgcagcat	gtcaagatca	cagattttgg	gctggccaaa	2580
	ctgctgggtg	cggaagagaa	agaataccat	gcagaaggag	gcaaagtgcc	tatcaagtgg	2640
45	atggcattgg	aatcaatttt	acacagaatc	tataccacc	agagtgatgt	ctggagctac	2700
	ggggtgaccg	tttgggagtt	gatgaccttt	ggatccaagc	catatgacgg	aatccctgcc	2760
	agcgagatct	cctccatcct	ggagaaaagg	gaacgcctcc	ctcagccacc	catatgtacc	2820
	atcgatgtct	acatgatcat	ggtcaagtgc	tggtgatag	acgcagatag	tcgccccaaag	2880
	ttccgtgagt	tgatcatcga	attctccaaa	atggcccag	acccccagcg	ctacctgtgc	2940
50	attcaggggg	atgaaagaat	gcatttgcca	agtcctacag	actccaactt	ctaccgtgcc	3000
	ctgatgggat	aagaagacat	ggacgacgtg	gtggatgccg	acgagtacct	catcccacag	3060
	cagggtctct	tcagcagccc	ctccacgtca	cggactcccc	tcttgagctc	tctgagtcga	3120
	accagcaaca	attccaccgt	ggcttgcat	gtagaaaatg	ggctgcaaa	ctgtcccatc	3180
	aaggaagaca	gcttcttgca	gcgatacagc	tcagacccca	caggcgctt	gactgaggac	3240
55	agcatagacg	acaccttctt	cccagtgcc	gaatacataa	accagtcctg	tcccaaaagg	3300
	cccgtgggct	ctgtgcagaa	tctgtctat	cacaatcagc	ctctgaaccc	cgcgcccagc	3360
	agagaccac	ctaccagga	ccccacagc	actcagtg	gcaacccga	gtatctcaac	3420
	actgtccagc	ccacctgtgt	caacagcaca	ttcgacagcc	ctgcccactg	ggcccagaaa	3480
	ggcagccacc	aaattagcct	ggacaaccct	gactaccagc	aggacttctt	tcccaaggaa	3540
60	gccaagccaa	atggcatctt	taagggtccc	acagctgaaa	atgcagaata	cctaagggtc	3600
	gcgccacaaa	gcagtgaatt	tattggagca	tga			3633

```

<210> 52
<211> 3768
<212> DNA
5  <213> Homo sapiens

<300>
<302> ERBB2
<310> NM004448
10
<400> 52
atggagctgg cggccttgtg ccgctggggg ctcctcctcg ccctcttgcc ccccgagacc 60
gcgagcacc aagtgtgcac cggcacagac atgaagctgc ggctccctgc cagtcccag 120
accacactgg acatgctccg ccacctctac cagggctgcc aggtgggtgca gggaaacctg 180
15 gaactcacct acctgcccac caatgccagc ctgtccttcc tgcaggatat ccaggagggtg 240
cagggctacg tgctcatcgc tcacaaccaa gtgaggcagg tcccactgca gaggtgcgg 300
attgtgcgag gcacccagct ctttgaggac aactatgccc tggccgtgct agacaatgga 360
gaccgctga acaataccac ccctgtcaca ggggcctccc caggaggcct gcgggagctg 420
cagcttcgaa gcctcacaga gatcttgaaa ggaggggtct tgatccagcg gaacccccag 480
20 ctctgctacc aggacacgat tttgtggaag gacatcttcc acaagaacaa ccagctgggt 540
ctcacactga tagacaccaa ccgctctcgg gcctgccacc cctgttctcc gatgtgtaag 600
ggctcccgct gctggggaga gaggttctgag gattgtcaga gcctgacgcg cactgtctgt 660
gccggtggct gtgcccgtg caaggggcca ctgcccactg actgctgcca tgagcagtg 720
gctgccggct gcacgggccc caagcactct gactgcctgg cctgcctcca cttcaaccac 780
25 agtggcatct gtgagctgca ctgcccagcc ctggtcacct acaacacaga cacgtttgag 840
tccatgccc atcccagggg ccggtataca ttccggcgcca gctgtgtgac tgcctgtccc 900
tacaactacc tttctacgga cgtgggatcc tgcaccctcg tctgccccct gcacaaccaa 960
gaggtgacag cagaggatgg aacacagcgg tgtgagaagt gcagcaagcc ctgtgcccga 1020
gtgtgctatg gtctgggcat ggagcacttg cgagaggtga gggcagttac cagtgccaat 1080
30 atccaggagt ttgctggctg caagaagatc tttgggagcc tggcatttct gccggagagc 1140
tttgatgggg acccagcctc caacactgcc ccgctccagc cagagcagct ccaagtgttt 1200
gagactctgg aagagatcac aggttaccta tacatctcag catggccgga cagcctgcct 1260

```

	tacccccgtg	tgccctgtgga	ggaacttttc	aagctgctga	aggaggggtca	ccgcatggac	2160
	aagcccagta	actgcaccaa	cgagctgtac	atgatgatgc	gggactgctg	gcatgcagtg	2220
	ccctcacaga	gacccacctt	caagcagctg	gtggaagacc	tggaccgcat	cgtggccttg	2280
	acctccaacc	aggagtacct	ggacctgtcc	atgcccctgg	accagtactc	ccccagcttt	2340
5	cccgcacccc	ggagctctac	gtgctcctca	ggggaggatt	ccgtcttctc	tcatgagccg	2400
	ctgcccagag	agccctgcct	gccccgacac	ccagcccagc	ttgccaatgg	cggactcaaa	2460
	cgccgctga						2469
10	<210> 72						
	<211> 2409						
	<212> DNA						
	<213> Homo sapiens						
15	<300>						
	<302> FGFR4						
	<310> XM003910						
	<400> 72						
20	atgcccgtgc	tgctggccct	gttgggggtc	ctgctgagtg	tgccctgggcc	tccagtcttg	60
	tccctggagg	cctctgagga	agtggagctt	gagccctgcc	tggctcccag	cctggagcag	120
	caagagcagg	agctgacagt	agcccttggg	cagcctgtgc	ggctgtgctg	tgggcgggct	180
	gagcgtggtg	gccactggta	caaggagggc	agtcgcctgg	cacctgctgg	ccgtgtacgg	240
	ggctggaggg	gccgcctaga	gattgccagc	ttcctacctg	aggatgctgg	ccgctacctc	300
25	tgccctggcac	gaggctccat	gatcgtcctg	cagaatctca	ccttgattac	aggtgactcc	360
	ttgacctcca	gcaacgatga	tgaggacccc	aagtcccata	gggacctctc	gaataggcac	420
	agttaccccc	agcaagcacc	ctactggaca	cacccccagc	gcatggagaa	gaaactgcat	480
	gcagtacctg	cggggaacac	cgtcaagtcc	cgtgtgccag	ctgcaggcaa	ccccacgccc	540
	accatccgct	ggcttaagga	tggacaggcc	tttcatgggg	agaaccgcat	tggaggcatt	600
30	cggctgcgcc	atcagcactg	gagtctcgtg	atggagagcg	tgggtgccctc	ggaccgcggc	660
	acatacacct	gcctggtaga	gaacgctgtg	ggcagcatcc	gttataacta	cctgctagat	720
	gtgctggagc	gggtccccga	ccggcccatc	ctgcaggccg	ggctcccggc	caacaccaca	780
	gccgtgggtg	gcagcgacgt	ggagctgctg	tgcaaggtgt	acagcgatgc	ccagccccac	840
	atccagtggc	tgaagcacat	cgtcatcaac	ggcagcagct	tccgagccga	cggtttcccc	900
35	tatgtgcaag	tcctaaagac	tgcagacatc	aatagctcag	aggtggaggt	cctgtacctg	960
	cggaaacgtg	cagccgagga	cgcaggcgag	tacacctgcc	tcgcaggcaa	ttccatcgcc	1020
	ctctcctacc	agtctgcctg	gctcacggtg	ctgccagagg	aggacccccac	atggaccgca	1080
	gcagcgcccc	aggccaggtg	tacggacatc	atcctgtacg	cgtcgggctc	cctggccttg	1140
	gctgtgctcc	tgctgctggc	caggctgtat	caggggcagg	cgtcccacgg	ccggcaccccc	1200
40	cgcccccccc	ccactgtgca	gaagctctcc	cgttccctc	tggccccgaca	gttctccctg	1260
	gagtcaggct	cttccggcaa	gtcaagctca	tccttggtac	gaggcgctcg	tctctcctcc	1320
	agcggccccc	ccttgctcgc	cggcctcgtg	agtctagatc	tacctctcga	cccactatgg	1380
	gagttccccc	gggacaggct	ggtgcttggg	aagcccctag	gcgagggctg	ctttggccag	1440
	gtagtacgtg	cagaggcctt	tggcatggac	cctgcccggc	ctgaccaagc	cagcactgtg	1500
45	gccgtcaaga	tgctcaaaga	caacgcctct	gacaaggacc	tggccgacct	ggtctcggag	1560
	atggaggtga	tgaagctgat	cggccgacac	aagaacatca	tcaacctgct	tggtgtctgc	1620
	accaggaag	ggccccgtga	cgtgatcgtg	gagtgcgccg	ccaagggaag	cctgcgggag	1680
	ttcctgcggg	cccggcgccc	cccaggcccc	gacctcagcc	ccgacggctc	tccgagcagt	1740
	gaggggcggc	tctccttccc	agtcctgggt	tcctgcgcct	accaggtggc	ccgaggcatg	1800
50	cagtatctgg	agtcctcgaa	gtgtatccac	cgggacctgg	ctgcccgcga	tgtgctggtg	1860
	actgaggaca	atgtgatgaa	gattgtcgac	tttgggctgg	ccgcggcgct	ccaccacatt	1920
	gactactata	agaaaaccag	caacggccgc	ctgcctgtga	agtggatggc	gcccagggcc	1980
	ttgtttgacc	gggtgtacac	acaccagagt	gacgtgtggt	cttttgggat	cctgctatgg	2040
	gagatcttca	ccctcggggg	ctccccgtat	cctggcatcc	cgggtggagga	gctgttctcg	2100
55	ctgctgcggg	agggacatcg	gatggaccga	ccccacact	gccccccaga	gctgtacggg	2160
	ctgatgcgtg	agtgctggca	cgcagcgccc	tcccagaggc	ctaccttcaa	gcagctggtg	2220
	gaggcgctgg	acaaggctct	gctggccgtc	tctgaggagt	acctcgacct	ccgcctgacc	2280
	ttcggaccct	attccccctc	tgggtggggac	gccagcagca	cctgctcctc	cagcgattct	2340
	gtcttcagcc	acgacccccct	gccattggga	tccagctcct	tccccttcgg	gtctggggtg	2400
60	cagacatga						2409

<210> 73  
<211> 1695  
<212> DNA  
<213> Homo sapiens

5

<300>  
<302> MT2MMP  
<310> D86331

10

<400> 73  
atgaagcggc cccgctgtgg ggtgccagac cagttcgggg tacgagtga agccaacctg 60  
cggcggcgctc ggaagcgcta cgccctcacc gggaggaagt ggaacaacca ccacttgacc 120  
tttagcatcc agaactacac ggagaagtgt ggctggtacc actcgatgga ggcggtgcgc 180  
agggccttcc gcgctgtggga gcaggccacg cccctggtct tccaggaggt gccctatgag 240  
15 gacatccggc tgcggcgaca gaaggaggcc gacatcatgg tactctttgc ctctggcttc 300  
cacggcgaca gctcgccgtt tgatggcacc ggtggctttc tggcccacgc ctatttcctt 360  
ggccccggcc taggcgggga caccattttt gacgcagatg agccctggac cttctccagc 420  
actgacctgc atggaacaa cctcttcctg gtggcagtg atgagctggg ccacgcgtg 480  
gggctggagc actccagcaa ccccaatgcc atcatggcg cgttctacca gtggaaggac 540  
20 gttgacaact tcaagctgcc cgaggacgat ctccgtggca tccagcagct ctacggtacc 600  
ccagacggtc agccacagcc taccagcct ctcccactg tgacgccacg gcggccaggc 660  
cggcctgacc accggccgcc cggcctccc cagccaccac cccaggtgg gaagccagag 720  
cggcccccaa agcggggccc ccagtcag ccccgagcca cagagcggcc cgaccagtat 780  
ggccccaa ca tctcgacgg ggactttgac acagtggcca tgcttcgagg ggagatgttc 840  
25 gtgttcaagg gccgctgggt ctggcgagtc cggcacaacc gcgtcctgga caactatccc 900  
atgcccatcg ggcacttctg gcgtggtctg cccggtgaca tcagtgtctg ctacgagcgc 960  
caagacggtc gttttgtctt tttcaaagg gaccgctact ggctctttcg agaagcgaac 1020  
ctggagcccg gctaccaca gccgctgacc agctatggc tgggcatccc ctatgaccgc 1080  
attgacacgg ccactctggt ggagcccaca ggccacacct tcttcttcca agaggacagg 1140  
30 tactggcgct tcaacgagga gacacagcgt ggagaccctg ggtaccccaa gccatcagt 1200  
gtctggcagg ggatccctgc ctcccctaaa ggggccttcc tgagcaatga cgcagcctac 1260  
acctacttct acaagggcac caaatactgg aaattcgaca atgagcgctt gcggatggag 1320  
cccggctacc ccaagtccat cctgcgggac ttcattgggt gccaggagca cgtggagcca 1380  
ggccccgat ggcccgacgt ggcccgccg ccctcaacc cccacggggg tgagagccc 1440  
35 gggcgcgaca gcgcagaggg cgacgtgggg gatggggatg gggactttgg ggcgggggtc 1500  
aacaaggaca gggcgagccg cgtgggtgtg cagatggagg aggtggcacg gacggtgaac 1560  
gtggtgatgg tgctggtgcc actgctgctg ctgctctgag tcctgggcct cacctacgag 1620  
ctggtgcaga tgcagcga gggtgcgcca cgtgtcctgc tttactgcaa gcgctcgctg 1680  
caggagtggg tctga 1695

40

<210> 74  
<211> 1824  
<212> DNA  
<213> Homo sapiens

45

<300>  
<302> MT3MMP  
<310> D85511

50

<400> 74  
atgatcttac tcacattcag cactggaaga cgggttgatt tcgtgcatca ttcgggggtg 60  
tttttcttgc aaaccttgct ttggatttta tgtgctacag tctgcggaac ggagcagtat 120  
ttcaatgtgg aggtttgggt acaaaagtac ggctaccttc caccgactga cccagaaatg 180  
55 tcagtgtctg gctctgcaga gacctgcag tctgccttag ctgcatgca gcagtctat 240  
ggcatttaaca tgacaggaaa agtgacaga aacacaattg actggatgaa gaagccccga 300  
tgcggtgtac ctgaccagac aagaggtagc tccaaatttc atattcgtcg aaagcgatat 360  
gcattgacag gacagaaatg gcagcacaag cacatcactt acagtataaa gaacgtaact 420  
ccaaaagtag gagacctga gactcgtaaa gctattcgcc gtgcctttga tgtgtggcag 480  
60 aatgtaactc ctctgacatt tgaagaagt ccctacagt aattagaaaa tggcaaacgt 540  
gatgtggata taaccattat ttttgcattt ggtttccatg gggacagctc tccctttgat 600  
ggagagggag gatttttggc acatgcctac ttccctggac caggaattgg aggagatacc 660

catttttgact cagatgagcc atggacacta ggaaatccta atcatgatgg aaatgactta 720  
 tttcttgtag cagtccatga actgggacat gctctgggat tggagcattc caatgacccc 780  
 actgccatca tggctccatt ttaccagtac atggaaacag acaacttcaa actacctaata 840  
 gatgatttac agggcatcca gaagatatat ggtccacctg acaagattcc tccacctaca 900  
 5 agacctctac cgacagtgc cccacaccgc tctattcctc cggctgaccc aaggaataat 960  
 gacaggccaa aacctcctcg gcctccaacc ggcagaccct cctatcccgg agccaaaccc 1020  
 aacatctgtg atgggaactt taacactcta gctattcttc gtcgtgagat gtttggtttc 1080  
 aaggaccagt ggttttggtg agtgagaaac aacagggtga tggatggata cccaatgcaa 1140  
 attacttact tctggcgggg cttgcctcct agtatcgatg cagtttatga aaatagcgac 1200  
 10 gggaattttg tgttctttaa aggtaacaaa tattgggtgt tcaaggatac aactcttcaa 1260  
 cctgggttacc ctcagtactt gataaccctt ggaagtggaa ttccccctca tggatttgat 1320  
 tcagccattt ggtgggagga cgtcgggaaa acctatttct tcaagggaga cagatattgg 1380  
 agatatagtg aagaaatgaa aacaatggac cctggctatc ccaagccaat cacagtctgg 1440  
 aaagggatcc ctgaatctcc tcaggggagca tttgtacaca aagaaaatgg ctttacgtat 1500  
 15 ttctacaaag gaaaggagta ttggaaattc aacaaccaga tactcaagg agaacctgga 1560  
 tatccaagat ccctcctcaa ggattttatg ggtgtgatg gaccaacaga cagagttaaa 1620  
 gaaggacaca gccaccaga tgatgtagac attgtcatca aactggacaa cacagccagc 1680  
 actgtgaaag ccatagctat tgtcattccc tgcattctgg ccttatgcct ccttgatttg 1740  
 gtttacactg tgttccagtt caagaggaaa ggaacacccc gccacatact gtactgtaaa 1800  
 20 cgctctatgc aagagtgggt gtga 1824

<210> 75  
 <211> 1818  
 25 <212> DNA  
 <213> Homo sapiens

<300>  
 <302> MT4MMP  
 30 <310> AB021225

<400> 75  
 atgcggcgcc gcgcagccc gggacccggc ccgcccggc caggggccgg actctcgcg 60  
 ctgcccgtgc tgcccgtgcc gctgctgctg ctgctggcgc tggggaccgg cgggggctgc 120  
 35 gccgcgccgg aaccgcgcgc gcgcgccgag gacctcagcc tgggagtgga gtggctaagc 180  
 aggttcgggtt acctgcccc ggctgacccc acaacagggc agctgcagac gcaagaggag 240  
 ctgtctaagg ccatacagac catgcagcag tttggtggcc tggaggccac cggcatcctg 300  
 gacgaggcca ccctggccct gatgaaaacc ccacgctgct ccctgccaga cctccctgtc 360  
 ctgacccagg ctgcgaggag acgccaggct ccagcccca ccaagtggaa caagaggaaac 420  
 40 ctgtcgtgga gggtcgggac gttcccacgg gactcaccac tggggcacga cagggtgcgt 480  
 gcactcatgt actacgccct caaggctctg agcgacattg cgcccctgaa cttccacgag 540  
 gtggcgggca gcaccgcga catccagatc gacttctcca aggcgacca taacgacggc 600  
 tacccttctg acgcccggcg gcaccgtgcc cacgccttct tcccggcca ccaccacac 660  
 gccgggtaca ccactttaa cgtatgacgag gcctggacct tccgctctc ggatgccac 720  
 45 gggatggacc tgtttgcagt ggctgtccac gagtttggcc acgccattgg gtttaagccat 780  
 gtggccgctg cacactccat catgcggccg tactaccagg gcccggtggg tgaccgctg 840  
 cgctacgggc tcccctacga ggacaagggt cgcgtctggc agctgtacgg tgtgcgggag 900  
 tctgtgtctc ccacggcgca gcccaggag cctcccctgc tgccggagcc ccagacaac 960  
 cggctccagc ccccgccag gaaggacgtg cccacagat gcagactca ctttgacgag 1020  
 50 gtggcccaga tccggggtga agctttcttc ttaaaaggca agtacttctg gcggctgacg 1080  
 cgggaccggc acctggtgc cctgcagcgc gcacagatgc accgcttctg gcggggcctg 1140  
 ccgctgcacc tggacagcgt ggacgctgtg tacgagcgca ccagcgacca caagatcgtc 1200  
 ttctttaaaag gagacaggta ctgggtgttc aaggacaata acgtagagga aggatacccg 1260  
 cgccccgtct ccgacttcag cctcccgcct ggccggcatc acgctgcctt ctccctgggc 1320  
 55 cacaatgaca ggaattattt ctttaaggac cagctgtact ggcgctacga tgaccacacg 1380  
 aggcacatgg accccggcta ccccgcctgt agcccggtgt ggagggtgtg ccccgacag 1440  
 ctggacgacg ccactgcctg gtccgacggt gcctcctact tcttccgtgg ccaggagtag 1500  
 tggaaagtgc tggatggcga gctggaggtg gcacccgggt acccacagtc cacggcccgg 1560  
 gactggctgg tgtgtggaga ctacacggcc gatggatctg tggctgcggg cgtggacgag 1620  
 60 gcagaggggc ccgcgcccc tccaggacaa catgaccaga gccgctcgga ggacggttac 1680  
 gaggtctgct cctgcacctc tggggcatcc tctcccggg gggcccagg cccactggtg 1740  
 gctgccacca tgctgctgct gctgcgcca ctgtcaccag gcgcctgtg gacagcgcc 1800

caggccctga cgctatga

1818

5 <210> 76  
<211> 1938  
<212> DNA  
<213> Homo sapiens

10 <300>  
<302> MT5MMP  
<310> AB021227

<400> 76  
15 atgccgagga gccggggcgg ccgcgcgcgc cgggggcgcg cgcgcgcgcg gccgcgcgcg 60  
ggccaggccc cgcgctggag ccgctggcgg gtccctgggc ggctgctgct gctgctgctg 120  
cccgcgctct gctgcctccc gggcgccgcg cggcggcgcg cggcggcgcg gggggcaggg 180  
aaccgggcag cgggtggcgg ggccgggtgg cggcggcgag aggcggaggc gcccttcgcc 240  
gggcagaact ggttaaagtc ctatggctat ctgcttccct atgactcacg ggcatctgct 300  
ctgcactcag cgaaggcctt gcagtcggca gtctccacta tgcagcagtt ttacgggata 360  
20 ccggtcaccg gtgtgttgga tcagacaacg atcgagtgga tgaagaaacc ccgatgtggt 420  
gtccctgata acccccactt aagccgtagg cggagaaaca agcgctatgc cctgactgga 480  
cagaagtgga ggcaaaaaca catcacctac agcattcaca actatacccc aaaagtgggt 540  
gagctagaca cgcggaaagc tattcgccag gctttcgatg tgtggcagaa ggtgaccca 600  
ctgacctttg aagagggtgc ataccatgag atcaaaagtg accggaagga ggcagacatc 660  
25 atgatctttt ttgcttctgg ttccatggc gacagctccc catttgatgg agaaggggga 720  
ttcctggccc atgcctactt ccctggccca gggattggag gagacacca ctttgactcc 780  
gatgagccat ggacgctagg aaacgccaac catgacggga acgacctctt cctgggtggc 840  
gtgcatgagc tgggcccacg cctgggactg gagcactcca gcgaccccag cgccatcatg 900  
gcgcccctct accagtacat ggagacgcac aacttcaagc tgccccagga cgatctccag 960  
30 ggcattccaga agatctatgg acccccagcc gagcctctgg agcccacaag gccactccct 1020  
acactccccg tccgcaggat ccactacca tcggagagga aacacgagcg ccagcccagg 1080  
ccccctcggc cgcctctcgg ggaccggcca tccacaccag gcaccaaacc caacatctgt 1140  
gacggcaact tcaacacagt ggccctcttc cggggcgaga tgtttgtctt taaggatcgc 1200  
tggttctggc gtctgcgcaa taaccgagtg caggagggct accccatgca gatcgagcag 1260  
35 ttctggaagg gcctgcctgc ccgcctcgac gcagcctatg aaaggccga tgggagattt 1320  
gtcttcttca aaggtgacaa gtattgggtg tttaaggagg tgacgggtga gcctgggtac 1380  
ccccacagcc tgggggagct gggcagctgt ttgccccgtg aaggcattga cacagctctg 1440  
cgctgggaac ctgtgggcaa gacctacttt ttcaaaggcg agcggtagtg gcgctacagc 1500  
gaggagcggc gggccacgga ccctggctac cctaagccca tcaccgtgtg gaagggcac 1560  
40 ccacagctc cccaaggagc cttcatcagc aaggaaggat attacaccta ttctctaca 1620  
ggccgggact actggaagtt tgacaaccag aaactgagcg tggagccagg ctacccgcg 1680  
aacatcctgc gtgactggat gggctgcaac cagaaggagg tggagcggcg gaaggagcgg 1740  
cggctgcccc aggacgacgt ggacatcatg gtgaccatca acgatgtgct gggctccgtg 1800  
aacgccgtgg ccgtggtcat ccctgcac 1860  
45 accatcttcc agttcaagaa caagacaggc cctcagcctg tcacctacta taagcggcca 1920  
gtccaggaat ggggtgta 1938

50 <210> 77  
<211> 1689  
<212> DNA  
<213> Homo sapiens

55 <300>  
<302> MT6MMP  
<310> AJ27137

<400> 77  
60 atcgggctgc ggctccggct tctggcgctg ctgcttctgc tgetggcacc gccgcgcgcg 60  
gcccgaagc cctcggcgca ggacgtgagc ctgggctgag actggctgac tgcctatggt 120  
tacctgccgc caccacccc tgcccaggcc cagctgcaga gccctgagaa gttgcgcgat 180  
gccatcaaag tcatgcagag gttcgcgggg ctgcccggaga cggccgcgat ggaccaggg 240

```

5  acagtggcca ccatgcgtaa gccccgctgc tccctgcctg acgtgctggg ggtggcgggg 300
   ctggtcaggc ggcgtcgccg gtacgctctg agcggcagcg tgtggaagaa gcgaaccctg 360
   acatggaggg tacgttcctt cccccagagc tcccagctga gccaggagac cgtgcgggtc 420
   ctcattgagct atgccctgat ggcctggggc atggagtcag gcctcacatt tcatgaggtg 480
   gattcccccc agggccagga gcccgcacac ctcactgact ttgcccgcgc cttccaccag 540
   gacagctacc ccttcgacgg gttggggggc accctagccc atgccttctt ccttggggag 600
   caccctatct ccggggacac tcactttgac gatgaggaga cctggacttt tgggtcaaaa 660
   gacggcgagg ggaccgacct gtttgccgtg gctgtccatg agtttgacca cgccttgggc 720
   ctggggccact cctcagcccc caactccatt atgaggccct tctaccaggg tccggtgggc 780
10 gacctgaca agtaccgcct gtctcaggat gaccgcgatg gcctgcagca actctatggg 840
   aaggcgcccc aaaccccata tgacaagccc acaaggaaac ccttggctcc tccgccccag 900
   cccccggcct cgccacaca cagcccatcc ttcccatcc ctgatcgatg tgagggcaat 960
   tttgacgcca tcgccaacat ccgaggggaa actttcttct tcaaaggccc ctggttctgg 1020
   cgcctccagc cctccgaca gctggtgtcc ccgcgaccg cacggctgca ccgcttctgg 1080
15 gaggggtgc ccgcccaggt gaggggtgtg caggccgcct atgctcggca ccgagacggc 1140
   cgaatcctcc tctttagcgg gcccagttc tgggtgttcc aggaccggca gctggagggc 1200
   ggggcgcggc cgctcacgga gctggggctg cccccgggag aggaggtgga cgccgtgttc 1260
   tcgtggccac agaacgggaa gacctacctg gtccgcggcc ggcagtactg gcgctacgac 1320
   gaggcggcgg cgcgcccgga ccccggttac cctcgcgacc tgagcctctg ggaaggcgcg 1380
20 cccccctccc ctgacgatgt caccgtcagc aacgcagggt acacctactt cttcaagggc 1440
   gccactact ggcgcttccc caagaacagc atcaagaccg agccggacgc cccccagccc 1500
   atggggccca actggctgga ctgccccgcc ccgagctctg gtccccgcgc ccccgagccc 1560
   cccaaagcga ccccgctgtc cgaaacctgc gattgtcagt gcgagctcaa ccaggccgca 1620
   ggacgttggc ctgctcccat cccgctgctc ctcttgcccc tgctggtggg ggggtgtagc 1680
25 tcccgtga
   1689

```

&lt;210&gt; 78

&lt;211&gt; 1749

30 &lt;212&gt; DNA

&lt;213&gt; Homo sapiens

gatgatgccacagagaaaga cttttctgat ctggtgtcag agatggagat gatgaagatg 1620  
 attgggaaacacaagaatat cataaatctt ctggagcct gcacacagga tgggcctctc 1680  
 tatgtcatag ttgagtatgc ctctaaaggc aacctccgag aatacctccg agcccgagg 1740  
 ccaccggga tggagtactc ctatgacatt aaccgtgttc ctgaggagca gatgaccttc 1800  
 5 aaggacttgg tgtcatgcac ctaccagctg gccagaggca tggagtactt ggcttcccaa 1860  
 aaatgtattc atcgagattt agcagccaga aatgttttgg taacagaaaa caatgtgatg 1920  
 aaaatagcag actttggact cgccagagat atcaacaata tagactatta caaaaagacc 1980  
 accaatgggc ggcttccagt caagtggatg gctccagaag ccctgtttga tagagtatac 2040  
 actcatcaga gtgatgtctg gtccttcggg gtgttaatgt gggagatctt cactttaggg 2100  
 10 ggctcgccct acccagggat tcccggtggag gaacttttta agctgctgaa ggaaggacac 2160  
 agaatggata agccagccaa ctgcaccaac gaactgtaca tgatgatgag ggactgttgg 2220  
 catgcagtgc cctcccagag accaacgttc aagcagttgg tagaagactt ggatcgaatt 2280  
 ctactctca caaccaatga ggaatacttg gacctcagcc aacctctcga acagtattca 2340  
 cctagtacc ctgacacaag aagttcttgt tcttcaggag atgattctgt tttttctcca 2400  
 15 gaccccatgc cttacgaacc atgccttctt cagtatccac acataaacgg cagtgttaaa 2460  
 acatga 2466

<210> 86  
 20 <211> 2421  
 <212> DNA  
 <213> Homo sapiens

<300>  
 25 <302> FGFR3  
 <310> NM000142

<400> 86  
 atgggcgccc ctgcctgcgc cctcgcgctc tgcgtggcgc tggccatcgt ggccggcgcc 60  
 30 tctctggagt ccttggggac ggagcagcgc gtctggggc gagcggcaga agtcccgggc 120  
 ccagagcccg gccagcagga gcagttggtc ttccggcagc gggatgctgt ggagctgagc 180  
 tgtccccgcg ccgggggtgg tcccatgggg cccactgtct gggcgaagga tggcacaggg 240  
 ctggtgccct cggagcgtgt cctgggtggg cccagcggc tgcaggtgct gaatgcctcc 300  
 cagcaggact ccggggccta cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360  
 35 ttcagtgtgc ggggtacaga cgctccatcc tccggagatg acgaagacgg ggaggacgag 420  
 gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccg gcgatggac 480  
 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgccc agccgctggc 540  
 aacccactc cctccatctc ctggctgaag aacggcagg agttccgcgg cgagcaccgc 600  
 attggaggca tcaagctgcg gcacagcag tggagcctgg tcatggaaag cgtggtgccc 660  
 40 tcggaccgcy gcaactacac ctgcctcgtg gagaacaagt ttggcagcat ccggcagacg 720  
 tacacgtcgg acgtgctgga gcgtccccc caccggccca tctgcaggc ggggctgcgg 780  
 gccaaaccaga cggcgggtgct gggcagcgac gtggagttec actgcaaggt gtacagtgc 840  
 gcacagcccc acatccagt gctcaagcac gtggaggtga acggcagcaa ggtgggccc 900  
 gacggcacac cctacgttac cgtgctcaag acggcgggcy ctaacaccac cgacaaggag 960  
 45 ctagaggttc tctccttgca caacgtcacc tttgaggacg ccggggagta cacctgcctg 1020  
 gcgggcaatt ctattgggtt ttctcatcac tctgcgtggc tgggtggtgct gccagccgag 1080  
 gaggagctgg tggaggctga cgaggcgggc agtggtgatg caggcatcct cagctacggg 1140  
 gtgggcttct tctgttcat cctgggtggt gcggctgtga cgctctgccc cctgcgcagc 1200  
 cccccaaaga aaggcctggg ctccccacc gtgcacaaga tctcccgtt cccgctcaag 1260  
 50 gcacaggtgt ccttgagtc caacgcgtcc atgagctcca acacaccact ggtgcgcate 1320  
 gcaaggctgt cctcagggga gggcccccac ctggccaagt tctccgagct cgagctgcct 1380  
 gccgaccca aatgggagct gtctcgggcc cggtgaccc tgggcaagcc ccttggggag 1440  
 ggctgcttcg gccaggtggg catggcggag gccatcggca ttgacaagga ccgggcccgc 1500  
 aagcctgtca ccgtagcgt gaagatgctg aaagacgat ccactgacaa ggacctgtcg 1560  
 55 gacctggtgt ctgagatgga gatgatgaag atgatcggga aacacaaaaa catcatcaac 1620  
 ctgctgggcy cctgcacgca gggcggggcc ctgtactgct tgggtggagta cgcgccaaag 1680  
 ggtaacctgc gggagtttct gcgggcgcgg cgcccccg gcttgacta ctcttcgac 1740  
 acctgcaagc cgcccgagga gcagctcacc ttcaaggacc tgggtgtcctg tgcctaccag 1800  
 gtggcccggg gcatggagta cttggcctcc cagaagtgc tccacaggga cctggctgcc 1860  
 60 cgcaatgtgc tgggtgacga ggacaacgtg atgaagatcg cagacttcgg gctggcccgg 1920  
 gacgtgcaca acctcgacta ctacaagaag gccggtgccc cgtgaagtgg 1980  
 atggcgccctg aggccttgtt tgaccgagtc tacactcacc agagtgcgt ctggtccttt 2040



5 ggggtcctgc tctgggagat cttcacgctg gggggctccc cgtaccccg ccatccctgtg 2100  
 gaggagctct tcaagctgct gaaggagggc caccgcatgg acaagcccgc caactgcaca 2160  
 cacgacctgt acatgatcat gcgggagtg cggcatgccg cgccctccca gaggccacc 2220  
 ttcaagcagc tgggtggagga cctggaccgt gtccttaccg tgacgtccac cgacgagtac 2280  
 ctggacctgt cggcgccctt cgagcagtac tccccgggtg gccaggacac cccagctcc 2340  
 agctcctcag gggacgactc cgtgtttgac cagacctgc tgcccccggc cccaccagc 2400  
 agtgggggct cgcggacgtg a 2421

10 <210> 87  
 <211> 2102  
 <212> DNA  
 <213> Homo sapiens

15 <300>  
 <302> HGF  
 <310> E08541

20 <400> 87  
 atgcagaggg acaaaggaaa agaagaaata caattcatga attcaaaaaa tcagcaaaga 60  
 ctaccctaata caaaatagat ccagcactga agataaaaaa caaaaaagt aatactgcag 120  
 accaatgtgc taatagatgt actaggaata aaggacttcc attcacttgc aaggcttttg 180  
 tttttgataa agcaagaaaa caatgcctct ggttccccct caatagcatg tcaagtggag 240  
 tgaaaaaaga atttggccat gaatttgacc tctatgaaaa caaagactac attagaaact 300  
 25 gcatcattgg taaaggacgc agctacaagg gaacagtatc tatcactaag agtggcatca 360  
 aatgtcagcc ctggagttcc atgataccac acgaacacag ctttttgcc tgcagctatc 420  
 ggggtaaaga cctacaggaa aactactgtc gaaatcctcg aggggaagaa gggggaccct 480  
 ggtgtttcac aagcaatcca gaggtacgct acgaagtctg tgacattcct cagtgttcag 540  
 aagttgaatg catgacctgc aatggggaga gttatcgagg tctcatggat catacagaat 600  
 30 caggcaagat ttgtcagcgc tgggatcatc agacaccaca ccggcacaaa ttcttgcccg 660  
 aaagatatcc cgacaagggc tttgatgata attattgccg caatcccgat ggccagccga 720  
 ggccatgggt ctatactctt gaccctcaca cccgctggga gtactgtgca attaaaacat 780  
 gcgctgacaa tactatgaat gacactgatg ttcttttgga aacaactgaa tgcattcaag 840  
 gtcaaggaga aggtacagg ggcactgtca ataccatttg gaatggaatt ccatgtcagc 900  
 35 gttgggattc tcagtatcct cagcagcatg acatgactcc tgaaaatttc aagtgaagg 960  
 acctacgaga aaattactgc cgaaatccag atgggtctga atcaccctgg tgttttacca 1020  
 ctgatccaaa catccgagtt ggctactgct cccaaattcc aaactgtgat atgtcacatg 1080  
 gacaagattg ttatcgtggg aatggcaaaa attatatggg caacttatcc caaacaagat 1140  
 ctggactaac atgttcaatg tgggacaaga acatggaaga cttacatcgt catatcttct 1200  
 40 ggggaaccga tgcaagtaag ctgaatgaga attactgccg aaatccagat gatgatgctc 1260  
 atggaccctg gtgctacacg ggaaatccac tcattccttg ggattattgc cctatttctc 1320  
 gttgtgaagg tgataccaca cctacaatag tcaatttaga ccatcccgta atatcttggt 1380  
 ccaaaaggaa acaattgcga gttgtaaatg ggattccaac acgaacaaac ataggatgga 1440  
 tggttagttt gagatacaga aataaacata tctgcggagg atcattgata aaggagagtt 1500  
 45 gggttcttac tgcacgacag tgtttccctt ctcgagactt gaaagattat gaagcttggc 1560  
 ttggaattca tgatgtccac ggaagaggag atgagaaatg caaacagggt ctcaatgttt 1620  
 cccagctggg atatggccct gaaggatcag atctggtttt aatgaagctt gccaggcctg 1680  
 ctgtcctgga tgattttggt agtacgattg atttacctaa ttatggatgc acaattcctg 1740  
 aaaagaccag ttgcagtgtt tatggctggg gctacactgg attgatcaac tatgatggcc 1800  
 50 tattacgagt ggcacatctc tatataatgg gaaatgagaa atgcagccag catcatcgag 1860  
 ggaaggtgac tctgaatgag tctgaaatat gtgtggtggc tgaaaagatt ggatcaggac 1920  
 catgtgaggg ggattatggt ggccacttg tttgtgagca acataaaatg agaatgggtc 1980  
 ttggtgtcat tgttcctggt cgtggatgtg ccattccaaa tctgcctggt atttttgtcc 2040  
 gagtagcata ttatgcaaaa tggatacaca aaattatatt aacatataag gtaccacagt 2100  
 55 ca 2102

60 <210> 88  
 <211> 360  
 <212> DNA  
 <213> Homo sapiens

<300>  
<302> ID3  
<310> XM001539

5 <400> 88  
atgaaggcgc tgagcccggt gcgcggctgc tacgaggcgg tgtgctgcct gtcggaacgc 60  
agtctggcca tcgcccgggg ccgagggaag ggcccggcag ctgaggagcc gctgagcttg 120  
ctggacgaca tgaaccactg ctactcccgc ctgcgggaac tggtaaccgg agtcccgaga 180  
ggcactcagc ttagccagggt ggaaatccta cagcgcgtca tcgactacat tctcgacctg 240  
10 caggtagtcc tggccgagcc agcccctgga cccctgatg gccccacct tcccatccag 300  
acagccgagc tcactccgga acttgtcatc tccaacgaca aaaggagctt ttgccactga 360

<210> 89  
15 <211> 743  
<212> DNA  
<213> Homo sapiens

<300>  
20 <302> IGF2  
<310> NM000612

<400> 89  
25 atgggaaatcc caatggggaa gtcgatgctg gtgcttctca ccttcttggc cttegccctcg 60  
tgctgcattg ctgcttaccg cccagtgag accctgtgcy gcggggagct ggtggacacc 120  
ctccagttcg tctgtgggga ccgcggcttc tacttcagca ggcccgaag ccgtgtgagc 180  
cgtcgcagcc gtggcatcgt tgaggagtgc tgtttccgca gctgtgacct ggccctcctg 240  
gagacgtact gtgctacccc cgccaagtcc gagaggagcg tgtcgacccc tccgaccgtg 300  
30 cttccggaca acttccccag ataccctctg ggcaagtctt tccaatatga cacctggaag 360  
cagtcacccc agcgctgcg caggggcctg cctgccctcc tgcgtgcccg ccggggtcac 420  
gtgctcgcca aggagctcga ggcgttcagg gaggccaaac gtcaccgtcc cctgattgct 480  
ctaccacccc aagaccccgc ccacgggggc gcccccccag agatggccag caatcggaag 540  
tgagcaaaac tgccgcaagt ctgcagcccg gcgccaccat cctgcagcct cctcctgacc 600  
acggagcttt ccacaggtt ccaccccgaa aatctctcgg ttccacgtcc ccctggggct 660  
35 tctcctgacc cagtccccgt gcccgcctc ccgaaaacag gctactctcc tcggccccct 720  
ccatcgggct gaggaagcac agc 743

<210> 90  
40 <211> 7476  
<212> DNA  
<213> Homo sapiens

<300>  
45 <302> IGF2R  
<310> NM000876

<400> 90  
50 atggggggccg ccgcccggccg gagccccac ctggggcccg cggccgcccg ccgcccgcag 60  
cgctctctgc tcctgtgca gctgctgctg ctgctgctg ccccggggtc cagcgaggcc 120  
caggccgccc cgttccccga gctgtgcagt tatacatggg aagctgttga taccaaaaat 180  
aatgtacttt ataaaatcaa catctgtgga agtgtggata ttgtccagtg cgggccatca 240  
agtgtctgtt gtatgcacga cttgaagaca cgcactatc attcagtggg tgactctgtt 300  
55 ttgagaagtg caaccagatc tctcctggaa ttcaacaaa cagtgaactg tgaccagcaa 360  
ggcacaatc acagagtcca gagcagcatt gccttctgt gtgggaaaac cctgggaact 420  
cctgaatttg taactgcaac agaattgtgt cactactttg agtggaggac cactgcagcc 480  
tgcaagaaag acatatatta agcaataag gaggtgccat gctatgtgtt tgatgaagag 540  
ttgaggaagc atgatctcaa tcctctgatc aagcttagtg gtgcctactt ggtggatgac 600  
tccgatcccg acacttctct attcatcaat gttttagtag acatagacac actacgagac 660  
60 ccaggttcac agctcggggc ctgtccccc ggactgccc cctgcctggt aagaggacac 720  
cagggttttg atgttgcca gcccgggac ggactgaagc tgggtgcgaa ggacaggctt 780  
gtcctgagtt acgtgagggg agaggcagga aagctagact tttgtgatgg tcacagccct 840

	gcggtgacta	ttacatttgt	ttgcccgtcg	gagcggagag	agggcaccat	tcccaaactc	900
	acagctaaat	ccaactgccg	ctatgaaatt	gagtggtatta	ctgagtatgc	ctgccacaga	960
	gattacctgg	aaagtaaaac	ttgttctctg	agcggcgagc	agcaggatgt	ctccatagac	1020
	ctcacaccac	ttgcccagag	cggaggttca	tcctatatatt	cagatggaaa	agaatatttg	1080
5	ttttatttga	atgtctgtgg	agaaactgaa	atacagttct	gtaataaaaa	acaagctgca	1140
	gtttgccaaag	tgaaaaagag	cgatacctct	caagtcaaaag	cagcaggaag	ataccacaat	1200
	cagaccctcc	gatattcgga	tggagacctc	accttgatat	atgttgagg	tgatgaatgc	1260
	agctcagggt	ttcagcggat	gagcgtcata	aactttgagt	gcaataaaac	cgcaggtaac	1320
	gatgggaaag	gaactcctgt	attcacaggg	gaggttgact	gcacctactt	cttcacatgg	1380
10	gacacggaat	acgcctgtgt	taaggagaag	gaagacctcc	tctgcggtgc	caccgacggg	1440
	aagaagcgct	atgacctgtc	cgcgctggtc	cgcatgacag	aaccagagca	gaattgggaa	1500
	gctgtggatg	gcagtcagac	ggaaacagag	aagaagcatt	ttttcattaa	tatttgtcac	1560
	agagtgtctg	aggaaggcaa	ggcacgaggg	tgtcccagg	acgcggcagt	gtgtgcagtg	1620
	gataaaaatg	gaagtaaaaa	tctgggaaaa	tttatttcct	ctcccatgaa	agagaaagga	1680
15	aacattcaac	tctcttattc	agatggtgat	gatttgtggtc	atggcaagaa	aattaaaact	1740
	aatatcacac	ttgtatgcaa	gccaggtgat	ctggaaaagt	caccagtgtt	gagaacttct	1800
	ggggaaggcg	gttgctttta	tgagtttgag	tggcgcacag	ctgcggcctg	tgtgtgtctt	1860
	aagacagaag	gggagaactg	cacggtcttt	gactcccagg	cagggttttc	ttttgactta	1920
	tcacctctca	caaagaaaaa	tggtgcctat	aaagttgaga	caaagaagta	tgacttttat	1980
20	ataaatgtgt	gtggcccggg	gtctgtgagc	ccctgtcagc	cagactcagg	agcctgccag	2040
	gtggcaaaaa	gtgatgagaa	gacttggaa	ttgggtctga	gtaatgcgaa	gctttcatat	2100
	tatgatggga	tgatccaact	gaactacaga	ggcgccacac	cctataacaa	tgaaagacac	2160
	acaccgagag	ctacgctcat	cacctttctc	tgtgatcgag	acgcgggagt	gggcttccct	2220
	gaatatcagg	aagaggataa	ctccacctac	aacttccggt	ggtacaccag	ctatgcctgc	2280
25	ccggaggagc	ccctggaatg	cgtagtgacc	gacccctcca	cgtggagca	gtacgacctc	2340
	tccagctctg	caaaatctga	aggtggcctt	ggaggaaaact	ggtatgccat	ggacaactca	2400
	ggggaacatg	tcacgtggag	gaaatactac	attaacgtgt	gtcggcctct	gaatccagt	2460
	ccgggctgca	accgatatgc	atcggttgc	cagatgaagt	atgaaaaaga	tcagggtctc	2520
	ttcactgaag	tggtttccat	cagtaacttg	ggaatggcaa	agaccggccc	ggtggttgag	2580
30	gacagcggca	gcctccttct	ggaatacgtg	aatgggtcgg	cctgcaccac	cagcgatggc	2640
	agacagacca	catataccac	gaggatccat	ctcgtctgct	ccaggggcag	gctgaacagc	2700
	caccccatct	tttctctcaa	ctgggagtgt	gtggtcagtt	tcctgtggaa	cacagaggct	2760
	gcctgtccca	ttcagacaac	gacggataca	gaccaggctt	gctctataag	ggatcccaac	2820
	agtggatttg	tgtttaatct	taatccgcta	aacagttcgc	aaggatataa	cgtctctggc	2880
35	attgggaaga	tttttatgtt	taatgtctgc	ggcacaatgc	ctgtctgtgg	gaccatcctg	2940
	ggaaaacctg	cttctggctg	tgaggcagaa	accaaaactg	aagagctcaa	gaattggaag	3000
	ccagcaaggc	cagtcggaat	tgagaaaagc	ctccagctgt	ccacagaggg	cttcactact	3060
	ctgacctaca	aagggcctct	ctctgccaaa	ggtaccgctg	atgcttttat	cgtccgcttt	3120
	gtttgcaatg	atgatgttta	ctcaggggccc	ctcaaatcc	tgcatcaaga	tatcgactct	3180
40	gggcaaggga	tccgaaacac	ttactttgag	tttgaaaccg	cgttggcctg	tgttccctct	3240
	ccagtggtg	gccaagtac	cgacctggct	ggaaatgagt	acgacctgac	tggcctaagc	3300
	acagtcagga	aaccttggac	ggctgttgac	acctctgtcg	atgggagaaa	gaggactttc	3360
	tatttgagcg	tttgcaatcc	tctcccttac	attcctggat	gccagggcag	cgcagtgggg	3420
	tcttgcttag	tgtcagaagg	caatagctgg	aatctgggtg	tggtgcagat	gagtcctcaa	3480
45	gccgcggcga	atggatcttt	gagcatcatg	tatgtcaacg	gtgacaagt	tgggaaccag	3540
	cgcttctcca	ccaggatcac	gtttgagtgt	gctcagatat	cgggctcacc	agcatttcag	3600
	cttcaggatg	gttgtgagta	cgtgtttatc	tggagaactg	tggaagcctg	tcccggtgtc	3660
	agagtggaa	gggacaactg	tgaggtgaaa	gacccaaggc	atggcaactt	gtatgacctg	3720
	aagccccctg	gcctcaacga	caccatcgtg	agcgtggcg	aatacactta	ttacttccgg	3780
50	gtctgtggga	agctttctct	agacgtctgc	cccacaagt	acaagtccaa	ggtggtctcc	3840
	tcattgcagg	aaaagcggga	accgcaggga	tttcacaaa	tggcaggtct	cctgactcag	3900
	aagctaactt	atgaaaatgg	cttgtaaaaa	atgaacttca	cgggggggga	cacttgccat	3960
	aagggtttatc	agcgctccac	agccatcttc	ttctactgtg	accgcggcac	ccagcggcca	4020
	gtattttctaa	aggagacttc	agattgttcc	tacttgtttg	agtggcgaa	gcagtatgcc	4080
55	tgcccacctt	tcatctgac	tgaatgttca	ttcaaagatg	gggctggcaa	ctccttcgac	4140
	ctctcgtccc	tgtcaaggta	cagtgaacac	tgggaagcca	tcactgggac	gggggacccg	4200
	gagcactacc	tcatcaatgt	ctgcaagtct	ctggccccgc	aggctggcac	tgagcgtgct	4260
	cctccagaag	cagccgcgtg	tctgctgggt	ggctccaagc	ccgtgaacct	cggcagggta	4320
	agggacggac	ctcagtggag	agatggcata	attgtcctga	aatacgttga	tggcgactta	4380
60	tgtccagatg	ggattcggaa	aaagtcaacc	accatccgat	tcacctgcag	cgagagccaa	4440
	gtgaactcca	ggcccatgtt	catcagcgcc	gtggaggact	gtgagtacac	ctttgcttgg	4500
	cccacagcca	cagcctgtcc	catgaagagc	aacgagcatg	atgactgcca	ggtcaccaac	4560

	ccaagcacag	gacacctggt	tgatctgagc	tccttaagtg	gcagggcggg	attcacagct	4620
	gcttacagcg	agaagggggt	ggtttacatg	agcatctgtg	gggagaatga	aaactgccct	4680
	cctggcgtgg	gggcctgctt	tggaacagacc	aggattagcg	tgggcaaggc	caacaagagg	4740
	ctgagatacg	tggaccagggt	cctgcagctg	gtgtacaagg	atgggtcccc	ttgtccctcc	4800
5	aaatccggcc	tgagctataa	gagtgtgatc	agtttcgtgt	gcaggcctga	ggccggggcca	4860
	accaataggg	ccatgctcat	ctccctggac	aagcagacat	gcactctctt	cttctcctgg	4920
	cacacgccgc	tggcctgcga	gcaagcgacc	gaatgttccg	tgaggaatgg	aagctctatt	4980
	gttgacttgt	ctccccttat	tcatcgcact	ggtggttatg	aggcttatga	tgagagttag	5040
	gatgatgcct	ccgataccaa	ccctgatttc	tacatcaata	tttgtcagcc	actaaatccc	5100
10	atgcacgcag	tgccctgtcc	tgccggagcc	gctgtgtgca	aagttcctat	tgatgggtccc	5160
	cccatagata	tcggccgggt	agcaggacca	ccaatactca	atccaatagc	aaatgagatt	5220
	tacttgaatt	ttgaaagcag	tactccttgc	ttagcggaca	agcatttcaa	ctacacctcg	5280
	ctcatcgct	ttcactgtaa	gagaggtgtg	agcatgggaa	cgcctaagct	gttaaggacc	5340
	agcagtgctg	actttgtgtt	cgaatgggag	actcctgtcg	tctgtcctga	tgaagttagg	5400
15	atggatggct	gtaccctgac	agatgagcag	ctcctctaca	gcttcaactt	gtccagcctt	5460
	tccacgagca	cctttaagggt	gactcgcgac	tcgcgcacct	acagcgttgg	ggtgtgcacc	5520
	tttgagtcg	ggccagaaca	aggaggtgtg	aaggacggag	gagtcctgtc	gctctcaggc	5580
	accaaggggg	catcctttgg	acggctgcaa	tcaatgaaac	tggattacag	gcaccaggat	5640
	gaagcggctg	ttttaagtta	cgtgaatggt	gatcgttgcc	ctccagaaac	cgatgacggc	5700
20	gtcccctgtg	tcttcccctt	catattcaat	gggaagagct	acgaggagtg	catcatagag	5760
	agcagggcga	agctgtggtg	tagcacaact	gcggactacg	acagagacca	cgagtggggc	5820
	ttctgcagac	actcaaacag	ctaccggaca	tccagcatca	tatttaagtg	tgatgaagat	5880
	gaggacattg	ggaggccaca	agtcttcagt	gaagtgcgtg	ggtgtgatgt	gacatttgag	5940
	tggaaaacaa	aagttgtctg	ccctccaaag	aagttggagt	gcaaattcgt	ccagaaacac	6000
25	aaaacctacg	acctgcggct	gctctcctct	ctcaccgggt	cctgggtccct	ggtccacaac	6060
	ggagtctcgt	actatataaa	tctgtgccag	aaaatatata	aaggggccct	gggtgctct	6120
	gaaagggcca	gcatttgcag	aaggaccaca	actggtgacg	tccaggtcct	gggactcgtt	6180
	cacacgcaga	agctgggtgt	cataggtgac	aaagtgtgtg	tcacgtactc	caaaggttat	6240
	ccgtgtggtg	gaaataagac	cgcacctccc	gtgatagaat	tgacctgtac	aaagacggtg	6300
30	ggcagacctg	cattcaagag	gtttgatata	gacagctgca	cttactactt	cagctgggac	6360
	tcccgggctg	cctgcgccgt	gaagcctcag	gaggtgcaga	tggtgaatgg	gaccatcacc	6420
	aaccctataa	atggcaagag	cttcagcctc	ggagatattt	attttaagct	gttcagagcc	6480

	cctgaagttc	tcgatgattc	cataaatatg	aaacattttg	aatccttcaa	acgtgctgac	1200
	atctatgcaa	tgggcttagt	attctgggaa	attgctcgac	gatgttccat	tgggtggaatt	1260
	catgaagatt	accaactgcc	ttattatgat	cttgtagcct	ctgacccatc	agttgaagaa	1320
	atgagaaaag	ttgtttgtga	acagaagtta	aggccaaata	tcccaaacag	atggcgagagc	1380
5	tgtgaagcct	tgagagtaat	ggctaaaatt	atgagagaat	gttgggtatgc	caatggagca	1440
	gctaggctta	cagcattgcy	gattaagaaa	acattatcgc	aactcagtca	acaggaaggc	1500
	atcaaaatgt	aa					1512
10	<210> 94						
	<211> 4044						
	<212> DNA						
	<213> Homo sapiens						
15	<300>						
	<302> Flk1						
	<310> AF035121						
	<400> 94						
20	atgcagagca	agggtgctgct	ggccgctcgcc	ctgtggctct	gcgtggagac	ccgggcccgc	60
	tctgtggggt	tgcctagtgt	ttctcttgat	ctgcccaggc	tcagcataca	aaaagacata	120
	cttacaatta	aggctaatac	aactcttcaa	attacttgca	ggggacagag	ggacttggac	180
	tggctttggc	ccaataatca	gagtggcagt	gagcaaagg	tggaggtgac	tgagtgcagc	240
	gatggcctct	tctgtaagac	actcacaatt	ccaaaagtga	tcggaaatga	cactggagcc	300
25	tacaagtgtc	tctaccggga	aactgacttg	gcctcggta	tttatgtcta	tgttcaagat	360
	tacagatctc	catttattgc	ttctgttagt	gaccaacatg	gagtcgtgta	cattactgag	420
	aacaaaaaca	aaactgtggt	gattccatgt	ctcgggtcca	tttcaaactc	caacgtgtca	480
	ctttgtgcaa	gatacccaga	aaagagattt	gttcctgatg	gtaacagaat	ttcctgggac	540
	agcaagaagg	gctttactat	tcccagctac	atgatcagct	atgctggcat	ggtcttctgt	600
30	gaagcaaaaa	ttaatgatga	aagttaccag	tctattatgt	acatagtgtg	cgttgtaggg	660
	tataggattt	atgatgtggt	tctgagtcgg	tctcatggaa	ttgaactatc	tgttggagaa	720
	aagcttgtct	taaattgtac	agcaagaact	gaactaaatg	tggggattga	cttcaactgg	780
	gaataccctt	cttcgaagca	tcagcataag	aaacttgtaa	accgagacct	aaaaacccag	840
	tctgggagtg	agatgaagaa	atttttgagc	accttaacta	tagatgggtg	aacccggagt	900
35	gaccaaggat	tgtacacctg	tgcagcatcc	agtgggctga	tgaccaagaa	gaacagcaca	960
	tttgtcaggg	tccatgaaaa	accttttgtt	gcttttgtaa	gtggcatgga	atctctgggtg	1020
	gaagccacgg	tgggggagcg	tgtcagaatc	cctgcgaagt	accttggtta	cccaccccca	1080
	gaaataaaat	ggtataaaaa	tgggaataccc	cttgagtcca	atcacacaat	taaagcgggg	1140
	catgtactga	cgattatgga	agtgagtga	agagacacag	gaaattacac	tgtcatcctt	1200
40	accaatccca	tttcaaagga	gaagcagagc	catgtggtct	ctctggttgt	gtatgtccca	1260
	cccagatttg	gtgagaaatc	tctaactctc	cctgtggatt	cctaccagta	cggcaccact	1320
	caaacgctga	catgtacggt	ctatgccatt	cctccccgc	atcacatcca	ctggtattgg	1380
	cagttggagg	aagagtgcgc	caacgagccc	agccaagctg	tctcagtgc	aaaccctac	1440
	ccttgtgaag	aatggagaag	tgtggaggac	ttccaggagg	gaaataaaat	tgaagttaat	1500
45	aaaaatcaat	ttgctcta	tgaaggaaaa	aacaaaactg	taagtaccct	tgttatccaa	1560
	gcggcaaatg	tgtcagcttt	gtacaaatgt	gaagcgggtc	acaaagtcgg	gagaggagag	1620
	agggtgatct	ccttccacgt	gaccaggggt	cctgaaatta	ctttgcaacc	tgacatgcag	1680
	cccactgagc	aggagagcgt	gtctttgtgg	tgcactgcag	acagatctac	gtttgagaac	1740
	ctcacatggt	acaagcttgg	cccacagcct	ctgccaatcc	atgtgggaga	gttgcccaca	1800
50	cctgttttga	agaacttgg	tactctttgg	aaattgaatg	ccaccatgtt	ctctaatagc	1860
	acaaatgaca	ttttgatcat	ggagcttaag	aatgcatcct	tgcaggacca	aggagactat	1920
	gtctgccttg	ctcaagacag	gaagaccaag	aaaagacatt	gcgtgggtcag	gcagctcaca	1980
	gtcctagagc	gtgtggcacc	cacgatcaca	ggaaacctgg	agaatcagac	gacaagtatt	2040
	ggggaaaagca	tcgaagtctc	atgcacggca	tctgggaatc	cccctccaca	gatcatgtgg	2100
55	tttaaagata	atgagaccct	tgtagaagac	tcaggcattg	tattgaagga	tgggaaccgg	2160
	aacctcacta	tccgcagagt	gaggaaggag	gacgaaggcc	tctacacctg	ccaggcatcg	2220
	agtgttcttg	gctgtgcaaa	agtggaggca	tttttcataa	tagaagggtgc	ccaggaaaag	2280
	acgaacttgg	aaatcattat	tctagtaggc	acggcggtga	ttgccatgtt	cttctggcta	2340
	cttcttgtca	tcatcctacg	gaccgttaag	cgggccaatg	gaggggaact	gaagacaggc	2400
60	tacttgtcca	tcgtcatgga	tccagatgaa	ctcccattgg	atgaacattg	tgaacagctg	2460
	ccttatgatg	cagcaaatg	ggaattcccc	agagaccggc	tgaagctagg	taagcctctt	2520
	ggccgtgggtg	cctttggcca	agtgattgaa	gcagatgcct	ttggaattga	caagacagca	2580

5 acttcgagga cagtagcagt caaaatgttg aaagaaggag caacacacag tgagcatcga 2640  
 gctctcatgt ctgaactcaa gatcctcatt catattgggt accatctcaa tgtgggtcaac 2700  
 cttctaggtg cctgtaccaa gccaggaggg ccactcatgg tgatttggtga attctgcaaa 2760  
 tttggaaacc tgtccactta cctgaggagc aagagaaatg aatttgtccc ctacaagacc 2820  
 aaagggggac gattccgtca agggaaagac tacgttggag caatccctgt ggatctgaaa 2880  
 cggcgcttgg acagcatcac cagtagccag agctcagcca gctctggatt tgtggaggag 2940  
 aagtcctca gtgatgtaga agaagaggaa gctcctgaag atctgtataa ggacttctctg 3000  
 accttgagc atctcatctg ttacagcttc caagtggcta agggcatgga gttcttgga 3060  
 10 tcgcgaaagt gtatccacag ggacctggcg gcacgaaata tcctcttatc ggagaagaac 3120  
 gtgggttaaaa tctgtgactt tggcttggcc cgggatattt ataaagatcc agattatgtc 3180  
 agaaaaggag tgctcgctt ccttttgaat tggatggccc cagaaacaat ttttgacaga 3240  
 gtgtacacaa tccagagtga cgtctggtct tttgggtgtt tgctgtggga aatattttcc 3300  
 ttaggtgctt ctccatatcc tggggtaaag attgatgaag aattttgtag gcgattgaaa 3360  
 gaaggaaacta gaatgagggc ccctgattat actacaccag aatgtacca gacctgctg 3420  
 15 gactgctggc acggggagcc cagtcagaga cccacgtttt cagagttggt ggaacatttg 3480  
 ggaaatctct tgcaagctaa tgctcagcag gatggcaaag actacattgt tcttccgata 3540  
 tcagagactt tgagcatgga agaggattct ggactctctc tgctacctc acctgtttcc 3600  
 tgtatggagg agggaggaagt atgtgacccc aaattccatt atgacaacac agcaggaatc 3660  
 agtcagtatc tgcagaacag taagcgaag agccggcctg tgagtgtaaa aacatttgaa 3720  
 20 gatatcccg tagaagaacc agaagtaaaa gtaatcccag atgacaacca gacggacagt 3780  
 ggtatggttc ttgcctcaga agagctgaaa actttggaag acagaaccaa attatctcca 3840  
 tcttttgggtg gaatggtgcc cagcaaaagc agggagtctg tggcatctga aggctcaaac 3900  
 cagacaagcg gctaccagtc cggatatcac tccgatgaca cagacaccac cgtgtactcc 3960  
 agtgagggaag cagaactttt aaagctgata gagattggag tgcaaacgg tagcacagcc 4020  
 25 cagattctcc agcctgactc gggg 4044

<210> 95  
 <211> 4017  
 30 <212> DNA  
 <213> Homo sapiens

<300>  
 <302> Flt1  
 35 <310> AF063657

<400> 95  
 atggtcagct actgggacac cggggctctg ctgtgcgcgc tgctcagctg tctgcttctc 60  
 40 acaggatcta gttcaggttc aaaattaaaa gatcctgaac tgagtttaaa aggcacccag 120  
 cacatcatgc aagcaggcca gacactgcat ctccaatgca ggggggaagc agccataaa 180  
 tgggtctttg ctgaaatggt gagtaaggaa agcgaaggc tgagcataa taaatctgcc 240  
 tgtggaagaa atggcaaca attctgcagt actttaacct tgaacacagc tcaagcaaac 300  
 cacactggct tctacagctg caaatatcta gctgtacctt cttcaaagaa gaaggaaaca 360  
 45 gaatctgcaa tctatatatt tattagtgat acaggtagac ctttcgtaga gatgtacagt 420  
 gaaatcccg aaattataca catgactgaa ggaaggagc tcgtcattcc ctgccgggtt 480  
 agctcaccta acatcactgt tactttaaaa aagtttccac ttgacacttt gatccctgat 540  
 ggaaaacgca taatctggga cagtagaaag ggcttcatca tatcaaatgc aacgtacaaa 600  
 gaaatagggc ttctgacctg tgaagcaaca gtcaatgggc atttgtataa gacaaactat 660  
 50 ctcacacatc gacaaaccaa tacaatcata gatgtccaaa taagcacacc acgcccagtc 720  
 aaattactta gaggccatac tctgtcctc aattgtactg ctaccactcc cttgaacacg 780  
 agagttcaaa tgacctggag ttacctgat gaaaaaata agagagcttc cgtaaggcga 840  
 cgaattgacc aaagcaattc ccatgccaac atattctaca gtgttcttac tattgacaaa 900  
 atgcagaaca aagacaaagg actttatact tgtcgtgtaa ggagtggacc atcattcaaa 960  
 55 tctgttaaca cctcagtga tatatatgat aaagcattca tcactgtgaa acatcgaaaa 1020  
 cagcaggtgc ttgaaaccgt agctggcaag cggctctacc ggctctctat gaaagtgaag 1080  
 gcatttccct cgccggaagt tgtatggtta aaagatgggt tacctgcgac tgagaaatct 1140  
 gctcgtctatt tgactcgtgg ctactcgtta attatcaagg acgtaactga agaggatgca 1200  
 ggggaattata caatcttgct gagcataaaa cagtcaaatg tgtttaaaaa cctcactgcc 1260  
 60 actctaattg tcaatgtgaa accccagatt tacgaaaagg ccgtgtcatc gtttccagac 1320  
 ccggtctctc accactggg cagcagacaa atcctgactt gtaccgcata tggatctcct 1380  
 caacctcaaa tcaagtgtt ctggcaccct atcattccga agcaagggtg 1440  
 gacttttgtt ccaataatga agagtcttct atcctggatg ctgacagcaa catgggaaac 1500

	agaattgaga	gcatcactca	gcgcattggca	ataatagaag	gaaagaataa	gatggctagc	1560
	accttggttg	tggctgactc	tagaatttct	ggaatctaca	tttgcatagc	ttccaataaa	1620
	gttgggactg	tgggaagaaa	cataagcttt	tatatcacag	atgtgccaaa	tgggtttcat	1680
	gttaacttgg	aaaaaatgcc	gacggaagga	gaggacctga	aactgtcttg	cacagttaac	1740
5	aagttcttat	acagagacgt	tacttggatt	ttactgcgga	cagttaataa	cagaacaatg	1800
	cactacagta	ttagcaagca	aaaaatggcc	atcactaagg	agcactccat	cactcttaat	1860
	cttaccatca	tgaatgtttc	cctgcaagat	tcaggcacct	atgcctgcag	agccaggaat	1920
	gtatacacag	gggaagaaat	cctccagaag	aaagaaatta	caatcagaga	tcaggaagca	1980
	ccatacctcc	tgcgaaacct	cagtgtacac	acagtggcca	tcagcagttc	caccacttta	2040
10	gactgtcatg	ctaattggtg	ccccgagcct	cagatcactt	ggtttaaaaa	caaccacaaa	2100
	atacaacaag	agcctggaat	tatttttagga	ccaggaagca	gcacgctgtt	tattgaaaga	2160
	gtcacagaag	aggatgaagg	tgtctatcac	tgcaaagcca	ccaaccagaa	gggctctgtg	2220
	gaaagttcag	catacctcac	tgttcaagga	acctcggaca	agtctaattct	ggagctgac	2280
	actctaact	gcacctgtgt	ggctgcgact	ctcttctggc	tcctattaac	cctctttatc	2340
15	cgaaaaatga	aaaggtcttc	ttctgaaata	aagactgact	acctatcaat	tataatggac	2400
	ccagatgaag	ttccttttga	tgagcagtg	gagcggctcc	cttatgatgc	cagcaagtgg	2460
	gagtttggcc	gggagagact	taaactgggc	aaatcacttg	gaagaggggc	ttttggaaaa	2520
	gtggttcaag	catcagcatt	tggcattaag	aaatcaccta	cgtgccggac	tgtggctgtg	2580
	aaaatgtctga	aagagggggc	cacggccagc	gagtacaaag	ctctgatgac	tgagctaaaa	2640
20	atcttgaccc	acattggcca	ccatctgaac	gtgggttaacc	tgctgggagc	ctgcaccaag	2700
	caaggagggc	ctctgatggt	gattgttgaa	tactgcaaat	atggaaatct	ctccaactac	2760
	ctcaagagca	aacgtgactt	attttttctc	aacaaggatg	cagcactaca	catggagcct	2820
	aagaaagaaa	aaatggagcc	aggcctggaa	caaggcaaga	aaccaagact	agatagcgct	2880
	accagcagcg	aaagctttgc	gagctccggc	tttcaggaag	ataaaagtct	gagtgatgtt	2940
25	gaggaagagg	aggattctga	cggtttctac	aaggagccca	tcactatgga	agatctgatt	3000
	tcttacagtt	ttcaagtggc	cagaggcatg	gagttcctgt	cttccagaaa	gtgcattcat	3060
	cgggacctgg	cagcgagaaa	cattctttta	tctgagaaca	acgtgggtgaa	gatttgtgat	3120
	tttggccttg	cccgggatat	ttataagaac	cccgattatg	tgagaaaagg	agatactcga	3180
	cttcctctga	aatggatggc	tcctgaatct	atctttgaca	aaatctacag	caccaagagc	3240
30	gacgtgtggt	cttacggagt	attgctgtgg	gaaatcttct	ccttaggtgg	gtctccatac	3300
	ccaggagtac	aaatggatga	ggacttttgc	agtcgcctga	gggaaggcat	gaggatgaga	3360
	gctcctgagt	actctactcc	tgaaatctat	cagatcatgc	tggactgctg	gcacagagac	3420
	ccaaaagaaa	ggccaagatt	tgcagaactt	gtggaaaaac	taggtgattt	gcttcaagca	3480
	aatgtacaac	aggatggtaa	agactacatc	ccaatcaatg	ccatactgac	aggaaatagt	3540
35	gggtttacat	actcaactcc	tgccttctct	gaggacttct	tcaaggaaag	tatttcagct	3600
	ccgaagttaa	attcaggaag	ctctgatgat	gtcagatatg	taaatgcttt	caagttcatg	3660
	agcctggaaa	gaatcaaaac	ctttgaagaa	cttttaccga	atgccacctc	catgtttgat	3720
	gactaccagg	gcgacagcag	cactctgttg	gcctctccca	tgctgaagcg	cttcacctgg	3780
	actgacagca	aaccaagggc	ctcgctcaag	attgacttga	gagtaaccag	taaaagtaag	3840
40	gagtcggggc	tgtctgatgt	cagcaggccc	agtttctgcc	attccagctg	tgggcacgct	3900
	agcgaaggca	agcgcaggtt	cacctacgac	cacgctgagc	tggaaaggaa	aatcgcgtgc	3960
	tgtccccgc	ccccagacta	caactcgggtg	gtcctgtact	ccaccccacc	catctag	4017
45	<210> 96						
	<211> 3897						
	<212> DNA						
	<213> Homo sapiens						
50	<300>						
	<302> Flt4						
	<310> XM003852						
	<400> 96						
55	atgcagcggg	gcgcgcgct	gtgcctgcga	ctgtggctct	gcctgggact	cctggacggc	60
	ctgggtgagt	gctactccat	gacccccccg	accttgaaca	tcacggagga	gtcacacgct	120
	atcgacaccg	gtgacagcct	gtccatctcc	tgacggggac	agcaccacct	cgagtgggct	180
	tggccaggag	ctcaggaggc	gccagccacc	ggagacaagg	acagcgagga	cacgggggtg	240
	gtgcgagact	gcgagggcac	agacgccagg	ccctactgca	agggtgttgct	gctgcacgag	300
60	gtacatgccca	acgacacagg	cagctacgtc	tgctactaca	agtacatcaa	ggcacgcac	360
	gagggcacca	cggccgccag	ctcctacgtg	ttcgtgagag	actttgagca	gccattcatc	420
	aacaagcctg	acacgctctt	ggtcaacagg	aaggacgcca	tgtgggtgct	ctgtctggtg	480

5 tccatccccg gcctcaatgt cacgctgcgc tcgcaaagct cgggtgctgtg gccagacggg 540  
 caggaggtgg tgtgggatga cgggcggggc atgctcgtgt ccacgccact gctgcacgat 600  
 gccctgtacc tgcagtgcga gaccacctgg ggagaccagg acttcctttc caacccttc 660  
 ctggtgcaca tcacaggcaa cgagctctat gacatccagc tgttgcccag gaagtgcgtg 720  
 gagctgctgg taggggagaa gctggctctg aactgcaccg tgtgggctga gtttaactca 780  
 ggtgtcacct ttgactggga ctaccagggg aagcaggcag agcggggtaa gtgggtgcc 840  
 gagcgacgct ccacagcagc ccacacagaa ctctccagca tcctgacct ccacaacgtc 900  
 agccagcacg acctgggctc gtatgtgtgc aaggccaaca acggcatcca gcgatttcgg 960  
 gagagcacgg aggtcattgt gcatgaaaat cccttcatca gcgtcgagt gctcaaagga 1020  
 10 cccatcctgg agggcacggc aggagacgag ctggtgaagc tgcccgtgaa gctggcagcg 1080  
 taccctccgc ccgagttcca gtggtacaag gatggaaaagg cactgtccgg gcgccacagt 1140  
 ccacatgccc tgggtgctcaa ggaggtgaca gaggccagca caggcaccta caccctcgcc 1200  
 ctgtggaact ccgctgctgg cctgaggcgc aacatcagcc tggagctggg ggtgaatgtg 1260  
 cccccccaga tacatgagaa ggaggcctcc tccccagca tctactcgcg tcacagccgc 1320  
 15 caggccctca cctgcacggc ctacgggggtg cccctgcctc tcagcatcca gtggcactgg 1380  
 cggccctgga caccctgcaa gatgtttgcc cagcgtagtc tccggcggcg gcagcagcaa 1440  
 gacctcatgc cacagtgcgg tgactggagg gcggtgaccg cgcaggatgc cgtgaacccc 1500  
 atcgagagcc tggacacctg gaccgagttt gtggaggga agaataagac tgtgagcaag 1560  
 ctggtgatcc agaattgcaa cgtgtctgcc atgtacaagt gtgtggtctc caacaagggtg 1620  
 20 ggccaggatg agcggctcat ctacttctat gtgaccacca tccccagcg cttcaccatc 1680  
 gaatccaagc ctccgagga gctactagag ggccagccgg tgcctctgag ctgccagc 1740  
 gacagctaca agtacgagca tctgcgctgg taccgctca acctgtccac gctgcacgat 1800  
 ggcacggga acccgcttct gctcactgc aagaacgtgc atctgttcgc caccctctg 1860  
 gccgccagcc tggaggaggt ggcacctggg gcgcgccacg ccacgctcag cctgagtatc 1920  
 25 ccccgctcg cggccgagca cgagggccac tatgtgtgcg aagtgaaga ccggcgcagc 1980  
 catgacaagc actgccaaa gaagtacctg tcggtgcagg cctgggaagc cctcggtc 2040  
 acgcagaact tgaccgacct cctggtgaac gtgagcgact cgctggagat gcagtgcctg 2100  
 gtggccggag cgcacgcgcc cagcatcgtg tggtaaaaag acgagaggct gctggaggaa 2160  
 aagtctggag tcgacttggc ggactccaac cagaagctga gcatccagcg cgtgcgcgag 2220  
 30 gaggatgcgg gacgctatct gtgcagcgtg tgcaacgcca agggctgcgt caactcctc 2280  
 gccagctgg ccgtggaagg ctccgaggtt aagggcagca tggagatcgt gatcctgtc 2340  
 ggtaccggcg tcatcgctgt cttcttctgg gtccctctcc tcctcatctt ctgtaacatg 2400  
 aggaggccgg cccacgcaga catcaagacg ggctacctgt ccacatcat ggaccccg 2460  
 gaggtgcctc tggaggagca atgcgaatac ctgtcctacg atgccagcca gtgggaattc 2520  
 35 ccccgagagc ggctgcacct ggggagagtg ctcggtacg gcgccttcgg gaagggtgtg 2580  
 gaagcctccg ctttcggcat ccacaaggcg acagctgtg acaccgtggc cgtgaaaatg 2640  
 ctgaaagagg gcgccagggc cagcgagcag cgcgcgtga tgtcggagct caagatcctc 2700  
 attcacatcg gcaaccacct caacgtggtc aacctcctcg gggcgtgcac caagccgag 2760  
 ggccctccta tggatgatcg ggagttctgc aagtacggca acctctcaa cttcctgcgc 2820  
 40 gccaaagcgg acgccttcag cccctgcgcg gagaagtctc ccgagcagcg cggacgcttc 2880  
 cgcgcctagg tggagctcgc caggctggat cggaggcggc cggggagcag cgacagggtc 2940  
 ctcttcgcgc ggttctcgaa gaccgagggc ggagcagggc gggcttctcc agaccaagaa 3000  
 gctgaggacc tgtggctgag ccgctgacc atggaagatc ttgtctgcta cagcttcag 3060  
 gtggccagag ggatggagtt cctggcttcc cgaaagtga tccacagaga cctggctgct 3120  
 45 cggaacattc tgctgtcgga aagcgacgtg gtgaagatct gtgactttgg ccttgcccgg 3180  
 gacatctaca aagaccccga ctacgtccgc aagggcagtg cccggctgcc cctgaagtgg 3240  
 atggcccttg aaagcatctt cgacaagggtg tacaccacgc agagtgcgt gtggtccttt 3300  
 ggggtgcttc tctgggagat cttctctctg ggggcctccc cgtaccctgg ggtgcagatc 3360  
 aatgaggagt tctgccagcg gctgagagac ggcacaagga tgaggggccc ggagctggcc 3420  
 50 actcccgcga tacgccgat catgctgaac tgcctggtcc gagaccccaa ggcgagacct 3480  
 gcattctcgg agctggtgga gatcctgggg gactctctcc agggcagggg cctgcaagag 3540  
 gaagaggagg tctgcatggc cccgcgcagc tctcagagct cagaagaggg cagcttctcg 3600  
 cagggtgcca ccatggccct acacatcgcc caggctgacg ctgaggacag cccgccaaagc 3660  
 ctgcagcgcc acagcctggc cgccaggtat tacaactggg tgccttctcc cgggtgcctg 3720  
 55 gccagagggg ctgagaccgg tggttcctcc aggatgaaga catttgagga attccccatg 3780  
 gcccacaaga cctacaagg ctctgtggac aaccagacag acagtgggat ggtgctggcc 3840  
 tcggaggagt ttgagcagat agagagcagg catagacaag aaagcggctt caggtag 3897

60 <210> 97  
 <211> 4071  
 <212> DNA



<213> Homo sapiens

<300>

<302> KDR

5 <310> AF063658

<400> 97

	atggagagca	aggtgctgct	ggccgctcgcc	ctgtgggtct	gcgtggagac	ccggggccgcc	60
	tctgtgggtt	tgcctagtgt	ttctcttgat	ctgcccaggc	tcagcataca	aaaagacata	120
10	cttacaatta	aggctaatac	aactcttcaa	attacttgca	ggggacagag	ggacttggac	180
	tggctttggc	ccaataatca	gagtggcagt	gagcaaaggg	tggaggtgac	tgagtgcagc	240
	gatggcctct	tctgtaagac	actcacaatt	ccaaaagtga	tcggaaatga	cactggagcc	300
	tacaagtgtc	tctaccggga	aactgacttg	gcctcgggtc	tttatgtcta	tgttcaagat	360
	tacagatctc	catttattgc	ttctgttagt	gaccaacatg	gagtcgtgta	cattactgag	420
15	aacaaaaaca	aaactgtggt	gattccatgt	ctcgggtcca	tttcaaactc	caacgtgtca	480
	ctttgtgcaa	gatacccaga	aaagagattt	gttcctgatg	gtaacagaat	ttcctgggac	540
	agcaagaagg	gctttactat	tcccagctac	atgatcagct	atgctggcat	ggtcttctgt	600
	gaagcaaaaa	ttaatgatga	aagttaccag	tctattatgt	acatagttgt	cgttgtaggg	660
	tataggattt	atgatgtggt	tctgagtccg	tctcatggaa	ttgaactatc	tgttgagaaa	720
20	aagcttgtct	taaattgtac	agcaagaact	gaactaaatg	tggggattga	cttcaactgg	780
	gaataccctt	cttcgaagca	tcagcataag	aaacttgtaa	accgagacct	aaaaacccag	840
	tctgggagtg	agatgaagaa	atttttgagc	accttaacta	tagatgggtg	aaccggagt	900
	gaccaaggat	tgtacacctg	tgcagcatcc	agtgggctga	tgaccaagaa	gaacagcaca	960
	tttgtcaggg	tccatgaaaa	accttttgtt	gcttttgtaa	gtggcatgga	atctctgggtg	1020
25	gaagccacgg	tgggggagcg	tgtcagaatc	cctgcgaagt	accttggtta	cccccccca	1080
	gaaataaaaat	ggtataaaaa	tgggaatacc	cttgagtcca	atcacacaat	taaagcgggg	1140
	catgtactga	cgattatgga	agtgagtga	agagacacag	gaaattacac	tgtcatcctt	1200
	accaatccca	tttcaaagga	gaagcagagc	catgtggtct	ctctggttgt	gtatgtccca	1260
	ccccagattg	gtgagaaatc	tctaattctc	cctgtggatt	cctaccagta	cggcaccact	1320
30	caaacgctga	catgtacggt	ctatgccatt	cctccccgc	atcacatcca	ctggtatttg	1380
	cagttggagg	aagagtgcgc	caacgagccc	agccaagctg	tctcagtgac	aaaccatac	1440
	ccttgtgaag	aatggagaag	tgtggaggac	ttccagggag	gaaataaaaat	tgaagttaat	1500

5 tttgatgatg atgaaacctg gacaagtagt tccaaaggct acaacttggt tcttgttgct 660  
 gcgcagtagt tcggccactc cttagggtctt gaccactcca aggaccctgg agcactcatg 720  
 ttctctatct acacctacac cggcaaaagc cactttatgc ttcttgatga cgatgtacaa 780  
 gggatccagt ctctctatgg tccaggagat gaagacccca accctaaaca tccaaaaacg 840  
 ccagacaaat gtgacccttc cttatccctt gatgccatta ccagtctccg aggagaaaca 900  
 atgatcttta aagacagatt cttctggcgc ctgcatcctc agcagggtga tgcggagctg 960  
 tttttaacga aatcattttg gccagaactt cccaaccgta ttgatgctgc atatgagcac 1020  
 ccttctcatg acctcatctt catcttcaga ggtagaaaat tttgggctct taatggttat 1080  
 gacattctgg aagggttatcc caaaaaata tctgaactgg gtcttccaaa agaagttaag 1140  
 10 aagataagtg cagctgttca ctttgaggat acaggcaaga ctctcctggt ctccaggaaac 1200  
 caggctctgga gatgatga tactaaccat attatggata aagactatcc gagactaata 1260  
 gaagaagact tcccaggaat tgggtgataaa gtagatgctg tctatgagaa aaatgggtat 1320  
 atctatctttt tcaacggacc catacagttt gaatacagca tctggagtaa ccgtattggt 1380  
 cgcgctcatgc cagcaaatcc cattttgtgg tggttaa 1416

15

&lt;210&gt; 103

&lt;211&gt; 1749

&lt;212&gt; DNA

20 &lt;213&gt; Homo sapiens

&lt;300&gt;

&lt;302&gt; MMP14

&lt;310&gt; NM004995

25

&lt;400&gt; 103

30 atgtctcccg ccccaagacc cccccgttgt ctctgctcc ccctgctcac gctcggcacc 60  
 gcgctcgcct ccctcggttc ggcccaaagc agcagcttca gcccgaagc ctggctacag 120  
 caatatggct acctgcctcc cggggaccta cgtaccaca cacagcgctc accccagtca 180  
 ctctcagcgg ccacgcgtgc catgcagaag ttttacggct tgcaagtaac aggcaaagct 240  
 gatgcagaca ccatgaaggc catgaggcgc cccgatgtg gtgttccaga caagtctggg 300  
 gctgagatca aggccaatgt tcgaagggaag cgtacgcca tccagggtct caaatggcaa 360  
 cataatgaaa tcactttctg catccagaat tacaccccca aggtgggcga gtatgccaca 420  
 tacgaggcca ttcgcaaggc gttccgcgtg tgggagagtg ccacaccact gcgcttccgc 480  
 35 gaggtgccct atgcctacat ccgtgagggc catgagaagc aggccgacat catgatcttc 540  
 tttgccgagg gcttccatgg cgacagcacg ccttcgatg gtgagggcgg cttcctggcc 600  
 catgcctact tcccaggccc caacattgga ggagacaccc actttgactc tgccgagcct 660  
 tggactgtca ggaatgagga tctgaatgga aatgacatct tcctggtggc tgtgcacgag 720  
 ctggggccatg ccctggggct cgagcattcc agtgaccct cggccatcat ggccccttt 780  
 40 taccagtgga tggacacgga gaattttgtg ctgcccgatg atgaccgccc gggcatccag 840  
 caactttatg ggggtgagtc aggggtcccc accaagatgc cccctcaacc caggactacc 900  
 tcccggcctt ctgttctga taaacccaaa aacccacact atgggcccga catctgtgac 960  
 gggaaactttg acaccgtggc catgctccga ggggagatgt ttgtcttcaa ggagcgctgg 1020  
 ttctggcggg tgaggaataa ccaagtgatg gatggatacc caatgcccac tggccagttc 1080  
 45 tggcggggcc tgctgcgtc catcaacact gcctacgaga ggaaggatgg caaatctgct 1140  
 ttcttcaaag gagacaagca ttgggtgttt gatgaggcgt ccctggaacc tggctacccc 1200  
 aagcacatta aggagctggg ccgagggctg cctaccgaca agattgatgc tgcctctctc 1260  
 tggatgcccc atggaaagac ctacttcttc cgtggaaaca agtactaccg tttcaacgaa 1320  
 gagctcaggg cagtggatag cgagtacccc aagaacatca aagtctggga agggatccct 1380  
 50 gagtctccca gagggctcatt catgggcagc gatgaagtct tcaattactt ctacaagggg 1440  
 aacaaatact ggaatttcaa caacagaag ctgaaggtag aaccgggcta cccaagtca 1500  
 gccctgaggg actggatggg ctgcccacg ggaggccggc cggatgaggg gactgaggag 1560  
 gagacggagg tgatcatcat tgagggtggac gaggagggcg gcggggcggt gagcgcggct 1620  
 gccgtggtgc tgcccgtgct gctgctgctc ctggtgctgg cggtgggcct tgcagtcttc 1680  
 55 ttcttcagac gccatgggac ccccaggcga ctgctctact gccagcgctc cctgctggac 1740  
 aaggtctga 1749

60

&lt;210&gt; 104

&lt;211&gt; 2010

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<300>  
 <302> MMP15  
 <310> NM002428

5

<400> 104

atgggcagcg	acccgagcgc	gcccggacgg	ccgggctgga	cgggcagcct	cctcggcgac	60
cgggaggagg	cggcgcggcc	gcgactgctg	ccgtgctcc	tggtgcttct	gggctgcctg	120
ggccttgggc	tagcggccga	agacgcggag	gtccatgccg	agaactggct	gcggctttat	180
ggctacctgc	ctcagcccag	ccgccatatg	tccaccatgc	gttccgcca	gatcttggcc	240
tcggcccttg	cagagatgca	gcgcttctac	gggatcccag	tcaccgggtg	gctcgacgaa	300
gagaccaagg	agtggatgaa	gcggccccgc	tgtgggggtg	cagaccagtt	cggggtacga	360
gtgaaagcca	acctgcggcg	gcgtcggaag	cgctacgccc	tcaccgggag	gaagtggaa	420
aaccaccatc	tgacctttag	catccagaac	tacacggaga	agttgggctg	gtaccactcg	480
atggaggcgg	tgcgaggggc	cttccgcgtg	tgggagcagg	ccacgcccct	ggtcttccag	540
gaggtgccct	atgaggacat	ccggctgcgg	cgacagaagg	aggccgacat	catgggtact	600
tttgccctctg	gcttccacgg	cgacagctcg	ccgcttgatg	gcaccgggtg	ctttctggcc	660
cacgcctatt	tccctggccc	cggcctaggg	ggggacaccc	attttgacgc	agatgagccc	720
tggaccttct	ccagcactga	cctgcattga	aacaacctct	tcctgggtgg	agtgcattag	780
ctggggccac	cgctggggct	ggagcactcc	agcaacccca	atgccatcat	ggcgccgttc	840
taccagtggg	aggacgttga	caacttcaag	ctgcccagag	acgatctccg	tggcatccag	900
cagctctacg	gtaccccaaga	cggtcagcca	cagcctaccc	agcctctccc	cactgtgacg	960
ccacggcggc	caggccggcc	tgaccaccgg	ccgccccggc	ctccccagcc	accaccccca	1020
ggtgggaagc	cagagcggcc	cccaaagccg	ggccccccag	tccagccccg	agccacagag	1080
cgggcccgacc	agtatggccc	caacatctgc	gacggggact	ttgacacagt	ggccatgctt	1140
cgcgggggaga	tggttcgtgt	caaggggccg	tggttctggc	gagtcgggca	caaccgcgtc	1200
ctggacaact	atcccatgcc	catcgggcac	ttctggcggt	gtctgcccgg	tgacatcagt	1260
gctgcctacg	agcgccaaga	cggtcggttt	gtctttttca	aaggtagacc	ctactggctc	1320
tttcgagaag	cgaacctgga	gcccggctac	ccacagccgc	tgaccagcta	tggcctgggc	1380
atccccatg	accgcattga	cacggccatc	tggtgggagc	ccacaggcca	caccttcttc	1440
ttccaagagg	acaggctactg	gcgcttcaac	gaggagacac	agcgtggaga	ccttgggtac	1500
cccaagccca	tcagtgtctg	gcaggggatc	cctgcctccc	ctaaaggggc	cttctctgag	1560
aatgacgcag	cctacacctg	cttctacaag	ggcaccaa	actggaaatt	cgacaattag	1620
cgctgcgga	tggagcccg	ctaccccaag	tccatcctgc	gggacttcat	gggctgccag	1680
gagcacgtgg	agccaggccc	ccgatggccc	gacgtggccc	ggccgcctt	caacccccac	1740
gggggtgcag	agcccggggc	ggacagcgca	gagggcgacg	tgggggatgg	ggatggggag	1800
tttggggccg	gggtcaacaa	ggacgggggc	agccgcgtgg	tgggtgcagat	ggaggagggtg	1860
gcacggacgg	tgaacgtggt	gatggtgctg	gtgccactgc	tgctgctgct	ctgcgtcctg	1920
ggcctcacct	acgcgctggt	gcagatgcag	cgcaagggtg	cgccacgtgt	cctgctttac	1980
tgcaagcgct	cgctgcagga	gtgggtctga				2010

<210> 105  
 <211> 1824  
 <212> DNA  
 <213> Homo sapiens

45

<300>  
 <302> MMP16  
 <310> NM005941

50

<400> 105

atgatcttac	tcacattcag	cactggaaga	cggttggatt	tcgtgcatca	ttcgggggtg	60
tttttcttgc	aaaccttgc	ttggatttta	tgtgctacag	tctgcggaac	ggagcagtat	120
ttcaatgtgg	agggttgggt	acaaaagtac	ggctaccttc	caccgactga	ccccagaatg	180
tcagtgtcgc	gctctgcaga	gacctgcaga	ctgcccctag	ctgccatgca	gcagttctat	240
ggcattaaca	tgacaggaaa	agtggacaga	aacacaattg	actggatgaa	gaagcccca	300
tgcggtgtac	ctgaccagac	aagaggtagc	tccaaatttc	atattcgtcg	aaagcgatat	360
gcattgacag	gacagaaatg	gcagcacaa	cacatcactt	acagtataaa	gaacgtaact	420
ccaaaagtga	gagaccctga	gactcgtaaa	gctattcgcc	gtgcctttga	tgtgtggcag	480
aatgtaaactc	ctctgacatt	tgaagaagtt	ccctacagtg	aattagaaaa	tggcaaacgt	540
gatgtggata	taaccattat	ttttgcatct	ggtttccatg	gggacagctc	tccctttgat	600

5 ggagagggag gatttttggc acatgcctac ttccctggac caggaattgg aggagatacc 660  
 cattttgact cagatgagcc atggacacta ggaaatccta atcatgatgg aaatgactta 720  
 tttctttag cagtccatga actgggacat gctctgggat tggagcattc caatgacccc 780  
 actgccatca tggctccatt ttaccagtac atggaaacag acaacttcaa actacctaata 840  
 gatgatttac agggcatcca gaaaatataat ggtccacctg acaagattcc tccacctaca 900  
 agacctctac cgacagtgcc cccacaccgc tctattcctc cggctgacct aaggaaaaat 960  
 gacaggccaa aacctcctcg gctccaacc ggcagaccct cctatcccgg agccaaaccc 1020  
 aacatctgtg atgggaactt taacactcta gctattcttc gtcgtgagat gtttgttttc 1080  
 aaggaccagt ggttttggcg agtgagaaac aacagggtga tggatggata cccaatgcaa 1140  
 10 attacttact tctggcgggg cttgcctcct agtatcgatg cagtttatga aaatagcgac 1200  
 gggaattttg tgttctttaa aggtaacaaa tattgggtgt tcaaggatac aactcttcaa 1260  
 cctggttacc ctcagtactt gataaccctt ggaagtggaa ttccccctca tgggtattgat 1320  
 tcagccattt ggtgggagga cgtcgggaaa acctatttct tcaagggaga cagatattgg 1380  
 agatatagtg aagaaatgaa aacaatggac cctggctatc ccaagccaat cacagtctgg 1440  
 15 aaagggatcc ctgaatctcc tcaggggagca tttgtacaca aagaaaatgg ctttacgtat 1500  
 ttctacaaag gaaaggagta ttggaaattc aacaaccaga tactcaaggt agaacttga 1560  
 catccaagat ccactctcaa ggattttatg ggctgtgatg gaccaacaga cagagttaaa 1620  
 gaaggacaca gccaccaga tgatgtagac attgtcatca aactggacaa cacagccagc 1680  
 actgtgaaag ccatagctat tgtcattccc tgcattctgg ccttatgcct ccttgtattg 1740  
 20 gtttacactg tgttccagtt caagaggaaa ggaacacccc gccacatact gtactgtaaa 1800  
 cgctctatgc aagagtgggt gtga 1824

25 <210> 106  
 <211> 1560  
 <212> DNA  
 <213> Homo sapiens

30 <300>  
 <302> MMP17  
 <310> NM004141

35 <400> 106  
 atgcagcagt ttggtggcct ggaggccacc ggcattcctgg acgaggccac cctggccctg 60  
 atgaaaaacc cagctgctc cctgccagac ctccctgtcc tgaccaggc tcgcaggaga 120  
 cgccaggctc cagcccccac caagtggaaac aagaggaacc tgtcgtggag ggtccggagc 180  
 ttcccacggg actcaccact ggggcacgac acggtgcgtg cactcatgta ctacgccctc 240  
 aaggtctgga ggcacattgc gcccctgaac ttccacgagg tggcgggcag caccgccgac 300  
 atccagatcg acttctccaa ggccgaccat aacgacggct accccttcga cggccccggc 360  
 40 ggcaccgtgg cccacgcctt cttccccggc caccaccaca ccgccgggga caccacttt 420  
 gacgatgacg aggcctggac cttccgctcc tcggatgccc acgggatgga cctgtttgca 480  
 gtggctgtcc acgagtttgg ccacgccatt ggggtaagcc atgtggccgc tgcacactcc 540  
 atcatgcggc cgtactacca gggcccggtg ggtgaccgc tgcgctacgg gctcccctac 600  
 gaggacaagg tgcgctctg gcagctgtac ggtgtgcggg agtctgtgtc tcccacggcg 660  
 45 cagcccgagg agcctccctt gctgcggag cccccagaca accggtccag cggcccgccc 720  
 aggaaggacg tgccccacag atgcagcact cactttgacg cgggtggcca gatccggggt 780  
 gaagctttct tcttcaaagg caagtacttc tggcggctga cgcgggaccg gcacctggtg 840  
 tccctgcagc cggcacagat gcaccgcttc tggcggggcc tgccgctgca cctggacagc 900  
 gtggacgccc tgtacgagcg caccagcgac cacaagatcg tcttctttaa aggagacagg 960  
 50 tactgggtgt tcaaggacaa taacgtagag gaaggatacc cgcgccccgt ctccgacttc 1020  
 agcctcccgc ctggcggcat cgacgtgccc tctcctggg cccacaatga caggacttat 1080  
 ttctttaaagg accagtgtga ctggcgctac gatgaccaca cgaggcacat ggacccggc 1140  
 taccgccccc agagccccct gtggaggggt gtccccagca cgctggacga cgcctatgcg 1200  
 tggctccgac gtgcctccta cttcttccgt ggccaggagt actggaaagt gctggatggc 1260  
 55 gagctggagg tggcaccggg gtacccacag tccacggccc gggactggct ggtgtgtgga 1320  
 gactcacagg ccgatggatc tgtggctgag ggcgtggacg cggcagaggg gccccgcgc 1380  
 cctccaggac aacatgacca gagccgctcg gaggacggtt acgaggtctg ctcagtgcac 1440  
 tctggggcat cctctcccc gggggccccca ggccactgg tggctgccac catgctgctg 1500  
 60 ctgctgccc cactgtcacc aggcgcctg tggacagcgg cccaggccct gacgctatga 1560

<210> 107

<211> 1983  
<212> DNA  
<213> Homo sapiens

5 <300>  
<302> MMP2  
<310> NM004530

<400> 107

10 atggaggcgc taatggcccg gggcgcgctc acgggtcccc tgagggcgct ctgtctcctg 60  
ggctgcctgc tgagccacgc cgccgcccgc ccgtcgccca tcatcaagtt ccccgcgat 120  
gtcgccccca aaacggacaa agagttaggca gtgcaatacc tgaacacctt ctatggctgc 180  
cccaaggaga gctgcaacct gtttgtgctg aaggacacac taaagaagat gcagaagttc 240  
tttggaactgc ccagacagg tgatcttgac cagaatacca tcgagaccat gcggaagcca 300  
15 cgctgcggca acccagatgt ggccaactac aacttcttcc ctgcgaagcc caagtgggac 360  
aagaaccaga tcacatacag gatcattggc tacacacctg atctggacct agagacagtg 420  
gatgatgcct ttgctcgtgc cttccaagtc tggagcgatg tgacccact gcggttttct 480  
cgaatccatg atggagaggc agacatcatg atcaactttg gccgctggga gcatggcgat 540  
ggatacccct ttgacggtaa ggacggactc ctggctcatg ccttcgcccc aggcactggg 600  
20 gttggggggg actcccattt tgatgacgat gagctatgga ccttgggaga aggccaagtg 660  
gtccgtgtga agtatggcaa cgccgatggg gactactgca agttcccctt cttgttcaat 720  
ggcaaggagt acaacagctg cactgatact ggccgcagcg atggcttctt ctggtgctcc 780  
accacctaca actttgagaa ggatggcaag tacggcttct gtcccatga agccctgttc 840  
accatgggcg gcaacgctga aggacagccc tgcaagtttc cattccgctt ccagggcaca 900  
25 tcctatgaca gctgcaccac tgagggccgc accgatggct accgctggg cggcaccact 960  
gaggactacg accgcgacaa gaagtatggc ttctgccctg agaccgccat gtccactgtt 1020  
ggtgggaact cagaagggtgc cccctgtgtc tcccccttca ctttcttggg caacaaatat 1080  
gagagctgca ccagcgccgg ccgcagtgcac ggaaagatgt ggtgtgcgac cacagccaac 1140  
tacgatgacg accgcaagtg gggcttctgc cctgaccaag ggtacagcct gttcctcgtg 1200  
30 gcagcccacg agtttggcca cgccatgggg ctggagcact cccaagacct tggggccctg 1260  
atggcaccga ttacaccta caccaagaac ttocgtctgt ccaggatga catcaagggc 1320  
attcaggagc tctatggggc ctctcctgac attgaccttg gcaccggccc cccccaca 1380  
ctgggcccctg tcaactcctga gatctgcaaa caggacattg tatttgatgg catcgctcag 1440  
atccgtgggtg agatcttctt cttcaaggac cgggttcattt ggcggaactgt gacgccacgt 1500  
35 gacaagccca tggggcccct gctggtggcc acattctggc ctgagctccc ggaaaagatt 1560  
gatgcggtat acgaggcccc acaggaggag aaggctgtgt tctttgcagg gaatgaatac 1620  
tggtactact cagccagcac cctggagcga gggtagccca agccactgac cagcctggga 1680  
ctgccccctg atgtccagcg agtggatgcc gcctttaact ggagcaaaaa caagaagaca 1740  
tacatctttg ctggagacaa attctggaga tacaatgagg tgaagaagaa aatggatcct 1800  
40 ggctttccca agctcatcgc agatgcctgg aatgccatcc ccgataacct ggatgccgtc 1860  
gtggactcgc agggcggcgg tcacagctac ttcttcaagg gtgcctatta cctgaagctg 1920  
gagaacccaa gtctgaagag cgtgaagttt ggaagcatca aatccgactg gctaggctgc 1980  
tga 1983

45 <210> 108  
<211> 1434  
<212> DNA  
<213> Homo sapiens

50 <300>  
<302> MMP2  
<310> XM006271

55 <300>  
<302> MMP3  
<310> XM006271

<400> 108

60 atgaagagtc ttccaatcct actgttgctg tgcgtggcag tttgctcagc ctatccattg 60  
gatggagctg caaggggtga ggacaccagc atgaaccttg ttcagaaata tctagaaaac 120  
tactacgacc tcgaaaaaga tgtgaaacag tttgttagga gaaaggacag tggctcctgtt 180

gttaaaaaaa tccgagaaat gcagaagttc cttggattgg aggtgacggg gaagctggac 240  
tccgacactc tggaggtgat gcgcaagccc aggtgtggag ttcctgacgt tggtcacttc 300  
agaacctttc ctggcatccc gaagtggagg aaaaccacc ttacatacag gatttgtaat 360  
tatacaccag atttgccaaa agatgctgtt gattctgctg ttgagaaagc tctgaaagtc 420  
5 tgggaagagg tgactccact cacattctcc aggtgtgatg aaggagaggc tgatataatg 480  
atctcttttg cagttagaga acatggagac ttttaccctt ttgatggacc tggaaatgtt 540  
ttggcccatg cctatgcccc tgggccaggg attaatggag atgccactt tgatgatgat 600  
gaacaatgga caaaggatac aacagggacc aatttatttc tcgttgctgc tcatgaaatt 660  
ggccactccc tgggtctctt tcaactcagc aacactgaag ctttgatgta ccactctat 720  
10 cactcactca cagacctgac tcggttccgc ctgtctcaag atgatataaa tggcattcag 780  
tccctctatg gacctcccc tgactccct gagaccccc tggtagccac ggaacctgtc 840  
cctccagaac ctgggacgcc agccaactgt gatcctgctt tgcctttga tgctgtcagc 900  
actctgaggg gagaaatcct gatctttaa gacaggcact tttggcgcaa atccctcagg 960  
aagcttgaac ctgaattgca tttgatctct tcattttggc catctcttcc ttcaggcgtg 1020  
15 gatgccgcat atgaagttac tagcaaggac ctctgtttca tttttaagg aaatcaattc 1080  
tgggcatca gaggaatga ggtacgagct ggatacccaa gaggcatacca caccctaggt 1140  
ttccctccaa ccgtgaggaa aatcgatgca gccatttctg ataaggaaaa gaacaaaaca 1200  
tatttctttg tagaggacaa atactggaga tttgatgaga agagaaattc catggagcca 1260  
ggctttccca agcaaatagc tgaagacttt ccagggattg actcaaagat tgatgctgtt 1320  
20 tttgaagaat ttgggttctt ttatttcttt actggatctt cacagttgga gtttgacca 1380  
aatgcaaaga aagtgcaca cactttgaag agtaacagct ggcttaattg ttga 1434

<210> 109  
25 <211> 1404  
<212> DNA  
<213> Homo sapiens

<300>  
30 <302> MMP8  
<310> NM002424

<213> Homo sapiens

<300>

<302> PKC eta

5 <310> NM006255

<400> 114

```

atgtcgtctg gcaccatgaa gttcaatggc tatttgaggg tccgcatcgg tgaggcagtg 60
gggctgcagc ccacccgctg gtccctgcgc cactcgtctt tcaagaaggg ccaccagctg 120
10 ctggaccctt atctgacggg gagcgtggac caggtgcgcg tgggcccagac cagcaccaag 180
cagaagacca acaaaccac gtacaacgag gagttttgcg ctaacgtcac cgacggcggc 240
cacctcgagt tggccgtctt ccacgagacc cccctgggct acgacttcgt ggccaactgc 300
accctgcagt tccaggagct cgtcggcacg accggcgcct cggacacctt cgagggttg 360
gtggatctcg agccagaggg gaaagtattt gtggtaataa ccctaccgg gagtttctact 420
15 gaagctactc tccagagaga cggatcttcc aaacatttta ccaggaagcg ccaaagggtt 480
atgcgaaggc gaggccacca gatcaatgga cacaagttca tggccacgta tctgaggcag 540
cccacctact gctctcactg cagggagttt atctggggag tggttgaggaa acaggggttat 600
cagtgccaag tgtgcacctg tgtcgtccat aaacgctgcc atcatctaata tgttacagcc 660
tgtacttgcc aaaacaatat taacaaagtg gattcaaaga ttgcagaaca gaggttcggg 720
20 atcaacatcc cacacaagtt cagcatccac aactacaaag tgccaacatt ctgcgatcac 780
tgtggctcac tgcctctggg aataatgcga caaggacttc agtgtaaaat atgtaaaatg 840
aatgtgcata ttcgatgtca agcgaacgtg gccctaact gtggggtaaa tgcgggtgaa 900
cttgccaaga ccctggcagg gatgggtctc caaccgggaa atatttctcc aacctcgaaa 960
ctcgtttcca gatcgaccct aagacgacag ggaaaggaga gcagcaaaga aggaaatggg 1020
25 attgggggta attcttccaa ccgacttggt atcgacaact ttgagttcat ccgagtgttg 1080
gggaagggga gttttgggaa ggtgatgctt gcaagagtaa aagaaacagg agacctctat 1140
gctgtgaagg tgctgaagaa ggacgtgatt ctgctggatg atgatgtgga atgcaccatg 1200
accgagaaaa ggatcctgtc tctggcccgcc aatcaccctt tcctcactca gttgttctgc 1260
tgctttcaga ccccgatcg tctgtttttt gtgatggagt ttgtgaatgg ggggtgacttg 1320
30 atgttccaca ttcagaagtc tgcgtctttt gatgaagcac gagctcgctt ctatgctgca 1380
gaaatcattt cggctctcat gttcctccat gataaaggaa tcactctatag agatctgaaa 1440
ctggacaatg tctgtttgga ccacgagggt cactgtaaac tggcagactt cggaatgtgc 1500
aaggagggga tttgcaatgg tgtcaccacg gccacattct gtggcacgcc agactatata 1560
gctccagaga tcctccagga aatgctgtac gggcctgcag tagactgggt ggcaatgggc 1620
35 gtgttgctct atgagatgct ctgtggtcac gcgccttttg aggcagagaa tgaagatgac 1680
ctctttgagg ccatactgaa tgatgaggtg gtctacccta cctggctcca tgaagatgcc 1740
acagggatcc taaaatcttt catgaccaag aaccccacca tgcgcttggg cagcctgact 1800
cagggaggcg agcacgccat cttgagacat ccttttttta aggaaatcga ctgggcccag 1860
ctgaaccatc gccaaataga accgcctttc agaccagaa tcaaataccc agaagatgtc 1920
40 agtaattttg accctgactt cataaaggaa gagccagttt taactccaat tgatgaggga 1980
catcttccaa tgattaacca ggatgagttt agaaactttt cctatgtgtc tccagaattg 2040
caaccatag 2049

```

45 <210> 115

<211> 948

<212> DNA

<213> Homo sapiens

50 <300>

<302> PKC epsilon

<310> XM002370

<400> 115

```

atgttgagcag aactcaaggg caaagatgaa gtatatgctg tgaagggtctt aaagaaggac 60
gtcatccttc aggatgatga cgtggactgc acaatgacag agaagaggat tttggctctg 120
55 gcacggaaac accgtacct taccacactc tactgctgct tccagaccaa ggaccgcctc 180
tttttcgtca tggaaatagt aaatgggtgga gacctcatgt ttcagattca gcgctcccga 240
aaattcgacg agcctcgctt acgggttctat gctgcagagg tcacatcggc cctcatgttc 300
60 ctccaccagc atggagtcac ctacagggat ttgaaactgg acaacatcct tctggatgca 360
gaaggtcact gcaagctggc tgacttcggg atgtgcaagg aagggtattct gaatgggtgtg 420
acgaccacca cgttctgtgg gactcctgac tacatatgctc ctgagatcct gcaggagttg 480

```

5	gagtatggcc ggacagcctc gacgtgctgt acgaagaatc aagcagcacc ccacccttca acccgggaag gaggaattca	ccttcctgga cctttgaggc acccagctctg cccacaagcg cattcttcaa aaccacgcat agccggtact aaggtttctc	ctgggtggcc cgacaatgag gctcagcaag cctgggctgt agagattgac taaaaccaaa cacccttgtg ctactttggt	ctgggggtgc gacgacctat gaggtctgtca gtggcatcgc tgggtgtccg agagacgtca gacgaagcaa gaagacctga	tgtatgtacga ttgagtccat gcatcttgaa agaatggcga tggagcagaa ataattttga ttgtaaagca tgccctga	gatgatggct cctccatgac agctttcatg ggacgccatc gaagatcaag ccaagacttt gatcaaccag	540 600 660 720 780 840 900 948
10	<210> 116 <211> 1764 <212> DNA <213> Homo sapiens						
15	<300> <302> PKC iota <310> NM002740						
20	<400> 116 atgtcccaca gcctactacc ctttgcaatg tggatagatg tttagacttt ccagaacgtc cgccgctgga aggcgtgctc aagtgcacat tgtgggcggc tctgaccatg gttggtgaag ggtcttcagg ttggttcgat gttaatgatg tccaatcatc tttgttatag cttcctgaag catgagcgag ggccacatta accagcactt tatggtttca aggctctcat ctcttccaag gcaagtgttc caaacaggat atggagcaaa gacaactttg attgtgagga atgtctgcag	cggtcgcagg gcggggatat agggttcgaga aggaaggaga atgagctaaa ctgggatgcc gaaagcttta actgtgccat actgcaaact attctttgcc cacagacagt aaaaagaggg attttgattt taaaaaaac atgaggatat ctttccttgt agtatgtaaa tctcctgaag ggataattta aactcactga tctgtggtac gtgttgactg ttgatattgt ttattttggg tgaagagttt ttgctgatat aacagctggt attctcagtt agattgatca aagaatgtgt	cggcggcagc catgataaca catgtgttct cccgtgtaca caaggattct ttgtccagga ttgtgccaat ctgcacagac cttggttcat acaggaacca aattccatat aatgaacacc gctccgggta agatcgtatt tgattgggta tggtgctcat tgaggagagc attttactct tagagatttg ctacggcatg tcctaattac gtgggtctct tgggagctcc aaaacaaatt tcttaataag tcaggggacac acctccttt tactaatgaa gtctgaattt ctga	ggggaccatt cattttgaac tttgacaacg gtatcatctc gaactcttga gaagataaat ggccacactt cgaatatggg aagaagtgcc gtgatgccca aggaaagtgt ataggaagag tatgcaatga cagacagaga tcttgctttc ctaattgttc gcagaaatca aaactggaca tgtaagggaag attgctcctg ggagtgtctt gataaccctg cgcataccac gacctaaagg ccgttcttcc aaaccaataa cctgtccagc gaaggttttg	cccaccaggt cttccatctc agttggagtt ttcatgtgtt ccatctaccg tccaagccaa gacttggacg ataaactcgt tggatcagtc gtcatgagag gcaaagcttc gaagtatatg aagtttgtga agcatgtgtt agacagaaag atatgcagcg gtctagcatt atgtattact gattacggcc aaattttaag tgtttgagat accagaacac gttctctgtc aacgattggg gaaatgttga tttctgggga tcactccaga agtatatcaa	ccgggtgaaa ctttgagggc caccatgaaa agaagaagcc cccttgtgta tagaggtgca gcgtttcaac ccaaggatat cacaattgaa atccatgcat tttggatcaa atccagtcta caaagtactg aaaagagctt tgagcaggca cagattgttc acaaagaaaa aaattatctt ggactctgaa aggagatata aggagaagat gatggcagga agaggattat tgtaaaaagct ttgtcatcct ttgggatatg atttggtttg tgacgatgac tcctcttttg	60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1680 1740 1764
55	<210> 117 <211> 2451 <212> DNA <213> Homo sapiens						
60	<300> <302> PKC mu <310> XM007234  <400> 117						



	atgtatgata	agatcctgct	ttttcgccat	gacctacct	ctgaaaacat	ccttcagctg	60
	gtgaaagcgg	ccagtgatat	ccaggaaggc	gatcttattg	aagtgggtctt	gtcagcttcc	120
	gccacctttg	aagactttca	gattcgtccc	cacgctctct	ttgttcattc	atacagagct	180
	ccagctttct	gtgatcactg	tggagaaatg	ctgtgggggc	tggtagctca	aggtctttaa	240
5	tgtaaggggt	gtggtctgaa	ttaccataag	agatgtgcat	ttaaaatacc	caacaattgc	300
	agcgggtgtga	ggcggagaag	gctctcaaac	gtttccctca	ctggggtcag	caccatccgc	360
	acatcatctg	ctgaactctc	tacaagtgcc	cctgatgagc	cccttctgca	aaaatcacca	420
	tcagagtctg	ttattggctg	agagaagagg	tcaaattctc	aatcatacat	tggacgacca	480
	attcaccttg	acaagattht	gatgtctaaa	gttaaagtgc	cgcacacatt	tgtcatccac	540
10	tcctacaccc	ggccacacgt	gtgccagtac	tgcaagaagc	ttctgaaggg	gcttttcagg	600
	cagggcttgc	agtgcacaaga	ttgcagattc	aactgccata	aacgttgtgc	accgaaagta	660
	ccaaaacaact	gccttggcga	agtgaaccatt	aatggagatt	tgcttagccc	tggggcagag	720
	tctgatgtgg	tcatggaaga	agggagtgat	gacaatgata	gtgaaaggaa	cagtgggctc	780
	atggatgata	tggagaagac	aatggtccaa	gatgcagaga	tggcaatggc	agagtgcag	840
15	aacgacagtg	gcgagatgca	agatccagac	ccagaccacg	aggacgcca	cagaaccatc	900
	agtcacatcaa	caagcaacaa	tatcccactc	atgagggtag	tgcatgtctg	caaacacacg	960
	aagaggaaaa	gcagcacagt	catgaaagaa	ggatggatgg	tccactacac	cagcaaggac	1020
	acgctgcgga	aacggcacta	ttggagattg	gatagcaaat	gtattaccct	ctttcagaat	1080
	gacacaggaa	gcagggtacta	caaggaaatt	cctttatctg	aaatthttgtc	tctggaacca	1140
20	gtaaaaactt	cagctthtaat	tcctaattggg	gccaatcctc	attgtttcga	aatcactacg	1200
	gcaaatgtag	tgtattatgt	gggagaaaat	gtggtcaatc	cttcagccc	atcaccaaat	1260
	aacagtgttc	tcaccagtgg	cgttgggtgca	gatgtggcca	ggatgtggga	gatagccatc	1320
	cagcatgccc	ttatgcccg	cattcccaag	ggctcctcgc	tgggtacagg	aaccaacttg	1380
	cacagagata	tctctgtgag	tatttcagta	tcaaattgcc	agattcaaga	aaatgtggac	1440
25	atcagcacag	tatatcagat	ttttcctgat	gaagtactgg	gttctggaca	gtttggaatt	1500
	gtttatggag	taaaacatcg	taaaacagga	agagatgtag	ctattaaaat	cattgacaaa	1560
	ttacgatttc	caacaaaaca	agaaagccag	cttcgtaatg	aggttgcaat	tctacagaac	1620
	cttcacaccc	ctggtgttgt	aaatthggag	tgtatgtttg	agacgcctga	aagagtgttt	1680
	gtttgttatg	aaaaactcca	tggagacatg	ctggaaatga	tcttgtcaag	tgaaaagggc	1740
30	aggttgccag	agcacataac	gaagtthtta	attactcaga	tactcgtggc	tttgcggcac	1800
	cttcattthta	aaaatatcgt	tcactgtgac	ctcaaaccag	aaaatgtgtt	gctagcctca	1860
	gctgatcctt	ttcctcaggt	gaaactthgt	gattthgggt	ttgcccggt	cattggagag	1920
	aagtctthtc	ggaggtcagt	ggtgggtacc	cccgttacc	tggctcctga	ggtcctaagg	1980
	aacaagggct	acaatcgctc	tctagacatg	tggctctgtt	gggtcatcat	ctatgtaagc	2040
35	ctaagcggca	cattcccatt	taatgaagat	gaagacatac	acgaccaa	tcagaatgca	2100
	gctthcatgt	atccaccaa	tccttggaag	gaaatatctc	atgaagccat	tgatcttata	2160
	aacaatthtc	tgcaagtaaa	aatgagaaag	cgctacagt	tggataagac	cttgagccac	2220
	ccttggtctac	aggactatca	gacctgggtta	gattthcgag	agctggaatg	caaaatcggg	2280
	gagcgctaca	tcacccatga	aagtgatgac	ctgaggtggg	agaagtatgc	aggcagagcag	2340
40	gggctgcagt	acccacacac	cctgatcaat	ccaagtgtca	gccacagtga	cactcctgag	2400
	actgaagaaa	cagaaatgaa	agccctcggt	gagcgtgtca	gcacccatg	a	2451
	<210> 118						
45	<211> 2673						
	<212> DNA						
	<213> Homo sapiens						
	<300>						
50	<302> PKC nu						
	<310> NM005813						
	<400> 118						
	atgtctgcaa	ataattcccc	tccatcagcc	cagaagtctg	tattaccac	agctattcct	60
55	gctgtgcttc	cagctgcttc	tccgtgttca	agtcctaaga	cgggactctc	tgcccagctc	120
	tctaattgaa	gcttcagtgc	accatcactc	accaactcca	gaggctcagt	gcatacagtt	180
	tcattttctac	tgcaaatthg	cctcacacgg	gagagtgtta	ccattgaagc	ccaggaactg	240
	tctttatctg	ctgtcaagga	tcttgtgtgc	tccatagttt	atcaaaagt	tccagagtgt	300
	ggattcttht	gcatgtatga	caaaattctt	ctctthcgcc	atgacatgaa	ctcagaaaa	360
60	atthttgcagc	tgattacctc	agcagatgaa	atacatgaag	gagacctagt	ggaagtgggt	420
	ctthtcagctt	tagccacagt	agaagacttc	cagattcgtc	cacatactct	ctatgtacat	480
	tctttacaaag	ctcctacttt	ctgtgattac	tgtgggtgaga	tgctgtgggg	attgggtacgt	540

	caaggactga	aatgtgaagg	ctgtggatta	aattaccata	aacgatgtgc	cttcaagatt	600
	ccaaataact	gtagtggagt	aagaaagaga	cgtctgtcaa	atgtatcttt	accaggaccc	660
	ggcctctcag	ttccaagacc	cctacagcct	gaatatgtag	cccttcccag	tgaagagtca	720
	catgtccacc	aggaaccaag	taagagaatt	ccttcttgga	gtggtcgccc	aatctggatg	780
5	gaaaagatgg	taatgtgcag	agtgaagtt	ccacacacat	ttgctgttca	ctcttacacc	840
	cgtcccacga	tatgtcagta	ctgcaagcgg	ttactgaaag	gcctctttcg	ccaagggaatg	900
	cagtgtaaag	attgcaaatt	caactgccat	aaacgctgtg	catcaaaagt	accaagagac	960
	tgccttggag	aggttacttt	caatggagaa	ccttccagtc	tgggaacaga	tacagatata	1020
	ccaatggata	ttgacaataa	tgacataaat	agtgatagta	gtcgggggtt	ggatgacaca	1080
10	gaagagccat	caccccaga	agataagatg	ttcttcttgg	atccatctga	tctcgatgtg	1140
	gaaagagatg	aagaagccgt	taaaacaatc	agcccatcaa	caagcaataa	tattccgcta	1200
	atgagggttg	tacaatccat	caagcacaca	aagaggaaga	gcagcacaat	ggtgaaggaa	1260
	gggtggatgg	tccattacac	cagcagggat	aacctgagaa	agaggcatta	ttggagactt	1320
	gacagcaaat	gtctaacatt	atttcagaat	gaatctggat	caaagtatta	taaggaaatt	1380
15	ccactttcag	aaattctccg	catatcttca	ccacgagatt	tcacaaacat	ttcacaaggc	1440
	agcaatccac	actgttttga	aatcattact	gatactatgg	tatacttcgt	tggtgagaac	1500
	aatggggaca	gctctcataa	tcctgttctt	gctgccactg	gagttggact	tgatgtagca	1560
	cagagctggg	aaaaagcaat	tcgccaagcc	ctcatgcctg	ttactcctca	agcaagtgtt	1620
	tgcactttctc	cagggcaagg	gaaagatcac	aaagatttgt	ctacaagtat	ctctgtatct	1680
20	aattgtcaga	ttcaggagaa	tgtggatata	agtactgttt	accagatctt	tgcagatgag	1740
	gtgcttgggt	caggccagtt	tggcatcggt	tatggaggaa	aacatagaaa	gactgggagg	1800
	gatgtggcta	ttaaagtaat	tgataagatg	agattcccca	caaaacaaga	aagtcaactc	1860
	cgtaatgaag	tggctatttt	acagaatttg	caccatcctg	ggattgtaaa	cctggaatgt	1920
	atgtttgaaa	ccccagaacg	agtcttttga	gtaatggaaa	agctgcatgg	agatatgttg	1980
25	gaaatgattc	tatccagtga	gaaaagtcgg	cttccagAAC	gaattactaa	attcatggtc	2040
	acacagatac	ttgttgcttt	gaggaaatctg	cattttaaga	atattgtgca	ctgtgattta	2100
	aagccagaaa	atgtgctgct	tgcatacagca	gagccatttc	ctcaggtgaa	gctgtgtgac	2160
	tttggatttg	cacgcatcat	tggtgaaaag	tcattcagga	gatctgtggg	aggaactcca	2220
	gcatacttag	ccccgaagt	tctccggagc	aaaggttaca	accgttccct	agatatgtgg	2280
30	tcagtgggag	ttatcatcta	tgtgagcctc	agtggcacat	ttccttttaa	tgaggatgaa	2340
	gatataaatg	accaaatcca	aaatgctgca	tttatgtacc	caccaaatcc	atggagagaa	2400
	atttctgggtg	aagcaattga	tctgataaac	aatctgcttc	aagtgaagat	gagaaaacgt	2460
	tacagtgttg	acaaatctct	tagtcatccc	tggctacagg	actatcagac	ttggcttgac	2520
	cttagagaaat	ttgaaactcg	cattggagaa	cgttacatta	cacatgaaag	tgatgatgct	2580
35	cgctgggaaa	tacatgcata	cacacataac	cttgataacc	caaagcactt	cattatggct	2640
	cctaataccag	atgatattgga	agaagatcct	taa			2673
	<210> 119						
40	<211> 2121						
	<212> DNA						
	<213> Homo sapiens						
	<300>						
45	<302> PKC tau						
	<310> NM006257						
	<400> 119						
	atgtcgccat	ttcttccgat	tggcttgtcc	aactttgact	gcgggtcctg	ccagtcttgt	60
50	cagggcgagg	ctgttaaccc	ttactgtgct	gtgctcgtca	aagagtatgt	cgaatcagag	120
	aacggggcaga	tgtatatcca	gaaaagcct	accatgtacc	caccctggga	cagcactttt	180
	gatgcccata	tcaacaaggg	aagagtcattg	cagatcattg	tgaaggcaa	aaacgtggac	240
	ctcatctctg	aaaccaccgt	ggagctctac	tcgctggctg	agaggtgcag	gaagaacaac	300
	gggaagacag	aaatatgggt	agagctgaaa	cctcaaggcc	gaatgctaata	gaatgcaaga	360
55	tactttcttg	aaatgagtga	cacaaaggac	atgaatgaat	ttgagacgga	aggcttcttt	420
	gctttgcatc	agcgccgggg	tgccatcaag	caggcaaaag	tccaccacgt	caagtgccac	480
	gagttcactg	ccaccttctt	cccacagccc	acattttgct	ctgtctgcca	cgagtttgtc	540
	tggggcctga	acaaacaggg	ctaccagtgc	cgacaatgca	atgcagcaat	tcacaagaag	600
	tgtattgata	aagttatagc	aaagtgcaca	ggatcagcta	tcaatagccg	agaaacctag	660
60	ttccacaagg	agagattcaa	aattgacatc	ccacacagat	ttaaagtcta	caattacaag	720
	agcccgacct	tctgtgaaca	ctgtgggacc	ctcgtgtggg	gactggcacg	gcaaggactc	780
	aagtgtgatg	catgtggcat	gaatgtgcat	catagatgcc	agacaaaggt	ggccaacctt	840

```

      tgtggcataa accagaagct aatggctgaa gcgctggcca tgattgagag cactcaacag 900
      gctcgctgct taagagatac tgaacagatc ttcagagaag gtccggttga aattggtctc 960
      ccatgctcca tcaaaaatga agcaaggccg ccatgtttac cgacaccggg aaaaagagag 1020
      cctcagggca tttcctggga gtctccgttg gatgaggtgg ataaaaatgtg ccatcttcca 1080
5     gaacctgaac tgaacaaaga aagaccatct ctgcagatta aactaaaaat tgaggatttt 1140
      atcttgcaaca aaatgttggg gaaaggaagt tttggcaagg tcttcctggc agaattcaag 1200
      aaaaccaatc aatttttcgc aataaaggcc ttaaagaaaag atgtggtcct gatggacgat 1260
      gatgttgagt gcacgatggg agagaagaga gttctttcct tggcctggga gcatccgttt 1320
      ctgacgcaca tgttttgtac attccagacc aaggaaaacc tcttttttgt gatggagtac 1380
10    ctcaacggag gggacttaat gtaccacatc caaagctgcc acaagttcga cctttccaga 1440
      gcgacgtttt atgctgctga aatcattctt ggtctgcagt tccttcattc caaaggaata 1500
      gtctacaggg acctgaagct agataacatc ctgttagaca aagatggaca tatcaagatc 1560
      gcggattttt gaatgtgcaa ggagaacatg ttaggagatg ccaagacgaa taccttctgt 1620
      gggacacctg actacatcgc cccagagatc ttgctgggtc agaaatacaa ccactctgtg 1680
15    gactggtggt ccttcggggg tctcctttat gaaatgctga ttggtcagtc gcctttccac 1740
      gggcaggatg aggaggagct cttccactcc atccgcattg acaatccctt ttaccacagg 1800
      tggctggaga aggaagcaaa ggaccttctg gtgaagctct tcgtgcgaga acctgagaag 1860
      aggctgggcg tgagggggaga catccgccag caccctttgt ttcgggagat caactgggag 1920
      gaacttgaac ggaaggagat tgaccacccg ttccggccga aagtgaatc accatttgac 1980
20    tgcagcaatt tcgacaaaga attcttaaac gagaagcccc ggctgtcatt tgccgacaga 2040
      gcactgatca acagcatgga ccagaatatg ttcaggaact ttccttcat gaaccccg 2100
      atggagcggc tgatatcctg a                                     2121

25    <210> 120
      <211> 1779
      <212> DNA
      <213> Homo sapiens

30    <300>
      <302> PKC zeta
      <310> NM2744

```

atggaccggg agatggcagc atcgtgcgga ggcgcgggtt tcgtaggtct gatactcttg 60  
 accttgtcac cgcactataa gctgttcctc gctaggctca tatggtggtt acaatatattt 120  
 atcaccaggg ccgaggcaca cttgcaagtg tggatcccc ccctcaacgt tcggggggggc 180  
 cgcgatgccg tcatcctcct cactgcgcg atccaccag agctaattctt taccatcacc 240  
 5 aaaatcttgc tcgccatact cggtcactc atggtgctcc aggctggtat aaccaaagtg 300  
 ccgtacttcg tgcgcgcaca cgggctcatt cgtgcatgca tgctggtgcg gaagggtgct 360  
 ggggggtcatt atgtccaaat ggctctcatg aagttggccg cactgacagg tacgtacgtt 420  
 tatgaccatc tcacccact gcgggactgg gccacgcgg gcctacgaga ccttgccgtg 480  
 gcagttgagc ccgtcgtctt ctctgatatg gagaccaagg ttatcacctg gggggcagac 540  
 10 accgcggcgt gtggggacat catcttgggc ctgcccgctt ccgccgcag ggggagggag 600  
 atacatctgg gaccggcaga cagccttgaa gggcaggggt ggcgactcct c 651

<210> 129  
 15 <211> 161  
 <212> DNA  
 <213> Hepatitis C virus

<300>  
 20 <302> NS4A  
 <310> AJ238799

<400> 129  
 25 gcacctgggt gctggtaggc ggagtcctag cagctctggc cgcgatttgc ctgacaacag 60  
 gcagcgtggg cattgtgggc aggatcatct tgtccggaaa gccggccatc attcccagaca 120  
 gggaaagtctt ttaccgggag ttcgatgaga tggaagagtg c 161

<210> 130  
 30 <211> 783  
 <212> DNA  
 <213> Hepatitis C virus

<300>  
 35 <302> NS4B  
 <310> AJ238799

<400> 130  
 40 gcctcacacc tcccttacat cgaacaggga atgcagctcg ccgaacaatt caaacagaag 60  
 gcaatcgggt tgctgcaaac agccaccaag caagcggagg ctgctgctcc cgtgggtggaa 120  
 tccaagtggc ggaccctcga agccttctgg gcgaagcata tgtggaattt catcagcggg 180  
 atacaatatt tagcaggctt gtccactctg cctggcaacc ccgcgatagc atcactgatg 240  
 gcattcacag cctctatcac cagcccgtc accaccaac ataccctcct gtttaacatc 300  
 ctggggggat ggggtggccg ccaacttgct cctcccagcg ctgcttctgc tttcgtaggc 360  
 45 gccggcatcg ctggagcggc tgttggcagc ataggccttg ggaaggtgct tgtggatatt 420  
 ttggcagggt atggagcagg ggtggcaggc gcgctcgtgg cctttaaggt catgagcggc 480  
 gagatgccct ccaccgagga cctggttaac ctactccctg ctatcctctc ccctggcgcc 540  
 ctagtctcgt gggctcgtgtg cgcagcgata ctgcgtcggc acgtgggccc aggggagggg 600  
 gctgtgcagt ggatgaaccg gctgatagcg ttcgcttcgc ggggtaacca cgtctcccc 660  
 50 acgcactatg tgccctgagag cgacgtgca gcacgtgtca ctcatgctt ctctagtctt 720  
 accatcactc agctgctgaa gaggcttcac cagtggatca acgaggactg ctccacgcca 780  
 tgc 783

<210> 131  
 55 <211> 1341  
 <212> DNA  
 <213> Hepatitis C virus

<300>  
 60 <302> NS5A  
 <310> AJ238799

<400> 131  
 tccggctcgt ggctaagaga tgtttgggat tggatatgca cgggtgttgac tgatttcaag 60  
 acctggctcc agtccaagct cctgccgcga ttgccgggag tcccccttctt ctcatgtcaa 120  
 5 cgtgggtaca agggagctctg gcggggcgac ggcacatgc aaaccacctg cccatgtgga 180  
 gcacagatca ccggacatgt gaaaaacggg tccatgagga tcgtggggcc taggacctgt 240  
 agtaacacgt ggcatggaac attccccatt aacgcgtaca ccacggggccc ctgcacgccc 300  
 tccccggcgc caaattattc tagggcgctg tggcgggtgg ctgctgagga gtacgtggag 360  
 gttacgcggg tgggggattt ccactacgtg acgggcatga ccactgacaa cgtaaagtgc 420  
 10 ccgtgtcagg ttccggcccc cgaattcttc acagaagtgg atgggggtgcg gttgcacagg 480  
 tacgtcccag cgtgcaaacc cctcctacgg gaggaggtca cattcctggt cgggctcaat 540  
 caatacctgg ttgggtcaca gctcccatgc gagcccgaac cggacgtagc agtgctcact 600  
 tccatgctca ccgacccctc ccacattacg gcggagacgg ctaagcgtag gctggccagg 660  
 ggatctcccc cctccttggc cagctcatca gctagccagc tgtctgcgcc ttccctgaag 720  
 15 gcaacatgca ctaccgctca tgactccccg gacgctgacc tcatcgaggc caacctcctg 780  
 tggcggcagg agatgggcgg gaacatcacc cgcgtggagt cagaaaataa ggtagtaatt 840  
 ttggactctt tcgagccgct ccaagcggag gaggatgaga gggaagtatc cgttccggcg 900  
 gagatcctgc ggaggtccag gaaattccct cgagcgatgc ccatatgggc acgcccggat 960  
 tacaaccctc cactgttaga gtccctggaag gacccggact acgtccctcc agtggtacac 1020  
 20 ggggtgtccat tgccgcctgc caaggccccct ccgataccac ctccacggag gaagaggacg 1080  
 gttgtcctgt cagaatctac cgtgtcttct gccttggcgg agctcgccac aaagaccttc 1140  
 ggcagctccg aatcgtcggc cgtcgacagc ggcacggcaa cggcctctcc tgaccagccc 1200  
 tccgacgacg gcgacgcggg atccgacggt gagtcgtact cctccatgcc ccccccttag 1260  
 25 ggggagccgg gggatcccga tctcagcgac ggggtcttgg ctaccgtaag cgaggaggct 1320  
 agtgaggacg tcgtctgctg c 1341

<210> 132  
 <211> 1772  
 30 <212> DNA  
 <213> Hepatitis C virus

<300>  
 <302> NS5B  
 35 <310> AJ238799

<400> 132  
 tcgatgtcct acacatggac aggcgcctctg atcacgccat gcgctgcgga ggaaaccaag 60  
 ctgcccacatca atgcactgag caactctttg ctccgtcacc acaacttgggt ctatgtctaca 120  
 40 acatctcgcga gcgcaagcct gcggcagaag aaggtcacct ttgacagact gcaggctcctg 180  
 gacgacctact accgggacgt gctcaaggag atgaaggcga aggcgtccac agttaaggct 240  
 aaacttctat ccgtggagga agcctgtaag ctgacgcccc cacattcggc cagatctaaa 300  
 tttggctatg gggcaaagga cgtccggaac ctatccagca aggcggttaa ccacatccgc 360  
 tccgtgtgga aggacttgct ggaagacact gagacaccaa ttgacaccac catcatggca 420  
 45 aaaaatgagg ttttctgcgt ccaaccagag aagggggggc gcaagccagc tcgccttatc 480  
 gtattcccag atttgggggt tcgtgtgtgc gagaaaatgg ccctttacga tgtggctctc 540  
 accctccctc aggcctgat gggctcttca tacggattcc aatactctcc tggacagcgg 600  
 gtcgagttcc tgggtgaatgc ctggaaagcg aagaaatgcc ctatgggctt cgcatatgac 660  
 acccgctgtt ttgactcaac ggtcactgag aatgacatcc gtgttgagga gtcaatctac 720  
 50 caatgtttgtg acttggcccc cgaagccaga caggccataa ggtcgctcac agagcggctt 780  
 tacatcgggg gccccctgac taattctaaa gggcagaact gcggctatcg ccggtgcgcg 840  
 gcgagcgggtg tactgacgac cagctgcggt aataccctca catgttactt gaaggccgct 900  
 gcggcctgtc gagctgcgaa gctccaggac tgcacgatgc tcgtatgcgg agacgacctt 960  
 gtcgttatct gtgaaagcgc ggggacccaa gaggacgagg cgagcctacg ggccttcacg 1020  
 55 gaggctatga ctagatactc tgccccccct ggggacccgc ccaaaccaga atacgacttg 1080  
 gagttgataa catcatgctc ctccaatgtg tcagtgcgc acgatgcac tggcaaaagg 1140  
 gtgtactatc tcaccctga cccaccacc ccccttgcgc gggctgcgtg ggagacagct 1200  
 agacacactc cagtcaattc ctggctaggc aacatcatca tgtatgcgcc caccttgtgg 1260  
 gcaaggatga tcctgatgac tcatttcttc tccatccttc tagctcagga acaacttgaa 1320  
 60 aaagccctag attgtcagat ctacggggcc tgttactcca ttgagccact tgacctacct 1380  
 cagatcattc aacgactcca tggccttagc gcattttcac tccatagtta ctctccaggt 1440  
 gagatcaata ggggtggcttc atgcctcagg aaacttgggg taccgcctt gcgagctcgg 1500

agacatcggg ccagaagtgt ccgcgctagg ctactgtccc aggggggggag ggctgccact 1560  
 tgtggcaagt acctcttcaa ctgggcagta aggaccaagc tcaaactcac tccaatcccc 1620  
 gctgcgtccc agttggattt atccagctgg ttctgttctg gttacagcgg gggagacata 1680  
 tatcacagcc tgtctcgtgc ccgacccccgc tggttcatgt ggtgcctact cctactttct 1740  
 5 gtaggggtag gcatctatct actccccaac cg 1772

<210> 133  
 <211> 1892  
 10 <212> DNA  
 <213> Hepatitis C virus

<300>  
 <302> NS3  
 15 <310> AJ238799

<400> 133  
 cgcctattac ggccactacc caacagacgc gaggcctact tggttgcatt atcactagcc 60  
 tcacaggccg ggacaggaac caggctcgagg gggagggtcca agtggtctcc accgcaacac 120  
 20 aatcttttct ggcgacctgc gtcaatggcg tgtgttggac tgtctatcat ggtgccggct 180  
 caaagaccct tgccggccca aaggggccaa tcacccaaat gtacaccaat gtggaccagg 240  
 acctcgtcgg ctggcaagcg cccccgggg cgcttcctt gacaccatgc acctgccgca 300  
 gctcggacct ttacttggtc acgaggcatg ccgatgtcat tccggtgcgc cggcggggcg 360  
 acagcagggg gagcctactc tccccaggc ccgtctccta cttgaagggc tcttcggggc 420  
 25 gtccactgct ctgcccctcg gggcacgctg tgggcatctt tccgggtgcc gtgtgcaccc 480  
 gaggggttgc gaaggcgggt gactttgtac ccgtcgagtc tatggaaacc actatgcggg 540  
 ccccggtctt caccgacaac tcgtcccctc cggccgtacc gcagacattc cagggtggcc 600  
 atctacacgc ccctactggg agcggcaaga gcactaagggt gccgggtgcg tatgcagccc 660  
 aagggtataa ggtgcttgtc ctgaacccgt ccgtcgccgc caccctagggt ttccggggcg 720  
 30 atatgtctaa ggcacatggt atcgacccta acatcagaac cggggttaagg accatcacca 780  
 cgggtgcccc catcacgtac tccacctatg gcaagtttct tgccgacggg ggttgcctct 840  
 ggggcgccta tgacatcata atatgtgatg agtgccactc aactgactcg accactatcc 900  
 tgggcatcgg cacagtcctg gaccaagcgg agacggctgg agcgcgactc gtcgtgctcg 960  
 ccaccgctac gcctccggga tcggtcaccg tgccacatcc aaacatcgag gaggtggctc 1020  
 35 tgtccagcac tggagaaatc cccttttatg gcaaagccat ccccatcgag accatcaagg 1080  
 gggggaggca cctcattttc tgccattcca agaagaaatg tgatgagctc gccgcgaagc 1140  
 tgtccggcct cggactcaat gctgtagcat attaccgggg ccttgatgta tccgtcatac 1200  
 caactagcgg agacgtcatt gtcgtagcaa cggacgctct aatgacgggc tttaccggcg 1260  
 atttcgactc agtgatcgac tgcaatacat gtgtcaccca gacagtcgac ttcagcctgg 1320  
 40 acccgacctt caccattgag acgacgaccg tgccacaaga cggggtgtca cgtcgcgagc 1380  
 ggcgaggcag gactggttag ggcaggatgg gcatttacag gtttgtgact ccaggagaac 1440  
 ggccctcggg catgttcgat tctcgggtc tgctcgagtg ctatgacgcg ggtgtgctt 1500  
 ggtacgagct cacgcccggc gagacctcag ttaggttgcg ggcttaccta aacacaccag 1560  
 ggttgcccgt ctgccaggac catctggagt tctgggagag cgtctttaca ggctcacc 1620  
 45 acatagacgc ccatttcttg tcccagacta agcaggcagg agacaacttc ccctacctgg 1680  
 tagcatacca ggctacgggt tgccgccagg ctcaggctcc acctccatcg tgggacaaa 1740  
 tgtggaagtg tctcatacgg ctaaagccta cgctgcacgg gccaacgccc ctgctgtata 1800  
 ggctgggagc cgttcaaaac gaggttacta ccacacaccc cataacaaa tacatcatgg 1860  
 50 catgcatgtc ggctgacctg gaggtcgtca cg 1892

<210> 134  
 <211> 822  
 <212> DNA  
 55 <213> Homo sapiens

<300>  
 <302> stmn cell factor  
 <310> M59964

60 <400> 134  
 atgaagaaga cacaacttg gattctcact tgcatttatc ttcagctgct cctatttaac 60

```

cctctcgtca aaactgaagg gatctgcagg aatcgtgtga ctaataatgt aaaagacgtc 120
actaaattgg tggcaaattct tccaaaagac tacatgataa ccctcaaata tgtccccggg 180
atggatgttt tgccaagtca ttgttggata agcgagatgg tagtacaatt gtcagacagc 240
ttgactgata ttctggacaa gttttcaaat atttctgaag gcttgagtaa ttattccatc 300
5 atagacaaac ttgtgaatat agtcgatgac cttgtggagt gcgtcaaaga aaactcatct 360
aaggatctaa aaaaatcatt caagagccca gaaccaggc tctttactcc tgaagaattc 420
tttagaattt ttaatagatc cattgatgcc ttcaaggact ttgtagtggc atctgaaact 480
agtgattgtg tggtttcttc aacattaagt cctgagaaag attccagagt cagtgtcaca 540
aaaccattta tgttaccccc tgttgcagcc agctccctta ggaatgacag cagttagcagt 600
10 aataggaagg ccaaaaatcc ccctggagac tccagcctac actgggcagc catggcattg 660
ccagcattgt tttctcttat aattggcttt gcttttggag ccttatactg gaagaagaga 720
cagccaagtc ttacaagggc agttgaaaat atacaaatta atgaagagga taatgagata 780
agtatgttgc aagagaaaga gagagagttt caagaagtgt aa 822

15
<210> 135
<211> 483
<212> DNA
<213> Homo sapiens

20
<300>
<302> TGFalpha
<310> AF123238

25
<400> 135
atggtccccct cggtcggaca gctcgccttg ttcgctctgg gtatttgtgt ggctgcgtgc 60
caggccttgg agaacagcac gtccccgctg agtcgagacc cgcccggtgg tcgacgagtg 120
gtgtcccat ttaatgactg ccagatttcc cacactcagt tctgcttcca tggaaacctgc 180
aggttttttg tgcaggagga caagccagca tgtgtctgcc attctgggta cgttgggtgca 240
30 cgctgtgagc atgcccagct cctggccgtg gtggtgcca gccagaagaa gcaggccatc 300
accgccttgg tgggtggtct catcgtggcc ctggtgtgcc ttatcatcac atgtgtgctg 360
atacactgct gccaggtccg aaaacactgt gagtgtgtgc gggccctcat ctgccggcac 420
gagaagccca gcgccctcct gaagggaaga accgcttgct gccactcaga aacagtgtgtc 480
35 tga 483

<210> 136
<211> 1071
<212> DNA
40 <213> Homo sapiens

<300>
<302> GD3 synthase
<310> NM003034

45
<400> 136
atgagccccct gcggggcgggc ccggcgacaa acgtccagag gggccatggc tgtactggcg 60
tggaagtctc cgcggaacct gctgcccatt ggagccagtg ccctctgtgt cgtggctctc 120
tgttggtctc acatcttccc cgtctaccgg ctgcccacag agaaagagat cgtgcagggg 180
50 gtagtgcaac agggcacggc gtggaggagg aaccagaccg cgccagagac gttcaggaaa 240
caaatggaag actgtgcga ccttgcccat ctctttgcta tgactaaaat gaattcccct 300
atggggaaga gcatgtggta tgacggggag tttttatact cattcaccat tgacaattca 360
acttactctc tcttcccaca ggcaacccca ttccagctgc cattgaagaa atgcgcggtg 420
gtgggaaatg gtgggattct gaagaagagt ggctgtggcc gtcaaataga tgaagcaaat 480
55 tttgtcatgc gatgcaatct ccctcctttg tcaagtgaat aactaagga tgttgatcc 540
aaaagtcagt tagtgacagc taatcccagc ataattcggc aaaggtttca gaaccttctg 600
tgggtccagaa agacatttgt ggacaacatg aaaatctata accacagtta catctacatg 660
cctgcctttt ctatgaagac aggaacagag ccattcttga gggtttatta tacactgtca 720
gatgttggtg ccaatcaaac agtgctgttt gccaaaccca actttctgcg tagcatttga 780
60 aagttctgga aaagtagagg aatccatgcc aagcgcctgt ccacaggact ttttctggtg 840
agcgcagctc tgggtctctg tgaagaggtg gccatctatg gcttctggcc ctctctgtg 900
aatatgcatg agcagcccat cagccaccac tactatgaca acgtcttacc cttttctggc 960

```

ttccatgccca tgcccagagga atttctccaa ctctgggtatc ttcataaaat cgggtgcactg 1020  
 agaatgcagc tggaccccatg tgaagatacc tcactccagc ccacttccta g 1071

5 <210> 137  
 <211> 744  
 <212> DNA  
 <213> Homo sapiens

10 <300>  
 <302> FGF14  
 <310> NM004115

<400> 137  
 15 atggccgcgg ccatcgctag cggcttgatc cgccagaagc ggcagggcgcg ggagcagcac 60  
 tgggaccggc cgtctgccag caggaggcgg agcagcccca gcaagaaccg cgggctctgc 120  
 aacggcaacc tgggtggatat cttctccaaa gtgcgcatct tcggcctcaa gaagcgcagg 180  
 ttgcggcgcc aagatcccca gctcaagggt atagtgacca gggtatattg caggcaaggc 240  
 tactacttgc aaatgcaccc cgatggagct ctcgatggaa ccaaggatga cagcactaat 300  
 20 tctacactct tcaacctcat accagtggga ctacgtgttg ttgccatcca gggagtgaag 360  
 acagggttgt atatagccat gaatggagaa gggtacctct acccatcaga actttttacc 420  
 cctgaatgca agtttaaaaga atctgttttt gaaaattatt atgtaatcta ctcatccatg 480  
 ttgtacagac aacaggaatc tggtagagcc tgggtttttg gattaaataa ggaagggcaa 540  
 gctatgaaag ggaacagagt aaagaaaacc aaaccagcag ctcattttct acccaagcca 600  
 25 ttggaagttg ccatgtaccg agaaccatct ttgcatgatg ttggggaaac ggtcccgaag 660  
 cctgggggtga cgccaagtaa aagcacaagt gcgtctgcaa taatgaatgg aggcaaacca 720  
 gtcaacaaga gtaagacaac atag 744

30 <210> 138  
 <211> 1503  
 <212> DNA



zur YFP- bzw. GFP-Sequenz ist

	<400> 150	
5	ccacaugaag cagcacgacu u	21
	<210> 151	
	<211> 21	
	<212> RNA	
10	<213> Künstliche Sequenz	
	<220>	
15	<223> Beschreibung der künstlichen Sequenz: antisense-Strang (S7B) einer dsRNA, die komplementär zur YFP- bzw. GFP-Sequenz ist	
	<400> 151	
	gucgugcugc uucauguggu c	21
20	<210> 152	
	<211> 24	
	<212> RNA	
25	<213> Künstliche Sequenz	
	<220>	
	<223> Beschreibung der künstlichen Sequenz: antisense-Strang (R2B) einer dsRNA, die komplementär zur MDR-1-Sequenz ist	
30	<400> 152	
	uacagcaagc cuggaaccua uagc	24
35	<210> 153	
	<211> 22	
	<212> RNA	
	<213> Künstliche Sequenz	
40	<220>	
	<223> Beschreibung der künstlichen Sequenz: sense-Strang (K1A) einer dsRNA, die homolog zur 5'-UTR der Neomycin-Sequenz ist	
45	<400> 153	
	acaggaugag gaucguuucg ca	22
50	<210> 154	
	<211> 22	
	<212> RNA	
	<213> Künstliche Sequenz	
55	<220>	
	<223> Beschreibung der künstlichen Sequenz: antisense-Strang (K1B) einer dsRNA, die komplementär zur 5'-UTR der Neomycin-Sequenz ist	
60	<400> 154	
	ugcgaaacga uccucauccu gu	22

5 <210> 155  
<211> 21  
<212> RNA  
<213> Künstliche Sequenz

10 <220>  
<223> Beschreibung der künstlichen Sequenz: sense-Strang  
(K3A) einer dsRNA, die homolog zur 5'-UTR der  
Neomycin-Sequenz ist

15 <400> 155  
gaugaggauca guuucgcaug a 21

20 <210> 156  
<211> 21  
<212> RNA  
<213> Künstliche Sequenz

25 <220>  
<223> Beschreibung der künstlichen Sequenz:  
antisense-Strang (K3B) einer dsRNA, die  
komplementär zur 5'-UTR der Neomycin-Sequenz ist

30 <400> 156  
augcgaaaacg auccucaucc u 21

35 <210> 157  
<211> 24  
<212> RNA  
<213> Künstliche Sequenz

40 <220>  
<223> Beschreibung der künstlichen Sequenz: sense-Strang  
(K2A) einer dsRNA, die homolog zur 5'-UTR der  
Neomycin-Sequenz ist

45 <400> 157  
acaggauag gaucguuucg caug 24

50 <210> 158  
<211> 24  
<212> RNA  
<213> Künstliche Sequenz

55 <220>  
<223> Beschreibung der künstlichen Sequenz:  
antisense-Strang (K2B) einer dsRNA, die  
komplementär zur 5'-UTR der Neomycin-Sequenz ist

60 <400> 158  
ugcgaaaacga uccucauccu gucu 24

<210> 159  
<211> 24  
<212> RNA  
<213> Künstliche Sequenz

<220>

<223> Beschreibung der künstlichen Sequenz:  
antisense-Strang (S4B) einer dsRNA, die  
komplementär zur YFP-bzw. GFP-Sequenz ist

5 <400> 159  
gaagucgugc ugcuucaugu gguc 24

<210> 160  
10 <211> 24  
<212> RNA  
<213> Künstliche Sequenz

<220>  
15 <223> Beschreibung der künstlichen Sequenz: sense-Strang  
(PKC1 A) einer dsRNA, die homolog zur  
Proteinkinase C-Sequenz ist

<400> 160  
20 cuucuccgcc ucacaccgcu gcaa 24

<210> 161  
<211> 22  
25 <212> RNA  
<213> Künstliche Sequenz

<220>  
30 <223> Beschreibung der künstlichen Sequenz:  
antisense-Strang (PKC2 B) einer dsRNA, die  
komplementär zur Proteinkinase C-Sequenz ist

<400> 161  
35 gcagcggugu gaggcggaga ag 22

<210> 162  
<211> 21  
40 <212> RNA  
<213> Künstliche Sequenz

<220>  
45 <223> Beschreibung der künstlichen Sequenz:  
antisense-Strang (S12B) einer dsRNA, die  
komplementär zur YFP- bzw. GFP-Sequenz ist

<400> 162  
aagucgugcu gcuucaugug g 21

50 <210> 163  
<211> 23  
<212> RNA  
<213> Künstliche Sequenz

55 <220>  
<223> Beschreibung der künstlichen Sequenz:  
antisense-Strang (S11B) einer dsRNA, die  
komplementär zur YFP- bzw. GFP-Sequenz ist

60 <400> 163  
aagucgugcu gcuucaugug guc 23

```

5      <210> 164
      <211> 20
      <212> RNA
      <213> Künstliche Sequenz

      <220>
      <223> Beschreibung der künstlichen Sequenz: sense-Strang
10      (S13A) einer dsRNA, die homolog zur YFP- bzw.
      GFP-Sequenz ist

      <400> 164
15      ccacaugaag cagcacgacu                                20

      <210> 165
      <211> 22
      <212> RNA
20      <213> Künstliche Sequenz

      <220>
      <223> Beschreibung der künstlichen Sequenz:
25      antisense-Strang (S13B) einer dsRNA, die
      komplementär zur YFP- bzw. GFP-Sequenz ist

      <400> 165
      agucgugcug cuucaugugg uc                                22

30      <210> 166
      <211> 20
      <212> RNA
      <213> Künstliche Sequenz

35      <220>
      <223> Beschreibung der künstlichen Sequenz:
      antisense-Strang (S14B) einer dsRNA, die
      komplementär zur YFP- bzw. GFP-Sequenz ist

40      <400> 166
      agucgugcug cuucaugugg                                20
      ,

45      <210> 167
      <211> 24
      <212> RNA
      <213> Künstliche Sequenz

50      <220>
      <223> Beschreibung der künstlichen Sequenz: sense-Strang
      (S4A) einer dsRNA, die homolog zur YFP- bzw.
      GFP-Sequenz ist

55      <400> 167
      ccacaugaag cagcacgacu ucuu                                24

      <210> 168
60      <211> 21
      <212> RNA
      <213> Künstliche Sequenz

```

<220>  
<223> Beschreibung der künstlichen Sequenz: sense-Strang  
(ES-7A) einer dsRNA, die homolog zur humanen  
5 EGFR-Sequenz ist

<400> 168  
aacaccgcag caugucaaga u 21

10 <210> 169  
<211> 21  
<212> RNA  
<213> Künstliche Sequenz

15 <220>  
<223> Beschreibung der künstlichen Sequenz:  
antisense-Strang (ES-7B) einer dsRNA, die  
komplementär zur humanen EGFR-Sequenz ist

20 <400> 169  
cuugacaugc ugcgguguuu u 21

25 <210> 170  
<211> 22  
<212> RNA  
<213> Künstliche Sequenz

30 <220>  
<223> Beschreibung der künstlichen Sequenz: sense-Strang  
(ES-8A) einer dsRNA, die homolog zur humanen  
EGFR-Sequenz ist

35 <400> 170  
aaguuaaaaau ucccgcgcgc au 22

40 <210> 171  
<211> 22  
<212> RNA  
<213> Künstliche Sequenz

45 <220>  
<223> Beschreibung der künstlichen Sequenz:  
antisense-Strang (ES-8B) einer dsRNA, die  
komplementär zur humanen EGFR-Sequenz ist

50 <400> 171  
ugauagcgcac gggaauuuua ac 22

55 <210> 172  
<211> 22  
<212> RNA  
<213> Künstliche Sequenz

60 <220>  
<223> Beschreibung der künstlichen Sequenz: sense-Strang  
(ES-2A) einer dsRNA, die homolog zur humanen  
EGFR-Sequenz ist

<400> 172  
agugugaucc aagcuguccc aa 22

5 <210> 173  
<211> 24  
<212> RNA  
<213> Künstliche Sequenz

10 <220>  
<223> Beschreibung der künstlichen Sequenz:  
.. antisense-Strang (ES-5B) einer dsRNA, die  
komplementär zur humanen EGFR-Sequenz ist

15 <400> 173  
uugggacagc uuggaucaca cuuu 24

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**